# FEDERAL REGISTER

VOLUME 36

NUMBER 8

Wednesday, January 13, 1971

Washington, D.C.


Pages 409-488

#### Agencies in this issue-

Agriculture Department Atomic Energy Commission Civil Aeronautics Board Coast Guard Consumer and Marketing Service Customs Bureau Domestic Commerce Bureau Environmental Protection Agency Federal Aviation Administration Federal Communications Commission Federal Housing Administration Federal Maritime Commission Federal Power Commission Federal Trade Commission Fish and Wildlife Service Food and Drug Administration Interior Department Interstate Commerce Commission Land Management Bureau Maritime Administration National Bureau of Standards Packers and Stockyards Administration Post Office Department Small Business Administration Transportation Department

Detailed list of Contents appears inside.

Wage and Hour Division





Now Available

## LIST OF CFR SECTIONS AFFECT

1949-1963

This volume contains a compilation of the "List of Sections Affected" for all titles of the Code of Federal Regulations for the years 1949 through 1963. All sections of the CFR which have been expressly affected by documents published in the daily Federal Register are enumerated.

Reference to this list will enable the user to find the precise text of CFR provisions which were in force and effect on any given date during the period covered.

Compiled by Office of the Federal Register, National Archives and Records Service, General Services Administration

Order from Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402



Published daily, Tuesday through Saturday (no publication on Sundays, Mondays, or on the day after an official Federal holiday), by the Office of the Federal Register, National Archives and Records Service, General Services Administration, Washington, D.C. 20408, pursuant to the authority contained in the Federal Register Act, approved July 26, 1936 (49 Stat. 500, as amended; 44 U.S.C., Ch. 15), under regulations prescribed by the Administrative Committee of the Federal Register, ap-

proved by the President (1 CFR Ch. I). Distribution is made only by the Superintendent of Documents, U.S. Government Printing Office, The Federal Register will be furnished by mail to subscribers, free of postage, for \$2.50 per month or \$25 per year, payable in advance. The charge for individual copies is 20 cents for each issue, or 20 cents for each group of pages as actually bound. Remit check or

money order, made payable to the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20403. The regulatory material appearing herein is keyed to the Code of Federal Regulations, which is published, under 50 titles, pursuant to section 11 of the Federal Register Act, as amended (44 U.S.C. 1510). The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first Federal Register Issue of each month. There are no restrictions on the republication of material appearing in the Federal Register or the Cody of Federal Regulations.

## Contents

AGRICULTURE DEPARTMENT	ENVIRONMENTAL PROTECTION	Applications for exemption: Foss Launch & Tug Co. and Foss
See also Consumer and Marketing	AGENCY	Alaska Line, Inc
Service; Packers and Stock- yards Administration.	Rules and Regulations	Puget Sound Tug & Barge Co 476
Rules and Regulations	Establishment of chapter and transfer of regulations 424	FEDERAL POWER COMMISSION
Employee responsibilities and conduct41	2 Proposed Rule Making	Proposed Rule Making
	Air quality control regions; pro-	Reliability of electric and gas
ATOMIC ENERGY COMMISSION	posed designations (2 docu- ments) 435, 436	service; extension of time to submit information 437
Notices	Notices	Notices
Virginia Electric & Power Co.; notice of application for con-	Interstate air pollution in Mt.	Hearings, etc.:
struction permit and operating	Storm, West Virginia-Gorman,	Continental Oil Co. et al 478 Cumberland Natural Gas Co
license 46	g Maryland, and Luke, Maryland- Keyser, West Virginia areas;	et al 481
CIVIL AERONAUTICS BOARD	conference of air pollution con-	Getty Oil Co. et al 479
Notices	trol agencies 474	Sun Oil Co. et al 480
Hearings, etc.:	FEDERAL AVIATION	FEDERAL TRADE COMMISSION
Continental Air Lines, Inc. 46	9 ADMINISTRATION	Proposed Rule Making
Eastern Air Lines, Inc. and National Airlines, Inc. 47	0 Rules and Regulations	Cooling-off period for door-to-
International Air Transport As-	Certain aircraft companies; air-	door sales 437
sociation (3 documents) 47 Mohawk Airlines, Inc. 47		FISH AND WILDLIFE SERVICE
United Air Lines, Inc. (2 docu-	Proposed Rule Making	Rules and Regulations
ments) 472, 47	Restricted areas; proposed altera-	Crab Orchard National Wildlife
COAST GUARD	tion and designation 435	Refuge, Ill.; sport fishing 431
Notices	FEDERAL COMMUNICATIONS	FOOD AND DRUG
Schlumberger Technology Corp.;	COMMISSION	ADMINISTRATION
qualification as a citizen 46	<sup>9</sup> Notices	Rules and Regulations
COMMERCE DEPARTMENT	Establishment of policies and pro-	Food additives:
See Domestic Commerce Bureau;	cedures for consideration of ap- plications to provide specialized	Paper and paperboard 423 Spectinomycin 423
Maritime Administration; Na- tional Bureau of Standards.	common carrier services in the	Ice cream; identity standard 422
	domestic public point-to-point microwave radio service; order	New animal drugs; topical-otic ointment 424
CONSUMER AND MARKETING SERVICE		Pesticide chemicals; tolerances
	FEDERAL HOUSING	and exemptions from toler- ances; redesignation; cross ref-
Rules and Regulations Lettuce grown in Lower Rio	ADMINISTRATION	erence 423
Grande Valley of South Texas:	Bulleting Basistation	Notices
shipment limitations 42	Delegations of basic authority and	New drug applications; notice of
CUSTOMS BUREAU	functions 424	opportunity for hearing 454
Proposed Rule Making	FEDERAL MARITIME	HEALTH, EDUCATION, AND
Merchandise whose classification	COMMISSION	WELFARE DEPARTMENT
is dependent upon proof of actual use 43		See Food and Drug Administra-
Notices	Agreements filed:	tion.
Certain metal dollies designed	American Mail Line, Ltd. and	HOUSING AND URBAN
to transport aircraft engines; instruments of international	Everett Orient Line 475 Caribbean Cruise Association 475	DEVELOPMENT DEPARTMENT
traffic 44	Outward Continental North Pa-	See Federal Housing Administra-
DOMESTIC COMMERCE BUREAU	cific Freight Conference 476 Port of Oakland and Seatrain	tion.
	Terminals of California, Inc.	INTERIOR DEPARTMENT
Notices Applications for duty-free entry	(2 documents) 476, 477 Showa Shipping Co., Ltd. and	See also Fish and Wildlife Service;
of scientific articles:	Sankyo Kajun Kabushiki	Land Management Bureau.
Harvard University, et al 44	Kaisha (2 documents) 477 Thailand/U.S. Atlantic & Gulf	Notices
Mallinckrodt Institute of Radi-	Conference, et al	Outer continental shelf off California; notice of hearings 448
ology, et al 45	Trans-Atlantic Passenger	(Continued of next page)
University of Wisconsin, et al. 45	Steamship Conference 478	411
· ·		344

412 **CONTENTS** 

ments of financial interest: Pence, William K	447 448 448	Rules and Regulations General agents, etc.; miscellaneous amendments	429	ADMINISTRATION  Rules and Regulations  Annual sales and annual receipts;	
INTERSTATE COMMERCE COMMISSION Proposed Rule Making		NATIONAL BUREAU OF STANDARDS Notices		definitions  Notices  AMOCO Venture Capital Co.; issuance of license to operate as a	421
General rules of practice; discovery rulesNotices	438	Liquid mouthwash preparations; proposed voluntary guidelines Liquid non-nutritive sweeteners; proposed voluntary package	454	minority enterprise small business investment company	481
Fourth section applications for re- lief Motor carriers:	482	guidelines	454	duct program activities in the field offices	481
Alternate route deviation notices (2 documents)  Applications and certain other proceedings  Temporary authority applications	482 483 485	PACKERS AND STOCKYARDS ADMINISTRATION Notices Mobile County Stockyards, Inc. et al.; posted stockyards	448	TRANSPORTATION DEPARTM See also Coast Guard; Federal Aviation Administration. Rules and Regulations National Highway Traffic Safety	
LABOR DEPARTMENT See Wage and Hour Division.		POST OFFICE DEPARTMENT Proposed Rule Making		Administration; establishment_ TREASURY DEPARTMENT	430
LAND MANAGEMENT BUREA	ΑU	Sexually oriented advertisements.	433	See Customs Bureau.	
Notices Colorado; proposed withdrawal and reservation of lands Oregon; classification of public lands for multiple-use management, correction	447 447			WAGE AND HOUR DIVISIO Rules and Regulations Certain industries in Puerto Rico; wage orders (3 documents)	<b>N</b> 427

## List of CFR Parts Affected

The following numerical guide is a list of the parts of each title of the Code of Federal Regulations affected by documents published in today's issue. A cumulative list of parts affected, covering the current month to date, appears at the end of each issue beginning with the second issue of the month.

A cumulative guide is published separately at the end of each month. The guide lists the parts and sections affected by documents published since January 1, 1971, and specifies how they are affected.

7 CFR		21 CFR		32A CFR	
0	413	20	422	NSA (Ch. XVIII):	400
971	421	120 (2 documents) 121 (2 documents)	423 423	AGE 2	429
13 CFR		135a	424	39 CFR	
121	421	420	424	Proposed Rules:	
14 CFR		24 CFR		124	433
39 (4 documents) 421, Proposed Rules:	422	200	424	42 CFR	
73	435	29 CFR		Proposed Rules:	
16 CFR		672	427	481 (2 documents) 435	, 436
PROPOSED RULES:		683	428	49 CFR .	
429	437	721	428 427		430
18 CFR		726	427	5	430
PROPOSED RULES:				7	430
2	437	•		95	431 431
19 CFR				99	431
PROPOSED RULES:	,			PROPOSED RULES:	
10	432			1100	438
	433	,		50 CFR	
25	433	•			431
54	433			<b>.</b>	102
13 16 25 54				50 CFR 33	431

## Rules and Regulations

### Title 7—AGRICULTURE

Subtitle A-Office of the Secretary of Agriculture

#### PART O-EMPLOYEE RESPONSIBILI-TIES AND CONDUCT

Part 0 of Title 7 of the Code of Federal Regulations is hereby revised in its entirety. Numerous editorial and clarifying changes have been made. Substantive changes appear in §§ 0.735-3, 0735-14, 0.735-31, 0735-34, and 0.735.43. These changes provide more specific assignment of responsibilities for counseling and advisory services; general and individual waivers to the conflict of interest prohibitions of 18 U.S.C. 208(a); criteria for inclusion of positions below GS-13 or equivalent among those requiring submission of a financial interest statement; clarification of the time and place for submission of financial interest statements; more specific assignment of responsibilities and clarification of procedures for reviewing financial interest making determinations statements, thereon, and documenting same.

The revised 7 CFR Part 0 reads as follows:

#### Subpart A—General Provisions

Sec. 0.735 - 1Purpose.

0.735-2Definitions. Counseling and advisory service. 0.735 - 3

0.735 - 4Agency supplementation.

0.735 - 5Remedial action.

#### Subpart B-Conduct and Responsibilities of **Employees**

0.735-11 Prohibited conduct-general. Gifts, entertainment, and favors. Outside employment and activity. 0.735 - 120.735-13 Conflict of interest. 0.735-14

0.735-15 Attendance and leave.

Use of Government property, faci-0.735-16 · lities, and services.
Use of vehicles.

0.735-17 Indebtedness.

Political activity. 0.735 - 190.735-20

Use, protection, and release of information. Activities with regard to farm or-0.735 - 21

ganizations. 0.735-22 Prohibitions upon employees serv-

ing abroad. 0.735-23 Miscellaneous provisions. 0.735-24 Miscellaneous statutory provisions.

Subpart C-Statements of Employment and Financial Interests

0.735-31 Employees required to submit statements.

0.735-32 Exceptions.

0.735-33 Identification of employees required to submit statements. 0.735-34 Time and place for submission of

employees' statements. Supplementary statements. 0.735-35

0.735 - 36Types of interests to be reported. 0.735-37 Information prohibited.

0.735-38 Interests of employee's relatives. 0.735-39 Information not known by employee.

0.735-40 Effect of employee's statement. Specific provisions for special Gov-ernment employees. 0.735 - 41

Review of statements and determination of conflicting interests. 0.735-43 Protection of employees' statements.

AUTHORITY: The provisions of this Part 0 issued under Executive Order 11222 of May 8, 1965, 30 F.R. 6469, 3 CFR, 1965 Supp.; 5 CFR

#### Subpart A—General Provisions § 0.735-1 Purpose.

The maintenance of unusually high standards of honesty, integrity, impartiality, and conduct by Government employees and special Government employees is essential to assure the proper performance of the Government business and the maintenance of confidence by citizens in their Government. The confidence of citizens in their Government is influenced not only by the manner in which employees serve the public but in the way they conduct themselves in the eyes of the public. The avoidance of misconduct and conflicts of interests on the part of Government employees and special Government employees through informed judgment is indispensable to the maintenance of these standards. To accord with these concepts, this part sets forth the regulations for employees of the U.S. Department of Agriculture, prescribing standards of conduct and responsibilities and governing the reporting of employment and financial interests.

#### § 0.735-2 Definitions.

In this part:

(a) "Agency" means an independent

(b) The partment of subagency of the U.S. Department of Agriculture.

(b) "Agency Head" is the Administrator or Chief Executive Officer of an agency.

(c) "Conflict of interest" means the situation that exists when there is a conflict, or appearance of conflict, between the interest of an employee and the performance of his Government

duties.
(d) "Employee" means a regular officer or employee of the Department of Agriculture including excepted and WOC employees and includes a special Government employee unless otherwise provided.

(e) "Special Government employee" means an officer or employee of the Department of Agriculture who is retained, designated, appointed, or employed to perform temporary duties either on a full-time or intermittent basis, with or without compensation, for not to exceed 130 days during any period of 365 consecutive days.

(f) "The Executive Order" means Executive Order 11222 of May 8, 1965.

§ 0.735-3 Counseling and advisory service.

(a) The Assistant General Counsel for Marketing, Regulatory Laws, Research and Operations, shall serve as the Department Counselor and designee to the Civil Service Commission on matters covered by the regulations in this part. He shall have overall responsibility for coordination of the Department's counseling and advisory service, and for assuring advice and interpretations on questions of conflicts or apparent conflicts of interest and other matters covered by the regulations in this part are available to Deputy Counselors and Assistant Deputy Counselors hereinafter designated.

(b) The Director of Personnel and the Chief. Security and Employee Conduct Division, Office of Personnel, shall be Department Deputy Counselors.

(c) Agency Heads will be Agency Deputy Counselors. If necessary in order to assure that counseling and advisory service is available to all Washington and field employees, the Agency Head may designate as Agency Assistant Deputy Counselors such employees as are qualified and in a position to give authoritative advice and guidance on most matters covered by this part.

(d) All employees are to be notified of the availability of counseling and by whom this service is provided. Initial notification must be made within 90 days after issuance of this part, and periodically thereafter. A new employee or new special Government employee must be notified at or before the time of his entrance on duty.

(e) Each new employee shall be furnished at the time of hiring a copy of this part. Current employees shall be furnished a copy of these regulations within 90 days following issuance. Subsequent changes to these regulations will be furnished employees upon issuance. Each employee shall be reminded of the regulations in this part semiannually.

#### § 0.735-4 Agency supplementation.

Agencies of the Department may issue such additional regulations as are necessary and consistent with the regulations in this part, subject to the prior approval of the Director of Personnel. Agencies are expected to issue such supplemental regulations, with respect to employees assigned to particular programs, as are necessary to prevent such employees from being in a potential conflict of interest situation or a situation giving the appearance of a conflict of interest. Such Agency regulations shall be furnished to employees in the same manner as the regulations in this part.

#### § 0.735-5 Remedial action.

(a) A violation of this part by an employee may be cause for remedial action. Remedial action may include, but is not limited to:

(1) Changes in assigned duties;

- (2) Divestment by the employee of a conflicting interest;
- (3) Disqualification for a particular assignment: or
- (4) Disciplinary action which may be in addition to any penalty prescribed by law.
- (b) Remedial action, whether disciplinary or otherwise, shall be effected in accordance with any applicable laws, Executive orders, and regulations.

## Subpart B—Conduct and Responsibilities of Employees

### § 0.735-11 Prohibited conduct—general.

- (a) An employee shall avoid any action, whether or not specifically prohibited by this subpart, which might result in or create the appearance of:
- (1) Using public office for private gain;
- (2) Giving preferential treatment to any person;
- (3) Impeding Government efficiency or economy:
- (4) Losing complete independence or impartiality;
- (5) Making a Government decision outside of official channels; or
- (6) Affecting adversely the confidence of the public in the integrity of the Government.
- (b) Employees are specifically prohibited from:
- (1) Engaging in criminal, infamous, dishonest, immoral, or notoriously disgraceful conduct, or other conduct prejudicial to the Government;
- (2) Betting or participating in any gambling activity, including the operation of a gambling device, conducting a lottery or pool, or selling or buying a number slip or ticket, while on Government-owned or leased property or while on duty for the Government;
- (3) Consuming intoxicating beverages on Government-owned or leased property, or transporting such beverages in Government-owned or leased vehicles, or using such beverages at any time or place to the extent that it adversely affects performance of official duties;
- (4) Lending funds at usurious interest rates:
- (5) Provoking or harassing other employees, or making unwarranted criticism or accusations against other employees:
- (6) Monitoring or recording, or authorizing or permitting others under their administrative control to monitor or record, telephone conversations for the purpose of taking a verbatim transcript of all or part of the conversation, unless such monitoring or recording is agreed to in advance by all participants in the conversation:
- (7) Utilizing a mechanical or electronic device to monitor or record nontelephone conversations, unless such monitoring or recording is agreed to in advance by all participants in the conversation;

(8) Soliciting, making collections, canvassing for the sale of any article, or distributing or posting literature, advertising matter, or any other graphic matter, in any space occupied by the Department, except as authorized in writing by the Director of Personnel;

(9) Soliciting money from, or selling tickets to, persons outside the Government for the benefit of any organization of the Department;

- (10) Taking any action which might prejudice the Government's interest in a criminal or civil case:
- (11) Giving aid or assistance, other than in the discharge of official duties, to any claimant in prosecuting any claim against the United States;
- (12) Distributing through the Department's mail and messenger service, or otherwise distributing or posting, in any space occupied by the Department, any circulars, flyers, announcements, pictures, or other graphic matter, etc., that:
- (i) Directly or indirectly attack or adversely reflect on the integrity of any official, officer or employee of any branch of the Government; or
- (ii) Directly or indirectly condemn or criticize the policies of any Government department or agency.

## § 0.735-12 Gifts, entertainment, and favors.

- (a) Except as provided in paragraphs (b) and (e) of this section, an employee shall not solicit or accept, directly or indirectly, any gift, gratuity, favor, entertainment, loan, unusual discount, or any other thing of monetary value from a person who:
- (1) Has, or is seeking to obtain, contractual or other business or financial relations with the Department;
- (2) Conducts operations or activities that are regulated by the Department; or
- (3) Has interests that may be substantially affected by the performance or nonperformance of his duty.
- (b) The restrictions in paragraph (a) of this section do not prohibit:
- (1) Acceptance of any of the usual courtesies in an obvious family or personal relationship (such as those between the employee and his parents, spouse, children, or close personal friends) when the circumstances make it clear that it is those relationships rather than the business of the persons concerned which are the motivating factors;
- (2) Acceptance of loans from banks or other financial institutions on customary terms to finance proper and usual activities of employees, such as home mortgage loans;
- (3) Acceptance of unsolicited advertising or promotional material, such as pens, pencils, note pads, calendars, and other things of nominal value; and
- (4) The exchange of usual social courtesies which are wholly free of any embarrassing or improper implications.
- (c) An employee shall not solicit a contribution from another employee for a gift to an official superior, make a donation as a gift to an official superior, or accept a gift from an employee receiving less pay than himself (5 U.S.C. 7351).

However, this paragraph does not prohibit the voluntary giving or acceptance of a gift of nominal value or donation in a nominal amount made on a special occasion such as marriage, illness, or retirement.

- (d) An employee shall not accept a gift, present, decoration, or other thing from a foreign government unless authorized by Congress as provided in 5 U.S.C. 7342.
- (e) Neither this section nor § 0.735-13(a) precludes an employee from receipt of bona fide reimbursement, unless prohibited by law, for expenses of travel and such other necessary subsistence as is compatible with this part for which no Government payment or reimbursement is made. However, this paragraph does not allow an employee to be reimbursed, or payment to be inade on his behalf, for excessive personal living expenses, gifts, entertainment or other personal benefits, nor does it allow an employee to be reimbursed by a person for travel on official business under agency orders when reimbursement is proscribed by Decision B-128527 of the Comptroller General dated March 7, 1967 (46 Comp. Gen. 689).

## § 0.735-13 Outside employment and activities.

- (a) An employee shall not engage in any outside employment or other outside activity not compatible with the full and proper discharge of the duties and responsibilities of his Government employment, whether on his own behalf, or for private individuals, firms, companies, institutions, or State or local governments. Incompatible activities include but are not limited to:
- (1) Outside employment or activity which may result in, or create the appearance of, a conflict of interests;
- (2) Outside employment or activities which tend to impair an employee's physical or mental capacity to perform his Government duties in an acceptable manner, or prevent him from rendering full-time service to the Government;
- (3) Outside work or activity which may be construed by the public to be official acts of the Department, or of a nature closely paralleling the work of the Department;
- (4) Outside work or activity which involves participation in a commercially sponsored broadcast, or which relates to a written discussion of policies or official work of the Department, unless authorized in advance by the Office of Information:
- (5) Outside work or activity which involves permission, or the appearance of permission, to use an employee's name in the advertising of organizations commercializing the results of research conducted by the Department, regardless of any merits which such enterprises may appear to possess.
- (6) Outside work or activity which may involve the use of information secured as the result of employment in the Department and to the detriment of the public service; and

- (7) Any outside work or activity which may tend to bring criticism on, or cause embarrassment to, the Department.
- (b) Employees are specifically prohibited from acting as the agent of a foreign principal registered under the Eoreign Agent's Registration Act (18 U.S.C. 219).
- (c) No employee, whether in a duty or nonduty status, shall accept employment, with or without compensation, from any foreign government, corporation, partnership, or individual without written prior approval from his Agency Head:
- (d) It is the policy of the Department to grant permission to an employee to teach, lecture, or write, including teaching, lecturing, or writing for the purpose of the special preparation of a person or class of persons for an examination of the Civil Service Commission or Board of Examiners for the Foreign Service, provided:

 Prior written authorization is obtained from the Agency Head;

- (2) Such teaching, lecturing, or writing is not performed at or for any educational institution or other organization that discriminates because of race, creed, color, or national origin in the admission or subsequent treatment of students;
- (3) Such teaching, Iecturing, or writing is not dependent on information obtained as a result of his employment with the Department, except when that information has been made available to the general public or when the Agency Head gives specific authorization for the use of nonpublic information in the public interest; and

(4) Such teaching, lecturing, or writing is not otherwise incompatible with the provisions of this part.

(e) Articles prepared officially are the property of the Government, and authors thereof may not accept payment for such articles published in outside journals, magazines, or newspapers.

(f) Employees may not accept honoraria for addresses on radio or television or other appearances performed as part of their official duties.

(g) No employee, except a special Government employee, shall accept compensation for services as consultant or advisor to any organization, public or private, in any manner which draws upon the experience, competence, or professional standing acquired or enhanced by or through his position in this Department unless he has received permission from his Agency Head. A special Government employee shall not use his employment with the Department for a purpose that is, or gives the appearance of being, motivated by the desire for private gain for himself or another.

#### § 0.735-14 Conflict of interest.

- (a) The following prohibitions apply to both a regular employee and a special Government employee:
- (1) He may not have a direct or indirect financial interest that conflicts substantially, or appears to conflict substantially, with his responsibilities and duties as a Federal employee.

- (2) He may not engage in, directly or indirectly, a financial transaction relying upon information obtained through his employment.
- (3) He may not participate directly or indirectly in any transaction concerning the purchase or sale of corporate stocks or bonds, commodities, or other property for speculative purposes if such action might tend to interfere with the proper and impartial performance of his duties or bring discredit upon the Department.
- (4) If he is concerned in any way with the administration of acts regulating trading in commodities for future delivery, programs for the purchase or sale of commodities, price support programs, commodity loan programs, or other programs which directly affect market prices of agricultural commodities, he may not directly or indirectly speculate in any agricultural commodity.
- (5) He may not, after his Government employment has ended, represent anyone other than the United States in connection with a matter in which the United States is a party or has an interest and in which he participated personally and substantially for the Government (18 U.S.C. 207(a)).
- (6) He may not, for 1 year after his Government employment has ended, represent anyone other than the United States in connection with a matter in which the United States is a party or has an interest and which was within the boundaries of his official responsibility during the last year of his Government service (18 U.S.C. 207(b)).
- (7) Except as permitted by paragraphs (b) and (c) of this section, he may not participate personally and substantially as a Government officer or employee, through decision, approval, disapproval, recommendation, the rendering of advice, investigation, or otherwise, in a judicial or other proceeding, application, request for a ruling or other determination, contract, claim, controversy, charge, accusation, arrest, or other particular matter in which, to his knowledge, he, his spouse, minor child, partner, organization in which he is serving as officer, director, trustee, partner, or employee, or any person or oganization with whom he is negotiating or has any arrangement concerning prospective employment, has a financial interest (18 U.S.C. 208(a)).
- (b) The prohibition in paragraph (a) (7) of this section shall not apply if the employee first advises his Agency Head or the Director of Personnel of the nature and circumstances of the particular Government matter involved and makes full disclosure of the financial interest and receives in advance a written determination made by the Agency Head or the Director of Personnel that the interest is not so substantial as to be deemed likely to affect the integrity of the services which the Government may expect from the employee. Authority to make such written determinations may not be redelegated by the Agency Head or the Director of Personnel.

- (c) The following types of interests, except where otherwise prohibited by statute or regulation, are exempted from the prohibition in paragraph (a) (7) and the requirements of paragraph (b) of this section as being too remote or too inconsequential to affect the integrity of an employee's services to the Government:
- (1) Any holding in a widely held mutual fund or regulated investment company which does not specialize in a particular industry or commodity and as to which the employee has no managerial control or directorship.
- (2) Ownership of shares of common or preferred stock, corporate bonds, or other corporate securities, if the aggregate value of the holdings in any single corporation or enterprise is less than \$5,000 and is less than 1 percent of the value of the outstanding stock, bonds, or other securities of that corporation or enterprise, and as to which the employee has no managerial control or directorship.

(d) The following prohibitions apply only to a regular employee:

(1) He may not, except in the discharge of his official duties, represent anyone else before a court or Government agency in a matter in which the United States is a party or has an interest (18 U.S.C. 203 and 205).

(2) He may not receive any salary, or supplementation of his Government salary, from a private source as compensation for his services to the Government (18 U.S.C. 209).

(e) The following prohibitions apply only to a special Government employee:

- (1) He may not, except in the discharge of his official duties, represent anyone else before a court or Government agency in a matter in which the United States is a party or has an interest and in which he has at any time participated personally and substantially for the Government (18 U.S.C. 203 and 205).
- (2) He may not, except in the discharge of his official duties, represent anyone else in a matter pending before the Government agency he serves unless he has served there no more than 60 days during the past 365 days (18 U.S.C. 203 and 205).
- (f) This section does not preclude an employee from:
- (1) Acting without compensation, and if not inconsistent with the faithful performance of his duties, as agent or attorney for any person who is the subject of disciplinary, loyalty, or other personnel administration proceedings in connection with those proceedings:
- (2) Giving testimony under oath or making statements required to be made under penalty for perjury or contempt; or
- (3) Having a financial interest or engaging in financial transactions to the same extent as a private citizen not employed by the Government, provided it is not prohibited by law, Executive Order 11222, 5 CFR Part 735, this part, or agency regulations supplementing this part.

(g) This section does not purport to paraphrase the restrictions contained in 18 U.S.C., Chapter 11. The omission of a restriction in no way relieves an employee of the legal effect of such restriction.

#### § 0.735-15 Attendance and leave.

(a) Employees must observe designated duty hours and be punctual in reporting for work and returning from lunch periods. Tardiness can result in employees being placed in a nonpay status or in a charge against annual or compensatory leave in multiples of 1

hour or remedial action.

- (b) Employees normally must obtain advance authorization for absence from duty. Where absence from duty results from illness or an emergency, employees are required to notify their supervisor or other appropriate person as soon as possible. When an employee fails to properly notify his supervisor absence may be charged as an unauthorized absence. It also may result in remedial
- (c) Sick leave is to be used by employees only when they are incapacitated from duty because of sickness or injury, when they need to obtain medical, dental, or optical examination or treatment, when they are subject to quarantine imposed by local health authorities, or when they are required to give care to a member of their immediate family who has a contagious disease.

## § 0.735-16 Use of Government property, facilities, and services.

(a) Employees are prohibited from directly or indirectly using, or allowing the use of, Government property, facilities, or services of any kind, including those leased to or otherwise paid for by the Government, for other than officially approved activities. Employees have a positive duty to conserve and protect Government property.

(b) Personal property offered for sale by the Department may be purchased by employees only when the sale of such property is based upon competitive bids, provided that no purchase may be made, either directly or indirectly, by the employee who was formerly accountable for the property, who formerly used the property, or who was in any way connected with its condemnation, declara-

tion as excess, or sale, except:

(1) Surplus perishable products may be sold to employees at the best price obtainable in quantities not exceeding the needs of their immediate households.

(2) Special clothing and other articles or personal equipment purchased for the exclusive use of and fitted to an individual employee may, when not otherwise usable by the Department and in all respects surplus to the needs of the Government, be sold to such employee at the best price obtainable in the event of his separation from the Service or permanent assignment to duties not requiring such clothing or equipment.

#### § 0.735-17 Use of vehicles.

(a) An employee who wilfully uses or authorizes the use of a Government-

- owned or leased passenger motor vehicle or aircraft for other than official purposes shall be suspended for 1 month or removed from office in accordance with 31 U.S.C. 638a(c) (2).
- (b) An employee who wilfully uses or authorizes the use of a Government-owned or leased motor vehicle other than passenger carrying for other than official purposes, is subject to disciplinary action up to and including removal.
- (c) An employee shall not store Government-owned or leased motor vehicles in or near his private residence or use such vehicles for transportation between his residence and place of employment unless such storage or use shall have been specifically authorized by the Secretary or another official to whom such authority has been delegated.

#### § 0.735-18 Indebtedness.

- (a) Employees who fail to pay their just financial obligations in a timely and proper manner will be subject to such disciplinary action as the Agency Head or his designee considers appropriate. For the purpose of this section, "just financial obligations" are those acknowledged by the employee, reduced to judgment by a court, or confirmed by a final administrative determination of a unit of the Federal, State, or local government. A "proper and timely manner" means in a manner which the Agency Head or his designee determines does not, under the circumstances, reflect adversely on the Department as his employer.
- (b) In cases where a legal judgment exists against the employee, the employee concerned will be required to satisfy the judgment within a reasonable period of time unless he can arrange to have it modified or set aside.
- (c) When an employee is the subject of a complaint for failure to pay taxes or other debts that are the subject of a final administrative determination by a unit of the Federal, State, or local government, he shall be advised of the complaint and told to make payment arrangements satisfactory with that unit of government.
- (d) When an employee is the subject of a letter of complaint from a creditor who does not hold a legal judgment, the Agency Head or his designee shall determine whether the employee acknowledges the debt and call the provisions of this section to the employee's attention. Subsequent action, if any, will be taken in accord with the facts of the case and the provisions of this section.

#### § 0.735-19 Political activity.

A Federal employee other than an officer exempted by 5 U.S.C. 7324(d) may not take an active part in political management or in a political campaign. He may not solicit or receive any assessment, subscription, or contribution for any political purpose from an officer or employee of the Government. Whatever the employee may not do directly, he may not do indirectly or through an agent, officer, or employee chosen by him or subject to his control.

- § 0.735-20 Use, protection, and release of information.
- (a) An employee is prohibited from using or giving information acquired through his official position, prior to its release to the general public, to advance the interests of himself, his family, associates, or friends, or any other person or enterprise.

(b) Classified defense information and restricted information shall be safe-guarded and released in accordance with the provisions of applicable directives, statutes, or regulations. For further information consult the USDA Records

Security Regulations.

(c) "For Official Use Only" material shall not be examined by, released to, nor discussed with any person except in the performance of official duties and as prescribed by Title 1, Chapter 9, Administrative Regulations, U.S. Department of Agriculture.

- (d) Unauthorized, premature disclosure of information which might influence or affect the market value of any product of the soil grown within the United States, or of information which by law or rule of the Department is required to be withheld from publication until a fixed time is punishable by fine and imprisonment.
- (e) The subject matter of public hearings with respect to the proposed issuance of an order, regulation or other administrative determination, after the close of the hearing and prior to issuance by the Secretary of the order, regulation, or other administrative determination shall not be discussed with any interested person or with any representative of an interested person without written permission of the Secretary. However, this shall not preclude an employee who has been assigned to or has supervision over a proceeding from discussing with interested persons or their representatives matters of procedure in connection with such proceeding.
- (f) Official mail shall be safeguarded from indiscriminate publication. It is prohibited to use or to quote in whole or in part any letters from the White House to this Department.
- (g) Information concerning inventions and patent applications may be revealed only for official purposes. Employee inventors and employees who handle or obtain information concerning inventions of employee inventors or concerning any other inventions in which the Department may have an interest shall not reveal such information prior to the issuance of the patent, except for official purposes.
- (h) The release of any list of names of employees of the Department of political purposes or for purposes of commercial solicitation is prohibited.
- (i) It is prohibited to release lists of names of farmers, businessmen, persons, organizations, or firms that may be available in the Department directly or indirectly to any person, firm or association if such lists will be used for solicitation purposes, or such lists directly or indirectly provide information which customarily would not be released to the

public by the person from whom the Department obtained it. Exceptions shall not be made unless authorized by the Director of Information, and it is clear that the public interest will be served and there will be negligible public expense or interruption of work. A request for a Department list must state the purpose for which the list will be used. Lists of manufacturers, dealers, breeders, etc., should not be furnished so as to imply that the Department endorses certain firms to the possible detriment of others or that the lists necessarily include all dealers of a certain line.

#### § 0.735-21 Activities with regard to farm organizations.

- (a) Department employees shall refrain from participating actively in meetings and in other activities concerned with the establishment of general or specialized farm organizations, or with recruiting members for existing organizations such as the national, regional, State, and local organizations of the National Grange, the American Farm Bureau Federation, the National Farmers Organization, the Farmers' Union, the National Association of Soil Conservation Districts, the National Rural Electric Cooperative Association, the National Council of Farmer Cooperatives and Breed and Commodity Organizations. This is a necessary corollary of the equally long-established policy of the Department that it shall deal fairly with all organizations and deal with each upon the same basis. As a continuation of this policy, it should be understood by employees of the Department that it is not permissible for any of them to:
- (1) Participate in establishing any general or specialized farm organization.
- (2) Act as organizer for any such organization, or hold any other office therein.
- (3) Act as financial or business agent for any such organization.
- (4) Participate in any way in any membership campaign or other activity designed to recruit members for any such organization.
- (5) Accept the use of free office space or contributions for salary or traveling expense from any such organization.
- (6) Advocate that any particular general or specialized organization of farmers is better adapted for carrying out the work of this Department than any individual citizen, group of citizens, or organizations.
- (7) Advocate that the responsibilities of any agency of this Department or any other Federal agency should be carried out through any particular general or specialized organization of farmers.

(8) Advocate or recommend that any State or local agency should carry out its responsibilities through any particular general or specialized organization

of farmers.

(9) Approve contracts for the Department with any cooperative or other commercial organization whenever such cooperative or other commercial organization deducts or checks off from payments due farmers, membership dues of such farmers to any general or specialized or-

ganization of farmers, except as it is determined that current authorization for such deduction has been knowingly filed by such individual farmers with the cooperative or other commercial organization.

(b) The restrictions set forth in paragraph (a) of this section do not:

(1) Apply to FHA County Committeemen.

(2) Apply to specialized organizations of farmers such as cow testing associations and similar groups.

(3) Prohibit employees from participating in the organization of groups that are needed in carrying out federally authorized programs; for example, an REA cooperative and similar groups determined by the appropriate Agency Head to be essential in effectuating federally authorized programs.

(c) If any violations of any of the provisions of this section should occur, full information with reference thereto should at once be submitted to the Office of the Inspector General by the head of the agency in which the person violating any of these provisions is employed.

§ 0.735-22 Prohibitions upon employees serving abroad.

An employee on foreign assignment may not:

- (a) Violate Department of State regulations governing the post to which he is assigned.
- (b) Receive a "profit" from the sale of his personal car or other property when such "profit" accrues from import privileges granted him by reason of his official status. "Profit" for the purposes of this paragraph is as defined in Department of State regulations or directives governing the post of assignment.
- (c) Engage in political activities in the country of assignment.
- (d) Violate the laws of the country in which he is assigned.
- (e) Have an interest in any business enterprise or engage in any profession in any country to which assigned.
- (f) Speculate in foreign real estate. bonds, shares, stocks, and currencies.

#### § 0.735-23 Miscellaneous provisions.

- (a) Any money, property, or other thing of value received by or coming into custody of an employee in connection with the discharge of his duties must be accounted for, deposited or otherwise disposed of in accordance with established procedures.
- (b) Employees are required under § 5.3 of Civil Service Rule V (5 CFR 5.3) to give the Civil Service Commission and its authorized representatives all information and testimony in regard to matters arising under laws, rules, and regulations administered by the Commission.
- (c) Employees are obligated to give information to authorized representatives of the Department when called upon if the inquiry relates to official matters and the information is obtained in the course of employment or as a result of relationships incident to such employment. Failure to respond to requests for information or to appear as a

witness in an official proceeding may result in disciplinary penalty.

(d) Agency officials have the authority transfer and reassign employees within their respective jurisdictions whenever necessary to meet operational needs. Employees have an obligation to the Department to accept transfers and changes in assignment. Failure to accept a transfer or reassignment may result in the separation of the employee.

#### § 0.735-24 Miscellaneous statutory provisions.

- (a) Each employee has a positive duty to acquaint himself with each statute that relates to his ethical and other conduct as an employee of his Agency, of the Department, and of the Government. The attention of each employee is directed to the following statutory provisions:
- (1) House Concurrent Resolution 175, 85th Congress, second session, 72A Stat. B12, the "Code of Ethics for Government Service."
- (2) Chapter 11 of title 18, United States Code, relating to bribery, graft, and conflicts of interest.

(3) The prohibition against lobbying with appropriated funds (18 U.S.C. 1913).

- (4) The prohibitions against disloyalty and striking (Executive Order 10450, 5 U.S.C. 7311, 18 U.S.C. 1918).
  (5) The prohibition against the em-
- ployment of a member of a Communist organization (50 U.S.C. 784).
- (6) The prohibitions against the disclosure of classified information (18 U.S.C. 798, 50 U.S.C. 783).
- (7) The prohibition against the disclosure of confidential information (18 U.S.C. 1905).
- (8) The provision relating to the habitual use of intoxicants to excess (5 U.S.C. 7352).
- (9) The prohibition against the misuse of a Government vehicle (31 U.S.C. 638a).
- (10) The prohibition against the misuse of the franking privilege (18 U.S.C. 1719).
- (11) The prohibition against the use of deceit in an examination or personnel action in connection with Government employment (18 U.S.C. 1917).
- (12) The prohibition against fraud or false statements in a Government matter (18 U.S.C. 1001).
- (13) The prohibition against mutilating or destroying a public record (18 U.S.C. 2071).
- (14) The prohibition against counterfeiting and forging transportation requests (18 U.S.C. 508).
- (15) The prohibition against embezzlement of Government money or property (18 U.S.C. 641).
- (16) The prohibition against embezzlement of the money or property of another person in the possession of an employee by reason of his employment (18 U.S.C. 654).
- (17) The prohibition against failing to account for public money (18 U.S.C. 643).
- (18) The prohibition against unauthorized use of documents relating to

U.S.C. 285).

(19) The prohibition against proscribed political activities (5 U.S.C. 7324, and 18 U.S.C. 602, 603, 607, and 608).

(20) The prohibition against an employee acting as an agent of a foreign principal registered under the Foreign Agents Registration Act (18 U.S.C. 219).

(21) The prohibition against the employment of a person convicted of a felony for participating in or promoting a riot or civil disorder (5 U.S.C. 7313).

(22) The prohibition against the publication of data and information obtained pursuant to the Commodity Exchange Act which would disclose the business transactions of any person. trade secrets or customer names (7

U.S.C. 12). (23) The prohibition against using or revealing information relative to formulas of products acquired by the Secretary incident to the registration of economic poisons, with intent to defraud (7 U.S.C.

135f(c)).
(24) The prohibition against the unauthorized release of information, in the Packers and Stockyards Act (7 U.S.C. 222).

(25) The prohibition against the release of information in an employee's possession concerning cotton standards, estimates, tests, and analyses unless authorized by the Secretary (7 U.S.C. 472).

(26) The prohibitions against the release of information acquired from parties to any marketing agreement, and handlers subject to marketing agreement orders, except as authorized by the Secretary for the purposes of suit or administrative hearings (7 U.S.C. 608d(2)).

(27) The prohibition against the unauthorized prediction as to cotton prices in a governmental publication (12 U.S.C. 1141j(d)).

(28) The prohibition against the making of false statements or reports, or wilfully overvaluing land, property or security to influence action in connection with agricultural loans (18 U.S.C. 1014).

(29) The prohibition against the will-ful disclosure of official information which might influence or affect the market value of crops prior to authorized publication. An employee acquiring by reason of his employment, information as to the market value of agricultural crops, which information is required to be withheld, is prohibited from speculating in such product (18 U.S.C. 1902).

(30) Limitations on the use or availability of information furnished in connection with marketing agreements and orders (7 U.S.C. 610(i)).

(31) The availability of information furnished in connection with marketing agreements and orders, applicable to marketing agreements and orders, applicable to marketing agreements for antihog-cholera serum and hog-cholera virus is restricted (7 U.S.C. 855).

(32) Information furnished in connection with collection of peanut statistics shall be used only for statistical purposes for which supplied. No publication shall be made where the data furnished

claims from or by the Government (18 by any establishment can be identified (7 U.S.C. 955).

(33) Information with respect to individual operations of processor, producer, or laborer will not be made public in connection with recommendations with respect to producer-processor and producer-labor contracts (7 U.S.C. 1159).

(34) Information furnished in connection with the establishment and adjustment of farm marketing quotas shall be disclosed only as authorized by the Secretary for the purpose of suit or administrative hearing (7 U.S.C. 1373(c)).

(35) The prohibition against a person licensed to inspect or grade grain, or employed by the Department to carry out the provisions of the Grain Standards Act being financially or otherwise interested in a grain elevator or employed by a grain elevator or warehouse (7 U.S.C. 87).

(36) The prohibition against persons administering the Sugar Act of 1948, from investing or speculating in sugar or liquid sugar, contracts relating thereto, or stock or membership interests of any association or corporation engaged in sugar production (7 U.S.C. 1157).

(37) The prohibition against persons administering activities concerned with cotton option contracts and commodity benefits as provided by the Agriculture Adjustment Act speculating in agricultural commodities or products to which such contracts or benefits apply, or in contracts relating thereto, or in the stock or membership interests of any association or corporation handling such commodities or products (7 U.S.C. 610(g)).

(38) The prohibition against an officer or employee being the beneficiary of or receiving any fee, commission or gift for or in connection with any transaction or business under the Consolidated Farmers Home Administration Act of 1961, other than such salary, fee or compensation as he may receive as an officer or employee. Members of a FHA County Committee making any certification with respect to a loan to purchase any land in which they or any person related to them have any financial interest (7 U.S.C. 1986).

(39) The prohibition against the making of false statements in connection with activities of the Commodity Credit Corporation or embezzlement or conversion of anything of value belonging or pledged to the Corporation, or conspiring to commit such acts (15 U.S.C. 714m).

(40) The prohibition against the acceptance of any fee, gift, or other consideration for compromise, adjustment, or cancellation of farm indebtedness (18 U.S.C. 217).

(41) The prohibition against the embezzlement of money or property of the Federal Crop Insurance Corporation and the Farmers Home Administration, and of pledged or entrusted property (18 U.S.C. 657).

(42) The prohibition against the conversion of property mortgaged or pledged to the Farmers Home Administration and the Federal Crop Insurance Corpo-. ration, with intent to defraud (18 U.S.C. 658).

(43) The prohibition against the making of false entries, or participation in any benefit through any transaction in connection with Departmental activities concerned with agricultural loans (18 U.S.C. 1006).

(44) The prohibition against speculation in agricultural commodities to which the Federal Crop Insurance Act applies or to contracts relating thereto, or stocker or membership interests of corporations or associations handling such commodities by any person administering such law (18 U.S.C. 1903).

(45) The prohibition against the compilation or issuance of false crop reports

(18 U.S.C. 2072).

(46) The prohibition against the acceptance by an employee of money or other things of value given with intent to influence a decision in connection with the performance of duties under the Federal Meat Inspection Act, or when received from a person or firm engaged in commerce given for any purpose whatever (21 U.S.C. 622)

(47) The prohibition against any person using to his own advantage or improperly revealing information concerning trade secrets acquired under the Poultry Products Inspection Act (21 U.S.C. 458).

(48) The prohibition against a public official appointing or promoting a relative, or advocating such an appointment

or promotion (5 U.S.C. 3110).

(49) The tax imposed on certain employees (e.g., Presidential appointces, employees excepted under Schedule C, employees in GS-16 or above or a comparable pay level) who knowingly engage in self-dealing with a private foundation (26 U.S.C. 4941, 4946). "Self-dealing" is defined in the statute to include certain transactions involving an employee's receipt of pay, a loan, or reimbursement for travel or other expenses from, or his sale to or purchase of property from, a private foundation.

(b) This section does not purport to enumerate or paraphrase all statutory restrictions imposed on employees. The omission of a restriction in no way relieves an employee of the legal effect of such restriction.

#### Subpart C-Statements of Employment and Financial Interests

§ 0.735-31 Employees required to submit statements.

Except as provided in § 0.735-32 the following employees shall submit a statement of employment and financial interests on USDA Form AD-392 in accordance with this part:

(a) Employees paid at a level of the Executive Schedule in Subchapter II of 5 U.S.C., Chapter 53.

(b) Employees appointed as Hearing Examiners under 5 U.S.C. 3105.

(c) Employees classified at GS-13 or above under 5 U.S.C. 5332, or at a comparable pay level under other authority, who are in positions the basic duties and responsibilities of which require the incumbent to exercise judgment in making a Government decision or in taking Government action on contracting or procurement, administering or monitoring grants or subsidies, regulating or auditing private or other non-Federal enterprise, or other activities where the decision or action has an economic impact on the interests of any non-Federal enterprise.

(d) Employees classified at GS-13 or above under 5 U.S.C. 5332, or at a comparable pay level under other authority, who are in positions which the Agency has determined have duties and responsibilities which require that the incumbents report their employment and financial interests in order to avoid involvement in a possible conflict-of-interests situation and carry out the purpose of law. Executive order, part 735 of the Civil Service Commission's regulations, this part, and applicable Agency regulations.

(e) Employees classified below GS-13 under 5 U.S.C. 5332, or at a comparable pay level under other authority, where the Agency has determined that they are in positions which otherwise meet the criteria in paragraphs (c) and (d) of this section and that a statement from them is essential to protect the integrity of the Government and avoid employee involvement in a possible conflict-of-interests situation, provided such determination has been approved in writing by the Civil Service Commission.

#### § 0.735-32 Exceptions.

(a) A statement of employment and financial interests is not required from a Presidential appointee covered by section 401(a) of the Executive order. Such appointees are subject to separate reporting requirements under section 401 of the Executive order.

(b) Employees in positions that meet the criteria in § 0.735-31(c) may be excluded from the reporting requirement when the Department Counselor deter-

mines that:

(1) The duties of a position are such that the likelihood of the incumbent's involvement in a conflict-of-interest

situation is remote or;

- (2) The duties of a position are at such a level of responsibility that the submission of a statement of employment and financial interests is not necessary because of the degree of supervision and review over the incumbent or the inconsequential effect on the integrity of the Government.
- (c) Exceptions will be considered by the Department Counselor at the request of the Agency Head.
- (d) An employee shall be afforded the opportunity for a review, through the Departmental grievance procedure as described in Chapter 771 of the Department Personnel Manual, of the designation of his position as one requiring the submission of a statement of employment and financial interests.

## § 0.735-33 Identification of employees required to submit statements.

For control and reporting purposes, those employees required to submit statements shall be specifically identified in the personnel records system.

§ 0.735-34 Time and place for submission of employees' statements.

(a) When a decision is reached to make an appointment to a position requiring submission of a statement of employment and financial interest, the prospective employee should be informed of the requirement, furnished a copy of these regulations and the statement form, and advised of the availability of counseling with respect thereto. Submission of the initial statement may be made prior to appointment. In that event, review of the statement and resolution of any conflict questions should be made promptly and, if possible, prior to appointment. Initial statements must be submitted no later than 30 days after entrance on duty in such position.

(b) Employees and prospective employees in the following positions will submit statements directly to the Direc-

tor of Personnel:

 Positions in the immediate staff and offices of the Office of the Secretary;
 Agency Heads, Associates, Depu-

ties, and Assistants; and
(3) Noncareer Executive or Schedule

C positions.

(c) Those in other positions will submit statements to the Agency Head or to an employee designated by him.

(d) Agencies are responsible for assuring that persons subject to the reporting requirements are notified of those requirements and are provided the necessary forms and instructions.

#### § 0.735-35 Supplementary statements.

Changes in, or additions to, the information contained in an employee's statement of employment and financial interests shall be reported in an annual supplementary statement as of March 31 each year. If no changes or additions occur, a report so stating is required. Notwithstanding the filing of the annual report required by this section, each employee shall at all times avoid acquiring a financial interest or taking an action that could result in a violation of the conflicts-of-interests provisions of section 208 of Title 18, United States Code, or § 0.735-14.

## § 0.735-36 Types of interests to be reported.

The financial statements shall include the following:

(a) A list of the names of all corporations, companies, firms, or other business enterprises, partnerships, nonprofit organizations and educational or other institutions with which the employee is connected as an employee, officer, owner, director, trustee, partner, advisor, or consultant, or in which he has any continuing financial interest through a pension or retirement plan, shared income or otherwise as a result of any current or prior employment or business or professional associations, or in which he has any financial interest through the ownership of stock, stock options, bonds, securities or other arrangements including trusts. Shares in credit unions, building and loan associations, social or religious organizations, or deposits in

savings and loan associations and banks, and interests exempted under § 0.735-14(c) need not be reported.

(b) A list of the names of his creditors other than those to whom he may be indebted by reason of a mortgage on property which he occupies as a personal residence or to whom he may be indebted for current and ordinary household and living expenses such as household furnishings, automobile, education, vacation, and similar expenses. Indebtedness on owner-occupied farms must be reported.

(c) A list of interests in real property or rights in land other than property which the employee occupies as a personal residence. Owner-occupied farms must be listed. Property acquired for the personal use of the employee and members of his family, such as beach lots and cemetery lots need not be listed.

(d) The interests and obligations as listed above of a spouse, minor child, or blood relations who are full-time residents of the employee's household.

#### § 0.735-37 Information prohibited.

The regulations in this part do not require an employee to submit any information relating to the employee's connection with, or interest in, a professional society or a charitable, religious, social, fraternal, recreational, public service, civic, or political organization or similar organization not conducted as a business enterprise. For the purpose of this section, educational and other institutions doing research and development or related work involving grants of money from or contracts with the Government are deemed "business enterprises" and are required to be included in employee's statement of employment and financial interest.

## § 0.735-38 Interests of employee's relatives.

(a) The financial interest of a spouse, minor child, or other member of an employee's immediate household shall be reported to the same extent as the financial interest of the reporting employee. An "other member" of the immediate household means blood relatives who are full-time residents of the employee's household.

(b) The employment of such persons need not be reported unless such person is engaged in an activity, which if held by the employee, would place him in a conflict or apparent conflict of interest

situation.

§ 0.735-39 Information not known by employee.

If any information required to be included on a statement of employment and financial interest, or supplement thereto, including holdings placed in trusts, is not known to the employee but is known to another person, the employee shall ask such person to furnish the information in his behalf.

§ 0.735-40 Effect of employee's statement.

The statements of employment and financial interests and supplementary

statements required under this part are in addition to, and not in substitution for, or in derogation of, any similar requirement imposed by law, the Executive order, or regulation. The submission of a statement or supplementary statement by an employee does not permit him or any other person to participate in a matter in which his or the other person's participation is prohibited by law, the Executive order, or the regulations in this part.

## § 0.735-41 Specific provisions for special Government employees.

- (a) Except as provided in paragraph (b) of this section, each special Government employee shall submit a statement of employment and financial interests on USDA Form AD-392A which reports:
- (1) All other employment; and (2) The financial interests of the special Government employee which relate either directly or indirectly to the duties and responsibilities of the special Government employee with the Department.
- (b) An Agency Head may waive the requirement in paragraph (a) of this section for the submission of a statement of employment and financial interests in the case of a special Government employee who is not a consultant or expert when the Agency Head finds that the duties of the position held by that special Government employee are of a nature and at such a level of responsibility that the submission of the statement by the incumbent is not necessary to protect the integrity of the Government. For the purpose of this paragraph, "consultant" and "expert" have the meanings given those terms by Chapter 304 of the Federal Personnel Manual but do not include:
- (1) A physician, déntist, or allied medical specialist whose services are procured to provide care and service to patients; or
- (2) A veterinarian whose services are procured to provide care and service to animals.
- (c) A statement of employment and financial interests required to be submitted under this section shall be submitted to the Agency Head of the Agency in which the special Government employee is to serve not later than the time of employment. Each special Government employee shall keep his statement of employment and financial interests current throughout his employment with the Department by the submission of supplementary statements.
- § 0.735-42 Review of statements and determination of conflicting inter-
- (a) The Director of Personnel is responsible for the review of, and determinations on, those statements submitted directly to him pursuant to § 0.735–34(b). The responsibility for an initial review and determination may be delegated to the Chief, Security and Employee Conduct Division, Office of Personnel, and to staff members of that Division. Final determinations in cases

involving substantial conflict questions shall be made only by the Director of Personnel, and he shall set criteria identifying the types of cases which must be referred to him for final determination.

- (b) Agency Heads are responsible for the review of, and determinations on, those statements submitted to an Agency official. This responsibility may be delegated, subject to the following restrictions:
- (1) Responsibility for an initial review and determination may be delegated only to responsible Agency officials who the Agency Head has determined have sufficient experience, judgment, and understanding of the conflict of interest problem to properly carry out such responsibility.
- (2) Responsibility for final determinations in cases involving substantial conflict questions may be delegated only to Associate, Deputy, and Assistant Agency Heads, except that in the Forest Service, such responsibility may be delegated to Regional Foresters, Station Directors, and Area Directors. The Agency Head shall set criteria identifying the types of cases which must be referred to such officials for final determination.
- (c) Delegations of review and determination responsibility must be in writing from the Director of Personnel or the Agency Head, as appropriate.
- (d) The Director of Personnel shall issue general guidelines covering the review of statements, recognizing possible conflicts or the appearance thereof, obtaining additional information, resolving conflict situations, documentation, and remedial action. Agencies shall supplement these with more specific guidelines applicable to the particular Agency. A copy of both the general and the specific guidelines shall be furnished to each employee to whom review and determination responsibility has been delegated.
- (e) Whenever a question of a conflict or the appearance of conflict arises, a written determination must be made. The basis of the determination must also be documented in writing. The employee must be advised in writing of the determination, and, if the determination involves a change in duties or disqualification for a particular assignment, a copy of the determination should be furnished to the employee's immediate supervisor. Where affirmative action by the employee is required, a report of his compliance shall be obtained and made a part of the record.
- (f) If a determination cannot be made at the Agency level, the case shall be referred to the Director of Personnel. If the Director of Personnel cannot make a determination, he shall refer the case to the Department Counselor for his determination or referral to the Secretary for determination. The record shall include copies of all pertinent documents and a written statement from each referring official setting forth his recommendation as to a final determination and the reasons therefor.

- (g) Before a final determination requiring any remedial action is made, the employee concerned shall be given an opportunity to explain the conflict or appearance thereof and to offer any suggestions he may wish as to how the matter might be resolved. If an employee feels that the final determination will cause him undue hardship, he may request a review and modification by forwarding to the Director of Personnel a written statement setting forth all the facts and circumstances in support of his request and any alternative solution which he thinks appropriate,
- (h) If the final determination requires positive action on the part of the employee, he shall take such action as soon as possible and advise the determining official when he has done so. Failure to take a required action within a reasonable time may result in disciplinary action.

## § 0.735-43 Protection of employees' statements.

- (a) The statements of employment and financial interests, and supplements thereto, required by or pursuant to the regulations in this part shall be held in confidence and afforded adequate physical security. No information as to the contents thereof shall be disclosed except to the head of the employing Agency and such other persons as may be designated custodians or reviewers of such reports unless specific authorization has been obtained from the Department Counselor. An official, custodian, reviewer, or other employee having possession of a statement of employment and financial interests shall not allow access to, or allow information to be disclosed from the statement except to carry out the purposes of this Subpart C.
- (b) Information from a statement of employment and financial interests shall not be disclosed outside of the Department except as the Civil Service Commission or the Secretary of Agriculture may determine for good cause shown.
- (c) Reports shall be separately maintained by the officials designated as custodians for such reports and shall not be made a part of the official personnel folders.
- (d) Regardless of the means or manner of transmission, when these reports leave the physical custody of the employee or a designated reviewer, they shall be enclosed in a double sealed envelope. The inner envelope shall be marked: "For Official Use Only," "Contains AD-392 (or AD-392-A)," as appropriate, and "To Be Opened By Addressee Only."

These amendments were approved by the Civil Service Commission on September 15, 1970, and are effective on publication in the Federal Register.

> CLIFFORD M. HARDIN, Secretary of Agriculture.

JANUARY 7, 1971.

[FR Doc.71-418 Filed 1-12-71;8:48 am]

Chapter IX—Consumer and Marketing Service (Marketing Agreements and Orders; Fruits, Vegetables, Nuts), Department of Agriculture

[Amdt. 2]

#### PART 971-LETTUCE GROWN IN LOWER RIO GRANDE VALLEY OF **SOUTH TEXAS**

#### Limitation of Shipments

Findings. (a) Pursuant to Marketing Agreement No. 144 and Order No. 971 (7 CFR Part 971), regulating the handling of lettuce grown in the Lower Rio Grande Valley in South Texas (Cameron, Hidalgo, Starr, and Willacy Counties), effective under the applicable provisions of the Agricultural Marketing Agreement Act of 1937, as amended (7 U.S.C. 601 et seq.), and upon the basis of the recommendation and information submitted by the South Texas Lettuce Committee, established pursuant to said marketing agreement and order, and upon other available information, it is hereby found that the amendment to the limitation of shipments hereinafter set forth will tend to effectuate the declared policy of the act.

(b) It is hereby found that it is impracticable and contrary to the public interest to give preliminary notice, or engage in public rule making procedure, and that good cause exists for not postponing the effective date of this amendment until 30 days after publication in the Federal Register (5 U.S.C. 553) in that (1) the time intervening between the date when information upon which this amendment is based became available and the time when this amendment must become effective in order to effectuate the declared policy of the act is insufficient, (2) compliance with this amendment will not require any special preparations on the part of handlers. (3) information regarding the committee's recommendation has been made available to producers and handlers in the production area, and (4) this amendment relieves the restriction that no person may package lettuce on Sunday, January 10, 1971.

Regulation, as amended:

In § 971.311 (35 F.R. 16360, 18261) the second sentence of the introductory paragraph is hereby amended to read as follows: -

#### § 971.311 Limitation of shipments.

\* \* \* Further, no person may package lettuce during the above period on any Sunday, with the exception of Sunday, January 10, 1971.

(Secs. 1-19, 48 Stat. 31, as amended; 7 U.S.C. 601 - 674)

Issued January 8, 1971, to become effective upon issuance.

> PAUL A. NICHOLSON, Deputy Director, Fruit and Vegetable Division, Consumer and Marketing Service.

[FR Doc.71-446 Filed 1-12-71;8:50 am]

## Title 13—BUSINESS CREDIT AND ASSISTANCE

Chapter I-Small Business Administration

[Revision 9, Amdt. 9]

#### PART 121-SMALL BUSINESS SIZE **STANDARDS**

Definition of Terms "Annual Sales" and "Annual Receipts"; Correction

On December 17, 1970, there was published in the FEDERAL REGISTER (35 F.R. 19077) an amendment to the title, chapter, and part as it appears in the above heading with the omission of the revision and amendment numbers. Revision 9, Amendment 9 should have been included in the headings as indicated above. The text of the material remains the

> EINAR JOHNSON, Acting Administrator.

JANUARY 6, 1971.

[FR Doc.71-391 Filed 1-12-71;8:46 am]

## Title 14—AERONAUTICS AND SPACE

Chapter I—Federal Aviation Administration, Department of Transportation

[Docket No. 70-EA-118; Amdt. 39-1142]

#### PART 39—AIRWORTHINESS **DIRECTIVES**

Air Cruisers Co. Life Rafts

The Federal Aviation Administration is amending § 39.13 of Part 39 of the Federal Aviation Regulations so as to issue an airworthiness directive applicable to certain liferaft models of Air Cruisers Co.

There have been reports of failures of the subject liferafts to fully inflate resulting from leakage in the O-ring area of the inflation valves due to corrosion. Since this deficiency can exist or develop in the rafts of similar design, an airworthiness directive is being issued which will require inspection and replacement of the valves where necessary.

Since a situation exists, requiring expeditious adoption of the rule, notice and public procedure herein are impractical and the rule may be made effective in less than 30 days.

In consideration of the foregoing and pursuant to the authority delegated to me by the Administrator, 14 CFR 11.89 (31 F.R. 13697), § 39.13 of Part 39 of the Federal Aviation Regulations is amended by adding the following new Airworthiness Directive:

AIR CRUISERS Co. LIFE RAFTS. Applies to Air Cruisers Co., Division of Garrett Corp., Life Raft Models 12D11751-7, 12D11751-8, and 18D23350-5.

Compliance required as indicated.

To prevent loss of pressure in the inflation bottles on the raits, accomplish the follow-

ing:
(a) Within 100 hours in service after the effective date of this AD, but not later than 100 hours in service since the last pressure check of the cylinder and valve assembly, unless the modification described in sub-paragraph (1) or (2) below has been accompliched, perform a pressure check of the cylinder and valve assembly. P/Ns cylinder and valve assembly, P/Ns 24C17382-1 and 24C17382-2. When pressure measures less than 2,600 p.s.i.g. in the former, or less than 2,000 p.s.i.g. in the latter, both at 70° P., or an equivalent pressure at other temperatures, before return to service, ac-complish the following:

Disaccemble the inflation valve assembly,

P/N 24D29261-1, and inspect for corresion

in the O-ring areas.

1. If no correction is found, replace the O-rings, in accordance with Air Cruisers Co. Service Bulletin 111-70-1, dated December 18, 1970.

2. If corresion is found, either:

(i) Strip and alodine the valve body, and replace the O-rings as described in paragraph (a)(1),or

(ii) Replace the valve with P/N 24D29261-2, modified in accordance with Air Cruisers Co. Service Bulletin 111-70-1, dated December 18, 1970.

(b) For those accemblies which have been (b) For those accemblles which have been modified in accordance with paragraph (a) (1) or (a) (2) (i) prior to the effective date of this AD, repeat the procedure decribed in para. (a) within 1,800 hours in tervice after the last inspection.

(c) Following the initial inspection pursuant of this AD, and must the modification of the control of the co

suant to this AD, and until the modification described in paragraph (a) (2) (ii) is accomplished:

1. For amemblies which did not demonstrate a pressure drop, repeat the procedure of paragraph (a) every 100 hours in service thereafter.

2. For accemblies which did demonstrate a pressure drop and which were modified pursuant to paragraphs (a) (1) or (a) (2) (1), reinspect every 1,800 hours in service there-

This amendment is effective January 14, 1971.

(Sec. 313(a), 601, 603, Federal Aviation Act of 1958, 49 U.S.C. 1354(a), 1421, 1423; sec. 6(c), Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in Jamaica, N.Y. on December 31, 1970.

LOUIS J. CARDINALI, Acting Director, Eastern Region. [FR Doc.71-393 Filed 1-12-71;8:46 am]

[Docket No. 70-EA-114; Amdt. 39-1139]

#### PART 39—AIRWORTHINESS **DIRECTIVES**

#### Piper Aircraft

The Federal Aviation Administration is amending § 39.13 of Part 39 of the Federal Aviation Regulations so as to issue an airworthiness directive applicable to Piper PA-31 type aircraft.

There have been reports of shorts in the battery system which caused the electrolyte to boil. The fumes resulting from the heating entered the overboard battery drains and upon being exhausted were drawn into the cabin because of the proximity of the drains to the cabin air intakes. Since this deficiency could develop or exist in aircraft of the same

type design, an airworthiness directive is being issued which will require relocation of the battery drain.

Since the foregoing requires expeditious adoption of this rule, notice and public procedure herein are impractical and the rule may be made effective in less than 30 days.

In consideration of the foregoing and pursuant to the authority delegated to me by the Administrator, 14 CFR 11.89 (31 F.R. 13697), § 39.13 of Part 39 of the Federal Aviation Regulations is amended by adding the following new Airworthiness Directive:

PIPER AIRCRAFT. Applies to Model PA-31 and

PA-31-300 S/Nos. 31-2 to 31-591. Compliance required within the next 100 hours time in service after the effective date

of this AD, unless already accomplished.

To prevent the hazards associated with toxic fumes from the battery being drawn into the cabin, accomplish the following:

(a) Relocate the battery drain in accordance with Piper Service Bulletin No. 325 dated November 10, 1970, or equivalent method approved by the Chief, Engineering and Manufacturing Branch, FAA Eastern Region.

This amendment is effective January 14, 1971.

(Secs. 313(a), 601, 603, Federal Aviation Act of 1958, 49 U.S.C. 1354(a), 1421, 1423; sec. 6 (c). Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in Jamaica, N.Y., on December 23, 1970.

Louis J. Cardinali, Acting Director, Eastern Region. [FR Doc.71-394 Filed 1-12-71;8:46 am]

[Docket No. 70-EA-119; Amdt. 39-1143]

#### PART 39—AIRWORTHINESS **DIRECTIVES**

#### **Pratt & Whitney Aircraft Engines**

The Federal Aviation Administration is amending § 39.13 of Part 13 of the Federal Aviation Regulations so as to issue an airworthiness directive applicable to Pratt & Whitney type JT4A aircraft engines.

There have been reports of failures of the 12th stage compressor rotor discs on the JT4A aircraft engine. Since this is a deficiency which can develop on other aircraft engines of the same type design, an airworthiness directive is being issued which will require removal of certain numbered discs. Because of the nature of the deficiency, this airworthiness directive was transmitted to all owners of affected aircraft by telegram under date of December 10, 1970. Since the same urgency exists, the rule may be made effective without notice and public procedure and in less than 30 days.

In consideration of the foregoing and pursuant to the authority delegated to me by the Administrator, 14 CFR 11.89 (31 F.R. 13697), § 39.13 of Part 39 of the Federal Aviation Regulations is amended by adding the following new Airworthiness Directive:

Applies to all Pratt & Whitney Aircraft JT4A series turbojet engines which incorporate the following serial number 12th stage compressor rotor disc part number 360112

170 6145

1F-6145	4F-0465	4F-8301
1F-6150	4F-0467	4F-8458
1F-6151	4F-0471	5F-6445
2F-2758	4F-0473	5F-6446
2F-2759	4F-0475	5F-6447
2F-2764	.4F-0477	5F-6449
2F-3781	4F-3006	5F-6452
2F-3785	4F-3690	5F-7606
2F-3788	4F-3692	5F-7748
2F-3926	4F-3699	5F-7749
2F-3927	4F-3700	5F-7835
through	4F-3828	5F-7837
2F-3933	4F-3830	5F-7838
2F-9674	4F-3831	5F-7839
2F-9675	4F-4569	5F-7840
2F-9676	4F-4570	5F7867
2F-9677	4F-4642	5F-7872
3F-0551	4F-4643	5F-7875
through	4F <del>-4</del> 645	5F-7985
3F-0558	4F-4648	5F-7987
3F-0559	4F-4747	5F-8031
3F-0560	4F-4748	5F-8032
3F-0563	4F-4749	5F'-8035
3F-8849	4F-4750	5F-8039
3F-8850	4F-4752	5F-8042
through	4F-4968	5F-8119
3F-8855	4F-5029	5F-8122
3F8856	through	5F-8123
3F-8920	4F-5035	5F-8342
3F-8921	4F-5059	5F-8346
3F-8923	through	5F-8405
3F-8924	4F-5063	5F-8510
3F-8926	4F-5087	5F-8512
3F-8927	4F-5039	5F-8522
3F-8928	4F-5090	5F-8529
3F-9114	4F-5091	5F-8589
3F-9115	4F-5092	-
3F-9116	through	
4F-0454	4F-5099	
4F-0461	4F-8300	

Compliance required as indicated.

To preclude 12th stage compressor rotor disc failure as the result of suspected material deficiency, accomplish the following:

(1) For all the previously listed serial number 12th stage compressor rotor discs:

a. With 5,000 cycles or more in service within the next 25 cycles in service after the effective date of this AD replace the suspect serial number disc.

b. With 5,000 cycles or less in service prior to the accumulation of 5,025 cycles in service replace the suspect serial number disc.

(2) Upon submission of substantiating data by an owner or operator through an FAA Maintenance Inspector, the Chief, Engineering and Manufacturing Branch, FAA, Eastern Region, may adjust the compliance

This airworthiness directive is effective January 14, 1971 and was effective as to all recipients of the telegram dated December 10, 1970, which contained this airworthiness directive.

(Secs. 313(a), 601 and 603, Federal Aviation Act of 1958, 49 U.S.C. 1354(a), 1421, and 1423; sec. 6(c), Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in Jamaica, N.Y., on December 31, 1970.

Louis J. Cardinali, Acting Director, Eastern Region.

[FR Doc.71-395 Filed 1-12-71;8:46 am]

[Docket No. 70-EA-112; Amdt. 39-1141]

#### PART 39—AIRWORTHINESS **DIRECTIVES**

#### Sikorsky Aircraft

The Federal Aviation Administration is amending § 39.13 of Part 39 of the Federal Aviation Regulations so as to amend AD 68–20–8 applicable to Sikorsky S61 type helicopters.

Subsequent to the promulgation of AD 68-20-8, the Administrator has determined, through industrial experience, that the repetitive inspection required in paragraph D may be relaxed from 200 hours to 1,200 hours. It is also intended to correct paragraph C to clarify the intent that the test must be performed prior to the next flight which utilizes the automatic flight control system.

Since the foregoing amendments are relaxatory and clarifying in nature, notice and public procedure hereon are unnecessary and the rule may be made effective in less than 30 days.

In consideration of the foregoing and pursuant to the authority delegated to me by the Administrator, 14 CFR 11.89 (31 F.R. 13697), AD 68-20-8, § 39.13 of Part 39 of the Federal Aviation Regulations is amended as follows:

1. Amend paragraph C so as to insert the words "After the effective date of this AD as amended and prior to the next AFCS Flight, if not already accomplished \* \* " before the word "with".

2. Amend paragraph D so as to delete the numbers "200" where they appear, and insert in lieu thereof "1,200"; delete in Section D.1. "B-1 through B-5 inclusive" and insert in lieu thereof "B-5".

This amendment is effective . January 14, 1971.

(Sec. 313(a), 601 and 603, Federal Aviation Act of 1958, 49 U.S.C. 1354(a), 1421, and 1423; sec. 6(c), Department of Transportation Act, 49 U.S.C. 1655(c))

Issued in Jamaica, N.Y., on December 31, 1970.

LOUIS J. CARDINALI, Acting Director, Eastern Region. [FR Doc.71-396 Filed 1-12-71:8:46 am1

### Title 21—FOOD AND DRUGS

Chapter I-Food and Drug Administration, Department of Health, Edvcation, and Welfare

PART 20—FROZEN DESSERTS

Ice Cream Identity Standard; Calcium Carbonate and Magnesium Carbonate as Optional Ingredients

In the matter of amending the identity standard for ice cream (21 CFR 20.1) to list calcium carbonate and magnesium carbonate as optional ingredients:

A notice of proposed rulemaking in the above-identified matter was published in the Federal Register of August 27, 1970 (35 F.R. 13667), based on a petition filed by the Food Adjuncts Association, Inc., 4804 Moorland Lane, Washington, DC 20014. In response to the notice, one comment was received from a frozen dessert ingredient supplier favoring the proposed change.

On the basis of the information submitted in the petition, the comment received, and other relevant information, the Commissioner of Food and Drugs concludes that it will promote honesty and fair dealing in the interest of consumers to adopt the proposed amend-

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 401, 701, 52 Stat. 1046, 1055, as amended 70 Stat. 919, 72 Stat. 948; 21 U.S.C. 341, 371) and under authority delegated to the Commissioner (21 CFR 2.120): It is ordered, That § 20.1(f) (8) (ii) be revised to read as follows:

- § 20.1 Ice cream; identity; label statement of optional ingredients.
  - (f) \* \* \*
- (8) \* \* \*
- (ii) Calcium oxide, magnesium oxide, calcium hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate, or any combination of two or more of these; but the total quantity of the solids of such ingredients is not more than 0.04 percent of the weight of the finished ice cream.

Due to cross-references, this amendment of the standard for ice cream (§ 20.1), upon becoming effective, will make the subject mineral salts permitted ingredients also of frozen custard (§ 20.2) and ice milk (§ 20.3).

Any person who will be adversely affected by the foregoing order may at any time within 30 days after its date of publication in the FEDERAL REGISTER file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, Md. 20852, written objections thereto. Objections shall show wherein the person filing will be adversely affected by the order and specify with particularity the provisions of the order deemed objectionable and the grounds for the objections. If a hearing is requested, the objections must state the issues for the hearing and such objections must be supported by grounds legally sufficient to justify the relief sought. Objections may be accompanied by a memorandum or brief in support thereof. All documents shall be filed in six copies.

Effective date. This order shall become effective 60 days after its date of publication in the Federal Register, except as to any provisions that may be stayed by the filing of proper objections. Notice of the filing of objections or lack thereof will be given by publication in the Fen-ERAL REGISTER.

(Secs. 401, 701, 52 Stat. 1046, 1055, as amended, 70 Stat. 919, 72 Stat. 948; 21 U.S.C. 341, 371)

Dated: December 31, 1970.

R. E. DUGGAN, Acting Associate Commissioner for Compliance.

[FR Doc.71-420 Filed 1-12-71;8:48 am]

PART 120—TOLERANCES AND EX-EMPTIONS FROM TOLERANCES FOR PESTICIDE CHEMICALS IN OR ON RAW AGRICULTURAL COM-MODITIES

#### Redesignation

CROSS REFERENCE: For a document redesignating Part 120 of Chapter I as Part 420 of a new Chapter III in Title 21, see F.R. Doc. 71-414, infra.

#### PART 121-FOOD ADDITIVES

Subpart C-Food Additives Permitted in Feed and Drinking Water of Animals or for the Treatment of Food-**Producing Animals** 

## ORAL DOSAGE FORMS

Spectinomycin Dihydrochloride Pentahydrate Soluble Powder

The Commissioner of Food and Drugs has evaluated a supplemental new animal-drug application (38-661V) filed by Amdal Co., Division of Abbott Laboratories, regarding the safe and effective use of spectinomycin dihydrochloride pentahydrate soluble powder in the drinking water of floor-raised broiler chickens for increasing the rate of weight gain and improving feed efficiency. The supplemental application is approved.

This order also provides for recodification of the existing regulation concerning said drug from Part 121 to Part 135c in accordance with § 3.517 (21 CFR 3.517).

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 512(i), 82 Stat. 347; 21 U.S.C. 360b(i)), in accordance with § 3.517, and under authority delegated to the Commissioner (21 CFR 2.120), Parts 121 and 135c are amended as follows:

#### § 121.329 [Amended]

- 1. Section 121.329 Spectinomycin is deleted from Part 121.
- 2. Part 135c is amended by adding the following new section:
- § 135c.32 Spectinomycin dihydrochloride pentahydrate soluble powder.
- (a) Specifications. The spectinomycin dihydrochloride pentahydrafe used in manufacturing the drug is the antibiotic substance produced by growth of Streptomyces flavopersicus (var. Abbott) or the same antibiotic substance produced by any other means.
- (b) Sponsor. Amdal Co., Division of Abbott Laboratories, Abbott Park, North Chicago, Ill. 60064.
- (c) Special considerations. The quantities of spectinomycin cited in this sec-

tion refer to the equivalent weight of base activity for the drug.

- (d) Related tolerances, See § 135g.24 of this chapter.
- (e) Conditions of use. (1) It is administered in the drinking water of growing chickens at 2 grams of spectinomycin per gallon of water as the only source of drinking water for the first 3 days of life and for 1 day following each vaccination It is administered as an aid in the prevention or control of losses due to CRD associated with M. gallisepticum (PPLO). Do not administer to laying chickens. Do not administer within 5 days of slaughter.
- (2) It is administered in the drinking water of floor-raised broiler chickens at 0.5 gram of spectinomycin per gallon of water as the only source of drinking water for the first 3 days of life and for 1 day following each vaccination. It is administered for increased rate of weight gain and improved feed efficiency. Do not administer to laying chickens. Do not administer within 5 days of slaughter.

Effective date. This order shall be ef-PART 135c—NEW ANIMAL DRUGS IN fective upon publication in the FEDERAL - REGISTER.

(Sec. 512(i), 82 Stat. 347; 21 U.S.C. 360b(i))

Dated: December 30, 1970.

JAMES O. GESLING. Acting Director, Bureau of Veterinary Medicine. [FR Doc.71-422 Filed 1-12-71;8:48 am]

#### PART 121—FOOD ADDITIVES

Subpart F—Food Additives Resulting From Contact With Containers or **Equipment and Food Additives** Otherwise Affecting Food

#### PAPER AND PAPEREOARD

The Commissioner of Food and Drugs, having evaluated the data in a petition (FAP OB2490) filed by The Dow Chemical Co., Midland, Mich. 48640, and other relevant material, concludes that § 121.2526 of the food additive regulations should be amended to provide for the safe use of poly[acrylamide-acrylic acid-N-(dimethylaminomethyl)acrylamidel as a drainage aid and retention aid employed prior to the sheetforming operation in the manufacture of paper and paperboard intended for use in contact with fatty foods.

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409(c)(1), 72 Stat. 1786; 21 U.S.C. 348(c)(1)) and under authority delegated to the Commissioner (21 CFR 2.120), § 121.2526(a) (5) is amended by alphabetically inserting in the list of substances a new item, as follows:

- § 121.2526 Components of paper and paperboard in contact with aqueous and fatty foods.
  - (a) · · ·
  - (5) \* \* \*

List of substances

Poly[acrylamide - acrylic acid - N - (dimethyl - For use only as a drainage aid and retenaminomethyl) acrylamide], produced by reacting polyacrylamide with dimethylamine and formaldehyde in the weight ratio 3.12:1.55:1, respectively, and containing no more than 0.2 percent monomer as acrylamide.

. . .

Any person who will be adversely affected by the foregoing order may at any time within 30 days after its date of publication in the Federal Register file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, written objections thereto in quintuplicate. Objections shall show wherein the person filing will be adversely affected by the order and specify with particularity the provisions of the order deemed objectionable and the grounds for the objections. If a hearing is requested, the objections must state the issues for the hearing. A hearing will be granted if the objections are supported by grounds legally sufficient to justify the relief sought. Objections may be accompanied by a memorandum or brief in support thereof.

Effective date. This order shall become effective on its date of publication in the FEDERAL REGISTER.

(Sec. 409(c)(1), 72 Stat. 1786; 21 U.S.C. 348(c) (1))

Dated: December 30, 1970.

. R. E. DUGGAN, Acting Associate Commissioner for Compliance.

[FR Doc.71-388 Filed 1-12-71;8:46 am]

#### PART 135a-NEW ANIMAL DRUGS FOR OPHTHALMIC AND TOPICAL USE

#### **Topical-Otic Ointment**

The Commissioner of Food and Drugs has evaluated an application (40-123V) filed by Elanco Products Co., Division of Eli Lilly & Co., Indianapolis, Ind. 46206, proposing the safe and effective use of cephalonium, polymyxin B sulfate, flumethasone, iodochlorhydroxyquin, and piperocaine hydrochloride in an antifungal, antibiotic, and corticosteroid ointment for topical and otic use in dogs and cats. The application is approved.

Therefore, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 512(i), 82 Stat. 347; 21 U.S.C. 360b(i)) and under authority delegated to the Commissioner (21 CFR 2.120), Part 135a is amended by adding a new section, as follows:

§ 135a.4 Cephalonium, polymyxin B sulfate, flumethasone, iodochlorhy-droxyquin, piperocaine hydrochlo-ride topical-otic ointment.

(a) Specifications. Each gram of the drug contains 10 milligrams cephalonium, 5,000 units polymyxin B sulfate, 0.25

Limitations

tion aid employed prior to the sheetforming operation in the manufacture of paper and paperboard for use in contact with fatty foods under conditions of use described in paragraph (c) of this section, table 2, conditions of use E, F, and G.

milligram flumethasone, 30 milligrams iodochlorhydroxyquin, and 40 milligrams piperocaine hydrochloride in a suitable and harmless ointment base.

- (b) Sponsor. Elanco Products Co., Division of Elf Lilly & Co., Indianapolis, Ind. 46206.
- (c) Conditions of use. The drug is recommended for dermal and otic use on dogs and cats for the treatment of the following conditions when complicated by bacteria, yeast, or fungus: Pyodermatitis, allergic dermatitis, dermatophytosis, nonspecific pruritus, and external otitis. For mild inflammations a periodic treatment of applying from once daily to twice weekly may be indicated. In severe conditions apply once or twice daily when continuous treatment may be indicated. Dosage per treatment should not exceed 300 milligrams of the ointment. For otic use treatment should not exceed a total of 12 days. For use only by or on the order of a licensed veterinarian.

Effective date. This order shall become effective on its date of publication in the FEDERAL REGISTER.

(Sec. 512(i), 82 Stat. 347; 21 U.S.C. 360b(i))

Dated: December 30, 1970.

JAMES O. GESLING, Acting Director. Bureau of Veterinary Medicine. [FR Doc.71-421 Filed 1-12-71;8:48 am]

## Chapter III—Environmental

#### Protection Agency ESTABLISHMENT OF CHAPTER AND TRANSFER OF REGULATIONS

The Environmental Protection Agency was created by Reorganization Plan No. 3 of 1970 (35 F.R. 15623). To implement the transfer of certain functions described by the plan, a new Chapter III is established in Title 21 of the Code of Federal Regulations to read as set forth

Certain parts formerly appearing in Chapter I of Title 21 are transferred to Chapter III and redesignated as follows:

Former Nem part No. Chapter III part No. Chapter I 120 Tolerances and exemptions from tolerances for pesticide chemicals in or on raw agricultural commodities \_\_\_.

Certain sections of Part 121, Chapter I, concerning food additives, are now being identified for transfer to Part 421, Chapter III.

The redesignation is interim pending the establishment of a new title in the Code of Federal Regulations which will contain all of the regulations of the Environmental Protection Agency. Until that time, the term "Department of Health, Education, and Welfare" will be deemed to mean "Environmental Pro-tection Agency", the term "Secretary" will be deemed to mean "Administrator" in the redesignated Part 420 and the terms "Commissioner" and "Petitions Control Branch" will be correspondingly changed as necessary.

Effective date. This amendment is offective as of publication in the FEDERAL REGISTER (Reorganization Plan No. 3 of 1970, 35 F.R. 15623).

> WILLIAM D. RUCKELSHAUS.  $oldsymbol{Administrator.}$

JANUARY 7, 1971.

[FR Doc.71-414 Filed 1-12-71;8:48 am]

## Title 24—Housing and HOUSING CREDIT

Chapter II—Federal Housing Administration, Department of Housing and Urban Development

SUBCHAPTER A-GENERAL

#### PART 200—INTRODUCTION

#### Subpart D—Delegations of Basic **Authority and Functions**

The following amendments are made to various delegations of authority to reflect recent internal transfers of functions and other changes in the organization of the Assistant Secretary for Housing Production and Mortgago Credit—Federal Housing Commissioner:

1. In the Table of Contents under Subpart D, the headings of §§ 200.78, 200.79, 200.80, 200.81, and 200.82 are amended as follows:

200.78 Director Accounting Division and

Deputy. Director Insurance Division and 200.79 Director Deputy.

Director Fiscal Division and Deputy.
Director Procedure: Division and 200.80 200.81

Deputies.
200.82 Director Financial Reports Division and Deputy.

2. In § 200.77, paragraphs (a), (g), (h), (m), (o), (p), (q), (t), (w), (y), (aa), (bb), (cc), (dd), and (ff) are amended and new paragraphs (gg), (hh), and (ii) are added to read as follows:

§ 200.77 Assistant Commissioner-Comptroller and Deputy.

(a) To be responsible for coordination and general supervision of the Accounting Division, the Insurance Division, the Fiscal Division, the Procedures Division, and the Financial Reports Division.

- (g) To direct and supervise, or cause to be directed and supervised, periodic portfolio examinations of institutions insured under the provisions of section 2 of title I of the National Housing Act.
  - (h) (1) \* \* \*
- (ii) The redemption or sale of investments in bonds or other obligations of the United States, or in bonds or other obligations guaranteed as to principal and interest by the United States, representing undisbursed mortgage proceeds relating to multifamily mortgages assigned to the Secretary; and
- (2) To recommend, or cause to be recommended under his direction, liquidation of investments and redemption of debentures; to execute, or cause to be executed under his direction, assignments in connection with the redemption of debentures held for the account of the FHA insurance funds or received in exchange for acquired security; and to maintain, or cause to be maintained under his direction, liaison with the Treasury Department in the execution of fiscal proposals.
- (i) To certify financial statements, and to execute and submit or to cause to be executed and submitted under his direction to the Treasury Department and/or to the Office of Management and Budget intergovernmental financial reports required by applicable statutes or regulations of the Treasury Department or Office of Management and Budget.
- . (m) To develop and maintain or cause to be developed and maintained under his direction a program for the fiscal servicing of all Secretary-held home and project mortgages; to execute or cause to be executed under his direction all vouchers for expenditures from mortgagor's escrow accounts, for payment of taxes on home and project properties where title is vested in the Secretary and, with respect to home properties acquired by the Secretary, vouchers for payment of excess proceeds to effect final settlement on certificates of claim; and to execute and receipt or cause to be executed and receipted under his direction applications and receipts for any payments received representing refunds of taxes or other payments made by the Secretary in connection with property acquired by the Secretary under the provisions of the National Housing Act.
- (o) To recommend the terms and conditions under which FHA offers to sell purchase money mortgages and assigned mortgage notes to approved mortgagees; upon approval of the recommendation make offers for the sale of such mortgages and assigned notes; and execute in the name of the Secretary acceptance of such offers.
- (p) To endorse, or cause to be endorsed under his direction, mortgage notes for insurance; to take, or cause to be taken under his direction, any action necessary to consummate the sale of Secretary-held mortgages to purchasers of such mortgages; and to execute, or cause to be executed, satisfactions of

Secretary-held mortgages when the mortgage indebtedness has been paid in full.

(q) To endorse, or cause to be endorsed under his direction, checks and other negotiable instruments for deposit or collection; to endorse, or cause to be endorsed under his direction, loss drafts relating to insurance coverage on Secretary-held home and project mortgages; to endorse, or cause to be endorsed under his direction, checks and other negotiable instruments in order to perfect negotiability for other parties at interest where the Secretary is not entitled to the proceeds of such instruments, relating to applications for insurance benefits; and to execute assignments and other instruments pertaining to the sale or other disposition of stock or other securities received as a result of agreements between mortgagors or other depositors and FHA.

(t) To approve or disapprove, or cause to be approved or disapproved under his direction, amounts claimed by mortgagees in their applications for insurance benefits, including amounts for operating, protecting and preserving properties prior to conveyance to the Secretary; to execute, or cause to be executed under his direction, Certificates of Claim; to certify, or caused to be certified under his direction, the requisitions to the Treasury Department for the issuance of debentures; to certify, or caused to be certified under his direction, vouchers for cash settlement of applications for insurance benefits; and to approve or disapprove, or cause to be approved or disapproved under his direction, the purchase of debentures submitted by mortgagees in connection with the payment of mortgage insurance premiums and adjusted premium charges.

(w) To issue, or cause to be issued, duplicate or corrective Mortgage Insurance Certificates; to cancel, or cause to be canceled under his direction, insurance endorsement or the Mortgage Insurance Certificate on insured mortgages where a joint request for termination is made by the mortgagor and mortgagee, or when the insurance endorsement or the Mortgage Insurance Certificate is otherwise to be canceled; and to exercise the authority of the Commissioner in any instance which is subject to the approval of the Commissioner in connection with the prepayment or voluntary termination of insured mortgages.

(y) To exercise, or cause to be exercised, the authority of the Commissioner to endorse any preferred stock certificate held by him in any corporation for the purpose of retirement and cancellation.

(aa) \* \* \*

(1) To reserve or, as appropriate, record, or cause to be reserved or recorded, all approved reservations of funds and to record and control, or cause to be recorded and controlled, all obligations of funds for loans under this fund.

(2) To disburse, or cause to be disbursed, moneys in the fund for making loans to sponsors for development of applications for commitments for project mortgages for projects under section 207 of the Appalachian Regional Development Act of 1965 approved pursuant to section 223 of such Act and for general expenses of administration of section 207 of such Act; and

(3) To collect, or cause to be collected, the loan repayments and interest

thereon.

(bb) With respect to section 1013 of the Demonstration Cities and Metropolitan Development Act of 1966: To perform, or cause to be performed, all fiscal duties and functions necessary to comply with the requirements of the agreement entered into between the Department of Defense and the Department of Housing and Urban Development.

(cc) \* \* \*

- (1) To reserve or, as appropriate, record, or cause to be reserved or recorded, all approved reservations of funds and to record and control, or cause to be recorded and controlled, all obligations of funds for loans made under the fund.
- (2) To disburse, or cause to be disbursed, moneys in the fund for making loans, without interest, to nonprofit sponsors of housing for low and moderate income families; and
- (3) To collect, or cause to be collected, the loan repayments.
- (dd) To reserve or, as appropriate, record, or cause to be reserved or recorded, all approved reservations of contract authority and to record and control, or cause to be recorded and controlled, all contractual obligations of contract authority pertaining to assistance payment contracts under section 235; interest reduction contracts under section 236; contracts for debt management or counseling services under section 237; and contracts for rent supplement payments, pursuant to section 101 of the Housing and Urban Development Act of 1965, and amendments thereto.
- (ff) To reendorse, or cause to be reendorsed, for insurance under section 222 eligible mortgages on single-family dwellings insured under other home mortgage sections of the Act, where the mortgages have been assumed by eligible servicemen.

(gg) To approve or disapprove, or cause to be approved or disapproved under his direction, the settlement of mortgagees' applications for insurance benefits without deduction from the insurance benefits for losses occasioned by fire damage to home properties or by fire and other hazards to multifamily properties, in accordance with the provisions of §§ 203.379(b) and 207.260(d), respectively, of the FHA regulations.

(hh) To extend, or cause to be extended under his direction, the period of time for assignment to the Secretary of a mortgage on which the assistance payment contract has been terminated because of nonoccupancy by the original mortgagor or qualified purchaser.

- (ii) To approve or disapprove, or cause to be approved or disapproved, certificates of interest rate changes submitted by mortgagees with respect to mortgages with flexible interest rates insured under section 236.
- 3. In § 200.78, the heading, introductory text, and paragraphs (a), (c), (f), (g), (h), and (i) are amended and new paragraphs (k), (l), (m), (n), and (o) are added to read as follows:

## § 200.78 Director Accounting Division and Deputy.

To the position of Director, Accounting Division, and under his general supervision to the position of Deputy Director, Accounting Division, there is delegated the following basic authority and functions:

- (a) To direct the activities of the Accounting Division.
- (c) To devise and establish procedures and policies and to maintain official records for all home properties and mortgages held by the Secretary.
- (f) To maintain liaison with the Government National Mortgage Association and other Government agencies on matters pertaining to the sale and insurance of Secretary-held mortgages.
- (g) To endorse mortgage notes for insurance and to take any action necessary to consummate the sale of Secretaryheld mortgages to purchasers of such mortgages.
- (h) To develop and maintain a program for the fiscal servicing of Secretary-held home mortgages including the execution of vouchers for expenditures from mortgagors' escrow accounts.
- (i) To execute vouchers for payment of taxes on home properties where title is vested in the Secretary and for payment of excess proceeds to effect final settlement with mortgagees on certificates of claim under provisions of the National Housing Act.
- (k) With respect to the Appalachian Housing Fund, pursuant to the Appalachian Regional Development Act of 1965:
- (1) To reserve or, as appropriate, record all approved reservations of funds and to record and control all obligations of funds for loans under this fund.
- (2) To disburse moneys in the fund for making loans to sponsors for development of applications for commitments for project mortgages for projects under section 207 of such Act, approved pursuant to section 223 of such Act, and for general expenses of administration of section 207 of such Act; and
- (3) To collect the loan repayments and interest thereon.
- (1) With respect to section 1013 of the Demonstration Cities and Metropolitan Development Act of 1966: To perform all fiscal duties and functions necessary to comply with the requirements of the agreement entered into between the Department of Defense and the Department of Housing and Urban Development.

(m) With respect to the Low and Moderate Income Sponsor Fund, pursuant to section 106 of the Housing and Urban Development Act of 1968:

(1) To reserve or, as appropriate, record all approved reservations of funds and to record and control all obligations of funds for loans made under the fund.

- (2) To disburse moneys in the fund for making loans, without interest, to nonprofit sponsors of housing for low and moderate income families; and
  - (3) To collect the loan repayments.
- (n) To reserve or, as appropriate, record all approved reservations of contract authority and to record and control all contractual obligations of contract authority pertaining to assistance payment contracts under section 235; interest reduction contracts under section 236; contracts for debt management or counseling services under section 237; and contracts for rent supplement payments, pursuant to section 101 of the Housing and Urban Development Act of 1965, and amendments thereto; and
- (o) To establish and maintain an account for the deposit of fees collected under the Interstate Land Sales Full Disclosure Act.
- 4. In § 200.79, the heading, introductory text, and paragraphs (a), (g), and (h) are amended and paragraphs (k), (l), (m), (o), and (p) are added to read as follows:

## § 200.79 Director Insurance Division and Deputy.

To the position of Director, Insurance Division, and under his general supervision to the position of Deputy Director, Insurance Division, there is delegated the following basic authority and functions:

(a) To direct the activities of the Insurance Division.

(g) To devise and maintain procedures relating to the fiscal servicing of Secretary-held project mortgages and to execute vouchers for payment of all expenditures from mortgagor escrow accounts relating thereto.

(h) To develop and maintain fiscal procedures for the operation of Secretary-owned project properties by agents of the Secretary under contract for the management of such properties; to provide advice and guidance to those agents with respect to such fiscal procedures, and to execute vouchers for payment of real estate taxes, special assessments, hazard insurance, and repairs relating to such properties.

(k) To direct and supervise periodic portfolio examinations of institutions insured under the provisions of section 2 of title I of the National Housing Act.

(1) To execute satisfactions and releases of Secretary-held mortgages when the mortgage indebtedness has been paid in full.

(m) To issue duplicate or corrective Mortgage Insurance Certificates.

(n) To exercise the authority of the Commissioner to endorse any preferred stock certificate held by him in any corporation for the purpose of retirement and cancellation.

- (o) To reendorse for insurance under section 222 eligible mortgages on single-family dwellings insured under other home mortgages sections of the Act, where the mortgages have been assumed by eligible servicemen; and
- (p) To approve or disapprove certificates of interest rate changes submitted by mortgagees with respect to mortgages with flexible interest rates insured under section 236.
- 5. In § 200.80 the heading, introductory text and paragraphs (a), (d), (e), and (f) are amended and new paragraphs (i), (j), (k), (l), (m), (n), and (o) are added as follows:

## § 200.80 Director Fiscal Division and Deputy.

To the position of Director, Fiscal Division, and under his general supervision to the position of Deputy Director, Fiscal Division, there is delegated the following basic authority and functions:

- (a) To direct the activities of the Fiscal Division.
- (d) To certify that all required documents, information and approvals with respect to operating and property expense and debenture transactions are present; to verify the accuracy of the computations and the consistency of the information included in the various documents; to determine that the transactions are in strict accordance with all applicable regulations, decisions and laws; to execute Certificates of Claim; to certify requisitions to the Treasury Department for the issuance of debentures; and to certify vouchers for cash settlement of applications for insurance benefits.
- (e) To approve or disapprove amounts claimed by mortgagees in their applications for insurance benefits, including amounts for operating, protecting and preserving properties prior to conveyance to the Secretary.
- (f) To extend the period of time for submission of fiscal data or title evidence supporting a mortgagee's application for insurance benefits.
- (i) To make disbursements to mortgagees for assistance payments under section 235; interest reduction payments under section 236; payments under contracts with public or private organizations to provide budget, debt management, and related counseling services to mortgagors whose mortgages are insured under section 237; and payments to mortgagors under contracts for rent supplement payments pursuant to section 101 of the Housing and Urban Development Act of 1965 and amendments thereto, and to process notices of termination of assistance payment contracts due to nonoccupancy by original mortgagors or qualified purchasers or for other reasons and collect any overpaid assistance payments.
- (j) To be responsible for the collection, receipt and deposit of all funds covering fees, premiums and other charges affecting FHA programs.

(k) To approve or disapprove the settlement of mortgagees' applications for insurance benefits without deduction from the insurance benefits for losses occasioned by fire damage to home properties or by fire and other hazards to multifamily properties, in accordance with the provisions of §§ 203.379(b) and 207.260(d), respectively, of the FHA regulations.

(1) To approve or disapprove the purchase of debentures submitted by mortgagees in connection with the payment of mortgage insurance premiums and

adjusted premium charges.

(m) To endorse checks and other negotiable instruments for deposit or collection; to endorse loss drafts relating to insurance coverage on Secretary-held home and project mortgages; to endorse checks and other negotiable instruments in order to perfect negotiability for other parties at interest, where the Secretary is not entitled to the proceeds of such instruments, relating applications for insurance benefits.

(n) To deposit fees collected under the Interstate Land Sales Full Disclosure Act, and to make disbursements from appropriated funds and receipts for general expenses of administration of land sales registration under such Act and make refunds of overpayments of land

sales registration fees.

(o) To extend the period of time for assignment to the Secretary of a mortgage on which the assistance payment contract has been terminated because of nonoccupancy by the original mortgagor or qualified purchaser.

6. In § 200.81 the heading and introductory text are amended as follows:

#### § 200.81 Director Procedures Division and Deputies.

To the position of Director, Procedures Division, and under his general supervision to the position of Deputy Director for Accounting Systems with respect to paragraphs (a), (b), (f), (g), (h), (i), and (j) of this section and to the position of Deputy Director for Automatic Data Processing with respect to paragraphs (c), (d), and (e) of this section, there is delegated the following basic authority and functions:

7. In § 200.82 the heading, introductory text, and paragraphs (a), (g), and (h) are amended and a new paragraph (1) is added to read as follows:

#### § 200.82 Director Financial Reports Division and Deputy.

To the position of Director, Financial Reports Division, and under his general supervision to the position of Deputy Director, Financial Reports Division, there is delegated the following basic authority and functions:

(a) To direct the activities of the Financial Reports Division.

(g) To execute and submit to the Treasury Department and/or to the Office of Management and Budget intergovernmental financial reports required by applicable statutes or regulations of

the Treasury Department or Office of Management and Budget.

(h) To maintain liaison with the General Accounting Office, Treasury Department and Office of Management and Budget on matters pertaining to financial activities, and with mortgagees concerning the acceptance of debentures in exchange for mortgages held by the Secretary.

(1) To recommend liquidation of investments and redemption of debentures; to execute assignments in connection with the redemption of debentures held for the account of the FHA insurance funds or received in exchange for acquired security; and to maintain liaison with the Treasury Department in the execution of fiscal proposals.

(Sec. 1 of National Housing Act, 48 Stat. 1246, 12 U.S.C. 1702; sec. 7(d) of Department of Housing and Urban Development Act, 79 Stat. 670, 42 U.S.C. 3535(d); Secretary's delegation to Assistant Secretary-Commissioner published at 35 F.R. 2749)

Issued at Washington, D.C., December 29, 1970.

WOODWARD KINGMAN, for Eugene A. Gulledge, Assistant Secretary-Commissioner.

[FR Doc.71-419 Filed 1-12-71;8:48 am]

### Title 29—LABOR

Chapter V-Wage and Hour Division, Department of Labor

PART 672-BUSINESS SERVICE, MO-TION PICTURE, AND MISCELLANE-OUS INDUSTRY IN PUERTO RICO

#### PART 726—CONSTRUCTION INDUSTRY IN PUERTO RICO

#### Wage Order

Pursuant to sections 5 and 8 of the Fair Labor Standards Act of 1938 (52 Stat. 1062, 1064, as amended; 29 U.S.C. 205, 208), and Reorganization Plan No. 6 of 1950 (3 CFR 1949-53 Comp. p. 1004), and by means of Administrative Orders No. 613 (35 F.R. 6436) and No. 615 (35 F.R. 15228), the Secretary of Labor appointed and convened Industry Committee No. 95-A for the Construction Industry in Puerto Rico and Industry Committee No. 95-C for the Construction, Business Service and Miscellaneous Industry in Puerto Rico, referred to the Committees the question of the minimum rate or rates of wages to be paid under section 6(c) of the Act to employees in the industries, and gave notice of hearings to be held by the Committees.

Subsequent to investigations and hearings conducted pursuant to the notice, the Committees have filed with the Administrator of the Wage and Hour Division of the Department of Labor reports containing their findings of fact and recommendations with respect to the matters referred to them. The recommendations of the Committees apply only to those employees brought into coverage by reason of the Fair Labor Standard Amendments of 1966 within the purview of 29 CFR, Parts 726 and

672, those of Committee No. 95-A being limited to the employees in the construction industry within the scope of Part 726, and those of Committee No. 95-C restricted to those employees in the business service, motion picture and miscellaneous industry in Part 672 as defined in § 672.2(b) (2).

Accordingly, as authorized and required by section 8 of the Fair Labor Standards Act of 1938, Reorganization Plan No. 6 of 1950, and 29 CFR 511.18, the recommendations of Industry Committee No. 95-A and No. 95-C are hereby published, to be effective January 28, 1971, in this order revising Part 672 and Part 726 of Title 29, Code of Federal Regulations. For a more systematic alignment of the construction industry in Puerto Rico, the pertinent wage determination for employees engaged in the construction industry brought within the scope of the Fair Labor Standards Act prior to the Amendments of 1966, currently included in Part 672 of this title. is transferred to and incorporated into Part 726.

Parts 672 and 726 of Title 29, Code of Federal Regulations are hereby revised as indicated below.

1. As revised, Part 672 reads as follows:

Sec. 672.1 Definition. 672,2 Wage rates. 672.3 Notices.

AUTHORITY: The provisions of this Part 672 issued under secs. 5, 6, 8, 52 Stat. 1062, 1064; 29 U.S.C. 205, 206, 203.

#### § 672.1 Definition.

The business service, motion picture, and miscellaneous industry in Puerto Rico is defined as follows: The activity carried on by any business or nonprofit enterprise performing real estate, professional, advertising, education, or research activities, or engaged in the furnishing of other facilities or services to industrial or commercial establishments or to the consumer; and the production of photographs and blueprints, the production and distribution of motion pictures and all activities incidental thereto; and all activities which are not included in the definitions of other industries in Puerto Rico for which wage orders have been issued: Provided, however, That the industry shall not include any activity carried on by an establishment primarily engaged in another industry in Puerto Rico for its own use.

#### § 672.2 Wage rates.

Wages at rates not less than those prescribed in this section shall be paid under section 6(c) of the Fair Labor Standards Act of 1938 by every employer to each of his employees in the business service. motion picture, and miscellaneous industry in Puerto Rico who in any workweek is engaged in commerce or in the production of goods for commerce or is employed in an enterprise engaged in commerce or in the production of goods for commerce, as those terms are defined in section 3 of the Act.

- (a) Pre-1966 coverage classification.
  (1) The minimum wage for this classification is \$1.60 an hour.
- (2) This classification is defined as all activities in the business service, motion picture, and miscellaneous industry in Puerto Rico to which section 6 of the Act would have applied prior to the Fair Labor Standards Amendments of 1966.
- (b) 1966 coverage classification. (1) The minimum wage for this classification is \$1.45 an hour for the period ending January 31, 1971, and \$1.60 an hour thereafter.
- (2) This classification is defined as all activities in the business service, motion picture, and miscellaneous industry in Puerto Rico to which section 6 of the Act applies solely by reason of the Fair Labor Standards Amendments of 1966.

#### § 672.3 Notices.

Every employer subject to the provisions of § 672.2 shall post in a conspicuous place in each department of his establishment where employees subject to the provisions of § 672.2 are working such notices of this part as shall be prescribed from time to time by the Administrator of the Wage and Hour Division of the U.S. Department of Labor and shall give such other notice as the Administrator may prescribe.

2. As revised, Part 726 reads as follows:

Sec., 726.1 Definition. 726.2 Wage rates. 726.3 Notices.

AUTHORITY: The provisions of this Part 726 issued under secs. 5, 6, 8, 52 Stat. 1062, 1064; 29 U.S.C. 205, 206, 208.

#### § 726.1 Definition.

The construction industry in Puerto Rico, to which this part shall apply, is defined as follows: The design, construction, reconstruction, alteration, repair and maintenance of buildings, structures, and other improvements on land; the assembling at the construction site and the installation of machinery and other facilities in or upon such improvements; and the dismantling, wrecking, or other demolition of such improvements: Provided, however, That the construction industry shall not include any activity carried on by an establishment in Puerto Rico for its own use to which another wage order for the primary business of such establishment would otherwise be applicable.

#### § 726.2 Wage rates.

Wages at rates not less than those prescribed in this section shall be paid under section 6(c) of the Fair Labor Standards Act of 1938 by every employer to each of his employees in the construction industry in Puerto Rico who in any workweek is engaged in commerce or in the production of goods for commerce or is employed in an enterprise engaged in commerce or in the production of goods for commerce, as these terms are defined in section 3 of the Act.

(a) Pre-1966 coverage classification.
(1) The minimum wage for this classification is \$1.60 an hour.

(2) This classification is defined as all activities in the construction industry in Puerto Rico to which section 6 of the Act would have applied prior to the Fair Labor Standards Amendments of 1966.

(b) 1966 coverage classification. (1) The minimum wage for this classification is \$1.45 an hour for the period beginning February 1, 1970, and ending January 31, 1971; and \$1.60 an hour thereafter.

(2) This classification is defined as all activities in the construction industry in Puerto Rico, to which section 6 of the Act applies solely by reason of the Fair Labor Standards Amendments of 1966.

#### § 726.3 Notices.

Every employer subject to the provisions of § 726.2 shall post in a conspicuous place in each department of his establishment where employees subject to the provisions of § 726.2 are working such notices of this part as shall be prescribed from time to time by the Administrator of the Wage and Hour Division of the U.S. Department of Labor and shall give such other notice as the Administrator may prescribe.

Signed at Washington, D.C. this 7th day of January 1971.

ROBERT D. MORAN, Administrator, Wage and Hour Division, U.S. Department of Labor.

[FR Doc.71-380 Filed 1-12-71;8:45 am]

## PART 683—WHOLESALING AND WAREHOUSING INDUSTRY IN PUERTO RICO

#### PART 721—RETAIL TRADE INDUSTRY IN PUERTO RICO

#### Wage Order

Pursuant to sections 5 and 8 of the Fair Labor Standards Act of 1938 (52 Stat. 1062, 1064, as amended; 29 U.S.C. 205, 208), and by means of Administrative Order No. 613 (35 F.R. 6436), the Secretary of Labor appointed and convened Industry Committee No. 96-A for the Retail Trade Industry in Puerto Rico, referred to the Committee the question of the minimum rate or rates of wages to be paid under section 6(c) of the Act to employees in the industry, and gave notice of a hearing to be held by the Committee.

Subsequent to an investigation and a hearing conducted pursuant to the notice, the Committee has filed with the Administrator of the Wage and Hour Division of the Department of Labor a report containing its findings of fact and recommendations with respect to the matters referred to it. The recommendations of Committee 96-A apply to those employees in the retail trade industry brought into coverage by reason of the

Fair Labor Standards Amendments of 1966 within the purview of 29 CFR, Part 721.

Accordingly, as authorized and required by section 8 of the Fair Labor Standards Act of 1938, Reorganization Plan No. 6 of 1950, and 29 CFR 511.18, the recommendations of Industry Committee No. 96-A are hereby published, to be effective January 28, 1971.

For a more systematic alignment of the retail trade industry in Puerto Rico, the pertinent wage determination for employees engaged in the retail trade industry brought within the scope of the Fair Labor Standards Act prior to the Amendments of 1966, currently included in Part 683 of this title, is transferred to and incorporated into Part 721.

Parts 683 and 721 of Title 29, Code of Federal Regulations, are hereby revised as indicated below.

1. As revised, Part 683 reads as follows:

Sec. 683.1 Definition. 683.2 Wage rates. 683.3 Notices.

AUTHORITY: The provisions of this Part 693 issued under secs. 5, 6, 8, 52 Stat. 1062, 1064; 29 U.S.C. 205, 206, 208.

#### § 683.1 Definition.

The wholesaling and warehousing industry in Puerto Rico is defined as follows: The wholesaling, warehousing, and other distribution of commodities, including, but without limitation, the wholesaling, warehousing, and other distribution activities of jobbers, importers and exporters, manufacturers' sales branches and offices engaged in distributing products manufactured outside of Puerto Rico, industrial distributors, brokers and agents, and public warehouses: Provided, however, That the industry shall not include the activities of employees who are engaged in wholesaling, warehousing, and other distribu-tion of products manufactured by their employer in Puerto Rico, or any activities included in the definition of the Communications, Utilities and Transportation Industry in Puerto Rico (29 CFR Part 671), or in the definition of the Tobacco Industry in Puerto Rico (29 CFR Part 657), or in the definition of the Food and Related Products Industry in Puerto Rico (29 CFR Part 673).

#### § 683.2 Wage rates.

Wages at rates not less than those prescribed in this section shall be paid under section 6(c) of the Fair Labor Standards Act of 1938 by every employer to each of his employees in each of the classifications in the industry who in any workweek is engaged in commerce or in the production of goods for commerce or is employed in an enterprise engaged in commerce or the production of goods for commerce as those terms are defined in section 3 of the Act.

(a) Employments covered prior to 1966 amendments. (1) The minimum wage for this classification is \$1.60 an hour.

- (2) This classification applies to all activities of employees in the wholesaling and warehousing industry in Puerto Rico to which section 6 of the Act applies without reference to the Fair Labor Standards Amendments of 1966.
- (b) 1966 coverage classification. (1) The minimum wage for this classification is \$1.45 an hour for the period beginning February 1, 1970, and ending January 31, 1971; and \$1.60 an hour thereafter.
- (2) This classification is defined as all activities in the wholesaling and warehousing industry in Puerto Rico, to which section 6 of the Act applies solely by reason of the Fair Labor Standards Amendments of 1966.

#### § 683.3 Notices.

Every employer subject to the provisions of section 683.2 shall post in a conspicuous place in each department of his establishment where employees subject to the provisions of section 683.2 are working such notice of this part as shall be prescribed from time to time by the Administrator of the Wage and Hour Division of the U.S. Department of Labor and shall give such other notice as the Administrator may prescribe.

- 2. As revised, Part 721 reads as follows:
- Sec.
- 721.1 Definition.
- 721.2 Wage rates.
- 721.3 Notices.

AUTHORITY: The provisions of this Part 721 issued under section 8, 52 Stat. 1064, as amended; 29 U.S.C. 208. Interpret or apply secs. 5, 6, 52 Stat. 1062, as amended; 29 U.S.C. 206, 205, 208.

#### § 721.1 Definition.

The retail trade industry in Puerto Rico, to which this part shall apply, is defined as follows: The selling at retail, and incidental activities performed by employees of an establishment so engaged including services on the goods sold and food service in such establishments: Provided, however, That the industry shall not include the activities of employees who are engaged in wholesaling, warehousing and other distribu-tion of products manufactured by their employer in Puerto Rico, or any activities included in the definitions of the Communications, Utilities, and Transportation Industry in Puerto Rico (29 CFR Part 671), The Hotel and Motel Industry in Puerto Rico (29 CFR Part 728), or the Restaurant and Food Service Industry in Puerto Rico (29 CFR Part 729).

#### § 721.2 Wage rates.

Wages at rates not less than those prescribed in this section shall be paid under section 6(c) of the Fair Labor Standards Act of 1938 by every employer to each of his employees in each of the classifications in the industry who in any workweek is engaged in commerce or in the production of goods for commerce or is employed in an enterprise engaged in commerce or the production of goods

for commerce as those terms are defined in section 3 of the Act.

- (a) Employments covered prior to 1966 amendments. (1) The minimum wage for this classification is \$1.60 an hour.
- (2) This classification applies to all activities of employees in the retail industry in Puerto Rico to which section 6 of the Act applies without reference to the Fair Labor Standards Amendments of 1966.
- (b) 1966 coverage classification. (1) The minimum wage for this classification is \$1.45 an hour for the period beginning February 1, 1970 and ending January 31, 1971, and \$1.60 an hour thereafter.
- (2) This classification is defined as all activities in the retail trade industry in Puerto Rico, to which section 6 of the Act applies solely by reason of the Fair Labor Standards Amendments of 1966.

#### § 721.3 Notices.

Every employer subject to the provisions of section 721.2 shall post in a conspicuous place in each department of his establishment where employees subject to the provisions of 721.2 are working such notices of this part as shall be prescribed from time to time by the Administrator of the Wage and Hour Division of the U.S. Department of Labor and shall give such other notice as the Administrator may prescribe.

Signed at Washington, D.C., this 7th day of January 1971.

ROBERT D. MORAN,
Administrator, Wage and Hour
Division, U.S. Department of
Labor.

[FR Doc.17-378 Filed 1-12-71;8:45 am]

## PART 724—HOSPITAL AND RELATED INSTITUTIONS INDUSTRY IN PUERTO RICO

#### Wage Order

Pursuant to sections 5 and 8 of the Fair Labor Standards Act of 1938 (52 Stat. 1062, 1064, as amended; 29 U.S.C. 205, 208), and by means of Administrative Order No. 613 (35 F.R. 6436), the Secretary of Labor appointed and convened Industry Committee No. 98-B for the Hospital and Related Institutions Industry in Puerto Rico, referred to the Committee the question of the minimum rate or rates of wages to be paid under section 6(c) of the Act to employees in the industry, and gave notice of a hearing to be held by the Committee.

Subsequent to an investigation and a hearing conducted pursuant to the notice, the Committee has filed with the Administrator of the Wage and Hour Division of the Department of Labor a report containing its findings of fact and recommendations with respect to the matters referred to it.

As authorized and required by section 8 of the Fair Labor Standards Act of 1938, Reorganization Plan No. 6 of 1950,

and 29 CFR 511.18, the recommendations of Industry Committee No. 98-B are hereby published, to be effective January 28, 1971, in this order amending section 724 of Title 29, Code of Federal Regulations.

Section 724.2 is amended by changing paragraphs (a), (b), and (c) and reads as follows.

#### § 724.2 Wage rates.

- (a) Application. Wages at rates not less than those prescribed in paragraphs (b) and (c) of this section shall be paid under section 6(c) of the Fair Labor Standards Act of 1938 by every employer to each of his employees in the hospital and related institutions industry in Puerto Rico who in any workweek is engaged in an activity brought within the purview of section 6 of the Act by the Fair Labor Standards Amendments of 1966.
- (b) Classification A. (a) The minimum wage for Classification A is \$1.45 an hour for the period beginning February 1, 1970 and ending January 31, 1971, and \$1.60 an hour thereafter.
- (c) Classification B. (1) The minimum wage for Classification B is \$1.35 an hour for the period beginning February 1, 1970, and ending January 31, 1971, and \$1.53 an hour thereafter.

(Secs. 5, 6, 8, 52 Stat. 1062, 1064, as amended; 29 U.S.C. 205, 206, 203)

Signed at Washington, D.C., this 7th day of January 1971.

ROBERT D. MORAN,
Administrator, Wage and Hour
Division, U.S. Department of
Labor.

[FR Doc.71-379 Filed 1-12-71;8:45 am]

## Title 32A—NATIONAL DEFENSE, APPENDIX

Chapter XVIII—National Shipping Authority, Maritime Administration, Department of Commerce

[NSA Order 3 (AGE-2, Amdt. 5)]

#### AGE-2—GENERAL AGENTS, AGENTS, AND BERTH AGENTS

#### Miscellaneous Amendments

In F.R. Doc. 70-17167, appearing in the FEDERAL REGISTER issue of December 22, 1970 (35 F.R. 19351), the bracketed line in the heading should read "INSA Order 3 (AGE-2, Amdt. 5)]", and the word "follow" beginning at the end of line 4 of the text of the document should read "follows."

Dated: January 6, 1971.

James S. Dawson, Jr., Secretary.

[FR Doc.71-404 Filed 1-12-71;8:47 am]

### Title 49—TRANSPORTATION

Subtitle A—Office of the Secretary of Transportation

[OST Dockets Nos. 1, 4, 2, 3, 15, 16; Amdts. Nos. 1-44, 5-3, 7-4, 9-3, 95-3, 99-3]

#### NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION

#### Establishment

The purpose of this amendment to Parts 1, 5, 7, 9, 95, and 99 of Subtitle A of title 49, Code of Federal Regulations is to reflect the abolishment of the National Highway Safety Bureau and the concurrent establishment of its successor organization, the National Highway Traffic Safety Administration. This organizational change was made by the Highway Safety Act of 1970 which was signed by the President on December 31, 1970. The changes made by this amendment are made primarily to insure continuity of operations, pending a more complete revision of existing delegations of authority relating to highway traffic safety.

Since the amendment relates to Departmental management, procedures, and practices, notice and public procedure thereon is unnecessary, and it may be made effective in less than 30 days after publication in the FEDERAL REGISTER.

In consideration of the foregoing, effective January 6, 1970, Parts 1, 5, 7, 9, 95, and 99 of title 49, Code of Federal Regulations, are amended as follows:

#### PART 1-ORGANIZATION AND DELE-**GATION OF POWERS AND DUTIES**

- (1) The table of contents is amended by striking out the item
- 1.51 Delegations to Director of National Highway Safety Bureau.

and inserting in place thereof

- 1.51 Delegations to National Highway Traffic Safety Administrator.
- (2) Section 1.2(g) is amended to read as follows:
- § 1.2 Definitions.
- (g) The Administrator of the National Highway Traffic Safety Administration.
- (3) Section 1.3(b)(7) is amended to read as follows:
- Organization of the Department. § 1.3
  - (b) \* \* \*
- (7) The National Highway Traffic Safety Administration, headed by the Administrator.
- (4) The caption of § 1.4(h) is amended to read as follows:
- § 1.4 General responsibilities.
- (h) The National Highway Traffic Safety Administration.
- (5) The caption of § 1.51 is amended to read as follows:

- § 1.51 Delegations to National Highway Traffic Safety Administrator.
- (6) The text of section 1.51 is amended by striking out the words "Director of the National Highway Safety Bureau" and inserting in place thereof the words "National Highway Traffic Safety Administrator."

#### PART 5-RULE MAKING

The text of section 5.1 is amended by striking out the words "National High-way Safety Bureau" and inserting in place thereof the words "National Highway Traffic Safety Administration.'

#### PART 7-PUBLIC AVAILABILITY OF INFORMATION

(1) The table of contents is amended by striking out the item

Appendix H-National Highway Safety Bureau

and inserting in place thereof,

Appendix H-National Highway Traffic Safety Administration.

(2) Section 7.5(g) is amended to read as follows:

§ 7.5 Definitions.

(g) The National Highway Traffic Safety Administration.

(3) Appendix H is amended to read as follows:

#### APPENDIX H

#### NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION

- 1. General. This appendix describes the document inspection facilities of the National Highway Traffic Safety Administration (NHTSA), the kinds of records that are available for public inspection and copying at these facilities, and the procedures by which members of the public may make requests for identifiable records.

  2. Document inspection facilities. Docu-
- ment inspection facilities are maintained for NHTSA Headquarters and each NHTSA regional office. These facilities are open to the public during regular working hours at the following addresses:

Washington Headquarters:

National Highway Traffic Safety Administration, Office of Administrative Services, Room 5108, 400 Seventh Street SW, Washington, DC 20591.

National Highway Traffic Safety Adminis-tration, Docket Section, Room 4223, 400 Seventh Street SW, Washington, DC 20591. (Material covered by paragraph 3(c) only.)

#### REGIONAL OFFICES

Region 1-Regional Administrator, NHTSA, Transportation Systems Center.

Broadway, Cambridge, MA 02412.
Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont.
Region II—Regional Administrator, NHTSA, 4 Normanskill Boulevard, Delmar, NY 12054.

New Jersey, New York, and Puerto Rico. Region III—Regional Administrator, NHTSA, Room 817, Federal Building, 31 Hopkins Plaza, Baltimore, MD 21201.

Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia.

Region IV—Regional Administrator, NHTSA, Suite 400, 1720 Peachtree Road NW., At-lanta, GA 30309.

Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee.

Region V—Regional Administrator, NHTSA, 18209 Dixie Highway, Hemewood, IL 60430.

Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin.

Region VI—Regional Administrator, NHTSA, Room 8A42, 819 Taylor Street, Fort Worth, TX 76102.

Arkansas, Louisiana, New Mexico, Oklahoma, and Texas.

Region VII—Regional Administrator, NHTSA.

Region VII—Regional Administrator, NRISA,
Post Office Box 7186, Country Club Station, Kansas City, MO 64113.
Iowa, Kansas, Missouri, and Nebraska.
Region VIII—Regional Administrator,
NHTSA, Room 107, Building 40, Denver

Federal Center, Denver, CO 80225.
Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming.
Region IX—Regional Administrator, NHTSA, 450 Golden Gate Avenue, Box 36096, San

Francisco, CA 94102.

Arizona, California, Havaii, and Novada.

Region K—Regional Administrator, NHTSA,

Room 301, Mohavk Building, 222 Southwest Morrison Street, Fortland, OR 97204

Alaska, Idaho, Oregon, and Washington. 3. Records available at document inspection facilities.

- (a) The following records are available at the NHTSA Headquarters document inspection facility.
- (1) Final opinions and orders made in the adjudication of cases and issued from within the National Highway Traffic Safety Administration.
- (2) Any policy or interpretation issued within the National Highway Traffic Safety Administration, including any policy or interpretation concerning a partioular factual situation, if that policy or interpretation can reasonably be expected to have precedential value in any case involving a member of the public in a similar situation.
- (b) The following records are available at all NHTSA document inspection facilities: NHTSA Orders. These orders are issued by National Highway Traffic Safety Administration and contain policy, instructions, and

general procedures. NHTSA Audit Manual. Audit Manual (issued by Audits & Investigation-FHWA).

NHTSA Notices. These notices are issued by National Highway Traffic Safety Administration and transmit one-time or shortterm announcements or temporary directives (90 days or less).

Motor Vehicle Safety Standards. These standards, issued by National Highway Traf-fic Safety Administration, apply to new motor vehicles and equipment thercon.

Highway Safety Standards. These standards, issued by National Highway Trafile Safety Administration, apply to State highway safety programs.

- (c) Informal interpretations and opinions concerning provisions of the National Traffic and Motor Vehicle Safety Act of 1966 and regulations and standards issued therounder which have been given to members of the public by National Highway Traffic Safety Administration officials are available at the NHTSA Docket Section.
- 4. Request for identifiable records under Subpart E of this part. Each person desiring to inspect a record, or to obtain a copy thereof, may submit his request, in writing, to any NHTSA document inspection facility. If that facility does not have custody of the record, it will forward the request to the appropriate office. Each request must be accompanied by the appropriate fee prescribed in Subpart H of this part.

5. Reconsideration of determinations not to disclose records. Any person to whom a record is not made available within a reasonable time after his request, and any person who has been notified that a record he has requested cannot be disclosed, may apply, in writing, to the Associate Administrator for Administration, National Highway Traffic Safety Administration. Nassif Building, 400 Seventh Street SW., Washington, DC 20591, for reconsideration of his request. The decision of the Associate Administrator for Administration is administratively final.

## PART 9—TESTIMONY OF EMPLOYEES OF THE DEPARTMENT AND PRODUCTION OF RECORDS IN LEGAL PROCEEDINGS

Section 9.3(g) is amended to read as follows:

§ 9.3 Definitions.

(g) The National Highway Traffic Safety Administration.

#### PART 95—ADVISORY COMMITTEES

The text of paragraph (a) of § 95.1 is amended by striking out the words "National Highway Safety Bureau" and inserting in place thereof the words "National Highway Traffic Safety Administration".

#### PART 99—EMPLOYEE RESPONSI-BILITIES AND CONDUCT

Section 99.735–3(g) is amended to read as follows:

§ 99.735-3 Definitions.

(g) The National Highway Traffic Safety Administration.

This action is taken under section 9 of the Department of Transportation Act (49 U.S.C. 1657).

Issued in Washington, D.C., on the 6th day of January 1971.

James M. Beccs, Acting Secretary of Transportation. [FR Doc.71-389 Filed 1-12-71;8:46 am]

## Title 50—WILDLIFE AND FISHERIES

Chapter I—Bureau of Sport Fisheries and Wildlife, Fish and Wildlife Service, Department of the Interior

PART 33—SPORT FISHING

Crab Orchard National Wildlife Refuge, III.

The following special regulation is issued and is effective on date of publication in the Federal Register.

§ 33.5 Special regulations; sport fishing; for individual wildlife refuges.

#### ILLINOIS

CRAB ORCHARD NATIONAL WILDLIFE REFUGE

Sport fishing on the Crab Orchard National Wildlife Refuge, Ill., is permitted only on the areas designated by signs as

open to fishing. These open areas comprising 8,800 acres are delineated on maps available at the refuge headquarters and from the office of the Regional Director, Bureau of Sport Fisheries and Wildlife, Federal Building, Fort Snelling, Twin Cities, MN 55111. Sport fishing shall be in accordance with all applicable State regulations subject to the following special conditions:

(1) The open season for sport fishing on the refuge extends from January 1, 1971, through December 31, 1971, in areas designated on map as I and III; and from March 15, 1971, through September 30, 1971, daylight hours only, in area designated on map as II; except bank fishing is permitted from the Wolf Creek Road and State Highway 148 causeways, during daylight hours, from January 1, 1971 through December 31, 1971.

(2) The use of boats and motors is permitted, except that use of a boat with a motor larger than ten (10) horsepower is prohibited on Devil's Kitchen Lake and on Little Grassy Lake.

The provisions of this special regulation supplement the regulations which govern fishing on wildlife refuge areas generally which are set forth in Title 50, Part 33, and are effective through December 31, 1971.

L. A. MEHRHOFF, Jr., Project Manager, Crab Orchard National Wildlife Refuge, Carterville, Ill.

JANUARY 5, 1971.

[FR Doc.71-385 Filed 1-12-71;8:45 am]

## Proposed Rule Making

### DEPARTMENT OF THE TREASURY

**Bureau of Customs** 

I 19 CFR Parts 10, 13, 16, 25, 54 I MERCHANDISE WHOSE CLASSIFICA-TION IS DEPENDENT UPON PROOF OF ACTUAL USE

#### Notice of Proposed Rule Making

General Headnote 10(e) (ii), Tariff Schedules of the United States, sets forth conditions under which importers may be entitled to duty free entry or entry at reduced rates for imported merchandise classifiable under a tariff provision controlled by actual use of the merchandise in the United States. These conditions include a 3-year time limitation in which to prove actual use.

It has been decided to revise the Customs Regulations to delete the repetitious requirements for specified merchandise, and to substitute new provisions relating to proof of actual use which will be generally applicable when classification is controlled by actual use.

Accordingly, notice is hereby given that under authority of R.S. 251 (19 U.S.C. 66), General Headnote 11, Tariff Schedules of the United States (19 U.S.C. 1202, Gen. Hdnte. 11), and section 624, Tariff Act of 1930 (19 U.S.C. 1624), it is proposed to amend the Customs Regulations as follows:

## PART 10—ARTICLES CONDITIONALLY FREE; SUBJECT TO A REDUCED RATE, ETC.

1. Part 10 is amended by adding at the end thereof a center heading and new §§ 10.131 through 10.139 reading as follows:

RATE OF DUTY DEPENDENT UPON ACTUAL USE

§ 10.131 Circumstances in which applicable.

The provisions of §§ 10.131 through 10.139 are applicable in those circumstances in which the rate of duty applicable to merchandise is dependent upon actual use, unless there is a specific provision in this part or Part 54 of this chapter which governs the treatment of the merchandise.

§ 10.132 Examples of actual use provisions.

Examples of actual use provisions found in the Tariff Schedules of the United States (19 U.S.C. 1202) which will be subject to the provisions of §§ 10.131 through 10.139 are:

- (a) Rice \* \* \* Patna, cleaned, for use in the manufacture of canned soups (Item 131.37, Tariff Schedules of the United States);
- (b) Woven bolting cloths, wholly of silk, imported to be used for milling pur-

poses, and marked so as to be fit for such purposes (Item 375.25, Tariff Schedules of the United States); and

(c) Limestone, crude, broken, or crushed, when imported to be used in the manufacture of fertilizer (Item 480.05, Tariff Schedules of the United States).

#### § 10.133 Conditions required to be met.

When the tariff classification of any article is controlled by its actual use in the United States, three conditions must be met in order to qualify for free entry or a lower rate of duty unless the language of the particular item of the Tariff Schedules of the United States applicable to the merchandise specifies other conditions. The conditions are that:

- (a) Such use is intended at the time of importation.
  - (b) The article is so used.
- (c) Proof of use is furnished within 3 years after the date the article is entered or withdrawn from warehouse for consumption.

(77A Stat. 14; 19 U.S.C. 1202 (Gen. Hdnte. 10(e)(ii))

#### § 10.134 Declaration of intent.

A showing of intent by the importer as to the actual use of imported merchandise shall be made by filing at the time of filing the entry for consumption or for warehouse a declaration as to the intended use of the merchandise, or by entering the proper item number of an actual use provision of the Tariff Schedules of the United States and the reduced or free rate of duty on the entry form. Entry made under an actual use provision of the Tariff Schedules of the United States may be construed as a declaration that the merchandise is entered to be used for the purpose stated in the schedules, provided the district director is satisfied the merchandise will be so used. However, the district director shall require a written declaration to be filed if he is not satisfied that merchandise entered under an actual use provision will be used for the purposes stated in the schedules.

#### § 10.135 Deposit of duties.

When the requirement of § 10.134 has been met the merchandise may be entered or withdrawn from warehouse for consumption without deposit of duty when proof of use will result in free entry, or with deposit of duty at the lower rate when proof of use will result in a lower rate of duty. For bond requirements, see section 8.28 of this chapter.

#### § 10.136 Suspension of liquidation.

Liquidation of an entry covering merchandise for which a declaration of intent has been made pursuant to § 10.134 and any required deposit of duties made, shall be suspended until proof of use is furnished or the 3-year period allowed for production thereof has expired.

#### § 10.137 Records of use.

- (a) Maintenance by importer. The importer shall maintain accurate and detailed records showing the use or other disposition of the imported merchandise. The burden shall be on the importer to keep records so that the claim of actual use can be readily established.
- (b) Retention of records. The importer shall retain records of use or disposition for a period of 3 years from the date of liquidation of the entry.
- (c) Examination of records. The records required to be kept by paragraph (a) shall be available at all times for examination and inspection by an authorized Customs officer.

#### § 10.138 Proof of use.

Within 3 years from the date of entry or withdrawal from warehouse for consumption, the importer shall submit in duplicate in support of his claim for free entry or for a reduced rate of duty a certificate executed by (1) the superintendent or manager of the manufacturing plant, or (2) the individual end-user or other person having knowledge of the actual use of the imported article. The certificate shall include a description of the processing in sufficient detail to show that the use contemplated by the law has actually taken place. A blanket certificate covering all purchases of a given type of merchandise from a particular importer during a given period, or all such purchases with specified exceptions, may be accepted for this purpose, provided the importer shall furnish a statement showing in detail, in such manner as to be readily identified with each entry, the merchandise which he sold to such manufacturer or end-user during such period.

#### § 10.139 Liquidation.

- (a) In general. Upon satisfactory proof of timely use of the merchandlse for the purpose specified by law, the entry shall be liquidated free of duty or at the lower rate of duty specified by law. When such proof is not filed within 3 years from the date of entry or withdrawal from warehouse for consumption, the entry shall be liquidated dutiable under the appropriate item of the Tariff Schedules of the United States.
- (b) Exception for blackstrap molasses. An entry covering blackstrap molasses, as hereinafter defined, may be accepted and liquidated with duty at a lower rato upon compliance with section 10.134. Blackstrap molasses is "final" molasses practically free from sugar crystals, containing not over 58 percent total sugars and having a ratio of

total sugars×100

not in excess of 71. In the event of doubt, an ash determination may be made. An

ash content of not less than 7 percent indicates a blackstrap molasses within the meaning of this paragraph.

2. Part 10 is further amended as follows:

In § 10.43, paragraph (c) and footnote 40 appended thereto are deleted.

Section 10.88 and footnote 79 appended thereto are deleted.

Section 10.100 and footnotes 92a and 92b appended thereto are deleted.

Section 10.101 and footnote 93 appended thereto are deleted.

Section 10.111 is deleted. Section 10.113 is deleted.

(R.S. 251, 77A Stat. 14, Sec. 624, 46 Stat. 759; 19 U.S.C. 66, 1202 (Gen. Hdntes. 10 and 11), 1624)

#### PART 13—EXAMINATION, MEASURE-MENT, AND TESTING OF CERTAIN PRODUCTS

3. Part 13 is amended by deleting § 13.4 and footnotes 3 and 4 appended thereto. (R.S. 251, Sec. 624, 46 Stat. 759; 19 U.S.C. 66, 1624)

#### PART 16-LIQUIDATION OF DUTIES

4. In § 16.3, paragraph (b) is amended to read:

(b) The liquidation of entries covering articles entered at a conditionally reduced rate or conditionally free of duty under provisions of the Tariff Schedules of the United States in accordance with sections 10.131–10.135 of this chapter relating to actual use shall be suspended in accordance with section 10.136 of this chapter.

(R.S. 251, sec. 624, 46 Stat. 759; 19 U.S.C. 66, 1624)

#### PART 25—CUSTOMS BONDS

5. In section 25.18, paragraph (b) is amended to read as follows:

(b) In cases where there is a 3-year limitation for furnishing proof of the use or disposition of merchandise in, or exportation from, the United States, and such proof is not furnished within the prescribed period, the district director may extend the 3-year period for further periods of 1 year each, but not to exceed 5 years from the date of entry. However, no extensions shall be granted extending the 3-year limitation for suspension of liquidation provided by 10.136 of this chapter.

(R.S. 251, sec. 624, 46 Stat. 759; 19 U.S.C. 66, 1624)

#### PART 54—CERTAIN IMPORTATIONS TEMPORARILY FREE OF DUTY

6. Part 54 is amended as follows; Section 54.4 is deleted. Section 54.7 is deleted.

(R.S. 251, sec. 624, 46 Stat. 759; 19 U.S.C. 66, 1624)

Prior to the issuance of the proposed amendment, consideration will be given to any relevant data, views, or arguments which are submitted in writing to the Commissioner of Customs, Washington, D.C. 20226, and received not later than 60 days from the date of publication in the Federal Register. No hearing will be held.

[SEAL] EDWIN F. RAINS,
Acting Commissioner of Customs.

Approved: December 22, 1970.

Eugene T. Rossides, Assistant Secretary of the Treasury.

[FR Doc.71-445 Filed 1-12-71;8:50 am]

### POST OFFICE DEPARTMENT

[ 39 CFR Part 124 ]

## SEXUALLY ORIENTED ADVERTISEMENTS

#### Notice of Proposed Rule Making

Section 3010(a)' of title 39, United States Code, as enacted by the Postal Reorganization Act (Public Law 91-375, approved August 12, 1970) provides that any person who mails or causes to be mailed any sexually oriented advertisement shall place on the envelope or cover thereof his name and address as the sender thereof and such mark or notice as the Postal Service may prescribe. Section 3010(d) defines sexually oriented advertisement. The Department implemented section 3010(a) by issuing regulations as § 125.9 of Title 39, Code of Federal Regulations, on pages 18743 and 18744 of the daily issue of December 10. 1970.

The Department now intends to implement subsections (b) and (c) of section 3010. These subsections relate basically to the right of citizens not to receive sexually oriented advertisements if that is their wish. The proposed regulations are set forth below. It should be noted that the regulations incorporate, without substantive change, the regulations implementing section 3010(a), cited above.

Interested persons who desire to do so may submit written data, views, and arguments concerning 'hese proposed regulations to the Assistant General Counsel, Mailability Division, Post Office Department, Washington, D.C. 20260, at any time prior to January 20, 1971. After consideration of all comments received, the Department will then promulgate the final regulations decided upon, to be effective February 1, 1971, which is the effective date of section 3010 of title 39.

Accordingly, the Department proposes the following regulations, to be effective February 1, 1971.

In Part 124 new § 124.9 is added, reading as follows:

#### § 124.9 Sexually oriented advertisements.

(a) General. (1) Section 3010 of title 39, United States Code, provides a means by which a member of the public can act to protect himself and his minor children from receiving unsolicited sexually oriented advertisements through the mails. This section permits any person

who is served by the U.S. Postal Service to file with the Postal Service a statement that he does not desire to receive any sexually oriented advertisements through the mails. Any mailer who sends that person an unsolicited sexually oriented advertisement more than 30 days after the date on which the Postal Service adds his name to its reference list of those who desire this protection, may be subject to both civil and criminal sanctions, as provided in 39 U.S.C. 3011 and in 18 U.S.C. 1735-37.

(2) 39 U.S.C. 3010(d) defines a "sexually oriented advertisement" as "any advertisement that depicts, in actual or simulated form, or explicitly de-scribes, in a predominantly sexual context, human genitalia, any act of natural or unnatural sexual intercourse, any act of sadism or masochism, or any other erotic subject directly related to the foregoing." It further provides that "material otherwise within the definition of this subsection shall be deemed not to constitute a sexually oriented advertisement if it constitutes only a small and insignificant part of the whole of a single catalog, book, periodical or other work the remainder of which is not primarily devoted to sexual matters."

(3) The responsibility for ensuring that no unsolicited sexually oriented advertisement is sent through the mails to any person in violation of section 3010 is placed by that section on the mailers of sexually oriented advertisements. No provision of Postal Service regulations may be used to place this responsibility upon the Postal Service. For example, the privilege of a sender to recall a piece of mail provided by section 153.5 of this chapter may not be so used, although it may be used in good faith to request the recall of a specific piece of mail inadvertently deposited in the mails addressed to a person on the List.

(b) Application for listing. (1) A person may invoke the protection of section 3010 by completing and filing, with any postmaster or other designated Postal Service representative, Part II of Application for Listing Pursuant to 39 U.S.C. 3010, PS Form 2201, which may be obtained at any post office. Form 2201 bears a preprinted identifying number in two places: On the instruction portion (Part I) and on the application portion (Part II). After filing the application portion the customer should retain the instruction portion and should use the identifying number in any subsequent communication with the Postal Service concerning his application.

(2) A person may file on his own behalf and on behalf of any of his children under the age of 19 years who reside with him or are under his care, custody, supervision. An authorized officer, agent, fiduciary, surviving spouse or other representative, may file in behalf of a corporation, firm, association, estate, or deceased or incompetent addressee.

(3) Each postmaster shall transmit all applications received at his post office to the Office of ADP Management, Finance and Administration Department, U.S. Postal Service, Box 677, Washington, DC 20044 on a daily basis. The applications shall be packaged so that they will not be subject to folding, bending or other mutilation or damage.

(4) The Office of ADP Management, Finance and Administration Department, as soon as practical after receipt of a Form 2201, shall place the customer's name and address, the names and addresses of his minor children if any are included on the application, on the Postal Service's List (hereafter, "List") of persons desiring not to receive sexually oriented advertising. The 30-day period provided by section 3010(b) starts on the day that the person's name and address are placed on the List.

- (5) A person's name and address will be retained on the List for a period of 5 years, unless a request for revocation is sooner filed by that person. A person must file a new application at the end of the 5-year period if he desires to continue his name on the List. The names and addresses of minor children will be automatically removed from the List when they attain 19 years of age. A minor must file an original application in his own behalf if he desires to continue his name on the List after reaching 19 years of age.
- (6) The filing of a single application results in the listing of a single address for the person filing. A person who receives mail at more than one address and who wishes the protection of section 3010 at more than one address should file a separate application for each. A person who moves must file a new application to receive the protection of section 3010 at his new address. The submission of Change of Address Order PS Form 3575 will not be effective for this purpose. It would not be a violation of section 3010 to mail a sexually oriented advertisement to a person at an address other than that which is shown for him on the List. It would be a violation, however, to mail such an advertisement to him at the address shown for him even though he has moved from that address.
- (c) Revocation of listing. A person, at any time, may request the removal of his name and address, or that of one or more of his minor children, from the List by so notifying his postmaster. It would not be evidence of a violation of section 3010 if a person received a sexually oriented advertisement in the mails on or after the date he gives such notice.
- (d) Availability of Postal Service List.

  (1) Copies of the List and periodic amendments thereto shall be available to any person by annual subscription. A subscription year runs from January 1 through December 31. Requests for information on subscriptions and requests for subscriptions should be submitted to the Director, Office of Mail Classification, Finance & Administration Department, U.S. Postal Service, Washington, DC 20260. Requests for subscriptions must be accompanied by a check for \$5,000 payable to the U.S. Postal Service. This money will be applied to the subscription price at the end of the year.

and any excess will be refunded to the subscriber. The annual subscription price will be established following each subscription year, and will represent the cost, prorated among the subscribers, of compiling, processing, printing, and distributing the List. In no event will the subscription price \$10,000. The List will be in the form of a reduced reproduction of computer print outs. For an additional fee a computer tape of the listings can also be secured in conjunction with subscriptions to the List. Details of the List format may be obtained from the Director, Office of Mail Classification.

- (2) This List may be used by mailers only to protect persons whose names appear on it from receiving unwanted sexually oriented advertisements through the mails. No person, including a subscriber to the List, may use the List for any other purpose, and no person may. sell, lease, rent, lend, exchange or license another to use this List for any purpose whatsoever, including its use by another to remove names from a list of persons to whom sexually oriented advertise-ments will be sent. No person may use the List or a copy thereof for the purpose of preparing mailing or other lists for sale, lease, rent, loan, exchange or use by another. Violators are subject to criminal prosecution.
- (e) Marking of envelope. Section 3010
  (a) authorizes and directs the Postal Service to provide a mark or notice which must be placed on the envelope or cover of any sexually oriented advertisement sent through the mails, together with the name and address of the sender. The following provisions are in implementation of this authority and direction:
- (1) Any person who mails or causes to be mailed any sexually oriented advertisement shall place in the upper lefthand corner of the exterior face of the mail piece, whereon appear the addressee designation and postmarks, postage stamps, or indicia thereof, the sender's name and address. In the right-hand portion below the postage stamp, or indicia thereof, and above the addressee designation, there shall be placed "Sexually Oriented Ad."
- (2) The name and address of the sender and the legend required by subparagraph (1) of this paragraph shall be printed in a size type no smaller than that used for any other word on the envelope or other cover, and in no event smaller than 12-point type. Such type shall be no less conspicuous than the boldest type used to print other words on the exterior face of the mail plece.
- (3) The contrast between the background and printing of the sender's name and address and the contrast between the background and the printing of the prescribed notice shall be no less than the contrast between the background and printing of any other words on the envelope or other wrapper.
- (4) A clear space no less than onequarter of an inch wide shall surround the sender's name and address and the notice, separating them from anything

else appearing on the exterior face of the mail piece.

- (f) Violations. (1) The following is a partial list of conduce which may violate 39 U.S.C. section 3010 or U.S.C. section 1735:
- (i) The mailing of a sexually oriented advertisement in an envelope or other wrapper which does not bear the name and address of the sender and the legend "sexually oriented ad" as provided by paragraph (e) of this section;
- (ii) The mailing directly or indirectly of a sexually oriented advertisement to a person whose name and address have been on the List for more than 30 days:
- (iii) The sale, loan, lease, or licensing the use of the List or a copy thereof in whole or in part;
- (iv) The use of the List or a copy of it in whole or in part for any other purpose than to insure that no mailings of sexually oriented advertisements are made to persons on the List.
- (2) A person who wishes to report that he has received an unsolicited sexually oriented advertisement after his name and address have been on the List for more than 30 days should submit the entire mail piece, including the envelope or other wrapper, to any postmaster. The mail piece must be opened by the addressee. When submitting the mail piece. the addressee must endorse the envelope or other wrapper in substance as follows: "I received this mail piece on (date)" and sign the statement. He should also state the identifying number appearing on his application if it is known to him. See paragraph (b) (1) of this section. The postmaster of the installation to which the mail piece is submitted shall send it without delay to the Postal Inspector in Charge of the Division which has geographical jurisdiction over the address of the mailer.
- (3) If a violation of paragraph (d) of this section comes to the attention of any postal officer or employee, he shall, through his postmaster, report such violation to the postal inspector whose territory includes his postal installation. Mail of a mailer in violation or apparent violation of section 3010 may not be refused for dispatch or delivery without a proper court order. Appropriate instructions to postmasters will be issued in the event that a court order is obtained.
- (4) A customer who wishes to ascertain whether his name has been placed on the List should direct his inquiry to the Director, Office of Mail Classification, Finance and Administration Department, U.S. Postal Service, Washington, DC 20260.
- (g) Disposal of Original Form PS 2201. (1) It is anticipated that because of the possible volume of filings pursuant to paragraph (b) (1) of this section it may be an undue burden upon the Postal Service to retain the original executed application forms. If it is determined by the Assistant Postmaster General (Finance and Administration Department) to be such a burden, each application shall be photographed on

microfilm as soon as the information required for compliance with paragraph (b) (4) of this section has been obtained and shall thereafter be destroyed.

> DAVID A. NELSON, General Counsel.

JANUARY 11, 1971.

[FR Doc.71-501 Filed 1-12-71;8:50 am]

## DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

I 14 CFR Part 73 I

[Airspace Docket No. 70-SO-99]

RESTRICTED AREAS

#### Proposed Designation and Alteration

The Federal Aviation Administration (FAA) is considering proposals submitted by the Department of the Navy that would designate temporary restricted areas in the coastal region adjacent to Jacksonville, Beaufort, and Lake Waccamaw, N.C., and alter Restricted Area R-5306A.

Interested persons may participate in the proposed rule making by submitting such written data, views, or arguments as they may desire. Communications should identify the airspace docket number and be submitted in triplicate to the Director, Southern Region, Attention: Chief, Air Traffic Division, Federal Aviation Administration, Post Office Box 20636, Atlanta, GA 30320. All communications received within 30 days after publication of this notice in the FEDERAL REGISTER will be considered before action is taken on the proposed amendments. The proposals contained in this notice may be changed in the light of comments received...

An official docket will be available for examination by interested persons at the Federal Aviation Administration, Office of the General Counsel, Attention: Rules Docket, 800 Independence Avenue SW., Washington, DC 20590. An informal docket also will be available for examination at the office of the Regional Air Traffic Division Chief.

The FAA is considering the designation of the following temporary restricted areas and alteration of R-5306A:

1. Name: R-5305 Exotic Dancer IV Joint Military Exercise.

Location: Jacksonville, N.C.

Boundaries: Beginning at point on the northwest boundary of Restricted Area R-5306A at lat. 35°02'00" N., long. 76°58'15" W.; thence southwest and southeast along the boundary of R-5306A, R-5306B, and R-5306G to lat. 34°30′20″ N., long. 77°15′50″ W.; thence southwest along the boundary of Warning Area W-122 to lat. 34°17'45" N., Warning Area W-122 to lat. 34°17'45" N., long. 77°37'50" W.; to lat. 34°35'30" N., long. 77°42'30" W.; to lat. 34°37'30" N., long. 77°50'00" W.; to lat. 34°55'00" N., long. 77°49'30" W.; to lat. 35°15'00" N., long. 77°30'00" W.; thence counterclockwise along the boundary of the New Bern control zone to the point of beginning, excluding the air-

space below 5,000 feet MSL within the Jackspace seriow 5,000 feet firsh within the stack-sonville, N.C., control zone and Jacksonville transition area (8.5 statute mile radius of New River MCAS lat. 34°42′25″ N., long. 77°26′35″ W., and 6.5 statute mile radius of Albert Ellis, N.C., Airport lat. 34°49′49″ N., long. 77°36′42″ W.); excluding that airppace below 5,000 feet MSL, 4 nautical miles either side of the New River, N.C. (NCA), radio beacon 312° M bearing extending from New River MCAS to the Albert Ellis Airport; transition area; and that airspace from 1,000 to 5,000 feet MSL within 4 nautical miles either side of the Wilmington, N.C., VORTAC 047° M (051° T) radial, extending from the Jacksonville transition area southwest to the restricted area boundary; excluding that airspace from 1,000 to 5,000 feet MSL within 4 nautical miles either side of the Fayetteville, N.C., VORTAC 102° M (100° T) radial, ex-tending from the Jacksonville transition area, westward to the restricted area boundary, and excluding the airspace below 3,000 feet MSL, within a 5-statute-mile radius of Beaufort-Morehead City Airport and within 5 statute miles each side of a line extending from the Airport to the New Bern VOR.

Designated Altitude: Surface to 17,000 feet MSL.

Time of Designation: Continuous, May 1 through May 14, 1971.

Controlling Agency: FAA, Washington ARTC Center, Leesburg, Va.
Using Agency: U.S. Atlantic Command,

Norfolk, Va.

2. Name: R-5307 Exotic Dancer IV Joint Military Exercise.

Location: Beaufort, N.C.

Boundaries: Beginning at the northeast corner of Restricted Area R-5305A at lat. 35\*-04\*30" N., long. 76\*04\*30" W.; to lat. 35\*00\*-30" N., long. 76\*01'20" W.; thence southwest along the boundary of Warning Area W-122 to lat. 34\*37'30" N., long. 76\*56'20" W.; thence north and northeast along the eastern boundary of R-5306A to point of beginning, excluding the airspace below 3,000 feet MSL, within a 5-statute-mile radius of the Beaufort-Morehead City Airport and within 5 statute miles each side of a line extending from the Airport to the New Bern VOR.

Designated Altitude: Surface to FL 350. Time of Designation: Continuous, May 1 through May 14, 1971.

Controlling Agency: FAA, Washington ARTC Center, Leesburg, Va. Using Agency: U.S. Atlantic Command, Norfolk, Va. 3. Name: R-5309 Exotic Dancer IV Joint

Military Exercise. Location: Lake Waccamaw, N.C

Boundaries: Beginning at lat. 34°23'30" N., long. 78°35'00" W.; to lat. 34°19'30" N., long. 78°20'30" W.; to lat. 34°11'40" N., long. 78°-15'30" W., to lat. 34°05'30" N., long. 78°25'-00" W.; to lat. 34°15'30" N., long. 78°35'00"

W.; thence to point of beginning.
Designated Altitude: Surface to 17,000 feet

Time of Designation: April 23 through May 13, 1971.

Controlling Agency: FAA, Washington ARTC Center, Leesburg, Va. Using Agency: U.S. Atlantic Command,

Norfolk, Va.

4. Alter Restricted Area R-5308A to exclude temporarily from May 1, 1971, through May 14, 1971, the aircpace below 3,000 feet MSL, within a 5-statute-mile radius of the Beaufort-Morehead city Airport and within 5 statute miles each side of a line extending from the Airport to the New Bern VOR.

The proposed restricted areas would be utilized for a Joint Military Training Exercise, wherein during the designated period extensive air drop and landing

forces. Tactical air maneuvers will be contained in the proposed special use airspace under both VFR and IFR conditions through direct control by the appropriate Military Air Traffic Regulations Center. Nonexercise air traffic generated by civil airports within the proposed restricted area will be handled on a coordinated basis using preferential routings, altitudes and coordinated times to effect safe ingress and egress of the proposed area.

These amendments are proposed under the authority of sec. 307(a) of the Federal Aviation Act of 1958 (49 U.S.C. 1348) and sec. 6(c) of the Department of Transportation Act (49 U.S.C. 1655(c)).

Issued in Washington, D.C., on January 8, 1971.

> T. McCormack, Acting Chief, Airspace and Air Traffic Rules Division.

[FR Doc.71-442 Filed 1-12-71;8:50 am]

## ENVIRONMENTAL PROTECTION **AGENCY**

[ 42 CFR Part 481 ]

#### AIR QUALITY CONTROL REGIONS

Proposed Designation and Redesignation of Regions; Consultation With Appropriate State and Local **Authorities** 

Notice is hereby given of a proposal to designate Intrastate Air Quality Control Regions in the State of Virginia as set forth in the following new §§ 481.143-481.146 inclusive which would be added to Part 481 of Title 42, Code of Federal Regulations. It is proposed to make such designations effective upon republication.

In addition to the proposal to designate the new Intrastate Air Quality Control Regions, it is proposed to change the name of the presently designated Metropolitan Norfolk Intrastate Air Quality Control Region (§ 481.93) to the Hampton Roads Intrastate Air Quality Control Region.

Interested persons may submit written data, views, or arguments in triplicate to the Office of the Acting Commissioner, Air Pollution Control Office, Room 17-82, 5600 Fishers Lane, Rockville, MD 20852. All relevant material received not later than 30 days after the publication of this notice will be considered.

Interested authorities of the States of Virginia, Maryland, West Virginia, and North Carolina and appropriate local authorities, both within and without the proposed regions, who are affected by or interested in the proposed designations and redesignation, are hereby given notice of an opportunity to consult with representatives of the Administrator concerning such designations and redesignation. Such consultation will take place at 10 a.m., January 12, 1971, in the Department of Highways Auditorium, 1221 East Broad Street, Richmond, VA.

Mr. Doyle J. Borchers is hereby desigassaults will occur in support of ground nated as Chairman for the consultation. The Chairman shall fix the time, date, and place of later sessions and may convene, reconvene, recess, and adjourn the sessions as he deems appropriate to expedite the proceedings.

State and local authorities wishing to participate in the consultation should notify the Chairman, Air Pollution Control Office, Environmental Protection Agency, Room 17–82, 5600 Fishers Lane, Rockville, MD 20852.

In Part 481 the following new sections are proposed to be added to read as follows:

#### § 481.143 Central Virginia Intrastate Air Quality Control Region.

The Central Virginia Intrastate Air Quality Control Region consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

#### In the State of Virginia:

#### COUNTIES

Amelia. Franklin. Amherst. Halifax. Appomattox. Henry. Bedford. Lunenburg. Brunswick. Mecklenburg. Buckingham. Nottoway. Campbell. Patrick. Charlotte. Pittsylvania. Cumberland, Prince Edward.

#### CITIES

Bedford, Martinsville.
Danville, South Boston.
Lynchburg,

#### § 481.144 Northeastern Virginia Intrastate Air Quality Control Region.

The Northeastern Virginia Intrastate Air Quality Control Region consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

#### In the State of Virginia:

#### COUNTES

Accomack. Louisa. Madison. Albemarle. Caroline. Mathews. Culpeper. Middlesex. Essex. Nelson. Fauquier. Northampton. Fluvanna. Northumberland. Gloucester. Orange. Rappahannock. Greene. King and Queen. Richmond. King George. Spotsylvania. King William. Stafford. Lancaster.

#### CITIES

Charlottesville.

Fredericksburg.

## § 481.145 State Capital Intrastate Air Quality Control Region.

The State Capital Intrastate Air Quality Control Region (Virginia) consists of

the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited);

#### In the State of Virginia:

#### COUNTIES

Charles City. Henrico.
Chesterfield. New Kent.
Dinwiddie. Powhatan.
Goochland. Prince George.
Greensville. Surry.
Hanover. Sussex.

#### CITIES

Colonial Heights. Emporia. Hopewell. Petersburg. Richmond.

#### § 481.146 Valley of Virginia Intrastate Air Quality Control Region.

The Valley of Virginia Intrastate Air Quality Control Region consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

#### In the State of Virginia:

#### COUNTIES

Highland. Alleghany. Montgomery. Augusta. Bath. Page. Botetourt. Pulaski. Clarke. Roanoke. Craig. Rockbridge. Rockingham. Floyd. Frederick. Shenandoah. Warren. Giles.

#### CITIES

Buena Vista. Roanoke.
Clifton Forge. Salem.
Covington. Staunton.
Harrisonburg. Waynesboro.
Lexington. Winchester.
Radford.

This action is proposed under the authority of sections 107(a) and 301(a) of the Clean Air Act, section 2, Public Law 90-148, 81 Stat. 490, 504; 42 U.S.C. 1857c-2(a), 1857g(a).

Dated: January 7, 1971.

William T. Ruckelshaus,
Administrator.

[FR Doc.71-415 Filed 1-12-71;8:48 am]

#### I 42 CFR Part 481 1

#### AIR QUALITY CONTROL REGIONS

#### Proposed Designation of Regions; Consultation With State and Local Authorities

Notice is hereby given of a proposal to designate Intrastate Air Quality Control Regions in the State of North Carolina as set forth in the following new §§ 481.147–481.153 inclusive which would

be added to Part 481 of title 42, Code of Federal Regulations. It is proposed to make such designations effective upon republication.

Interested persons may submit written data, views, or arguments in triplicate to the Office of the Acting Commissioner, Air Pollution Control Office, Environmental Protection Agency, Room 17–82, 5600 Fishers Lane, Rockville, MD 20852, All relevant material received not later than 30 days after the publication of this notice will be considered.

Interested authorities of the States of North Carolina, Virginia, South Carolina, and Tennessee, and appropriate local authorities, both within and without the proposed regions, who are affected by or interested in the proposed designations, are hereby given notice of an opportunity to consult with representatives of the Administrator concerning such designations. Such consultation will take place at 10 a.m., January 13, 1971, in the Governor's Conference Room, Administration Building, 116 West Jones Street, Raleigh, NC.

Mr. Gene B. Welsh is hereby designated as Chairman for the consultation. The Chairman shall fix the time, date, and place of later sessions and may convene, reconvene, recess, and adjourn the sessions as he deems appropriate to expedite the proceedings.

State and local authorities wishing to participate in the consultation should notify the Chairman, Mr. Welsh, Air Pollution Control Office, Environmental Protection Agency, Room 404, 50 Seventh Street NE., Atlanta, GA 30323.

In Part 481 the following new sections are proposed to be added to read as follows:

#### § 481.147 Eastern Mountain Intrastate Air Quality Control Region.

The Eastern Mountain Intrastate Air Quality Control Region (North Carolina) consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

In the State of North Carolina;
Alexander County,
Alleghany County.
Ashe County.
Avery County.
Burke County.
Caldwell County.
McDowell County.

Mr Area County.
McDowell County.

Mr Alexander County.
Mitchell County.
Watauga County.
Wilkes County.
Yancey County.

#### § 481.148 Eastern Piedmont Intrastate Air Quality Control Region.

The Eastern Piedmont Intrastate Air Quality Control Region (North Carolina) consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f))

geographically located within the outermost boundaries of the area so delimited):

In the State of North Carolina:

Chatham County.
Durham County.
Edgecombe County.
Franklin County.
Granville County.
Halifax County.
Johnston County.
Lee County.
Nash County.

Northampton
County.
Orange County.
Person County.
Vance County.
Wake County.
Warren County.
Wilson County.

#### § 481.149 Northern Coastal Plain Intrastate Air Quality Control Region.

The Northern Coastal Plain Intrastate Air Quality Control Region (North Carolina) consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

In the State of North Carolina:

Beaufort County.
Bertie County.
Camden County.
Chowan County.
Currituck County.
Dare County.
Gates County.

Hertford County.

Hyde County.
Martin County.
Pasquotank County.
Perquimans County.
Pitt County.
Tyrrell County.
Washington County.

#### § 481.150 Northern Piedmont Intrastate Air Quality Control Region.

The Northern Piedmont Intrastate Air Quality Control Region (North Carolina) consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

In the State of North Carolina:

Alamance County. Caswell County. Davidson County. Davie County. Forsyth County. Guilford County. Randolph County.
Rockingham
County.
Stokes County.
Surry County.
Yadkin County.

## § 481.151 Sandhills Intrastate Air Quality Control Region.

The Sandhills Intrastate Air Quality Control Region (North Carolina) consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

In the State of North Carolina:

Anson County.
Bladen County.
Cumberland County.
Harnett County.
Hoke County.
Montgomery County.

Moore County. Richmond County. Robeson County. Sampson County. Scotland County.

#### § 481.152 Southern Coastal Plain Intrastate Air Quality Control Region.

The Southern Coastal Plain Intrastate
Air Quality Control Region (North Caro-

lina) consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

In the State of North Carolina:

Brunswick County. Carteret County. Columbus County. Craven County. Duplin County. Greene County. Jones County. Lenoir County.
New Hanover
County.
Onclow County.
Pamileo County.
Pender County.
Wayne County.

#### § 481.153 Western Mountain Intrastate Air Quality Control Region.

The Western Mountain Intrastate Air Quality Control Region (North Carolina) consists of the territorial area encompassed by the boundaries of the following jurisdictions or described area (including the territorial area of all municipalities (as defined in section 302(f) of the Clean Air Act, 42 U.S.C. 1857h(f)) geographically located within the outermost boundaries of the area so delimited):

In the State of North Carolina:

Buncombe County. Cherokee County. Clay County. Graham County. Haywood County. Henderson County. Jackson County.
Macon County.
Madison County.
Swain County.
Transylvania
County.

This action is proposed under the authority of sections 107(a) and 301(a) of the Clean Air Act, section 2, Public Law 90–148, 81 Stat. 490, 504; 42 U.S.C. 1857c–2(a), 1857g(a).

Dated: January 7, 1971.

WILLIAM D. RUCKELSHAUS,
Administrator.

[FR Doc.71-416 Filed 1-12-71;8:48 am]

### FEDERAL POWER COMMISSION

[ 18 CFR Part 2 ]

[Docket No. R-405]

#### RELIABILITY OF ELECTRIC AND GAS SERVICE

Notice of Extension of Time

JANUARY 11, 1971.

On December 16, 1970, the National Electric Reliability Council filed a request for an extension of time within which to submit information required to be filed on or before January 7, 1971, by the "Policy Statement Notice of Investigation and Proposed Rulemaking with Respect to Developing Emergency Plans" (Notice) issued on November 4, 1970, in the above-designated matter.

Upon consideration, notice is hereby given that the time is extended to and including January 27, 1971, within which the information heretofore required to be filed by January 7, 1971, by the Notice,

issued November 4, 1970, shall be filed with the Commission.

Gordon M. Grant, Secretary.

[FR Doc.71-532 Filed 1-12-71;10:00 am]

### FEDERAL TRADE COMMISSION

I 16 CFR Part 429 1

## COOLING-OFF PERIOD FOR DOOR-TO-DOOR SALES

Notice of Additional Hearing Dates and Extension of Time for Submitting Data, Views, or Arguments Regarding Proposed Trade Regulation Rule

Notice of a public hearing regarding the proposed Trade Regulation Rule to be held on January 19, 1971, at the Federal Trade Commission Building in Washington, D.C. was published in the Federal Register September 29, 1970 on page 15164 (35 F.R. 15164). The notice also set forth the text of the proposed rule.

The Federal Trade Commission has scheduled an additional hearing on the above-captioned rule. The hearing will be held on February 23 and 24, 1971, commencing at 10 a.m., c.s.t., each day in Room 204A, U.S. Courthouse and Federal Office Building, 219 South Dearborn

Street, Chicago, IL.

All interested persons desiring to orally present views at the hearing should so inform Mr. Jerome S. Lamet, Senior Attorney, Federal Trade Commission, Room 486, U.S. Courthouse and Federal Office Building, 219 South Dearborn Street, Chicago, IL 60604, not later than February 16, 1971, and state the estimated time required for such oral presentation. Reasonable limitations upon the length of time allotted to any person may be imposed. In addition, all parties desiring to deliver a prepared statement at the hearing should file such statement with Mr. Lamet, on or before February 16, 1971.

The Commission has extended from January 12, 1971, until February 16, 1971, the closing date for the submission of written data, views, or arguments concerning the proposed rule. These should be submitted to the Assistant Director for Industry Guidance, Bureau of Consumer Protection, Federal Trade Commission, Pennsylvania Avenue and Sixth Street NW., Washington, DC 20580.

To the extent practicable, persons filing written presentations or prepared statements which are in excess of two pages should submit 20 copies.

Copies of the original notice including the proposed rule may be obtained upon request to the Federal Trade Commission at either of the addresses shown herein.

Issued: January 13, 1971.

By direction of the Commission.

AL] JOSEPH W. SHEA, Secretary,

[FR Doc.71-405 Filed 1-12-71;8:47 am]

#### PROPOSED RULE MAKING

## INTERSTATE COMMERCE COMMISSION

I 49 CFR Part 1100 1

[Ex Parte No. 55 (Sub-No. 3)]

## GENERAL RULES OF PRACTICE (DISCOVERY RULES)

#### Notice of Proposed Rule Making

At a general session of the Interstate Commerce Commission, held at its office in Washington, D.C., on the 23d day of December 1970.

This general investigation and rulemaking proceeding is directed to a thorough examination and evaluation of our existing discovery procedures and techniques, and certain revisions of those discovery practices proposed by the Association of Interstate Commerce Commission Practitioners, the Committee on Practice and Procedure of the Motor Carrier Lawyers' Association, and the Administrative Conference of the United States. The recognized aim of discovery in an administrative agency proceeding is to ensure that each party to the proceeding has access to all pertinent, unprivileged information prior to the actual presentation of the evidence, in order to enable all parties to participate more fairly and effectively in the administrative decision-making process. We intend here to consider the needs of all partiesindustry and consumer representatives alike-for more effective and efficient discovery devices than those now specified in our Rules of Practice, with a view toward adopting those discovery and other related procedures that will best aid in developing the fairest and most complete record that may be compiled in each case coming before this Commission for decision.

During the past several years, we have become increasingly concerned with the efficacy of our present rules and regulations (49 CFR Part 1100), concerning discovery as reproduced in Appendix A to this notice. While specific discovery tools such as depositions (49 CFR 1100.57 through 1100.67) and prehearing conferences (49 CFR 1100.68) are provided in our present Rules of Practice, any participant in any of our proceedings may petition this Commission for the prescription of appropriate discovery procedures tailored to the special requirements of the particular case (49 CFR 1100.102). The expense, delay, and inconvenience of deposition procedures, the impracticality of, and costs entailed in scheduling prehearing conferences in the many cases annually presented to this Commission, and the uncertainties involved in the general petition procedures-all seem to discourage efforts by parties having genuine interests in proceedings pending before this Commission to avail themselves of these discovery techniques. As a result, recourse to such procedures has been sought only in rare instances.

This Commission's regulatory responsibility is exceptionally broad, and we are daily confronted with a sweeping variety of cases ranging from a relatively simple motor carrier licensing case to a complex rail merger or general rate increase proceeding, and affecting the public interest and the National Transportation Policy to varying degrees. Certain of these proceedings lend themselves readily to the scheduling of prehearing conferences and the use of specific discovery devices. Others do not warrant the burden and expense entailed in such procedures. To fit all these cases into one unyielding judicialized mold would, in our view, be contrary to sound administration and inimical to fair, efficient, and expeditious decision-making.

To cite but one example, which represents by far the greatest majority of formal proceedings presented to this Commission—those involving applications for motor carrier operating authority-we have found it necessary to require full disclosure by applicants of the nature and identity of supporting testimony upon which they intend to rely. See Schaeffer and Schaeffer Extension— New York City, 106 M.C.C. 100 (1967), as modified in Carl Subler Trucking, Inc., Extension—Canned Goods, 111 M.C.C. 624 (1970), and Carolina Transit Lines, Com. Car. Applic., 111 M.C.C. 630 (1970). Protests filed by those opposing the applications also must contain more information in greater detail. (49 CFR 1100.247) Additionally, in individual proceedings involving applications for motor carrier authority and in rulemaking proceedings, we have specified explicit procedures to require a greater degree of disclosure by all parties concerned. Disclosure, however, concerns only that information within the possession of a party which the party itself desires or is required by our regulations to be made known, and does not generally permit the latitude for information-gathering which may be possible pursuant to appropriate discovery procedures.

Each of the many and varied proceedings presented for decision should, we think, be governed by procedures which will facilitate and make effective the participation of Government and private interests alike, including the actual suppliers and customers of transportation services as well as the ultimate consumer, and yet do so without increased expense or delay. We are especially concerned that consumer groups may be unable, in appropriate proceedings, properly to prepare their presentations, and thus have adequate representation, due either to a lack of sufficient information now discoverable or to the absence of proper procedures to facilitate discovery. We must thus accommodate the needs of the interested parties and this Commission for greater and more reliable information with the essential requirements for a just, speedy, and inexpensive determination of the issues presented. In this process of accommodation, we are convinced that the door to the administrative decisional process must always remain open to those who cannot afford to hire talented counsel, for these are the very persons whom administrative agencies such as this Commission were initially created to hear without the aid of a go-between. Fair and expeditious decisions and economical procedures are prerequisites to sound regulation.

A number of studies of administrative discovery methods have been made by this Commission, the Administrative Conference of the United States, the Motor Carrier Lawyers' Association, and the Association of Interstate Commerce Commission Practitioners. As a result of these studies, and in order to consider certain recommendations made therein, we are, by this notice and order, instituting this general investigation and rulemaking proceeding to examine our existing discovery procedures, and to consider the desirability of either modifying the existing rules or replacing them with entirely new, and broadened discovery measures.

The comments of the Administrative Conference of the United States concerning existing administrative-agency discovery methods and general recommendations for change are set forth in Appendix B; and proposed discovery rules to replace those now in force as recommended by the Motor Carrier Lawyers' Association and the Association of Interstate Commerce Commission Practitioners are respectively reproduced in Appendices C and D to this notice and order. The Administrative Conference recommends that each agency adopt certain minimum standards for discovery in adjudicatory proceeding subject to 5 U.S.C. 554, 556, and 557 (the Administrative Procedure Act). In general, the rules prepared by the Practitioners' association would permit unlimited dis-covery in certain classes of cases in much the same manner as the Federal Rules of Civil Procedure, while those advanced by the Motor Carrier Lawyers' Association would require affirmative action by this Commission prior to discovery.

In order to develop a complete record upon which the necessary determinations may here be made, the procedures in this rulemaking proceeding will permit any interested person or persons to present written comments, suggestions, or proposals concerning the matters under consideration. Parties should be cognizant that any discovery procedures, if not drawn and administered in the most careful manner, can result in creating added expenses and increased procedural delays, instead of accomplishing their intended purposes. As a consequence, persons electing to participate in this proceeding are requested to address themselves to the following questions in addition to any additional suggestions or comments they may wish to present:

(1) Is there a need to modify this Commission's existing discovery procedures in whole or in part?

(2) Are the recommended minimum standards set forth by the Administrative Conference properly applicable and

<sup>&</sup>lt;sup>1</sup> Filed as part of the original document.

necessary to proceedings before this Commission? How can we best accommodate the needs of the parties and this Commission for information with the requirement for a just, speedy, and inexpensive determination of the issues?

(3) Should any broadened discovery rules be made applicable to all cases, to certain specified classes of cases, or only to specific cases individually designated

by appropriate order?

(4) With respect to the proposals of the Motor Carrier Lawyers' Association and the Interstate Commerce Commission Practitioners Association, should these proposed rules be adopted, rejected, or modified; and, as so recommended, do they contain significant omissions or duplications? Are the proposed rules as simple and clear as possible?

(5) What safeguards are necessary to prevent abuse of such discovery procedures as may be adopted? Are the opportunities for delays or the burdens on

the parties too great?

The proposals and comments set forth in this notice and order are merely representative of the matters and things here under investigation, and are not intended to be all-inclusive; they should not be construed as limiting in any manner the scope of this proceeding which is designed to enable this Commission to take all action with respect to discovery and other related procedures as the facts and circumstances developed on the record in this proceeding may justify or

Upon consideration of the abovedescribed matters, and good cause ap-

pearing therefor:

It is ordered, That a proceeding be, and it is hereby, instituted under the authority of the Interstate Commerce Act (49 U.S.C. § 1 et seq.), including more specifically sections 12 and 17, and pursuant to 5 U.S.C. 553 and 559 (the Administrative Procedure Act), to determine whether the revised rules set forth in the appendices to this notice, or other rules or regulations of similar effect should be adopted to establish new (or modify existing) discovery procedures, and for the purpose of taking such other and further action as the facts and cir-

cumstances may justify or require.

It is further ordered, That the Bureau of Enforcement of this Commission be. and it is hereby, authorized and directed

to participate in this proceeding.

It is further ordered, That no oral hearings be scheduled for the taking of testimony in this proceeding unless a need therefor should later appear, but that any interested person may participate in this proceeding by submitting for consideration written statements of facts, views, arguments, and suggestions on the subjects mentioned above, or any other subjects pertinent to this proceeding.

It is further ordered, That any person intending to participate in this proceeding by submitting initial statements or reply statements shall notify this Commission, by filing with the Interstate Commerce Commission, Washington, D.C. 20423, on or before February 1, 1971, the original and one copy of a statement of his intention to participate; that this Commission shall then prepare and make available to all such persons a list containing the names and addresses of all parties to this proceeding, upon whom copies of all statements must be filed; and that at the time of the service of the service list this Commission will fix the time within which initial statements and reply statements must be filed.

And it is further ordered, That a copy of this order be mailed to the Governor of every State and to the Public Utilities Commissions or Boards of every State; that a copy be posted in the Office of the Secretary, Interstate Commerce Commission, Washington, D.C., for public inspection, and that a copy be delivered to the Director, Office of the Federal Register, for publication in the FEDERAL REG-ISTER as notice to all interested persons.

By the Commission.

ROBERT L. OSWALD, Secretary.

APPENDIX B-RECOMMENDATIONS OF THE AD-MINISTRATIVE CONFERENCE OF THE UNITED

Recommendation 21: Discovery in Agency Adjudication

Prehearing discovery in agency adjudica-tion insures that the parties to the proceed-ing have access to all relevant, unprivileged information prior to the hearing. Its primary objectives include the more expeditious conduct of the hearing itself, the encourage-ment of settlement between the parties, and greater fairness in adjudication. Agencies that conduct adjudicatory proceedings generally enjoy broad investigatory powers, and fairness requires that private parties have equal access to all relevant, unprivileged information at some point prior to the hearing.

#### RECOMMENDATION

It is therefore recommended that each agency recognize the Yollowing minimum standards for discovery in adjudicatory proceedings subject to sections 5, 7, and 8 of the Administrative Procedure Act, now codified as 5 U.S.C. 554, 556, and 557, Individual agencies may permit additional discovery where appropriate and may tallor the recommended standards to meet the needs of particular types of proceedings where special or less elaborate discovery procedures will ac-complish the same basic objectives or where the protective measures here recommended will be inadequate to achieve the ends sought. Each agency should undertake to train its hearing examiners in the application of the rules it promulgates to implement these standards. This training should draw upon the experience of other agencies, the Federal Courts, private practitioners, and bar associations.

The recommended minimum standards in-

clude the following procedures:

1. Prehearing conferences. The preciding officer should have the authority to hold one or more prehearing conferences during the course of the proceeding on his own motion or at the request of a party to the proceeding. The presiding officer chould normally hold at least one prehearing conference in proceedings where the issues are complex or where it appears likely that the hearing will last a considerable period of time. The presiding officer at a prehearing conference should have the authority to direct the parties to exchange their evidentiary exhibits and witness lists prior to the hearing. Where

good cause exists, the parties should have the right at any time to amend, by deletion or supplementation, their evidentiary exhibits and witness lists.

2. Depositions. A party to the proceeding should be able to take depositions of witnexes upon oral examination or written questions for purposes of discovering relevant, unprivileged information, subject to the following conditions:

(1) The taking of depositions should nor-

mally be deferred until there has been at

least one prehearing conference;

(2) The party seeking to take a deposition should apply to the presiding officer for an order to do so:

- (3) The party seeking to take a deposition should serve copies of the application on the other party or parties to the proceeding, who chould be given an opportunity, along with the deponent, to notify the presiding officer of any objections to the taking of the deposition;
- (4) The presiding officer should not grant an application to take a deposition if he finds that the taking of the deposition would result in undue delay;
- (5) The preciding officer should otherwise grant an application to take a deposition unless he finds that there is not good cause for doing so; and
- (6) The deposing of an agency employee should only be allowed upon an order of the preciding officer based on a specific finding that the party applying to take the deposi-tion is seeking algorithmat, unprivileged in-formation not discoverable by alternative means. Any such order should be subject to an interlocutory appeal to the agency.

An order to take a deposition should be enforceable through the issuance of a sub-

poens ed testificandum.

3. Witnesses-(a) Prior statements. At the prehearing conference or at some other reasonable time prior to the hearing the at-torney or employee appearing on behalf of the agency in the proceeding should make available to the other parties to the proceeding any prior statements of agency witnecces which are in the possession of the agency or obtainable by it from any other Federal agency and which relate to the subject matter of the expected testimony. "Statement" is defined to include only a written statement signed or adopted by the witness or a recording or transcription which is a substantially verbatim recital of an oral statement made by the witness to an agent of the Federal government.

(b) Narrative-summaries of expected testimony. At the prehearing conference or at come other reasonable time prior to the hearing each party to the proceeding should make available to the other parties to the proceeding the names of the witnesses he expects to call and a narrative summary of their expected testimony. The attorney or employee appearing on behalf of the agency in the proceeding should have the authority to designate any prior statement or statements of an agency witness which he makes ments of an agency witness which he makes available to the other parties under Recom-mendation 3(a) as all or part of the narra-tive summary of that witness's espected testimony. Where good cause exists, the parties should have the right at any time to amend, by deletion or supplementation, the list of names of the witnesses they plan to call and the narrative summaries of the expected testimony of those witnesses.

4. Witten Interrogatories to Parties-Arailability. A party to the proceeding should be able to cerve written interrogatories upon any other party for purposes of discovering relevant, unprivileged information. A party cerved with interrogatories should be able, before he must answer the interrogatories, to apply to the presiding officer for the holding of a prehearing conference for the

mutual exchange of evidentiary exhibits and other information. Each interrogatory which requests information not previously supplied at a prehearing conference should be an-swered separately and fully in writing under oath, unless it is objected to, in which event the reasons for the objection should be stated in lieu of an answer. The party upon whom the interrogatories have been served should serve a copy of the answers and objections within a reasonable time upon the party submitting the interrogatories. The party submitting the interrogatories may move the presiding officer for an order com-pelling an answer to an interrogatory or interrogatories to which there has been an objection or other failure to answer.

(b) Interrogatories directed to the agency.

Each agency should designate an appropriate each agency should designate an appropriate official on whom other parties to the proceeding may serve written interrogatories directed to the agency. That official should arrange for agency personnel with knowledge of the facts to answer and sign the interrogatories on behalf of the agency. The attorney or employee appearing on behalf of the agency in the proceeding should have the authority to make and sign objections to interrogatories served upon the agency. Interrogatories directed to the agency which seek information available only from the agency head, member, or members should only be allowed upon an order of the agency based on a specific finding that the interrogating party is seeking significant unprivi-leged information not discoverable by

alternative means.
5. Requests for admissions--(a) ability. A party to the proceeding should be able to serve upon any other party a written request for the admission, for purposes of the pending proceeding, of any relevant, un-privileged facts, including the genuineness of any document described in the request.

(b) Requests directed to the agency. Each agency should designate an appropriate official on whom other parties to the proceed-ing may serve requests for admissions directed to the agency. That official should arrange for agency personnel with knowledge of the facts to respond to the requests on behalf of the agency. The attorney or employee appearing on behalf of the agency in the proceeding should have the authority to make and sign objections to requests for admissions served upon the agency. Requests directed to the agency which seek admissions obtainable only from the agency head, member or members should only be allowed upon an order of the agency based on a specific finding that the requesting party is sceking significant, unprivileged information

not discoverable by alternative means.
6. Production of documents and tangible things—(a) From nonparties. A party to the proceeding should be able to obtain in accordance with agency rules a subpoena duces tccum requiring a nonparty to produce relevant designated documents and tangible things, not privileged, at a prehearing con-ference, at the taking of the nonparty's deposition, or at any other specific time and

place designated by the issuing officer.
(b) From parties. A party to the proceeding should be able to apply to the presiding officer for an order requiring any other party to produce and to make available for inspection, copying or photographing, at a prehearing conference or other specific time and place, any designated documents and tangible things, not privileged, which con-stitute or contain relevant evidence. The party seeking production should serve copies of the application on the other party or parties to the proceeding, who should be given an opportunity to notify the presiding officer of any objections. The presiding officer should order the production of such designated documents and tangible things unless

he finds that there is not good cause for

doing so.
(c) From the agency. For the purposes of Recommendation 6, the agency conducting the proceeding should be considered a party to the proceeding whether or not the agency staff participates as a party to the proceeding.
7. Role of the presiding officer—(a) Con-

trol over discovery. The presiding officer should have the authority to impose schedules on the parties to the proceeding speci-fying the periods of time during which the parties may pursue each means of discovery available to them under the rules of the agency. Such schedules and time periods should be set with a view to accelerating dis-position of the case to the fullest extent consistent with fairness.

(b) Interlocutory appeals. Except as provided by Recommendation 2(6) above, an interlocutory appeal from a ruling of the pre-siding officer on discovery should be allowed only upon certification by the presiding officer that the ruling involves an important question of law or policy which should be resolved at that time by the appropriate review authority. Notwithstanding the presiding officer's certification, the review authority should have the authority to dismiss summarily the interlocutory appeal if it should appear that the certification was improvident. An interlocutory appeal should not result in a stay of the proceedings ex-

cept in extraordinary circumstances.

8. Protective orders—(a) Authority of presiding officer in general. The presiding officer should have the authority, upon motion by a party or by the person from whom discovery is sought, and for good cause shown, to make any order which justice requires to protect a party or person from annoyance, embarrassment, oppression, or undue burden or expense, including one or more of the following: (1) That the discovery not be had; (2) that the discovery may be had only on specified terms and conditions, in-cluding a designation of the time or place; (3) that the discovery may be had only by a method of discovery other than that selected by the party seeking discovery; (4) that certain matters not be inquired into, or that the scope of the discovery be limited to certain matters; (5) that discovery be conducted with no one present except persons designated by the presiding officer; (6) that discovery be conducted with no one present except persons designated by the presiding officer; (6) that discovery before seeded by the president of the party of the president of the party o deposition after being sealed be opened only by order of the presiding officer; (7) that a trade secret or other confidential research, development, or commercial information not be disclosed or be disclosed only in a designated way; (8) that the parties simultaneously file specified documents or information enclosed in sealed envelopes to be opened as directed by the presiding officer.

(b) Names of witnesses. The presiding officer should have the authority upon motion by a party or other person, and for good cause shown, by order (a) to restrict or defer disclosure by a party of the name of a witness, a narrative summary of the expected testimony of a witness or, in the case of an agency witness, any prior statement of the witness, and (b) to prescribe other appro-priate measures to protect a witness. Any party affected by any such action should have an adequate opportunity, once he learns the name of a witness and obtains the narrative summary of his expected testimony or, in the case of an agency witness, his prior statement or statements, to prepare for cross-examination and for the presentation of his case.

(c) In camera proceedings. The presiding officer should have the authority to permit a party or person seeking a protective order to make all or part of the showing of good cause in camera. A record should be made of such in camera proceedings. If the presid-

ing officer enters a protective order following a showing in camera, the record of such showing should be sealed and precerved and made available to the agency or court in the

event of an appeal.

9. Subpoenas. The presiding officer should have the power to issue subpoenas ad testificandum and duces tecum at any time during the course of the proceeding. Agencies affected by these Recommendations that do not have the statutory authority to issue subpoenes should seek to obtain any necessary authority from the Congress.

Appendix C—Recommendations of the Com-MITTEE ON PRACTICE AND PROCEDURE OF THE MOTOR CARRIERS LAWYERS' ASSOCIATION

The proposed rules have been drafted so that they might be incorporated into the Commission's present rules of practice in the following manner:

- (1) The proposed rules may be physically substituted for present rules 57 through 67 and the present corresponding rules may be eliminated.
- (2) The caption preceding rule 55 should be changed to read "Notice of Hearing; Subpoenas; Depositions; Discovery."
- (3) Rule 102 should be amended by eliminating the parenthetical phrase "which relief shall be construed as including appropriate discovery procedures."

Rule 57-Discovery.

Parties may obtain discovery in any proceeding by serving written interrogatories in compliance with Rule 63 or by serving requests for admission in compliance with Rule 64. Discovery by deposition upon oral examination may be had only by order of the Commission issued pursuant to Rule 60 (a) (2), upon a showing of good cause in the petition requesting such an order. A showing of good cause supporting a request for an oral deposition for purposes of discovery must include a showing that preliminary discovery has been sought through written interrogatories and/or requests for admission or an explanation why preliminary dis-covery through such means was not at-tempted. If written interrogatories and/or requests for admission have been served prior to the filing of a petition for an order under Rule 60(a) (2), the required showing of good cause shall include an explanation why interrogatories and/or requests for admission already served have not provided adequate discovery. Discovery may also be had for production of documents or things or per-mission to enter on land or other property for inspection or other purposes as set forth in Rule 66.

Rule 58-Discovery; scope and protective

- (a) Scope. Unless otherwise ordered in accordance with these rules, parties may obtain discovery regarding any matter, not privi-leged, which is relevant to the subject matter involved in the pending proceeding, includ-ing the existence, description, nature, cus-tody, condition and location of any books, documents, or other tangible things and the identity and location of persons having knowledge of any discoverable matter. It is not ground for objection that the information sought will be inadmissible as evidence or relates to the position and burden of proof of another party, if the information sought appears reasonably calculated to lead to the discovery of admissible evidence.
- (b) Protective orders. Upon motion by any party, or by the person from whom discovery is sought, or by any person asserting an interest in the data, information or material sought to be discovered, and for good cause shown, any order which justice requires may be entered to protect a party or person from

annoyance, embarrassment, oppression, or undue burden or expense, or prevent the raising of issues untimely or inappropriate to the proceeding. Relief through a protective order may include one or more of the following: (1) That discovery not be had; (2) that discovery may be had only on specified terms and conditions, including a designation of the time or place; (3) that discovery be had only upon provision for indemnification to the party or person against whom discovery is sought: (4) that discovery may be had only by a method other than that selected by the party seeking discovery; (5) that certain matters not be inquired into, or that the scope of discovery be limited to certain matters; (6) that discovery be conducted with no one present except persons designated in the protective order; (7) that a deposition after being sealed be opened only by order of the Commission; (8) that a trade secret or other confidential research, development, or com-mercial information not be disclosed or be disclosed only in a designated way; (9) that the parties simultaneously file specified documents or information enclosed in sealed envelopes to be opened only by order of the Commission.

If the motion for a protective order is denied in whole or in part, an order may be entered, on such terms and conditions as are just, requiring any party or person to provide or permit discovery.

Rule 59—Discovery; supplementation of reponses and stipulations.

- (a) Supplementation of Responses. A person who has responded to a request for discovery with a response that was complete when made is under no duty to supplement his response to include information thereafter acquired, except as follows: (1) A person is under a duty seasonably to supplement his response with respect to any question directly addressed to (A) the identity and location of persons having knowledge of discoverable matters, and (B) the identity of each person expected to be called as an expert witness at the hearing and the subject matter on which he is expected to testify; (2) a person who knows or later learns that his response is incorrect is under a duty seasonably to correct the response; and (3) a duty to supplement responses may be imposed by order, agreement of the parties, or at any time prior to hearing or the submis-sion of verified statements under modified procedure, through requests for supplementation of prior responses.
- (b) Stipulations regarding discovery. Unless otherwise ordered, the parties may by written stipulation filed with the Commission (1) provide that depositions be taken before any person, at any time or place, upon any notice, and in any manner and when so taken may be used like other depositions, and (2) modify the procedures provided by these rules for other methods of discovery. Rule 60—Depositions.
- (a) Purpose. (1) The Commission will either upon its own initiative, or upon good cause shown by a party to the proceeding, issue an order to take the testimony of any person, including a party, by deposition upon oral examination for use as evidence. (2) The Commission may in accordance with Rule 57 issue an order to take the testimony of any person, including a party, by deposition upon oral examination for purposes of discovery, which may also include use of the deposition as evidence. The attendance of witnesses may be compelled by the use of subpenas as provided in Rule 56.
- (b) Officer before whom taken. Within the United States or within a territory or insular possession subject to the dominion of the United States, depositions shall be taken

before an officer authorized to administer caths by the laws of the United States or of the place where the examination is held. Within a foreign country a deposition may be taken before an officer or percon designated by the Commission, or a percon designated by written stipulation of all parties filed with the Commission.

(c) When taken. Unless special circumstances and good cause are shown, no deposition shall be taken within 10 days prior to the date assigned for commencement of hearing or the filing of opening statements of fact and argument under modified procedure, and when the deposition is taken in a foreign country it shall not be taken within 30 days prior to such dates.

(d) Fees. A witness whose deposition is taken pursuant to these rules and the officer taking same, unless he be employed by the Commission shall be entitled to the same fee paid for like service in the courts of the United States, which fee shall be paid by the party at whose instance the deposition is taken.

Rule 61-Depositions; petitions and orders.

(a) Petitions. A petition requesting an order to take a deposition and to produce documents and materials (1) shall be filed with due regard to the time periods specified in Rule 60(c); (2) shall be cerved upon all parties to the proceeding and upon the person sought to be deposed and/or the custodian of the documents or materials to be produced; (3) shall set forth the name and address of the witness, the place where, the time when, the name and office of the officer before whom, and the cause of reason why such deposition should be taken; and (4) shall specify with particularity the documents and materials which the deponent is requested to produce.

(b) Order. If the petition requesting an order to take a deposition is granted, which action may be taken without awaiting the possible filing of a reply, the Commission will serve upon the parties an order naming the witness whose deposition is to be taken, and specifying the time when, the place where, and the officer before whom the witness is to testify, but such time and place, and the officer before whom the deposition is to be taken, so specified in the Commission's order, may or may not be the same as set out in the petition.

(c) Where depositions shall be taken. Unless otherwise ordered or agreed to by stipulation, depositions shall be taken in the city or municipality wherein the office of deponent is located.

Rule 62-Depositions; procedures.

- (a) Examination. Examination and cross-examination of witnesses shall proceed as permitted at a hearing. All objections made as the time of the examination to the qualifications of the officer taking the deposition, or to the manner of taking it, or to the evidence presented, or to the conduct of any party, and any other objection to the proceedings, shall be noted by the officer upon the deposition. Evidence objected to shall be taken subject to the objections.
- (b) Motions to protect. At any time during the taking of the deposition, on motion of any party or of the deponent and upon a showing that the examination is being conducted in bad faith or in such manner as unreasonably to annoy, embarracy, or oppress the deponent or party, the officer conducting the examination may be ordered to cease forthwith from taking the deposition, or may limit the scope and manner of the taking of the deposition may be limited as provided in Rule 58(b). If the order made terminates the examination, it shall be resumed thereafter only if so ordered. Upon demand of the

objecting party or deponent, the taking of the deposition shall be suspended for the time necessary to make a motion for an order.

- necessary to make a motion for an order.

  (c) Recordation. The officer before whom the deposition is to be taken shall observe the provisions respecting appearances (Rule 71(a)), and typographical specifications (Rule 15), put the witness on oath, and shall personally, or by comeone acting under his direction and in his presence, record the testimony of the witness. The testimony shall be taken stenographically and transcribed unless the parties agree otherwise to record the evidence.
- (d) Signing. When the testimony fully transcribed or otherwise recorded the deposition of each witness shall be submitted to him for examination and shall be read to or by him unless such examination and reading are waived by the witness and the parties. Any changes in form or substance which the witness desires to make shall be entered upon the deposition by the officer with a statement of the reasons given by the witness for making them. The deposition shall then be signed by the witness unless the parties by stipulation waive the signing or the witness is ill or can not be found or refuses to sign. If the deposition is not signed by the witness within 15 days the officer shall sign it and state thereon the fact of the walver or of the illness or absence of the witness, or the fact of the refusal to sign, together with the reason, if any, given therefor, and the deposition may then be used as fully as though signed, unless, on a motion to suppress, it is otherwice found that the reasons given for the refusal to sign requires rejection of the depcoition in whole or in part.
- (a) Attestation. The officer shall certify on the deposition that the witness was duly sworn by him and that the deposition is a true record of the testimony given by the witness, and that the officer is not of councel or attorney for any of the parties, and that he is not interested in the event or the proceedings.
- (I) Return. The officer shall securely seal the deposition in an envelope endorsed with sufficient information to identify the proceeding and marked "Deposition of (here insert name of witness)" and shall promptly send the original and one copy thereof together with the original and one copy of all exhibits, by registered mail to the Secretary of the Commission. A deposition to be offered in evidence must reach the Commission not later than 5 days before the date it is to be so offered.
- (g) Notice. The party taking the deposition chall give prompt notice of its filing to all other parties.
- (h) Copies. Upon payment of reasonable charges therefor, the officer before whom the deposition is taken shall furnish a copy of it to any interested party or to the deponent.

Rule 63-Written interrogatories.

(a) Availability; procedures for use. Any party may serve upon any person written interrogatorics to be answered by the person served or, if the person served is a public or private corporation or a partnership or association, by any officer or agent, who shall furnish such information as is available to the person.

Each interrogatory shall be answered separately and fully in writing unless it is objected to, in which event the reasons for objection shall be stated in Heu of an answer. The answers are to be signed by the person making them and subscribed by an appropriate verification generally in the form prescribed in No. 6 of Appendix B to these rules, Objections are to be signed by the attorney making them. The person upon whom the interrogatories have been served

shall serve a copy of the answers and objections within a period designated by the party submitting the interrogatories, not

less than 15 days after the service thereof.
(b) Option to produce business records.
Where the answer to an interrogatory may be derived or ascertained from the business records of the person upon whom the interrogatory has been served or from an exami-nation, audit or inspection of such business records, or from a compilation, abstract or summary based thereon, and the burden of deriving or ascertaining the answer is sub-stantially the same for the party serving the interrogatory as for the person served, it is a sufficient answer to such interrogatory to specify the records from which the answer may be derived or ascertained and to afford to the party serving the interrogatory reasonable opportunity to examine, audit or inspect such records and to make copies thereof or compilations, abstracts or summaries therefrom.

If information sought is contained in computer runs, punch cards or tapes which also contain privileged or proprietary information or information the disclosure of which is proscribed by the Interstate Commerce Act, it shall be a sufficient response under these rules, that the person upon whom the interrogatory has been served is willing to make available to and permit an independent professional organization not interested in the proceeding and paid by the party serving the intercogatory to extract from such runs punch cards or tapes the information sought in the interrogatory that is not privileged or proprietary information or information the disclosure of which is proscribed by the Interstate Commerce Act.

Rule 64—Request for admission.

(a) Availability; procedures for use. A party may serve upon any other party a written request for the admission, for purposes of the pending proceeding only, of the truth of any matters within the scope of Rule 58 (a) set forth in the request, including the genuineness of any documents described in the request. Copies of documents shall be served with the request unless they have been or are otherwise furnished or made available for inspection.

Each matter of which an admission is requested shall be separately set forth. The matter is admitted unless, within a period designated in the request, not less than 15 days after service thereof the party to whom the request is directed serves upon the party requesting the admission a written answer or objection addressed to the matter, signed by the party or by his attorney. If objection is made, the reasons therefor shall be stated. The answer shall specifically deny the matter or set forth in detail the reasons why the answering party can not truthfully admit or deny the matter. A denial shall fairly meet the substance of the requested admission, and when good faith requires that a party qualify his answer or deny only a part of the matter of which an admission is requested, he shall specify so much of it as is true and qualify or deny the remainder. An answering party may not give lack of information or knowledge as a reason for failure to admit or deny unless he states that he has made reasonable inquiry and that the information known or readily obtainable by him is insufficient to enable him to admit or deny. A party who considers that a matter of which an admission has been requested presents a genuine issue for hearing may not, on that ground alone, object to the request; he may deny the matter or set forth reasons why he can not admit or deny it.

(b) Effect of admission. Any matter admitted under this rule is conclusively established unless it is ordered that withdrawal or amendment of the admission will be permitted. Any admission made by a party under this rule is for the purpose of the pending proceeding only and is not an admission by him for any other purpose nor may it be used against him in any other proceeding.

Rule 65-Depositions, request for admission and written interrogatories—inclusion in

At the oral hearing, or upon the submission of statements under modified procedure, depositions, requests for admission and written interrogatories may be offered in evidence by the party at whose instance they were taken. If not offered by such party, they may be offered in whole or in part by any other party. If only part of a deposition, request for admission or written interrogatory is offered in evidence by a party, any other party may require him to introduce all of it, which is relevant to the part introduced and any party may introduce any other parts. Such depositions, requests for admission and written interrogatories shall be admissible in evidence subject to such objections as to competency, relevancy, or materiality of the testimony as were noted at the time of their taking or are made at the time they are offered in evidence.

66-Production of documents and things and entry upon land for inspection and other purposes.

(a) Scope. Upon petition and if the Commission determines good cause is shown the Commission may issue an order and direct any party (1) to produce and permit the petitioning party to inspect any designated documents (including writings, drawings, graphs, charts, photographs, phonorecords, and other data compilations from which intelligence can be perceived, with or without the use of detection devices) or to inspect, test, or sample any tangible things which constitute or contain matters within the scope of Rule 58(a) and which are in the possession, custody or control of the party upon whom the order is served, but if the writings or data compilations (including computer runs, punch cards, and tapes) include privileged or proprietary information or information the disclosure of which is proscribed by the Interstate Commerce Act, such writings or data compilations need not be produced under this rule but may be provided pursuant to Rule 63(b); or (2) to permit, subject to appropriate liability releases, and safety and operating considerations, entry upon designated land or other property in the possession or control of the party upon whom the order is served for the purpose of inspection and measuring, surveying, photographing, testing, or sampling the property or any designated object or operation thereon, within the scope of Rule 58(a).

(b) Procedure. The petition shall set forth the items to be inspected either by individual item or by category, and describe each item and category with reasonable particularity. The petition shall specify a reasonable time. place and manner of making the inspection and performing related acts.

Rule 67-Failure to make discovery.

If a deponent fails to answer, or gives an evasive or incomplete answer to, a question propounded under Rule 62(a), or a person fails to answer, or gives evasive or incom-plete answers to, written interrogatories served pursuant to Rule 63(a), the discover-ing party may apply for an order compelling an answer, by motion filed with the Commission and served on all parties and persons affected thereby. On matters relating to a deposition on oral examination, the proponent of the question may complete or adjourn the examination before he applies for APPENDIX D-RECOMMENDATIONS OF THE AS-SOCIATION OF INTERSTATE COMMERCE COM-MISSION PRACTITIONERS

#### TABLE OF CONTENTS

§ 1100.151 General provisions governing discovery

- (a) Discovery methods.
- (b) Presiding officer.
- (c) Scope of discovery.
- (d) Protective orders. (e) Limitations on discovery from the Commission.
- (f) Sequence and timing of discovery.
- Supplementation of responses.
- Notices.
- Officer before whom taken,
- Where deposition shall be taken.
- § 1100.152 Stipulations regarding discovery. § 1100.153 Depositions upon oral examination.
  - When depositions may be taken.
  - (b) Notice of examination.
  - (c) Examination and cross examination;
  - record of examination; oath; objections.
    (d) Motion to terminate or limit examina-
  - (e) Submission to witnesses; changes;
- signing.
  (f) Certification and filing by officer; exhibits; copies; notice of filing.
  § 1100.154 Deposition of witnesses upon
- written questions.

  - (a) Serving questions; notice.(b) Officer to take responses and prepare record.
  - (c) Notice of filing.
- § 1100.155 Use of depositions in Commission

  - proceedings.
    (a) Use of depositions.
    (b) Objections to admissibility.

  - (c) Effect of taking or using depositions.
    (d) Effect of errors and irregularities in depositions.
  - (1) As to notice.
    (2) As to disqualification of officer.
    (3) As to taking of deposition.
    (4) As to completion and return of deposition.
- § 1100.156 Interrogatories to parties.
  - (a) Availability; procedures for use.
    (b) Scope; use at hearing.
    (c) Option to produce business records.
- § 1100.157 Production of documents and things and entry upon land for inspection and other purposes.
  - (a) Scope.
- (b) Procedure.
- § 1100.158 Requests for admission.
  - (a) Request for admission.
- (b) Effect of admission. § 1100.159 Failure to make discovery. (a) Motion for order compelling discovery.
  - (1) Appropriate officer.
  - (2) Motion.
- (3) Evasive or incomplete answer.
- § 1100.160 Subpoena for taking deposition.

INTERSTATE COMMERCE COMMISSION PROPOSED DISCOVERY RULES

Rule 151-General provisions governing discovery.

(a) Discovery methods. Parties may obtain discovery in any adversary proceeding which has been designated for oral hearing by one or more of the following methods, depositions upon oral examination or written questions; written interrogatories, production of doouments or things or permission to enter upon land or other property, for inspection and other purposes; and requests for admission. Unless the presiding officer orders otherwise, the frequency of use of these methods is unlimited.

Note: (1) "Oral Hearing" includes modified procedure cases only to the extent that they may be subsequently at the request of a party assigned for oral hearing on all or part of the issues.

(2) An "adversary proceeding" means not only cases involving direct formal adversaries, but is to be broadly construed to include those cases where parties technically in the same posture, such as common respondents, have in fact adversary interest. If the matter is questioned, the presiding officer shall make the determination upon the basis of the facts of the particular case.

(b) Presiding officer. The term "presiding officer" as used in Rules 151-160 of this part shall mean "officer" as defined in Rule 5 of

(c) Scope of Discovery. Unless otherwise ordered by the presiding officer in accordance with these rules, including orders entered after agreement of the parties or imposition of protective orders at prehearing confer-ences held pursuant to Rule 63, parties may obtain discovery regarding any matter, not privileged, which is relevant to the subject matter involved in the pending proceeding, whether it relates to the claim or defense of any other party, including the existence, description, nature, custody, condition, and location of any books, documents, or other tangible things and the identity and location of persons having knowledge of any discoverable matter. It is not ground for objection that the information sought will be inadmissible at the hearing if the information sought appears reasonably calculated to lead to the discovery of admissible evidence.

Note: (1) The purpose of this rule is to promote the efficient and expeditious conduct of discovery procedures and to encourage stipulations and agreements to enable the expeditious disposition of the proceeding.

(2) Under the rule, the issuance of an order is required by the presiding officer who can change the discovery procedure only through agreement between the parties or by protective order under Rule 151(d).

(d) Protective orders. Upon motion by any party, or by the person from whom discovery is sought, or by any person asserting an in-terest in the data, information or material sought to be discovered, and for good cause shown, the presiding officer may make any order which justice requires to protect a party or person from annoyance, embarrassment, oppression, or undue burden or ex-pense, or prevent the raising of issues untimely or inappropriate to the proceeding, including one or more of the following: (1) That discovery not be had; (2) that the discovery may be had only on specified terms and conditions, including a designation of the time or place; (3) that discovery be had only upon provision for indemnification to the party or person against whom discovery is sought; (4) that the discovery may be had only by a method of discovery other than that selected by the party seeking discovery; (5) that certain matters not be inquired into, or that the scope of the discovery be limited to certain matters; (6) that discovery be conducted with no one present except persons designated by the presiding offi-cer; (7) that a deposition after being sealed be opened only by order of the presiding officer; (8) that a trade secret or other confidential research, development, or commercial information not be disclosed or be disclosed only in a designated way; (9) that the parties simultaneously file specified documents or information enclosed in sealed envelopes to be opened as directed by the presiding officer; (10) that no discovery will be permitted because the data, information, or material sought to be discovered are otherwise available.

If the motion for a protective order is denied in whole or in part, the presiding officer may, on such terms and conditions as are just, order that any party or person pro-

vide or permit discovery.

Note. The provision for indemnification in subsection (d) (3) should be construed to in-

clude reasonable expenses including attorney's fees in the case of a percon other than

(e) Limitations on discovery from the Commission. Discovery from the Commission shall be subject to the following further limitations:

(1) Any documents which are within the exemption provisions of \$552(a) (4) of title 5 U.S.C. as amended by Public Law 80-23.

(2) Staff memoranda, staff investigation reports, and statements in the Commission's possession by persons interviewed shall be considered privileged documents.

(3) The informer's privilege shall be construed broadly and shall encompass information which may lead to the disclosure of an informer's identity.

(4) Commission perconnel may be questioned on oral deposition as to matters within their direct personal knowledge only. Other information, if not privileged, may be cought

by other discovery procedures.
(f) Sequence and timing of discovery. Unless the presiding officer upon motion, for the convenience of parties and witnesses and in the interests of justice, orders otherwise, or the parties involved in the discovery agree otherwise, methods of discovery may be used in any sequence.

(g) Supplementation of responses. A party who has responded to a request for discovery with a response that was complete when made is under no duty to supplement his response to include information thereafter ac-

quired, except as follows:

(1) A party is under a duty ceasonably to supplement his response with respect to any question directly addressed to (A) the identity and location of percons having knowledge of discoverable matters, and (B) the identity of each person expected to be called as an expert witness at the hearing and the subject matter on which he is expected to

(2) A party who knows or later learns that his response is incorrect in under a duty seasonably to correct the response.

(3) A duty to supplement responses may

be imposed by order of the preciding officer, agreement of the parties, or at any time prior to hearing through requests for supplementation of prior responses.

(h) Notices. All notices affecting discovery matters shall appropriately identify the pro-ceeding to which they relate, and two copies of every such notice shall be cerved on the Secretary of the Commission at the time they are served on the parties or percons from whom discovery is cought.

(i) Officer before whom taken. Within the United States or within a territory or incular possession subject to the dominion of the United States, depositions shall be taken before an officer authorized to administer oaths by the laws of the United States or of the place where the examination is held. Within a foreign country a deposition may be taken before an officer or person designated by the Commission.

(j) Where depositions shall be taken. Unless otherwise ordered by the presiding officer or agreed to by stipulation, depositions shall be taken in the city or municipality wherein the office of deponent is located.

COMMENT: The Commission's jurisdiction is nationwide, which distinguishes it from the several Federal courts for which the Federal rules were designed. If parties are permitted to require deponents to appear any place in the nation to suit the lawyers' convenience, discovery can easily constitute a device for harrassment of deponents. The proposed rules would eliminate that problem.

Rule 152-Stipulations regarding discovery procedure.

Unless the presiding officer orders otherwise, the parties may by written stipulation

(1) provide that depositions may be taken before any percon, at any time or place, upon any notice, and in any manner and when so taken may be used like other depositions, and (2) modify the procedures provided by there rules for other methods of discovery.

Rule 153-Depositions upon oral examination.

(a) When depositions may be taken. After commencement of the proceeding, any party may take the testimony of any person, in-cluding a party, by deposition upon oral examination. The attendance of witnesses may be compelled by the use of subpena as provided in Rule 169.

(b) Notice of examination: General requirements. (1) A party desiring to take the deposition of any person upon oral examination chall give reasonable notice in writing to every other party to the action. The notice chall state the time and place for taking the deposition and the name and address of each percon to be examined, if known, and, if the name is not known, a general description suf-ficient to identify him or the particular class or group to which he belongs. If a subpena duces tecum is to be served on the person to be examined, a designation of the materials to be produced thereunder shall be attached to or included in the notice.

(2) If a party taking a deposition wishes to have the testimony recorded by other than stenographic means, the notice shall specify the manner of recording, precerving, and filling the deposition. The presiding officer may require stenographic taking or make any other order to accure that the recorded testimony will be accurate and trustworthy. If requested by one of the parties, the testimony shall be transcribed at the expense of the requesting party.

(3) The notice to a party deponent may be accompanied by a request made in compli-ance with Rule 157 for the production of documents and tangible things at the tak-

ing of deposition.

- (4) A party may in his notice name as the deponent a public or private corporation or a partnership or accordation and must designate with reaconable particularity the mat-ters on which examination is requested. The organization to named shall designate one or more officers, directors, or managing agents, or other persons duly authorized and concenting to testify on its behalf. The percons to designated shall testify as to matters known or available to the organization. This subdivision (b) (4) does not preclude taking a deposition by any other procedure authorized in these rules.
- (c) Examination and cross-examination; record of examination; eath; objections. Examination and cross-examination of witneces may proceed as permitted at the hearing. The officer before whom the deposition is to be taken chall put the witness on eath and chall perconally, or by some one acting under his direction and in his presence, record the testimony of the witness. The testimony shall be taken stenographically or recorded by any other means designated in accordance with subdivision (b) (2) of this rule. If requested by one of the parties, the testimony shall be transcribed.

All objections made at the time of the examination to the qualifications of the offi-cer taking the deposition, or to the manner of taking it, or to the evidence presented, or to the conduct of any party, and any other objection to the proceedings, shall be noted by the officer upon the deposition. Evidence objected to shall be taken subject to the objections. In lieu of participating in the oral examination, parties may serve written ques-tions on the party taking the deposition and require him to transmit them to the officer, who shall propound them to the witness and record the answers verbatim.

- (d) Motion to terminate or limit examination. At any time during the taking of the deposition, on motion of any party or of the deposition, on motion of any party or of the deponent and upon a showing that the examination is being conducted in bad faith or in such manner as unreasonably to annoy, embarrass, or oppress the deponent or party, the presiding officer may order the officer conducting the examination to cease forthwith from taking the deposition, or may limit the scope and manner of the taking of the deposition as provided in Rule 151(d). If the order made terminates the examination, it shall be resumed thereafter only upon the order of the presiding officer before whom the proceeding is pending. Upon demand of the objecting party or deponent, the taking of the deposition shall be suspended for the time necessary to make a motion for an order.
- (e) Submission to witness; changes, signing. When the testimony is fully transcribed the deposition shall be submitted to the witness for examination and shall be read to or by him, unless such examination and reading are waived by the witness and by the parties. Any changes in form or substance which the witness desires to make shall be entered upon a deposition by the officer with a statement of the reasons given by the witness for making them. The deposition shall then be signed by the witness, unless the parties by stipulation waive the signing or the witness is ill or cannot be found or re-fuses to sign. If the deposition is not signed by the witness within 30 days of its submission to him, the officer shall sign it and state on the record the fact of the waiver or of the illness or absence of the witness or the fact of the refusal to sign together with the reason, if any, given therefor; and the deposition may then be used as fully as though signed, unless on a motion to sup-press under Rule 155(d) (4) the presiding officer holds that the reasons given for refusal to sign require rejection of the deposition in whole or in part.
- (f) Certification and filing by officer; exhibits; copies; notice of filing. (1) The officer shall certify on the deposition that the witness was duly sworn by him and that the deposition is a true record of the testimony given by the witness. He shall then securely seal the deposition in an envelope endorsed with sufficient information to identify the proceeding and marked "Deposition of (here insert name of witness)" and shall promptly file it with the presiding officer or send it by registered mail to the Secretary of the Commission.

Documents and things, unless objection is made to their production for inspection during the examination of the witness, shall be marked for identification and annexed to and returned with the deposition, and may be inspected and copied by any party, except that (A) the person producing the materials may substitute copies to be marked for identification, if he affords to all parties fair opportunity to verify the copies by comparison with the originals, and (B) if the person producing the materials requests their return, the officer shall mark them, and the materials may then be used in the same manner as if annexed to and returned with the deposition.

- (2) Upon payment of reasonable charges therefor, the officer shall furnish a copy of the deposition to any party or to the deponent.
- (3) The party taking the deposition shall give prompt notice of its filing to all other parties.
- Rule 154—Depositions of witnesses upon written questions.
- (a) Serving questions: notice. After a proceeding has been assigned for hearing, any party may take the testimony of any person,

including a party, by deposition upon written questions. The attendance of witnesses may be compelled by the use of subpena as provided in Rule 160.

A party desiring to take a deposition upon written questions shall serve them upon every other party with a notice stating (1) the name and address of the person who is to answer them, if known, and if the name is not known, a general description sufficient to identify him or the particular class or group to which he belongs, and (2) the name or descriptive title and address of the officer before whom the deposition is to be taken. A deposition upon written questions may be taken of a public or private corporation or a partnership or association in accordance with the provisions of Rule 153(b) (4).

Within 20 days after the notice and written questions are served, a party may serve cross questions upon all other parties. Within 20 days after being served with cross questions, a party may serve redirect questions upon all other parties. The presiding officer may for cause shown enlarge or shorten the time.

- (b) Officer to take responses and prepare record. A copy of the notice and copies of all questions served shall be delivered by the party taking the deposition to the officer designated in the notice, who shall proceed promptly, in the manner provided by Rule 153 (c), (e), and (f), to take the testimony of the witness in response to the questions and to prepare, certify, and file of mail the deposition, attaching thereto the copy of the notice and the questions received by him.
- (c) Notice of filing. When the deposition is filed the party taking it shall promptly give notice thereof to all other parties.

Rule 155—Use of depositions in commission proceedings.

- (a) Use of depositions. At the hearing or in a pleading, any part or all of a deposition, so far as admissible under the rules of evidence applied as though the witness were then present and testifying, may be used against any party who was present or represented at the taking of the deposition or who had reasonable notice thereof, in accordance with any one of the following provisions:
- (1) Any deposition may be used by any party for the purpose of contradicting or impeaching the testimony of deponent as a witness.
- (2) The deposition of a party or of any one who at the time of taking the deposition was an officer, director, or managing agent, or a person designated under Rule 153(b)(4) or 154(a) to testify on behalf of a public or private corporation, partnership or association which is a party may be used by an adverse party for any purpose.
- (3) The deposition of a witness, whether or not a party, may be used by any party for any purpose if the presiding officer finds: (A) that the witness is dead; or (B) that the witness is at a greater distance than 100 miles from the place of hearing, or is out of the United States, unless it appears that the absence of the witness was procured by the party offering the deposition; or (C) that the witness is unable to attend or testify because of age, sickness, or infirmity; or (D) that the party offering the deposition has been unable to procure the attendance of the witness by subpena; or (E) upon application and notice, that such exceptional circumstances exist as to make it desirable, in the interest of justice and with due regard to the importance of presenting the testimony of witnesses orally in open hearing, to allow the deposition to be used.
- (4) If only part of a deposition is offered in evidence by a party, an adverse party may require him to introduce all of it which is relevant to the part introduced, and any party may introduce any other parts.

Substitution of parties does not affect the right to use depositions previously taken; and, when a proceeding has been dismissed and another proceeding involving the same subject matter is afterward brought between the same parties or their representatives or successors in interest, all depositions lawfully taken and duly filed in the former proceeding may be used in the latter as if originally taken therefor.

(b) Objections to admissibility. Subject to the provisions of subdivision (d) (3) of this rule, objection may be made at the hearing to receiving in evidence any deposition or part thereof for any reason which would require the exclusion of the evidence if the witness were then present and testifying.

(c) Effect of taking or using depositions. A party does not make a person his own witness for any purpose by taking his deposition. The introduction in evidence of the deposition or any part thereof for any purpose other than that of contradicting or impeaching the deponent makes the deponent the witness of the party introducing the deposition, but this shall not apply to the use by an adverse party of a deposition as described in subdivision (a) (2) of this rule. At the hearing any party may rebut any relevant evidence contained in a deposition whether introduced by him or by any other party.

(d) Effect of errors and irregularities in depositions—(1) As to notice. All errors and irregularities in the notice for taking a deposition are waived unless written objection is promptly served upon the party giving the notice.

- (2) As to disqualification of officer. Objection to taking a deposition because of disqualification of the officer before whom it is to be taken is waived unless made before the taking of the deposition begins or as soon thereafter as the disqualification becomes known or could be discovered with reasonable diligence.
- (3) As to taking of deposition. (A) Objections to the competency of a witness or to the competency, relevancy, or materiality of testimony are not valved by failure to make them before or during the taking of the deposition, unless the ground of the objection is one which might have been obviated or removed if presented at that time.
- (B) Errors and irregularities occurring at the oral examination in the manner of tailing the deposition, in the form of the questions or answers, in the oath or affirmation, or in the conduct of parties and errors of any kind which might be obviated, removed, or cured if promptly presented, are waived unless seasonable objection thereto is made at the taking of the deposition.
- (C) Objections to the form of written questions submitted under Rule 154 are waived unless served in writing upon the party propounding them within the time allowed for serving the succeeding cross or other questions and within 10 days after service of the last questions authorized.
- (4) As to completion and return of deposition. Errors and irregularities in the manner in which the testimony is transcribed or the deposition is prepared, signed, certified, sealed, indorsed, transmitted, filed, or otherwise dealt with by the officer under Rules 163 and 154 are waived unless a motion to suppress the deposition or some part thereof is made with reasonable promptness after such defect is, or with due diligence might have been ascertained.

Rule 156-Interrogatories to parties.

(a) Availability; procedures for use. Any party may serve upon any other party written interrogatories to be answered by the party served or, if the party served is a public

or private corporation or a partnership or association, by any officer or agent, who shall furnish such information as is available to the party. Interrogatories may, without leave of the presiding officer, be served upon the party filing the initial pleading in an adversary proceeding and upon any other party with or after service or notice of the pleading

upon that party.

Each interrogatory shall be answered separately and fully in writing under oath, unless it is objected to, in which event the reasons for objection shall be stated in lieu of an answer. The answers are to be signed by the person making them, and the objections signed by the attorney making them. The party upon whom the interrogatories have been served shall serve a copy of the answers and objections within a period designated by the party submitting the interrogatories, not than 30 days after the service thereof or within such shorter or longer time as the presiding officer may allow. The party submitting the interrogatories may move for an order under Rule 159(a) with respect to any objection to or other failure to answer an interrogatory.

(b) Scope; use at hearing. Interrogatories may relate to any matters which can be inquired into under Rule 151(c), and the answers may be used to the extent permitted

by the rules of evidence.

An interrogatory otherwise proper is not objectionable merely because an answer to the interrogatory involves an opinion, contention, or legal conclusion, but the presiding officer may order that such an interrogatory be answered at a later time, or after designated discovery has been completed, or

at a prehearing conference.

(c) Option to produce business records. Where the answer to an interrogatory may be derived or ascertained from the business records of the party upon whom the interrogatory has been served or from an examination, audit or inspection of such business records, or from a compilation, abstract or summary based thereon, and the burden of deriving or ascertaining the answer is sub-stantially the same for the party serving the interrogatory as for the party served, it is a sufficient answer to such interrogatory to specify the records from which the answer may be derived or ascertained and to afford to the party serving the interrogatory reasonable opportunity to examine, audit or inspect such records and to make copies thereof or compilations, abstracts or summaries

If information sought is contained in computer runs, punch cards or tapes which also contain privileged or proprietary information or information proscribed by the Interstate Commerce Act, it shall be a sufficient response under these rules, that the party upon whom the interrogatory has been served is willing to make available to and permit an independent professional organization not interested in the proceeding and paid by the party serving the interrogatory to extract from such runs, punch cards or tapes the information sought in the interrogatory that is not privileged or proprietary information or information proscribed by the Interstate Commerce Act.

COMMENT: Computer runs, punch cards and tapes prepared in the usual course of business can contain a large volume of information, including information which a party is not entitled to receive under these rules. It is frequently a time-consuming and expensive task to rework such data and generally the personnel and machines are limited because their expense is such that no organization can afford to carry any excess capacity. A party should not be denied the benefit of the alternative provided in Rule

156(c) merely because the runs, punch cards or tapes include information that must be protected. Thus, a tender of the runs, punch cards or tapes to an independent cervice organization such as IBM, of integrity and professionally able to program a separation of the data entitled to protection, should be sufficient to give a party upon whom an interrogatory has been served the benefit of the option provided in Rule 156(c).

RULE 157-Production of documents and things and entry upon land for inspection and other purposes.

(a) Scope. Any party may cerve on any other party a request (1) to produce and permit the party making the request, or someone acting on his behalf, to inspect and copy, any designated documents (including writing, drawings, graphs, charts, photographs, phonorecords, and other data compilations from which intelligence can be perceived, with or without the use of detection devices) or to inspect and copy, test, or sample any tangible things which constitute or contain matters with the ccope of Rule 151(c) and which are in the percencion, custody or control of the party upon whom the request is served, but if the writings or data compilations (including computer runs, punch cards and tapes) includes privileged or proprietary information or information proscribed by the Interstate Commerce Act, such writings or data compilations need not be produced under this rule but may be provided pursuant to Rule 156(c); or (2) to permit, subject to appropriate liability releases, and cafety and operating conciderations, entry upon designated land or other property in the possession or control of the party upon whom the request is cerved for the purpose of inspection and measuring, surveying, photographing, testing, or cam-pling the property or any designated object or operation thereon, within the ecope of Rule 151(c).

(b) Procedure. The request may, without leave of the presiding officer be cerved upon any party at any time after the proceeding has been designated for oral hearing subject to the qualification in Rule 151(1), but not after the hearing has begun. The request shall set forth the items to be inspected either by individual item or by category, and describe each item and category with reaconable particularity. The request shall specify a reasonable time, place, and manner of making the inspection and performing related acts. Except as may be ordered by the presiding officer, any place other than the place wherein the records are kept and any time other than usual business hours chall

be considered unreasonable. The party upon whom the request is served shall serve a written response within a period designated in the request, not less than 30 days after the cervice thereof or within such shorter or longer time as the presiding officer may allow. The response shall state, with respect to each item or category, that inspection and related activi-ties will be permitted as requested, unless it is objected to, in which event the reasons for objection shall be stated. If objection is made to part of an item or category, the part shall be specified. The party submitting the request may move for an order under Rule 159(a) with respect to any objection to or other failure to respond to the request or any part thereof, or any failure to permit inspection as requested.

Rule 158-Requests for admission.

(a) Request for admission. A party may serve upon any other party a written request for the admission, for purposes of the pending proceeding only, of the truth of

any matters within the scope of Rule 151(c) cet forth in the request, including the genu-ineness of any documents described in the request. Copies of documents shall be coved with the request unless they have been or are otherwise furnished or made available for inspection and copying. The request may, without leave of the presiding officer, be cerved upon the party filing the initial pleading in an adversary proceeding and upon any party at any time after the proceeding has been designated for oral hearing subject to the qualification in Rule

Each matter of which an admission is requested chall be reparately set forth. The matter is admitted unless, within a period designated in the request, not less than 30 days after cervice thereof or within such chorter or longer time as the presiding officer may allow, the party to whom the request is directed corves upon the party requesting the admission a written answer or objection addressed to the matter, signed by the party or by his attorney. If objection in made, the reasons therefor shall be stated. The answer chall specifically deny the mat-ter or set forth in detail the reasons why the answering party cannot truthfully admit or deny the matter. A denial shall fairly meet the substance of the requested admiscion, and when good faith requires that a party qualify his answer or deny only a part of the matter of which an admission is requested, he shall specify so much of it as is true and qualify or deny the remainder. An answering party may not give lack of information or knowledge as a reason for failure to admit or deny unless he states that he has made reasonable inquiry and that the information known or readily obtainable by him is insufficient to enable him to admit or deny. A party who conciders that a matter of which an admiscion has been requested presents a genuine icque for hearing may not, on that ground alone, object to the request; he may deny the matter or set forth reasons why he cannot admit or deny it.

The party who has requested the admiscions may move for an order with respect to the answers or objections. Unless the preciding officer determines that an objection is justified, it shall order that an answer be corved. If the presiding officer determines than an answer does not comply with the requirements of this rule, he may order either that the matter is admitted or that an amended answer be served. The preciding officer may, in lieu of these orders, determine that final deposition of the request be made at a pre-hearing conference or at a designated time prior to hearing.

(b) Effect of admicsion. Any matter admitted under this rule is conclusively established unless the presiding officer on motion permits withdrawal or amendment of the admiction. The preciding officer may permit withdrawal or amendment when the presentation of the merits of the proceeding will be subserved thereby and the party who obtained the admission fails to satisfy the pre-olding officer that withdrawal or amendment will projudice him in maintaining his pasition on the merits. Any admission made by a party under this rule is for the purpose of the pending proceeding only and is not an admission by him for any other purpose nor may it be used against him in any other proseeding.

Rule 159-Fallure to make discovery.

(a) Motion for order compelling discovery. Upon reasonable notice to other parties and all persons affected thereby, a party may apply to the Commission for an order compolling discovery as follows:

(1) Appropriate officer. An application for an order to a party may be made to the presiding officer before whom the proceeding is pending. An application for an order to a deponent who is not a party shall be made to the presiding officer.

to the presiding officer.

(2) Motion. If a deponent falls to answer a question propounded or submitted under Rules 153 and 154, or a party falls to answer an interrogatory submitted under Rule 156, or if a party, in response to a request for inspection submitted under Rule 157, falls to respond that inspection will be permitted as requested or falls to permit inspection as requested, the discovery party may apply for an order compelling an answer or an order compelling inspection in accordance with the request. On matters relating to a deposition on oral examination, the proponent of the question may complete or adjourn the examination before he applies for an order.

(3) Evasive or incomplete answer. For purposes of this subdivision an evasive or incomplete answer is a failure to answer.

Rule 160-Subpena for taking depositions.

Proof of service of a notice to take a deposition as provided in Rule 153(a), 153(b), and 154(a) constitutes a sufficient authorization for the issuance by the presiding officer of subpenas for the persons named or described therein. The subpena may command the person to whom it is directed to produce designated books, papers, documents, or tangible things which constitute or contain matters within the scope of the examination permitted by Rule 151(c), but in that event the subpena will be subject to the provisions of Rule 151(d) and Rule 56(a) of the Commission's General Rules of Practice.

[FR Doc.71-437 Filed 1-12-71;8:50 am]

# **Notices**

### DEPARTMENT OF THE TREASURY

Bureau of Customs

[T.D. 71-10]

CERTAIN METAL DOLLIES DESIGNED TO TRANSPORT AIRCRAFT ENGINES

Instruments of International Traffic

JANUARY 4, 1971.

It has been established to the satisfaction of the Bureau of Customs that metal dollies, specially designed for the transportation of aircraft engines, are substantial, designed for and capable of repeated use in transportation, and used in substantial numbers in international traffic.

Under the authority of § 10.41a(a), Customs Regulations, I hereby designate the above-described dollies as "instru-ments of international traffic" within the meaning of section 322(a), Tariff Act of 1930, as amended. These dollies may be released under the procedures provided for in § 10.41a.

[SEAL]

MYLES J. AMBROSE, Commissioner of Customs.

[FR Doc.71-444 Filed 1-12-71;8:50 am]

### DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[OR 6920]

#### **OREGON**

Notice of Classification of Public Lands for Multiple-Use Management

In F.R. Doc. 70-16762 appearing at page 18987 in the issue of Tuesday, December 15, 1970, in the sixth line under "T. 23 S., R. 2 W.," the reference to "Sec. 2" should be changed to "Sec. 22".

[C-12187]

#### COLORADO

Notice of Proposed Withdrawal and Reservation of Lands

JANUARY 4, 1971.

The Bureau of Land Management, U.S. Department of the Interior, has filed the above application for the withdrawal of the lands described below from all forms of appropriation under the Public Land Laws, including the General Mining Laws but not the Mineral Leasing Laws, subject to valid existing rights.

The lands are to be set aside for public

recreation areas and protection of endangered species of wildlife.

For a period of 30 days from the date of publication of this notice, all persons who wish to submit comments, suggestions, or objections in connection with the proposed withdrawal may present their views in writing to the undersigned officer of the Bureau of Land Management, Department of the Interior, Colorado Land Office, Room 15019 Federal Building, 1961 Stout Street, Denver, CO 80202.

The Department's regulations (43 CFR 2311.1-3(c)) provide that the authorized officer of the Bureau of Land Management will undertake such investigations as are necessary to determine the existing and potential demand for the lands and their resources. He will also undertake negotiations with the applicant agency with the view of adjusting the application to reduce the area to the minimum essential to meet the applicant's needs, to provide for the maximum concurrent utilization of the lands for purposes other than the applicant's, to eliminate lands needed for purposes more essential than the applicant's, and to reach agreement on the concurrent management of the lands and their resources.

The authorized officer will also prepare a report for consideration by the Secretary of the Interior who will determine whether or not the lands will be withdrawn as requested by the applicant agency.

The determination of the Secretary on the application will be published in the Federal Register. A separate notice will be sent to each interested party of record.

If circumstances warrant, a public hearing will be held at a convenient time and place, which will be announced.

The lands involved in the application

SINTH PRINCIPAL MERIDIAN, COLORADO CATAMOUNT CREEK RECREATION SITE

T. 2 S., R. 84 W., Sec. 8, SW145W14.

LYONS GULCH RECREATION SITE

T. 4 S., R. 86 W.,

Sec. 18, lot 14.

GREATER PRAIRIE CHICKEN RANGE

T. 3 N., R. 43 W.,

Sec. 24, NE!\\NE!\\; Sec. 25, NE!\\\SE!\\.

The areas described aggregate approximately 137 acres.

J. ELLIOTT HALL, Chief, Division of Program Management and Land Office Manager.

[FR Doc.71-386 Filed 1-12-71;8:45 am]

#### Office of the Secretary WILLIAM K. PENCE

Report of Appointment and Statement of Financial Interests

January 6. 1971.

Pursuant to section 302(a) of Executive Order 10647, the following information on a WOC appointee in the Department of the Interior is furnished for publication in the FEDERAL REGISTER:

Name of appointee: William K. Pence. Name of employing agency: Department of the Interior, Defense Electric Power Administration.

The title of the appointee's position: Deputy Director, DEPA Area 6.

The name of the appointee's private employer or employers: Detroit Edison

The statement of "financial interests" for the above appointee is enclosed.

> WALTER J. HICKEL, Secretary of the Interior.

NOVEMBER 20, 1970.

APPORITEE'S STATEMENT OF FINANCIAL INTERESTS

In accordance with the requirements of section 302(d) of Executive Order 10647, I am filing the following statement for publication in the FEDERAL REGISTER.

(1) Names of any corporations of which I am, or had been within 60 days preceding my appointment, on November 20, 1970, as Deputy Director, DEPA Area 6, Defense Electric Power Administration, an officer or director:

(2) Names of any corporations in which I own, or did own within 60 days preceding my appointment, any stocks, bonds, or other financial interests:

Computer Sciences Corp.

(3) Names of any partnerships in which I am associated, or had been assoclated within 60 days preceding my appointment:

None.

(4) Names of any other businesses which I own, or owned within 60 days preceding my appointment:

None.

WILLIAM K. PENCE.

December 4, 1970.

[FR Doc.71-412 Filed 1-12-71;8:47 am]

#### NICHOLAS A. RICCI

#### Report of Appointment and Statement of Financial Interests

JANUARY 6, 1971.

Pursuant to section 302(a) of Executive Order 10647, the following information on a WOC appointee in the Department of the Interior is furnished for publication in the FEDERAL REGISTER:

Name of appointee: Nicholas A. Ricci. Name of employing agency: Department of the Interior, Defense Electric Power Administration.

The title of the appointee's position:

Director, DEPA Area 9.

The name of the appointee's private employer or employers: Wisconsin Electric Power Co.

The statement of "financial interests" for the above appointee is enclosed.

> WALTER J. HICKEL, Secretary of the Interior.

NOVEMBER 20, 1970.

APPOINTEE'S STATEMENT OF FINANCIAL INTERESTS

In accordance with the requirements of section 302(b) of Executive Order 10647, I am filing the following statement for publication in the FEDERAL REGISTER:

(1) Names of any corporations of which I am, or had been within 60 days preceding my appointment, on November 27, 1970, as Director, DEPA Area 9, Defense Electric Power Administration, an officer or director:

Director—Employes' Mutual Benefit Association, Milwaukee, Wis.

Director and Vice President—Employes' Mu-

tual Saving Building and Loan Association, Milwaukee, Wis.

(2) Names of any corporations in which I own, or did own within 60 days preceding my appointment, any stocks, bonds, or other financial interests:

Wisconsin Electric Power Co. Massachusetts Investors Trust. Weyenberg Shoe Co. CNA Financial Co. Master Lock Co. Sextant Corp. National Investors Trust.

(3) Names of any partnerships in which I am associated, or had been associated within 60 days preceding my appointment:

None.

(4) Names of any other businesses which I own, or owned within 60 days preceding my appointment:

None.

NICHOLAS A. RICCI.

DECEMBER 4, 1970.

[FR Doc.71-413 Filed 1-12-71;8:47 am]

#### JOHN A. ROLFING, JR.

#### Report of Appointment and Statement of Financial Interests

JANUARY 6, 1971.

Pursuant to section 302(a) of Executive Order 10647, the following in-

formation on a WOC appointee in the Department of the Interior is furnished for publication in the Federal Register:

Name of appointee: John A. Rolfing, Jr. Name of employing agency: Department of the Interior, Defense Electric Power Administration.

The title of the appointee's position: Director, DEPA Area 18.

The name of the appointee's private employer or employers: Hawaiian Electric Co., Inc.

The statement of "financial interests" for the above appointee is enclosed.

> WALTER J. HICKEL, Secretary of the Interior.

NOVEMBER 20, 1970.

#### APPOINTEE'S STATEMENT OF FINANCIAL INTERESTS

In accordance with the requirements of section 302(b) of Executive Order 10647, I am filing the following statement for publication in the FEDERAL REGISTER:

(1) Names of any corporations of which I am, or had been within 60 days preceding my appointment, on November 20, 1970, as Director, DEPA Power Area 18, an officer or director:

(2) Names of any corporations in which I own, or did own within 60 days preceding my appointment, any stocks, bonds, or other financial interests:

Hawaiian Electric Co., Inc. American Motors Corp. -General Investment Corp.

(3) Names of any partnerships in which I am associated, or had been associated within 60 days preceding my appointment:

None.

(4) Names of any other businesses which I own, or owned within 60 days preceding my appointment:

None.

J. A. ROLFING, Jr.

DECEMBER 11, 1970.

[FR Doc.71-411 Filed 1-12-71;8:47 am]

#### **OUTER CONTINENTAL SHELF OFF CALIFORNIA**

#### Notice of Hearings

Notice is hereby given that public hearings will be held beginning at 10 a.m. on January 13 and 14, 1971, in the Hearing Room of the Board of Supervisors of the County of Santa Barbara, Fourth Floor, County Administration Building, 105 East Anapamu Street, Santa Barbara, CA, for the purpose of receiving comments and suggestions relating to the emplacement of an additional drilling platform on each of two producing Federal oil and gas leases in Santa Barbara Channel.

The hearings on January 13, 1971, will be directed to the additional platform proposed for construction on Federal Lease P-0241 by Union Oil Co., operator

for itself and colessees, Gulf Oil Corp., Texas, Inc., and Mobil Oil Corp. The hearings on January 14, 1971, will be directed to the additional platforms proposed for construction on Federal Lease P-0240, by Sun Oil Co., operator for itself and colessees Marathon Oil Co. and Superior Oil Co.

The hearings referred to herein are not required by law or regulation. However, the lessees have applied for permission to install these new platforms and the Department has scheduled the hearings to obtain additional factual information in order to determine whether special conditions or stipulations should be imposed. Under the terms of the leases and 30 CFR Part 250, the Department is authorized to approve lease development plans, including the location, design and major features of drilling and production platforms.

A transcript of the hearings will be available for public examination. Statements by persons unable to make personal appearance will be received for inclusion in the record for a period of 10 days following the hearings. Such statements should be sent to the District Engineer, U.S. Geological Survey, Room 214, Post Office Building, 836 Anacapa Street, Santa Barbara, CA 93101. Requests to make oral presentations at the hearings must be made to the Office of the District Engineer, U.S. Geological Survey at the above indicated address by the close of business on January 12, 1971, in order to be scheduled.

Oral presentation at the hearings should be brief.

> Fred J. Russell, Under Secretary of the Interior,

JANUARY 8, 1971.

[FR Doc.71-452 Filed 1-12-71;8:50 am]

### DEPARTMENT OF AGRICULTURE

Packers and Stockyards Administration

MOBILE COUNTY STOCKYARDS, INC. ET AL.

#### **Posted Stockyards**

Pursuant to the authority delegated under the Packers and Stockyards Act, 1921, as amended (7 U.S.C. 181 et seq.), on the respective dates specified below, it was ascertained that the livestock markets named below were stockyards within the definition of that term contained in section 302 of the Act, as amended (7 U.S.C. 202), and notice was given to the owners and to the public by posting notices at the stockyards as required by said section 302.

> Name, location of stockyard and date of posting ALABAMA

Mobile County Stockyards, Inc., Mobile, Nov. 19, 1970.

MAINE

Benjamin R. Tilton, East Corinth, Nov. 17, 1970.

MINNESOTA

Top Livestock Auction, Edgerton, Dec. 26, 1970.

#### MONTANA

Baker Livestock Auction, Inc., Baker, Nov. 16, 1970.

TENNESSEE

Tri-County Livestock Auction Co., Dickson, Dec. 21, 1970.

TEXAS

Hubbard Auction Sale, Hubbard, Nov. 23, 1970.

Done at Washington, D.C., this 7th day of January 1971.

G. H. HOPPER, Chief, Registrations, Bonds, and Reports Branch, Livestock Marketing Division.

[FR Doc.71-417 Filed 1-12-71;8:48 am]

### DEPARTMENT OF COMMERCE

Bureau of Domestic Commerce HARVARD UNIVERSITY ET AL.

Notice of Applications for Duty-Free Entry of Scientific Articles

The following are notices of the receipt of applications for duty-free entry of scientific articles pursuant to section 6(c) of the Educational, Scientific, and Cultural Materials Importation Act of 1966 (Public Law 89-651; 80 Stat. 897). Interested persons may present their views with respect to the question of whether an instrument or apparatus of equivalent scientific value for the purposes for which the article is intended to be used is being manufactured in the United States. Such comments must be filed in triplicate with the Director, Scientific Instrument Evaluation Division, Bureau of Domestic Commerce, Washington, D.C. 20230, within 20 calendar days after date on which this notice of application is published in the Federal

Amended regulations issued under cited Act, as published in the October 14, 1969, issue of the Federal Register, prescribe the requirements applicable to comments.

A copy of each application is on file, and may be examined during ordinary Commerce Department business hours at the Scientific Instrument Evaluation Division, Department of Commerce, Washington, D.C.

Docket No. 71-00247-33-46500. Applicant: Harvard University, Purchasing Department, 75 Mount Auburn Street, Cambridge, MA 02138. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used for research and educational training in cellular anatomy, cellular biology (including vertebrate and invertebrate pathology, cellular anatomy, cellular physiology, morphogenesis, and immunology) as well as virology. Investigations concern structures of microtubules and more especially that of the sites from which they develop; and, effect of various biological substances on

cell membranes of Trypanosoma cruzi and its transformation. Application received by Commissioner of Customs: November 5, 1970.

Docket No. 71-00248-91-28600. Applicant: University of Illinois, Office of Business Affairs, Chicago Circle, Post Office Box 4348, Chicago, IL 60680. Article: SIRIGOR Gas-exchange chamber. Manufacturer: Siemens A.G., West Germany. Intended use of article: The article will be used for research on many species of plants having wide geographic ranges spreading over an array of habitats. Field measurements of CO<sub>2</sub> exchange rates for natural arctic, alpine, and temperate populations will be made during the summers (growing season). Controlled environmental studies will be made during the academic months. Application received by Commissioner of Customs: November 5, 1970.

Docket No. 71-00250-33-46500. Appli-

Docket No. 71-00250-33-46500. Applicant: The Lankenau Hospital, Lancaster and City Line Avenues, Philadelphia, PA 19151. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used by the Department of Pathology for examination of blopsy material for diagnostic purposes. The Division of Research is investigating lung transplantation, fine structure of human amnion and chorion, and virus infected cells and tissues. Application received by Commissioner of Customs; November 6, 1970.

Docket No. 71-00251-33-46500. Applicant: Veterans Administration Hospital, 113 Holland Avenue, Albany, NY 12208. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used to produce ultrathin sections for electron microscopic examination. Investigations concern the response of arterial disease to mechanical and hemodynamic injury. Application received by Commissioner of Customs: November 6, 1970.

Docket No. 71-00254-33-46040. Applicant: City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010. Article: Electron microscope, Model HS-8-1. Manufacturer: Hitachi, Ltd., Japan. Intended use of article: The article will be used primarily to investigate the structure of chromosomes of higher organisms utilizing the whole mount electron microscopy technique. Application received by Commissioner of Customs: November 9, 1970.

Docket No. 71-00255-33-46040. Applicant: University of Wisconsin, 750 University Avenue, Madison, WI 53706. Article: Electron microscope, Model HU-11E-1. Manufacturer: Hitachi, Ltd., Japan. Intended use of article: The article will be used by a research group whose prime interest is the integrated study of the structure and function of biological membranes in general and, since it is structurally a system of membranes, of the mitochondrion in particular. Such diverse membranes as human and animal red blood cell ghost membranes, chloroplast membranes from plants and retinal rod membranes from animal eyes will

be studied. Application received by Commissioner of Customs: November 9, 1970.

Docket No. 71-00256-33-46040. Applicant: New Jersey College of Medicine and Dentistry, Department of Biochemistry, 100 Bergen Street, Newark, NJ 07103. Article: Electron microscope, Model EM 300. Manufacturer: Philips Electronics NVD, The Netherlands. Intended use of article: The article will be used in studies involving structure and function at the subcellular level in both mammalian and bacterial systems. On-going projects concern elucidating ultrastructural changes in liver mitochondria during the process of energy transduction and discernment of novel structures in bacteria which are capable of being cultured on n-methylglycine as their sole source of carbon nitrogen and energy. Application received by Commissioner of Customs: November 10, 1970.

Docket No. 71-00257-33-46070. Applicant: Brigham Young University, Purchasing Department, Provo, UT 84601. Article: Scanning Electron Microscope, Model SSM-2. Manufacturer: Hitachi, Ltd., Japan. Intended use of article: The article will be used as a teaching and training instrument for undergraduate and graduate students in the biological sciences in courses entitled Electron Microscopy, Electron Microscopy Laboratory, Cell Biology, and Ultrastructural Interpretation. Application received by Commissioner of Customs: November 10, 1970.

Docket No. 71-00260-33-46500. Applicant: University of Missouri—Columbia. School of Veterinary Medicine, Department of Veterinary Anatomy, Columbia. MO 65201. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used for studies of biological tissues from mammalian sources and used for experimental purposes. These tissues include the central nervous system, infundibulum, hypophysis and testis of the newborn, immature and adult animal for research studying the fine structure of the neryous and endocrine systems. Application received by Commissioner of Customs: November 13, 1970.

Docket No. 71-00261-33-46500, Applicant: University of Southern California, School of Medicine, Dept. of Pathology, 2025 Zonal Avenue, Los Angeles, CA 90033. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used to produce both serial ultrathin sections and one micron thick sections of human and animal brain. Research includes preparation of human tissues obtained at surgery and autopsy in order to study material in which slow or latent viral infection are suspected; and the examination of primary tumors of the human nervous system to search for viral particles and to determine variant submicroscopic cellular differences. Educational purposes include instruction of graduate students in experimental pathology and residents in neuro-pathology. Application received by Commissioner of Customs: November 13, 1970.

Docket No. 71-00262-00-61600. Applicant: South Dakota State University, Brookings, SD 57006. Article: Slip ring Type SK5-40 with brushes SK5-ZB. Manufacturer: BLH Electronics, Inc., West Germany. Intended use of article: The article will be used in a Mechanical Engineering Laboratory course for dynamic measurements and for measurement of stresses of a rotating machine element. Application received by Commissioner of Customs: November 13, 1970.

Docket No. 71-00263-33-46500. Applicant: University of Pennsylvania, Center for Oral Health Research, 4001 Spruce Street, Philadelphia, PA 19104. Article: Ultramicrotome, Model OmU2. Manufacturer: C. Reichert Optische AG, Austria. Intended use of article: The article will be used for studies of the junction of dental tissues with their surrounding supporting structures and of gingival tissue. Experimental studies will involve straight morphological determinations on the dento-gingival junction of various animal species. Experimental alterations in the relationship of periodontal tissues to the tooth will also be studied. Application received by Commissioner of Customs: November 13, 1970.

Docket No. 71-00271-01-77030. Applicant: State University of New York at Buffalo, Office of Facilities Planning, Equipment Division, 3258 Main Street, Buffalo, NY 14214. Article: NMR spectrometer, Model JNM-MH-100. Manufacturer: Japan Electron Optics Lab., Co., Ltd., Japan. Intended use of article: The article will be used for high-sensitivity studies of C-13 sidebands; structure elucidation studies of products from photochemical and thermal reactions of aroylazetidines; and for high resolution spectra of small amounts of sparingly soluble natural products such as hirsutic acid. The article will also be used by graduate students for thesis research and in four undergraduate courses in chemistry. Application received by Commissioner of Customs: November 19, 1970.

Docket No. 71–00272–33–46500. Applicant: Georgetown University Medical School, Department of Obstetrics-Gynecology, 3800 Reservoir Road NW., Washington, DC 20007. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used to study a variety of tissues from the uterine wall with emphasis on the structure and both physiologic and pathologic changes during normal and complicated pregnancy. Application received by Commissioner of Customs: November 20, 1970.

Docket No. 71-00273-33-46500. Applicant: New Jersey College of Medicine and Dentistry, 100 Bergen Street, Newark, NJ 07103. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used for research on irradiated cardiac and aortic wall tissue from rabbits, and, corresponding tissue from untreated rabbits, as control, for comparison. The reactions of

rabbit cardiac and aortic wall tissues to X-irradiation at ultrastructural and histochemical levels will be studied. Application received by Commissioner of Customs: November 20, 1970.

Docket No. 71-00274-33-46040. Applicant: Northwestern University Medical School, Department of Pathology, 303 East Chicago Avenue, Chicago, IL 60611. Article: Electron microscope, Model HU-12. Manufacturer: Hitachi, Ltd., Japan. Intended use of article: The article will be used for studies of the properties of renal tubular basement membrane; the nature of structural and biochemical changes in irreversible ischemic cellular injury; and for protein transport studies. Application received by Commissioner of Customs: November 20, 1970.

Docket No. 71-00275-33-46500. Applicant: University of Illinois, Purchasing Division, Urbana-Champaign Campus, 223 Administration Building, Urbana, L. 61801. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used to thinsection a variety of materials from plants, animals and metals. The investigations involve the study of the ultrastructural properties of these materials and also, the localization and the role of enzymes in plant, animal and microbial cells. Application received by Commissioner of Customs: November 20, 1970.

Docket No. 71-00277-33-90000. Applicant: Carnegie-Mellon University, Mellon Institute, 4400 Fifth Avenue, Pittsburgh, Pa. 15213. Article: Rotating anode K-ray unit, Model GX6. Manufacturer: Elliot Automation Radar Systems, Ltd., United Kingdom. Intended use of article: The article will be used for research on the molecular structure of biological membranes. X-ray diffraction patterns of biological membranes will be recorded during which time the membranes will be maintained in a living condition. Application received by Commissioner of Customs: November 23, 1970.

Docket No. 71-00279-33-46595. Applicant: Retina Foundation, 20 Staniford Street, Boston, MA 02114. Article: Polytron tissue grinder Type PT 20 OD. Manufacturer: Apotheke Oberstrauss Switzerland. Intended use of article: The article will be used for research to evaluate the activity of the fragmented sarcoplasmic reticulum and motochondria in normal and diseased muscles in the hope of discovering causes and eventual cures for various diseases such as muscular dystrophy. Application received by Commissioner of Customs: October 24, 1970.

Docket No. 71-00278-33-4607. Applicant: Iowa State University of Science and Technology, Department of Zoology and Entomology, Ames, IA 50010. Article: Scanning electron microscope, Model JSM-S1. Manufacturer: Japan Electron Optics Lab., Co., Ltd., Japan. Intended use of article: The article will be used for studies relating to biological surface structures. In particular, the application of scanning electron microscopy to in-

sect surface structure will be used in the identification and classification of characters for the study of insect morphology and physiology. Courses in zoology, botany and biochemistry will use the article as a teaching and training tool. Application received by Commissioner of Customs: October 23, 1970.

Docket No. 71-00269-33-90000. Applicant: Duke University Medical Center, Department of Anatomy, Durham, NC 27706. Article: GX-6 X-ray diffraction equipment. Manufacturer: Elliott Automation Radar Systems Ltd., United Kingdom, Intended use of article: The article will be used for low angle X-ray diffraction of wet and living muscles, and experiments designed to explore the molecular behavior of contracting muscle. Application received by Commissioner of Customs: November 19, 1970.

CHARLEY M. DENTON,
Bureau of Domestic Commerce.
[FR Doc.71-381 Flied 1-12-71;8:45 am]

# MALLINCKRODT INSTITUTE OF RADIOLOGY ET AL.

#### Notice of Applications for Duty-Free Entry of Scientific Articles

The following are notices of the receipt of applications for duty-free entry of scientific articles pursuant to section 6(c) of the Educational, Scientific, and Cultural Materials Importation Act of 1966 (Public Law 89-651; 80 Stat. 897). Interested persons may present their views with respect to the question of whether an instrument or apparatus of equivalent scientific value for the purposes for which the article is intended to be used is being manufactured in the United States. Such comments must be filed in triplicate with the Director, Scientific Instrument Evaluation Division, Bureau of Domestic Commerce, Washington, D.C. 20230, within 20 calendar days after date on which this notice of application is published in the FEDERAL RECISTER.

Amended regulations issued under cited Act, as published in the October 14, 1969, issue of the Federal Register, prescribe the requirements applicable to comments.

A copy of each application is on file, and may be examined during ordinary Commerce Department business hours at the Scientific Instrument Evaluation Division, Department of Commerce, Washington, D.C.

Docket No. 71-00184-33-43780, Applicant: Mallinckrodt Institute of Radiology, 510 Kingshighway, St. Louls, MO 63110. Article: Fluoroscopic apparatus for replicating the geometrical factors relevant to positioning a therapeutic unit according to the size, location and extension of the tumor to be treated. Manufacturer: Toshiba (Tokyo Shibaura Electric Co., Ltd., Japan). Intended use of article: The article will be used to test and evaluate the efficacy of the fluoroscopic techniques in localizing and defining the extent of tumors, as well as to develop techniques for blocking of beams. Application received by

Commissioner of Customs: October 1, 1970.

Docket No. 71–00219–33–46070. Applicant: University of Missouri—Columbia, Hospital Purchasing Department, Room W128, Columbia; MO 65201. Article: Scanning electron microscope, Model SSM-2. Manufacturer: Hitachi, Ltd., Japan Intended use of article: The article will be used in a comparative pathology program of the departments of Medical Pathology, Veterinary Pathology, and Plant Pathology, for training electron microscopy techniques at the graduate level. Application received by Commissioner of Customs: October 21, 1970.

Docket No. 71-00226-00-46070. Applicant: University of Missouri—Rolla, General Services Building, Purchasing Department, Rolla, MO 65401. Article: Goniometer Stage. Manufacturer: Japan Electron Optics Lab. Co., Ltd., Japan. Intended use of article: The article is an accessory which will be used with an existing Model JSM-2 scanning electron microscope. Application received by Commissioner of Customs: October 28, 1970.

Docket No. 71–00231–88–43000. Applicant: University of California, Los Alamos, NM 87544. Article: Image Analysing Computer, Model 720. Manufacturer: Metals Research Ltd., United Kingdom. Intended use of article: The article will be used to determine particle size and particle distribution in fine fractions recovered from ceramic samples containing thorium oxide and plutonium oxide. The basis for the research is health safety considerations by determining the amount of breathable fines produced in these materials. Application received by Commissioner of Customs: October 27, 1970

Docket No. 71–00231–88–4300. Applicant: University of California, Los Alamos Scientific Laboratory, Post Office Box 990, Los Alamos, NM 87544. Article: Magnetometer, Model MF-2–100. Manufacturer: Scintrex Ltd., Canada. Intended use of article: The article will be used for a study of geology and hydrology to measure the micromagnetism of the earth's surface in various geographical areas. Application received by Commissioner of Customs: October 27, 1970.

Docket No. 71-00232-01-35000. Applicant: University of California, Los Alamos Scientific Laboratory, Accounting Department, Post Office Box 1663, Los Alamos, NM 87544. Article: Small optical two-circle goniometer. Manufacturer: Stoe & Co., West Germany. Intended use of article: The article will be used to study the interfacial angles of crystalline compounds of radioactive elements to determine crystal symmetry for identification by classification as to type and class. Application received by Commissioner of Customs: October 27, 1970.

Docket No. 71–00233–33–43780. Applicant: The Johns Hopkins University, Charles and 34th Streets, Baltimore, MD 21218. Article: Endoscope. Manufacturer: Manabu Medical Instruments Co., Ltd., Japan. Intended use of article: The article will be used in an otolarynology

residency course in Broncho-Esophagology. The content of the course includes a study of the endoscopic manifestations of diseases of the tracheobronchial tree and esophagus. Application received by Commissioner of Customs: October 27, 1970.

Docket No. 71-00238-99-03400. Applicant: United States Peace Corps, 32 Cristina Street, Ponce, PR 00731. Article: 24 Crusader projectors (battery operated, hand-held type for wall projection of educational materials). Manufacturer: Ray-O-Vac International Corp., Hong Kong. Intended use of article: The article will be used for the training of and the use by Peace Corps Volunteers for audiovisual presentation in connection with their jobs in Central America. Application received by Commissioner of Customs: October 28, 1970.

Docket No. 71-00239-33-46040. Applicant: The Rockefeller University, 66th and York Avenue, New York, NY 10021. Article: Electron microscope, Model EM 300. Manufacturer: Philips Electron NVD, The Netherlands. Intended use of article: The article will be used in the Department of Parasitology and Invertebrate Physiology for high resolution studies in host-parasite relationship of intracellular parasites such as malarla, Babesia and Leishmania as well as for the study of structures involved in the complex feeding mechanism of the protozoan Tokophrya infusionum. Application received by Commissioner of Customs: October 28, 1970.

Docket No. 71-00240-65-86300. Applicant: The University of Tennessee, Department of Chemical and Metallurgical Engr., Knoxville, TN 37916. Article: Viscoelastometer, Model DDV-II. Manufacturer: Toyo Measuring Instruments Co., Ltd., Japan. Intended use of article: The article will be used for the measurement of dynamic modulus and loss modulus for fibers, plastics, elastomers and composites over a range of frequencies and temperatures. Application received by Commissioner of Customs: October 28, 1970

Docket No. 71–00241–99–03400. Applicant: Schoellkopf Geological Museum, Prospect Park, Niagara Reservation, Niagara Falls, NY 14303. Article: Audiovisual equipment. Manufacturer: Creative Sight and Sound Ltd., Canada. Intended use of article: The article will be used in a program coordinated with the Geology Department of the State University of New York at Buffalo for the purposes of training graduate students of the geological sciences in the preparation of materials for the study of geology of the local area. Application received by Commissioner of Customs: October 30, 1970.

Docket No. 71-00242-33-46040. Applicant: Dartmouth College, Hanover, NH 03755. Article: Electron microscope, Model Elmiskop 101. Manufacturer: Siemens A.G., West Germany. Intended use of article: The article will be used for research concerning ribosomes, consisting of protein and ribonucleic acid; for studies on antibodies (convalently coupled to ferritin) against specific ribo-

somal proteins; and a number of macromolecules other than ribosomes will be studied to determine their structure, including RNA polymerase and aspartyl transcarbamylase.

Application received by Commissioner of Customs: October 30, 1970. Docket No. 71-00243-33-46040. Applicant: Duke University Medical Center, Department of Anatomy, Post Office Box 3011, Durham, NC 27706. Article: Electron microscope, Model Elmiskop 101. Manufacturer: Siemens A.G., West Germany. Intended use of article: The article will be used for studies of isolated protein molecules, crystalline bovine serum albumin, subunit structure of several crystalline protein molecules, and of metallic replicas of membrane fragments. Application received by Commissioner of Customs: November 3, 1970.

Docket No. 71-00244-33-46040. Applicant: Mayo Foundation, Rochester, MN 55901. Article Electron microscope, Model HU-12. Manufacturer: Hitachi, Ltd., Japan. Intended use of article: The article will be used for medical research concerning studies of the enlarged heart in experimental animals and in man; electron microscopic studies of the central nervous system; and for an investigation of degeneration of unmyelinated fibers in the central nervous system as well as the study of synaptic contacts and degeneration of these in brain stem nuclei. Application received by Commissioner of Customs: November 3, 1970.

Docket No. 71-00245-33-46040. Applicant: Brigham Young University, Purchasing Department, Provo, UT 24501. Article: Electron microscope, Model HS-8. Manufacturer: Hitachi, Ltd., Japan. Intended use of article: The article will be used as a teaching and training instrument for undergraduate and graduate students in the biological sciences. Courses include Electron Microscopy. Electron Microscopy Laboratory, Cell Biology and Ultrastructural Interpretation. Application received by Commissioner of Customs: November 4, 1970

Docket No. 71-00246-01-10100. Applicant: Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, NY 10461. Article: Temperature jump apparatus. Manufacturer: Messanlagen Studien. GmbH, West Germany. Intended use of article: The article will be used for research to elucidate the relations between the molecular structure and the function of hemoglobin. Other experiments include observations of ultraviolet difference spectra in hemoglobin and studies of the binding of protons with the use of indicators. Application received by Commissioner of Customs: November 4, 1970.

Docket No. 71-00249-65-46070. Applicant: Northwestern University, Department of Materials Science, The Technological Institute, Evanston, IL 60201. Article: Scanning electron microscope, Model JSM-U3. Manufacturer: Japan Electron Optics Lab. Co., Ltd., Japan. Intended use of article: The article will be used in research involving precipitation, nucleation and growth phenomena. The

formation of silicon carbide and silica from a solid solution of silicon containing carbon and/or oxygen will be studied. Another area of study involves catalysts which are used in polymerization reactions and for environmental control uses. Application received by Commissioner of Customs: November 5, 1970.

Docket No. 71-00253-33-46040. Applicant: California State Polytechnic College, 3801 West Temple Avenue, Pomona, CA 91768. Article: Electron microscope, Model EM 9S. Manufacturer: Carl Zeiss. Inc., West Germany. Intended use of article: The article will be used by a faculty member and his students in research concerning the fine structure of intracellular symbiotic bacteroids in insects. General Cytology and Experimental Biology and, Ultrastructural Studies are two courses in which the article will be used to teach electron microscope techniques in the simplest way possible. Application received by Commissioner of Customs: November 9, 1970.

Docket No. 71–00258–65–46040. Applicant: Newark College of Engineering, 323 High Street, Newark, NJ 07102. Article: Electron microscope, Model JEM-120. Manufacturer: Japan Electron Optics Lab. Co., Ltd., Japan. Intended use of article: The article will be used for graduate research in materials science, for undergraduate research and as a training instrument. Particular projects will deal with the relation of materials structure to stress corrosion, crystal growth, whisker formation, deformation charactertistics of polymers, composite materials and metals, creep studies, alloy behavior and fatigue. Application received by Commissioner of Customs: November 13, 1970.

Customs: November 13, 1970.

Docket No. 71–00264–33–01110. Applicant: University of Colorado Medical Center, 4200 East Ninth Avenue, Denver, CO 80220. Article: Amino acid analyzer, Model JLC-5AH. Manufacturer: Japan Electron Optics Lab. Co., Ltd., Japan. Intended use of article: The article will be used to analyze the amino acid composition of insulin and insulin peptides purified from single normal and diabetic pancreata. Studies concern the nature of the molecular difference between biologically abnormal diabetic insulins and the normal. Application received by Commissioner of Customs: November 19, 1970.

sioner of Customs: November 19, 1970.

Docket No. 71–00265–00–61800. Applicant: University of Wisconsin, Marathon County Campus, 518 South Seventh Avenue, Wausau, WI 54401. Article: Projection orrery. Manufacturer: Goto Manufacturing Co., Japan. Intended use of article: The article is an accessory for an existing planetarium instrument. Application received by Commissioner of Customs: November 19, 1970.

Docket No. 71-00266-33-46040. Applicant: Rockefeller University, The Population Council Bio-Medical Division, 66th and York Avenue, New York, NY 10021. Article: Electron microscope, Model EM 300. Manufacturer: Philips Electronics NVD, The Netherlands. Intended use of article: The article will be used for high resolution studies of the mechanism of

action of steroid hormones, namely estrogens at the subcellular level in target cells, by means of autoradiography, study of macromolecules such as proteins and nucleic acids, cellular organelles such as lysosomes, endoplasmic reticulum, golgi body, nuclear and cell membranes. Application received by Commissioner of Customs: November 19, 1970.

Docket No. 71–00267–00–61800. Applicant: University of Wisconsin, Marathon County Campus, 518 South Seventh Avenue, Wausau, WI 54401. Article: Geocentric Earth. Manufacturer: Goto Manufacturing Co., Japan. Intended use of article: The article is an accessory for an existing planetarium in the applicant institution. Application received by Commissioner of Customs: November 19, 1970.

CHARLEY M. DENTON,
Bureau of Domestic Commerce.

[FR Doc.71-382 Filed 1-12-71;8:45 am]

# UNIVERSITY OF WISCONSIN ET AL. Notice of Applications for Duty-Free Entry of Scientific Articles

The following are notices of the receipt of applications for duty-free entry of scientific articles pursuant to section 6(c) of the Educational, Scientific, and Cultural Materials Importation Act of 1966 (Public Law 89-651; 80 Stat. 897). Interested persons may present their views with respect to the question of whether an instrument or apparatus of equivalent scientific value for the purposes for which the article is intended to be used is being manufactured in the United States. Such comments must be filed in triplicate with the Director, Scientific Instrument Evaluation Division, Bureau of Domestic Commerce, Washington, D.C. 20230, within 20 calendar days after date on which this notice of application is published in the Federal Register.

Amended regulations issued under cited Act, as published in the October 14, 1969, issue of the Federal Register, prescribe the requirements applicable to comments.

A copy of each application is on file, and may be examined during ordinary Commerce Department business hours at the Scientific Instrument Evaluation Division, Department of Commerce, Washington, D.C.

Docket No. 71-00280-33-46040, Applicant: University of Wisconsin, 750 University Avenue, Madison, WI 53706. Article: Electron microscope, Model EM 801. Manufacturer: Associated Electrical Industries, Ltd., United Kingdom. Intended use of article: The article will be used for the examination of the mammalian central nervous system; the study of normal animals and those with specific operations or diseases; the determination of the manner in which nerve cells of the brain are interconnected; and a study of ultrathin specimens of mammalian brain. Application received by Commissioner of Customs: October 24, 1970.

Docket No. 71-00281-33-43780. Applicant: The Massachusetts General Hospi-

tal, Fruit Street, Boston, MA 02114. Article: 12 total hip joint replacements. Manufacturer: Protek Ltd., Switzerland. Intended use of article: The article will be used in the study and scientific assessment of hip reconstructions, using total hip replacement in contrast to previously existing modes of reconstructive hip surgery. Medical students will be trained in this technique. Application received by Commissioner of Customs: October 24, 1970.

Docket No. 71-00270-01-86500, Applicant: University of Pennsylvania, Office of Research Administration, Franklin Building, 3451 Walnut Street, Philadelphia, PA 19104. Article: Rheogoniometer, Model R.18. Manufacturer: Sangamo Controls, Ltd., United Kingdom. Intended use of article: The article will be used for studies of polymer solutions and melts, and for viscoelastic properties, including non-Newtonian viscosity and normal stresses, as functions of molecular structure of the polymers. Viscosity and normal stresses as functions of shear rate will be measured, as well as dynamic measurements (small amplitude sinusoidal shearing) with and without superimposed steady-state shearing. Application received by Commissioner Customs: November 19, 1970.

Docket No. 71-00282-33-46500. Appli-

Docket No. 71-00282-33-46500. Applicant: University of Wisconsin, Department of Pathology, Service Memorial Institute, 470 North Charter Street, Madison, WI 53706. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used for projects involving procedures for both investigative and diagnostic examination of a variety of tissues (kidney, brain and lung) with diseases of interest to the immunopathologist. Application received by Commissioner of Customs: November 30, 1970.

Docket No. 71-00283-33-46500. Applicant: Michigan State University, Center for Laboratory Animal Resources, 127D Giltner Hall, East Lansing, MI 48823. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used for a comparative study of placental membranes involving descriptions of the vascular patterns and relationship between the maternal and fetal circulation; monitoring of enzyme activity during the course of pregnancy; and for studies of hormone receptor sites in the placenta. Application received by Commissioner of Customs: November 30, 1970.

Docket No. 71-00284-00-41200. Applicant: Health Research Inc., 666 Elm Street, Buffalo, NY 14203. Article: Klystron tube, Model VC 104. Manufacturer: Varian Associates of Canada, Ltd., Canada. Intended use of article: The article will be used in a study of radiation damage in organs and biological materials as well as radiation protection measures. Application received by Commissioner of Customs: November 30, 1970.

Docket No. 71-00285-91-46500. Applicant: Texas A. & M. University, Department of Biochemistry & Biophysics,

College Station, TX 77483. Article: Ultramicrotome, Model LKB 8800A. Manufacturer: LKB Produkter A.B., Sweden. Intended use of article: The article will be used for studies of tissues from plant embryos (shepherd's purse, peanut, coconut, cotton) and plant endosperm (coconut) to determine how seed specific proteins are synthesized and sequestered in aleurone vacuoles. Application received by Commissioner of Customs: November 30, 1970.

Docket No. 71–00286–58–46070. Applicant: Woods Hole Oceanographic Institution, Water Street, Woods Hole, MA 02543. Article: Scanning electron microscope, Model JSM–U3. Manufacturer: Japan Electron Optics Lab., Co., Ltd., Japan. Intended use of article: The article will be used for research concerning the morphology of small planktonic crustaceans called copepods, collected from widely different areas. Other investigations involve formainifera, radiolarians, bottom sediments and suspended materials in sea-water. Application received by Commissioner of Cusfoms: November 30, 1970.

Docket No. 71-00287-00-46040. Applicant: Cornell University, Ithaca, NY 14850. Article: Large angle goniometer hot stage, Model AHLG. Manufacturer: Japan Electron Optics Lab. Co., Ltd., Japan. Intended use of article: The article is an accessory for an existing JEM-200 electron microscope used for materials science research. Application received by Commissioner of Customs: October 28, 1970.

Docket No. 71-00288-01-28200. Applicant: University of North Carolina, Department of Chemistry, Chapel Hill, NC 27514. Article: Electron spin resonance spectrometer, Model JES-ME-3X. Manufacturer: Japan Electron Optics Lab Co., Ltd., Japan. Intended use of article: The article will be used for material studies on the properties of aromatic hydrocarbon radical anions and radical cations: quinone radical anions; oxygen, sulfur, nitrogen and carbon free radical intermediates; and multimetallic complexes of copper, nickel, cobalt, iron, and manganese. Application received by Commissioner of Customs: December 2, 1970.

Docket No. 71-00289-38-25100. Applicant: Princeton University, Purchasing Department, Post Office Box 33, Princeton, NJ 08540, Article: Computec C-114 Display System with Tektronix Oscilloscope 602. Manufacturer: Computec, Canada. Intended use of article: The article will be used in conjunction with a PDP-8/L computer in studying information processing in human subjects. Such spheres as attention, perception, memory, and reasoning will be examined. Experiments will involve the rapid presentation of stimulus materials (letters, words, numerals, patterns) to subjects, and the recording of their responses and reaction times. Application received by Commissioner of Customs: December 2,

Docket No. 71-00290-01-77030. Applicant: The Institute for Cancer Research, 7701 Burholme Avenue, Philadelphia, PA 19111. Article: NMR Spectrometer, Model

JNM-MH-60-II. Manufacturer: Japan Electron Optics Lab. Co., Ltd., Japan. Intended use of article: The article will be used to study organic chemicals of various types, principally nitrogen heterocycles (purine derivatives), sugar compounds and organophosphorus compounds which are being synthesized. The properties to be studled are the effects (inhibitory, or substrate) of analogs on a variety of enzymes. The objectives of the research are to control and analyze the synthesis of organic compounds to be used for the study of mechanism of enzyme action. Application received by Commissioner of Customs: December 2, 1970.

Docket No. 71-00291-33-01110. Applicant: Wayne State University School of Medicine, Medical Research Building (432), 550 East Canfield Avenue, Detroit, MI 48201. Article: Amino acid analyzer, Model JLC-5AH. Manufacturer: Japan Electron Optics Lab. Co., Ltd., Japan. Intended use of article: The article will be used for the determination of amino acid composition of proteins, analysis of peptides, sugars and nucleic acids, and determination of free amino acids in physiological fluids. Materials to be studied are tissues (including brain, kidney, liver, muscle, heart, etc.), serum, red cells, and urine. The experiments will be conducted with retarded children and for the study of genetics and evolution. Application received by Commissioner of Customs: December 4, 1970.

Docket No. 71-00292-01-07520. Applicant: University of Arizona, Department of Chemistry, Tucson, AZ 85721. Article: Microcalorimeter, Model LKB-10700-2B. Manufacturer: LKB Produkter AB., Sweden. Intended use of article: The article will be used to examine the heat of association of insulin; the heat of small changes in protein conformation, associated with enzymic processes (activation of zymogens and that induced by binding of substrate to lysozyme); and the heat of reaction of small, weakly bound ligands of lysozyme. Application received by Commissioner of Customs: December 4, 1970.

Docket No. 71–00293–00–61800: Applicant: Columbia Museum of Art Commission, 1519 Senate Street, Columbia, SC 29201. Article: Planetarium projector, Model MS-10. Manufacturer: Minolta Camera Co., Ltd., Japan. Intended use of article: The article will be used for astronomy courses for elementary and secondary grades as well as college freshman. Application received by Commissioner of Customs: December 4, 1970.

Docket No. 71–00294–33–46070. Applicant: The Ohio State University, Department of Otolaryngology, 190 North Oval Drive, Columbus, OH 43210. Article: Scanning electron microscope, Model Mark IIA. Manufacturer: Cambridge Instrument Co., Ltd., United Kingdom. Intended use of article: The article will be used for investigations of the surface topography of the inner ear; the study of the freeze drying process by means of a cold stage; the examination of the bone tissues of the middle and inner ears; the study of hearing damage following pro-

longed exposure to noisy environment; and for experiments on the ototoxicity of certain antibiotics. The microscope will be used in connection with courses dealing with various aspects of otolaryngology for medical students and resident physicians. Application received by Commissioner of Customs: December 7, 1970.

Docket No. 71-00295-00-46040. Applicant: University of California, San Francisco, Purchasing Department, 1438 South 10th Street, Richmond, CA 94804. Article: Image intensifier. Manufacturer: Siemens A.G., West Germany. Intended use of article: The article is an accessory for a previously imported Elmishop 101 electron miscroscope used for a study of macromolecules of biological origin. Application received by Commissioner of Customs: December 7, 1970.

Docket No. 71-00298-00-61800. Applicant: Central Florida Museum and Planetarium, 810 East Rollins Avenue, Orlando, FL 32803. Article: Planetarium projector, Model MS-10. Manufacturer: Minolta Camera Co., Ltd., Japan. Intended use of article: The article will be used with an existing control console in courses to demonstrate astronomical phenomena (related to astronomical and navigational sciences as the course subject may require) and also allow student participation and involvement. Application received by Commissioner of Customs: December 7, 1970.

Docket No. 71-00297-33-46040. Applicant: The University of Texas (Southwestern), Medical School at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235. Article: Electron microscope Model EM 9S-2. Manufacturer: Carl Zeiss, Inc., West Germany. Intended use of article: The article will be used by the Department of Anatomy for research on the development and differentiation in Drosophila. The Department of Internal Medicine's research centers around changes in the thickness of the capillary basement membrane in the tissues of persons suffering from diabetes mellitus. Courses in which the electron microscope will be used are Cell Biology, Techniquesiin Cell Biology, Advanced Topics in Anatomy-Electron Microscopy, and Research in Anatomy. Application received by Commissioner of Customs: December 8, 1970. Docket No. 71-00293-33-79200. Appli-

Docket No. 71-00293-33-79200. Applicant: Veterans Administration Hospital, Chief Supply Division, Veterans Administration Building 222, Fort Snelling, St. Paul, MN 55111. Article: Automatic electric all glass water still. Manufacturer: L.V.D. Scorah, United Kingdom. Intended use of article: The article will be used for research where water must be free from contamination, and of the highest purity. Pyrogen free water will be prepared for utilization in other elements for cancer research. Application received by Commissioner of Customs: December 9, 1970.

Docket No. 71-00300-33-46040. Applicant: Baptist Memorial Hospital, 899 Madison Avenue, Memphis, TN 38103. Article: Electron microscope, Model EMPA. Manufacturer: Carl Zeiss Inc., West Germany. Intended use of article: The

article will be used for studies of human and animal tissues as they are altered by hypertension, experimental and spontaneous. In particular, blood vessels from several locations will be examined and renal changes will be studied with special attention to the medullary interstitial cells. The educational programs of the Pathology Department will use the article to teach electron microscopy. Application received by Commissioner of Customs: December 9, 1970.

CHARLEY M. DENTON, Bureau of Domestic Commerce.

[FR Doc.71-383 Filed 1-12-71;8:45 am]

# National Bureau of Standards LIQUID MOUTHWASH PREPARATIONS

#### Notice of Proposed Voluntary Package Guidelines

Notice is hereby given of a proposal received by the National Bureau of Standards from certain manufacturers of liquid mouthwash that is designed to restrict voluntarily the quantities in which liquid mouthwash is packaged for retail sale. This proposal is the result of an informal suggestion by the National Bureau of Standards to a representative number of manufacturers of liquid mouthwash that they review the quantities in which liquid mouthwash is offered for sale. This suggestion was made by the National Bureau of Standards in. furtherance of the intent of Congress under the Fair Packaging and Labeling Act (Pub. L. 89-755; 80 Stat. 1296) to facilitate value comparisons by consumers. The proposal contained in this notice is not a Voluntary Product Standard developed under the formal procedures of the Department of Commerce (15 CFR, Part 10). This proposal represents a voluntary effort by the private manufacturers concerned and is not binding upon the industry. There is no sanction provided for noncompliance with the proposed guidelines.

This notice is published to solicit comments from distributors, consumers, and manufacturers who did not participate in the development of this proposal. These comments will be offered to the proponents of the proposed guidelines by the National Bureau of Standards for their, information and possible use although they are in no way bound to accept the comments. The substance of the proposal offered by the manufacturers of liquid mouthwash is set forth below. Adherence to these proposed guidelines would reduce the currently used 29 sizes to 11 sizes, a 62 percent reduction. Any comments pertaining to the proposed guidelines should be directed to the Office of Weights and Measures, National Bureau of Standards, Washington, D.C. 20234, within forty-five (45) days of the publication of this notice in the FEDERAL REGISTER.

VOLUNTARY PACKAGE GUIDELINES FOR LIQUID MOUTHWASH PREPARATIONS

When packaged in quantities greater than 32 fluid ounces, liquid mouthwash will be packaged in 8-ounce increments, such as 40 ounces, 48 ounces, 56 ounces, etc. When packaged in the quantity range of 4 ounces to 32 ounces, liquid mouthwash will be packaged in the following quantities: 4, 6, 7, 8, 12, 14, 16, 18, 20, 24, and 32 ounces.

Issued: January 7, 1971.

LEWIS M. BRANSCOME, Director.

Approved:

RICHARD O. SIMPSON,
Acting Assistant Secretary for
Science and Technology.

[FR Doc.71-406 Filed 1-12-71;8:47 am]

# LIQUID NON-NUTRITIVE SWEETENERS

#### Notice of Proposed Voluntary Package Guidelines

Notice is hereby given by the National Bureau of Standards of a proposal received from some manufacturers of liquid artificial sweeteners that is designed to restrict voluntarily the quantities in which liquid non-nutritive sweeteners are packaged for retail sale. This proposal is the result of an informal suggestion by the National Bureau of Standards to a representative number of manufacturers of liquid non-nutritive sweeteners that they review the quantities in which liquid non-nutritive sweeteners are offered for sale. This suggestion was made by the National Bureau of Standards in furtherance of the intent of Congress under the Fair Packaging and Labeling Act (Pub. L. 89-755; 80 Stat. 1296) to facilitate value comparisons by consumers. The proposal contained in this notice is not a Voluntary Product Standard developed under the formal procedures of the Department of Commerce (15 CFR, Part-10). This proposal represents a voluntary effort by the private manufacturers concerned and is not binding upon the industry. There is no sanction provided for noncompliance with the proposed guidelines.

This notice is published to solicit comments from distributors, consumers, and manufacturers who did not participate in the development of this proposal. These comments will be offered to the proponents of the proposed guidelines by the National Bureau of Standards for their information and possible use although they are in no way bound to accept the comments.

The substance of the proposal offered by the manufacturers of liquid non-nutritive sweeteners is set forth below. Adherence to these proposed guidelines would reduce the currently used 12 sizes to 10 sizes, a 16% percent reduction. Any comments pertaining to the proposed guidelines should be directed to the Office of Weights and Measures, National Bureau of Standards, Washington, D.C. 20234, within forty-five (45) days of the publication of this notice in the Federal

VOLUNTARY PACKAGE GUIDELINES FOR LIQUID NON-NUTRITIVE SWEETENERS

All manufacturers of liquid, non-nutritive sweeteners, in order to fulfill the

spirit of the Fair Packaging and Labeling Act and to assist consumers in making value comparisons, will concentrate their production in the following fluid ounce quantities:

1	6	12
2	8	16
3	10	20
4		

Further, when sweetness equivalent information is provided, it will be stated in terms of a teaspoon of sugar in addition to any other comparisons.

Issued: January 7, 1971.

LEWIS M. BRANSCOME, Director.

Approved:

RICHARD O. SIMPSON,
Acting Assistant Secretary for
Science and Technology.

[FR Doc.71-407 Filed 1-12-71;8:47 am]

### DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration
[Docket No. FDC-D-269; Various NDA's]

#### NEW DRUG APPLICATIONS

#### Notice of Opportunity for Hearing

The holders of the new-drug applications listed herein have advised the Food and Drug Administration that the new drugs involved were never marketed or marketing has been discontinued.

Notice is hereby given to each holder of the new-drug applications listed herein that the Commissioner of Food and Drugs proposes to issue an order under the provisions of section 505(0) of the Federal Food, Drug, and Cosmetic Act withdrawing approval of such applications and all approved amendments and supplements therete on the grounds that marketing of the articles having been discontinued or the articles having never been marketed, annual reports of experience with the drug required under section 505(j) of the Act (21 U.S.C. 355 (j)) and new-drug regulations 21 CFR 130.13 and 130.35 (e) and (f) have not been submitted for each new drug listed.

The objective of this action is to close a large number of new-drug files on drugs that have been discontinued or were never marketed. Some of the drugs involved may classify as not now requiring new-drug applications, depending upon composition and labeling claims. Withdrawal of approval of these applications is not for the purpose of classifying the products as new drugs or of applying the efficacy provisions of the act to drugs of the same composition marketed by other firms.

Upon request, the Commissioner will supply to any interested person directly concerned, a statement of the composition of any of the drugs listed herein to the extent that such information was disclosed or required by law to be disclosed in the labeling.

In accordance with the provisions of section 505 of the Act (21 U.S.C. 355) and the new-drug regulations (21 CFR Part 130), the Commissioner will give the applicants named, and any interested person who would be adversely affected by an order withdrawing such approvals. an opportunity for a hearing to show cause why approval of the following new-drug applications should not be withdrawn:

Abbott Labs, 14th and Sheridan Road, North Chicago, Illinois 60064. NDA's:

0-0005, Delsterol in Oil.

0-0103, Klotogen Solution & Capsules.

0–0476, Sulfapyridine Capsules.

0-1706, Anthralin Cream. 0-1848, Sodium Sulfapyridine & Sodium Sulfapyridine Monohydrate Injection. 0-2291, Kayquinone Capsules, Tablets & Drops.

0-2296, Nictinamide Elixir, Injection & Tablets.

0-2383, Progestin Injection. 0-2878, Sulfathiazole Tablets.

0-3269, Rotene Solution.

0-3351, Natopherol Capsules, Injection & Liquid.

0-3467, Sulfapyridine Enteric Coated Tablets.

0-4047, Stilrone Tablets.

0-4048, Stilrone Enteric Coated Tablets.

0-4050, Stilrone Suppository.

0-4120, Bejectal Injection. 0-4123, Sodium Sulfathiazole Anhydrous Injection.

0-4126, Camphacidol Solution.

0-4146, Syntopherol Actate Injection & Tablets.

0-4185, Hydrosorb Ointment.

0-4225, Sodium Sulfathiazole Sesquinhydrate Injection.

0-4226, Hammonds Mixture Tablets. 0-4249, Epinephrine in Oil Injection.

0-4442, Ca Phantothenate Injection & Tablets.

0-451, Mannitol Nitrate Tablets. 0-4597, Iso-Metaphen Injection. 0-4752, Sulfanilamide Cream, Tablets &

Ointment.

0-4754, Sulfathiazole Tablets.

0-4785, Sulfanilamide Powder. 0-4859, Cenolate-G Injection. 0-5008, Vitamin D Capsules. 0-5044, Sulfapac Paste.

0-5238, Glucophylline Injection.

0-5278, Sulf-opto Solution. 0-5430, Sulfamerazine Tablets. 0-5442, Stilpalmitrate Injection.

0-5524, Thrombin Local Solution.

0-5542, Vijectin Injection. 0-5647, Thiouracil 100 Mg. Tablets. 0-5764, Amethone & Nembutal Capsules

& Amethone Capsules. 0-6179, Folic Acid Injection & Tablets &

Folic Acid & Iron Tablets.

0-6193, Methadone Hc1 Injection, Solution, Syrup, & Tablets.
0-6229, Chloguanide Hc1, 0.1 Gm., 0.3 Gm. Tablets.

0-6246, Pentaquine Phosphate Tablets. 0-6279, Thenylene Hydrochloride Tablets

& Cream, 2%, Tablets, 25 mg., 50 mg.; Thenylene & Desoxyn Tablets; Thenyl-fred & Glucophylline Tablets; Thenylfred Tablets.

0-6298, Sulfedexan Liquid.

0-6408, Urethane Solution.

0-6432, Norothydroguaiarectic Acid.

0-6434, Mosical Tablets. 0-6557, Hepasolan Injection. 0-6594, Natopherol AC Capsules & In-

0–6597, Sorlate Capsules. 0–6916, Lissephen Capsules.

0-7035, Bevidox Crystalline Injection.

0-7095, Theophylline for Oral Injection. 0-7121, Bevidox Conc/Injection. 0-7258, Sucaryl Sodium Tablets.

0-7910, Alrizane Cl Tablets.

0–8090, Cumopyran Tablets.
0–8162, Tetracycine Hyperiodide Tablets.
0–8204, Vinisil Injection.
0–8471, Isolyn Tablets.

0-9550, Selsun 0.5% Cream. 0-000, Tenserina Tablets. 10-600, Amethone Hol Conc/Injection.

11-523, Dextran 1273 Injection. 11-681, Tral Injection.

11-701, Polybrene Sterile Solution Injection.

12-013, Traleyon Filmtab.

A. C. Barnes, New Brunswick, New Jersey. NDA 0-5997, Argypulvis Powder & Capsules.

Acme Scientific Company, Post Office Box 8826, Richmond, Virginia 23225. NDA's:

0–6465, Lotex Solution. 0–6941, A-Eleven Ointment.

A. H. Robins Company, Inc., 1407 Cummings Drive, Richmond, Virginia 23220. NDA's:

0–9907, Pabalate W/Cortisone Tablets. 12–256, Dimedrine Extentabs. 13–023, Tranpoise.

Air Reduction Company Inc., Murray Hill,

New Jersey 07974. NDA 0-9674, Vinamar Etaylvinyl Ether INH.

Aktiebolacet Kabi/Sweden/Stockholm, Swe-

den U.S. agent: Tuteuk Bio-Chemicals, New York 5, New York. NDA 12-781, Meprobamate Tablets. Alba Phamaceutical Company, Inc., Division Sterling Drug Inc., 80 Variek Street, New York, N.Y. 04100. York, N.Y. 94100.

NDA's:

0-0474, Desynon OPS.

0-2719, Sulfathiazole Powder,

0–3674, Sulfathiazole SOD Injection. Allergan Corporation, 18600 Von Karman Avenue, Irvine, California 92705.

NDA's: 0-9227, Cortefrin.

10-364, HY-Cortefrin 0.5% Ophthalmic Solution. 10-365, HY-Cortefrin 0.12% Ophthalmic

Solution. Allied Biochemical Labs, Inc., 33 Berry Street,

San Francisco, California 94100. NDA's 0-4322, Childrens Tablets Sulfathiazole

Tablets. 0-5052, Mandelacol Tablets.

0-5053, Mandelasol W/Chlorethamine Tablets.

Allied Labs, Inc., 12550 Euclid Avenue, Cleveland, Ohio 44106.

NDA 0-3645, Sulfathiazole Tablets.

Almay Division Schieffelin & Company, Apex, N.Y. 27502.

NDA 0-1886, Aloe Vera CPD Ointment, Veral Ont.

American Cyanamid Company, N.Y., N.Y. NDA 11X897, Trophenium.

American Home Products Corporation, 3600 American Drive, Chamblie, Georgia 30005.

NDA 0-5844, Bepadin Drops.

American Pharmaceutical Company, 120 Bruckner Blvd., Bronx, New York, 10454.

0-0335, Belexa Emulsion.

0-0337, Beleza Elixir.

0-0338, Beleza Tablets.

0-0339, Ferabex Tablets. 0-0340, Belexon, Capsulcs. 0-0391, All American Formula for Hair & Scalp Liquid.

0-0996, Isolo Liquid.

0–2409, Sulfapyridine Tablets. 0–7787, Pyrahist Tablets.

0-8464, Gentamin Tablets.

American Roland Corporation, 16 Hudson Street, New York, N.Y.

NDA 0-8583, Iconiazid Tablets, Ame: Company, Inc., 819 McNaughton Ave-nue, Elkhart, Indiana 46518.

NDA's: 0-7199, Para Aminocalicylic Acid Powder. 0-8187, Apromal Tablets. 0-9325, Nostyn Tablets.

11-216, Nostyn. AMM-I-DENT Inc., 257 Cornellison Avenue, Jercey City, N.J. 07302. NDA 0-9893, Ammoniated Dentrifrice W/

Fluoride TPT.

Anahist Company Inc., Yonkers, N.Y. NDA's:

0-7478, Anahist Solution and Anahist Atomizer Solution.

0-7593, Anahist Tablets.

0-7789, Anahlot Syrup. 10-081, Vita Boost Capsule & Tablets.

10-991, Vita Boost Capsule & Taolets.
Andromachus Corporation, 11 West 42nd
Street, New York, N.Y. 10013.
NDA 0-1561, BES-MIN Liquid.
Arlington Funk Labs, Division US Vitamin &
Pharmaceutical Corporation, 26 Vark
Street, Yonkers, New York.

NDA's: 11-474, Prednyl Tablets.

11-475, Prednis-CVP Capsules.

Armand Company, 124 Des Moines Street, Des Moines, Iowa.

NDA's:

0–5383, Alertin Solution. 0–5383, Alertin Compound.

Armour & Company, Division Armour Phar-maceutical Company, 401 N. Wabash Avenue, Chicago, Illinois, 60690.

NDA's: 0-2073, Folestrin Capsule, Injection &

Suppository. 0-2250, Suprarenal In-Gelatin Mixture Injection.

0-6288, Enterogastrone Hol Injection.

0-6365, Dial Scap. 0-6366, Formula 99 Antiseptic Liquid Hand Scap.

Armour Labs, Division Armour Pharmaceutical Company, Post Office Box 511, Kan-kakee, Ill. 69301.

NDA's:

0-1729, Progesterone Injection. 0-3499, Hydcholin Tablet. 0-4089, Stilbestrol Injection and Tablet. 0-4127, Liver Liquid Parenteral Injec-

tion.

0-5952, Flurcoteol Tablet & Bat. 0-6827, Vitamin B12 Conc Injection. 0-8904, Acthar in Oil Injection.

0-8164, Acthar Solution. 0-8465, Xiphisternal Cartilage Mis. 0-8497, Armazide Tablets.

0-8985, Infiltrace Injection.

0-9887, Armyl-F Tablets.

10-454, Nitensar Tablets. Atlas Pharmaceutical Labs, Inc., 13 Conant Ave., Detroit, Michigan 48212.

10-257, Recerpine Injection. 10-958, Cobalamin Conc Injection.

11-573, Drocode Bitar Trate. Avecno Corporation, 2300 North 17th Street, Philadelphia, Penncylvania. NDA 11-693, Bitupal-HC Cream.

Averat Labs, Division American Home Products Corporation, 685 Third Avenue, New York, N.Y. 10017.

NDA's: 0-4031, Estrobene Injection & Supposi-

tory.
0-6261, Tomectin Liquid.
0-8092, Diucardyn SOD Mercapomerin SOD Injection.

11–516, Vanay. 11–563, Hibitane Lozenge.

11-859, Theruhistin-SA Forte Tablets.

11–966, Timovan Tablets.	Bowman Brothers Drug-Company, 119	0-0094, Nicotinic Acid-Calco Tablets.
Ayerst, McKenna & Harrison Ltd., New York	Schroyer Avenue, S.W., Canton, Ohio.	0-0160, Sulfapyridine Tablets.
16, N.Y.	NDA's:	0-1679, Guanine HCL Calco Injection.
NDA's:	0–2398, Sulfapyridine Tablets.	0-1854, Sodium Sulfapyridino Monohy-
0–0902, Alphamin Capsule and Tablets.	0–3521, Sulfathiazole Tablets.	drate Injection.
0–3255, Kavitan Capsule.	0–8313, Cortisone AC Tablets.	0–2664, Nicotinicacidamido Bat.
0-4179, Estrobene Injection.	0–8533. Hexamethonium CL Tablets.	0–2729, Sulfathiazolo Tablets.
0-5547, Dicumarol Tablets.	0–8544, Isoniazide Tablets.	0–2906, Quino-Thrombin Tablets.
0–8005, Exorbin Tablets.	10–398, Obefat Tablets.	0–3203, Riboflavin Tablets.
0-8580, Deravine Tablets.	Boyle & Company, 6330 Chalet Drive, Com-	0-3264, Calcium Boro-Hibate Powder.
Bard-Saratoga Labs, 98-101 Sawmill River	merce, California 90022.	0-3331, Vi-Ferrin Capsules,
Road, Yonkers, N.Y. 10701.	NDA's:	0-3411, Sodium Sulfapyridine Tablets.
NDA 10-489, Harvamine Tablets.	0-6308, Stilbest-Oral.	0-3435, Sodium Sulfathiazole Injection.
Barlow-Maney Labs, Inc., Cedar Rapids, Iowa.	12–171, Antinergic Tablets.	0-4055, Sulfadiazine.
		0–4206, Sulfacetamide Tablets.
NDA's:	Chattanage Medicine Company, Division	0-4753, Pyridoxine Bat.
0-6998, Decyl Capsules & Ecc.	Chattanooga Medicine Company, 1715	Campbell Pharmaceuticals Inc., 685 Third
0-7096, Vitamin B-12.	West 38th Street, Chattanooga, Tennessee	
0-8369, VIR-I-PHYL ECT.	37409.	Avenue, N.Y., N.Y. 10017.
0-8393, Neothylline Rectal Suppository.	NDA's:	NDA's:
0-9123, Loten Tablets.	0–7375, Pyrabrom Tablets.	0-1419, Pernovin Tablets.
Barne-Hind Labs, Division Barnes-Hind	0–8660, Predema Tablets.	0-2395, Novatropine Injection.
Pharmaceutical, Inc., 895 Kifer Road,	Breon Labs, Inc., Sub Sterling Drug Inc., 90	0-5529, Mercupurin ECT.
Sunnyvale, California 94086.	Park Avenue, N.Y., N.Y. 10016	10-654, Keramin Injection.
NDA's:	NDA 10–699, Maxúkal Solution.	Campbell Products, Inc., 79 Madison Avenue,
0-7853, Pasna Lyophilized Injection.	Brewer & Company, 2900 North 17th Street,	N.Y., N.Y.
0-8742, Takon Skin Protectant Ointment.	Philadelphia, Pennsylvania 19132.	NDA:
10-735, Vitamin B-12 Injection.	NDA's:	0-3306, Alutropin Liquid.
Bauer & Black, Division Kendall Company,	0-3618, Vikon Capsules and Injection.	Carnrick Labs, Division G. W. Carnrick,
309 West Jackson Blvd., Chicago, Illinois	0-3839, Sulfathiazole Tablets.	65 Horse Hill Road, Cedar Knolls, N.J.
60606.		07927.
NDA's:	0-6519, Cytochrome C Injection.	NDA's:
	0-8133, Novapan DPS.	0-0131, Estrapropin Injection.
0-0903, Sutures made from Nylon.	0–8450, No-Na-Carb Sol.	
0-2246, Zytor Multifilament Suture.	0–8586, Arogesic Tab.	0-1000, Typsogen Tablets.
0-4607, Blue Jay Corn Plasters DRE.	0–9806, R S Thesodate Tablets.	0-1001, Typsogen ECT.
Baxter Labs. Inc., 6301 Lincoln Avenue, Mor-	11–115, Reserpine Tablets.	0-1031, Incresol Liquid.
ton Grove, Illinois 60053: Travenol Labs,	Bristol Meyers Company, Divisions Bristol	0-1057, VGN Tablets.
Inc.	Labs, Inc., & Bristol Myers Products, 630	Carroll Dunham Smith Pharmacal Company,
NDA's:	Fifth Avenue, N.Y., N.Y. 10020.	Division Smith, Miller & PATO, 903
0-4035, Dextrose-SOD Citrate-SOD CL	NDA's:	Broadway, N.Y., N.Y. 10010.
Solution.	0-6266, Folic Acid Tablets.	NDA's:
0-6041, 10% Alcohol & 5% Dextrose In-	0-9574, Sentry Sodium Fluoride TPT.	0–0667, Ferrous Sul Exsiccated Tablets.
jection.	10–016, Biogels Capsules.	0-0836, Estrusol Injection.
0-7710, Travenol Solution 6% Gelatin	10-363, Bi-Fluor Dentifrice TPT.	0–1118, Thiamin CL Elixir.
W/V in water and in o-9% Saline In-	10–494, Corto-Bufferin Tablets.	0-1424, Quabain Injection.
		0-1582, Nicotinic Acid Tablets.
jection.	Bryan JH, Spencer, West Virgina.	0-1869, Progesterol Injection.
12-798, Caregin IA and IV Injection.	NDA 0-2050, Vigor-Lax Liquid.	0-2053, Liver & Thismin Injection.
Bergen Pharmacal Company, Inc., 354 Mercer	Bryant Pharmaceutical Corporation, 70 Mac-	0-2168, Sulfapyridine Tablets.
Street, Jersey City, N.J. 07302.	questen Parkway South, Mt. Vernon, N.Y.	0-2315, Epinephrine-Gel Injection.
NDA 0-9688, Reserpine Alkaloid Tablets.	10550.	0–2568, Estrusol Tablets.
B. F. Ascher & Company, Inc., 5100 E. 59th	NDA 10-057, Reserpine Elixir.	0-2961, Aspir-Phenobarb w/CA Tablots.
Street, Kansas City, Missouri 64130.	Buffington Inc., 8 Sudbury Street, Worcester,	
NDA's:	Massachusetts.	0–2992, Somnol Tablets.
0-8796, Tridynex Tablets.	NDA's:	0-3066, Sulfathiazolo Tablets.
0–9624, Serolfia Tablets.	0-2191, Special Formula #152654 AJ	0-3537, Aspirpops Lozenge.
	Gaudet M.D. Tablets.	0-3712, Kanone Injection and Tablet.
Bilhuber-Knoll Corporation, Crane Street,	0-3378. Chola-K-Tablets.	0-4137, Pyridoxine HCL Injection & Tab-
Orange, N.J.	0-4070, Sulfathiazole Tablets.	lot.
NDA's:	0–4423, Entells Estrosyn.	0-4352, Stilbestrol Injection.
0-6045, Denethyl AMP.		
		0-4395, Liver Solution Injection.
0-8024, Paracodin Bitartrate Injection	0–4636, Allahzole PAS.	0–4395, Liver Solution Injection. 0–4480, Sacasu Injection.
	0–4636, Allahzole PAS. Burroughs Wellcome & Company, Inc., USA/	0–4395, Liver Solution Injection. 0–4480, Sacasu Injection. 0–4675, Estrusol Injection.
0-8024, Paracodin Bitartrate Injection and Tablets.	0–4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y.	0-4395, Liver Solution Injection. 0-4480, Secasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiourecil.
0-8024, Paracodin Bitartrate Injection and Tablets. Bishop Labs, Inc., 374 50th Street, Brooklyn,	0–4636, Allahzole PAS. Burroughs Wellcome & Company, Inc., USA/	0–4395, Liver Solution Injection. 0–4480, Sacasu Injection. 0–4675, Estrusol Injection.
0-8024, Paracodin Bitartrate Injection and Tablets. Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.	0–4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y.	0-4395, Liver Solution Injection. 0-4480, Secasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL.
0-8024, Paracodin Bitartrate Injection and Tablets. Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220. NDA 0-4671, Nitrallium Tablets.	0–4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracii. 0-6546, Isorenin Solution.
0-8024, Paracodin Bitartrate Injection and Tablets. Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220. NDA 0-4671, Nitrallium Tablets. Bisodol Company, New Haven, Connecticut.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:	0-4395, Liver Solution Injection. 0-4480, Secasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL.
0-8024, Paracodin Bitartrate Injection and Tablets. Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220. NDA 0-4671, Nitrallium Tablets. Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic So-	0-4395, Liver Solution Injection. 0-4480, Secasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut, NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracii. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets.
0-8024, Paracodin Bitartrate Injection and Tablets. Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220. NDA 0-4671, Nitrallium Tablets. Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets. Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule.	0-4395, Liver Solution Injection. 0-4480, Secasu Injection. 0-4675, Estrusol Injection. 0-6426, Propylithiomecil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets.
0-8024, Paracodin Bitartrate Injection and Tablets. Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220. NDA 0-4671, Nitrallium Tablets. Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets. Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701. NDA's:	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableta. 12-075, Triamar Tableta. Casimir Funk Labs, Division, US Vitamin
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Biair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's: 10-321, Serphylline Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's: 10-321, Serphylline Tablets. 10-322, Serphedrine Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic So- lution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL.BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableto. 12-075, Triamar Tableto. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's:
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut, NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Riboflavin Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fropylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableto. 12-075, Triamar Tableto. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Enelone Tablets.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's: 10-321, Serphylline Tablets. 10-322, Serphedrine Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trislicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Riboflavin Tablets. 0-2968, Avimal Elixir.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableta. 12-075, Triamar Tableta. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encacorb Tablets.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets.  10-322, Serphedrine Tablets.  10-323, Serphedrine Tablets.  10-324, Serphylline Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic So- lution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Ribofiavin Tablets. 0-2968, Avimal Elixir. 0-3262, Tabloid Koaxin Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Enclone Tablets. 0-7851, Encsorb Tablets. 0-8503, Tisin Tablets.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Riboflavin Tablets. 0-2968, Avimal Elixir. 0-3262, Tabloid Koaxin Tablets. 0-3263, Hypoloid Mewadlone Injections.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fstrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableto. 12-075, Triamar Tableto. 12-075, Triamar Tableto. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Enclone Tablets. 0-7851, Encscorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Biair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Ribofiavin Tablets. 0-2968, Avimal Elixir. 0-3262, Tabloid Koaxin Tablets. 0-3263, Hypoloid Mewadione Injections. 0-3387, Hypoloid N Cotine Acid Amide	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fertrusol Injection. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableta. 12-075, Triamar Tableta. 12-075, Triamar Tableta. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Enclone Tablets. 0-7851, Encscorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chi-
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut, NDA 0-4733, Aspertane Tablets.  Biair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Riboflavin Tablets. 0-2968, Avimal Elixir. 0-3262, Tabloid Koaxin Tablets. 0-3263, Hypoloid Mewadione Injections. 0-3887, Hypoloid N Cotine Acid Amide Injection.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableta. 12-075, Triamar Tableta. 12-075, Triamar Tableta. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encscorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60606.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. 10-324, Serphylline Tablets. 10-325, Serphedrine Tablets. 10-326, Serphylline Tablets. 10-327, Serphylline Tablets. 10-328, Serphylline Tablets.  Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic So- lution Drops and Spray.  0-0213, Magneslum Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encscorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60608. NDA's:
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets.  Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3887, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fertusol Injection. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Enclone Tablets. 0-7851, Encsorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60606. NDA's: 0-4685, Estrogonic Substance Injection.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Biair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets.  Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's: 0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Riboflavin Tablets. 0-2968, Avimal Elixir. 0-3262, Tabloid Koaxin Tablets. 0-3263, Hypoloid Mewadione Injections. 0-3387, Hypoloid N Cotine Acid Amide Injection. 0-3983, Stil Bestrol Tablets. 0-4151, Tabloid Stil Bestrol Tablets. 0-4291, Stil Bestrol Injection.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fetrusol Injection. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Enelone Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C.B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60606. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's:	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic So- lution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableta. 12-075, Triamar Tableta. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-8503, Tisin Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC, 309 W. Jackson Bivd., Chicago, Illinois, 60606. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets. 0-7697, Khellammin Tablets.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's: 0-2724, Brozanthine Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableto. 12-075, Triamar Tableto. 12-075, Triamar Tableto. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Enclone Tablets. 0-7851, Enescorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60608. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets. 0-7697, Khellammin Tableto. CD Smith Pharmacal Company, Now Bruns-
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. Black Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's:  0-2724, Brozanthine Tablets. 0-2824, Ephedromal Capsules.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2963, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3887, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.  0-7218, Nedepinine Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fertusol Injection. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encacorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60608. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets. 0-7697, Khellammin Tablets. CD Smith Pharmacal Company, New Brunswick, N.J.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's: 0-2724, Brozanthine Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/ INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray. 0-0213, Magnesium Trisilicate Granule. 0-0214, Phenobarbitol & Three Bromides Granule. 0-0898, Tabloid CA Manelate 8.5 GR. 0-2565, Special Formula NO NY 161 Ribofiavin Tablets. 0-2968, Avimal Elixir. 0-3262, Tabloid Koaxin Tablets. 0-3263, Hypoloid Mewadione Injections. 0-3837, Hypoloid N Cotine Acid Amide Injection. 0-3983, Stil Bestrol Tablets. 0-4151, Tabloid Stil Bestrol Tablets. 0-4291, Stil Bestrol Injection. 0-6453, Paludrine. 0-7217, Necepinine Spray. 0-7218, Nedepinine Tablets. 0-8441, Hexameton Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fetrusol Injection. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Enescorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60606. NDA's: 0-4685, Estrogenic Substance Injection. 0-7697, Khellammin Tablets. 0-7697, Khellammin Tablets. CD Smith Pharmacal Company, Now Brunswick, N.J. NDA 0-3595, B-Complex Injection.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's:  0-2724, Brozanthine Tablets.  0-2824, Ephedromal Capsules.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.  0-7218, Nedepinine Tablets.  0-8441, Hexameton Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableta. 12-075, Triamar Tableta. 12-075, Triamar Tableta. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encacorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60608. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stillbestrol Tableta. 0-7697, Khellammin Tableta. CD Smith Pharmacal Company, New Brunswick, N.J. NDA 0-3595, B-Complex Injection. Central Pharmacal Company, 120-128 E.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Biair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-322, Serphedrine Tablets. 10-323, Serphylline Tablets. 10-324, Serphylline Tablets. 10-324, Serphylline Tablets.  Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Fowder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's:  0-2724, Brozanthine Tablets.  0-2824, Ephedromal Capsules.  0-3196, Thiamine HCL Tablets.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.  0-7218, Nedepinine Tablets.  0-8441, Hexameton Tablets.  0-8441, Hexameton Injection.  0-8930, Hexameton Injection.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fertusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encscorb Tablets. 0-8503, Tisin Tablets. 0-9503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60606. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets. 0-7697, Khellammin Tablets. CD Smith Pharmacal Company, New Brunsvick, N.J. NDA 0-3595, B-Complex Injection. Central Pharmacal Company, 120-123 E. Third Street, Soymour, Indiana 47274.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut, NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-322, Serphedrine Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's: 0-2724, Brozanthine Tablets. 0-2824, Ephedromal Capsules. 0-3196, Thiamine HCL Tablets. 0-3529, Isofedrol Solution.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.  0-7218, Nedepinine Tablets.  0-8441, Hexameton Tablets.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tableta. 12-075, Triamar Tableta. 12-075, Triamar Tableta. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encacorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60608. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stillbestrol Tableta. 0-7697, Khellammin Tableta. CD Smith Pharmacal Company, New Brunswick, N.J. NDA 0-3595, B-Complex Injection. Central Pharmacal Company, 120-128 E.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Fowder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's: 0-2724, Brozanthine Tablets. 0-2824, Ephedromal Capsules. 0-3196, Thiamine HCL Tablets. 0-3529, Isofedrol Solution. 0-3752, Follestrol Injection.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.  0-7218, Nedepinine Tablets.  0-8441, Hexameton Tablets.  0-8441, Hexameton Injection.  0-8930, Hexameton Injection.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Fertusol Injection. 0-6425, Propylithiouracil. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Encscorb Tablets. 0-8503, Tisin Tablets. 0-9503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60606. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets. 0-7697, Khellammin Tablets. CD Smith Pharmacal Company, New Brunsvick, N.J. NDA 0-3595, B-Complex Injection. Central Pharmacal Company, 120-123 E. Third Street, Soymour, Indiana 47274.
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Blair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets. Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Powder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's: 0-2724, Brozanthine Tablets. 0-2824, Ephedromal Capsules. 0-3196, Thiamine HCL Tablets. 0-3529, Isofedrol Solution. 0-3752, Follestrol Injection. 0-3995, Synkay Tablet. 0-4784, Hemalirone Elixir.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Riboflavin Tablets.  0-2968, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3387, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.  0-7218, Nedepinine Tablets.  0-8441, Hexameton Tablets.  0-8442, Hexameton Injection.  0-8930, Hexameton Injection.  10-644, Pipadone Injection.  Calco Chemical Company, Division American Gvanamid Company, Bound Brook, NJ.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6475, Estrusol Injection. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Enceorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60608. NDA's: 0-4686, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets. 0-7697, Khellammin Tablets. CD Smith Pharmacal Company, New Brunswick, N.J. NDA 0-3595, B-Complex Injection. Central Pharmacal Company, 120-128 E. Third Street, Soymour, Indiana 47274. NDA's:
0-8024, Paracodin Bitartrate Injection and Tablets.  Bishop Labs, Inc., 374 50th Street, Brooklyn, N.Y. 11220.  NDA 0-4671, Nitrallium Tablets.  Bisodol Company, New Haven, Connecticut. NDA 0-4733, Aspertane Tablets.  Biair Labs, Inc., 99-101 Shaw Mill River Road, Yonkers, N.Y. 10701.  NDA's:  10-321, Serphylline Tablets. 10-322, Serphedrine Tablets. 10-323, Serphedrine Tablets. 10-324, Serphylline Tablets.  Block Drug Company, Inc., 257 Cornelison Avenue, Jersey City, N.J. 07302.  NDA 10-539, Wernets w/Hydroctisone AC Fowder.  Blue Line Chemical Company, 302 South Broadway, St. Louis, Missouri 63102.  NDA's:  0-2724, Brozanthine Tablets. 0-2824, Ephedromal Capsules. 0-3196, Thiamine HCL Tablets. 0-3529, Isofedrol Solution. 0-3752, Follestrol Injection. 0-3995, Synkay Tablet.	0-4636, Allahzole PAS.  Burroughs Wellcome & Company, Inc., USA/INC Scarsdale Road, Tuckahoe, N.Y. 10707.  NDA's:  0-0212, Vaporole Ephedrine Isotonic Solution Drops and Spray.  0-0213, Magnesium Trisilicate Granule.  0-0214, Phenobarbitol & Three Bromides Granule.  0-0898, Tabloid CA Manelate 8.5 GR.  0-2565, Special Formula NO NY 161 Ribofiavin Tablets.  0-2962, Avimal Elixir.  0-3262, Tabloid Koaxin Tablets.  0-3263, Hypoloid Mewadione Injections.  0-3887, Hypoloid N Cotine Acid Amide Injection.  0-3983, Stil Bestrol Tablets.  0-4151, Tabloid Stil Bestrol Tablets.  0-4291, Stil Bestrol Injection.  0-6453, Paludrine.  0-7217, Necepinine Spray.  0-7218, Nedepinine Tablets.  0-8441, Hexameton Injection.  0-8930, Hexameton Injection.  0-8930, Hexameton Injection.	0-4395, Liver Solution Injection. 0-4480, Sacasu Injection. 0-4480, Sacasu Injection. 0-4675, Estrusol Injection. 0-6576, Issrusol Injection. 0-6546, Isorenin Solution. 0-7012, VI-TWEL. 0-7601, VI-TWEL-BEX Injection. 0-9423, Hemo-Vitol Liquid. 10-738, Theracor Tablets. 12-075, Triamar Tablets. Casimir Funk Labs, Division, US Vitamin Corporation, New York, N.Y. NDA's: 0-7272, Encione Tablets. 0-7851, Enescorb Tablets. 0-8503, Tisin Tablets. 0-9002, Stanone. C. B. Kendall CC., 309 W. Jackson Bivd., Chicago, Illinois, 60606. NDA's: 0-4685, Estrogonic Substance Injection. 0-4790, Stilbestrol Tablets. 0-7697, Khellammin Tablets. CD Smith Pharmacal Company, New Brunsvick, N.J. NDA 0-3595, B-Complex Injection. Central Pharmacal Company, 120-123 E. Third Street, Seymour, Indiana 47274. NDA's: 0-3543, Sulfathiazole Tablets.

	Hones	491
0-7687, Theomersyl Injection.	0-3438, Calcium Levulinate Injection.	0-3835, Phenacy Tablet.
0-8979, Cenaten Tablets.	0-3476, Phenatrium Tablets.	0-3836, Posta-Cole Tablet.
0-9183, Neocylate w/Cortisone. 0-9890, Act Ylate, w/Cortisone Tablets.	0–3567, Trichlorplex Elixir. 0–3904, Rx #8 of FH Coeur-Barron MD	0–3885, Colagog Tablet.
10–362, Parmal Timules SRC.	Tablet.	0–4067, Gentian Violet Ect. 0–4079, VAD Capsules.
10-450, Resercen Timules SRC.	0-3916 2 Me-Naphihoquinone Tablets.	0–4095, FEV Tablets.
10–802, Neocylate-HC Tablets. 10–949, Rubecen-1000 Injection.	0–3980, Sulfathiazole Tablets.	0-4102, Pyreb Ointment.
11–050, Biosercen Capsules.	0-5534, Sulfed Solution. 0-5784, Podolin Ointment.	0–4133, Fetone Solution. 0–4145, CA Pantothenate Capsules.
Charles C. Haskell & Co. Inc., 223 E. Main	0-9107, Acetylduo Tablets.	0-4193, Klot Capsules.
Street, Richmond, Va.	10–115, Citrisan Tablets.	0-4393, Dietatilbestrol Tablets.
NDA's: 0-1139, Belphedribarb Tablets.	10–252, Resydess Tablets. 11–132, Reserpine.	0-4489, Angul Ointment. 0-4522, Chorionic Gonadotropin Injec-
0–2353, Hasac Tablets.	11–133, Reserpine.	tion.
0-2410, Belnesium Tablets.	11–246, Rouwolfia Serpentina.	0–4548, Biotal Tablets.
0–3557, Pantabee w/Iron Capsules. 0–3558, Pantabee Capsules.	Ciba Pharmaceutical Company, Division Ciba	0-4896, Redelfur Cream.
0-4082, Sulfanilamide Vaginal Supposi-	Corporation, 556 Morris Avenue, Sum- mit, NJ 07901.	0–4572, Dyccole Tablets. 0–4976, Arthol Tablets.
tory.	NDA's:	0-5077, Siazole Tablets.
0-4376, Duosulfon Ointment. 0-4446, Duoviron Tablets.	0–0499, Perandren Ointment.	0-5030, Vagiquin Tablets.
0-5061, Duosulfon Suspension.	0-0719, Perandrenal Ointment & Perandrenal Testosterone Ointment.	0-5978, Thiouracil Tablets. 0-7033, Crystalline Vitamin B12 Injec-
0-9636, Querserdin Tablets.	0-0741, Ovocylin Ointment, Solution,	tion.
Chas Pfizer & Company Inc., 235 E. 42nd Street, N.Y., N.Y. 10017.	Suppository & Tablet.	0-8300, Veracole Tablets.
NDA's:	0-0742, Ben-Ovocylin Injection.	0-9382, Colgeric Tablets.
0-8686, Cotinazin Injection.	0–0743, Lutocylin Injection. 0–2857, Sulfathiazole Tablets.	Colgate Palmolive Company, 300 Park Avenue, N.Y., N.Y. 10022.
0-8956, Neodrol Injection.	0-4584, Stilbestrol Tablets.	NDA's:
0–9226, Cortril Acetate. 0–9350, Bonine Chewing Tablets.	0–7873, Dibistine Tablets.	0-9553, Colgate Tooth Powder TPT.
10-291, Cortril Soluble Injection.	0-8056, Tricainal Suppository & Oint-	0-9764, Brick.
10-950, F-28 Ointment.	ment. 0–8115, Stenandren Injection & Tablets.	12-100, Coleo Antibacterial Deodorant w/TCSA Soap.
11–187, Moderil Elixir. 11–466, Ataraxoid Elixir.	0-8469, Cortisone Ac Oint. & Susp.	13-297, Coleo Antibacterial Decdorant
11–649, Dilombrin Iodide Tablets.	0–8478, Esomid CL Syrup & Tablets.	Scap.
Chase Chemical Company, 280 Chestnut	0-9534, Pyribenzamine Anesthetic Solu- tion & Tablet.	Colombus Pharmacal Company, Division
Street, Newark, N.J. 07105.	10–213, Serpatilin Tablets.	Philips Roxane Inc. 330 Oak Street, Columbus, Ohio 43216.
0-9237, Mephenesin.	10-631, Ecolid Chloride Injection.	NDA's:
0-9446, Rauwolfia Serpentina Tablets.	10-933, Serpasil-Ecolid Chloride Roto-	0-0141, Mycccide Powder.
0-9531, Rauwolfia Serpentina w/Vera-	cotes Tablets. 11–069, Doriden-Ritalin Tablets.	0-0142, Vitamin B Complex Syrup. 0-0277, Guala-Cream Cream.
trum Viride Tablets. 0–9666, Reserpine Tablets.	11-177, Transtine-PA Tablets.	0-0472, Protocaine Injection.
0-9767, Tocyl Capsules and Tablets.	11-237, Bradosol Bromide Powder, Solu-	0-0331, Vitamin B Complex Tablets.
Chattanooga Medicine Company, 1715 W.,	tion & Tincture.  11–480, Serpasil Ritalin Tablets.	0-1003, K CL Tablet. 0-1182, Vitamin B Complex w/Iron
38th Street, Chattanooga, Tennessee 37409.	11-540, Tessalon.	Tablets.
NDA 0-3740, Zyrone Liquid.	11–711, Bradoform Tablets.	0-1351, AAP Tablets.
Chemedic, Division Chicago Pharmaceutical	11-861, Orisul Sus/Children & Orisul Tablets.	0-1366, Vitamin B1 Injection. 0-1651, Hycosil Powder.
Company, 5547 N. Ravenswood Avenue,	11–915, Cosulid Capsules & Tablets.	0-1652, Nuclnal T 830 Tablets.
Chicago, Illinois 60640. NDA 12-566, Vial 90A Sterile Solution	12-053, Apresoline Lontabs.	0–1931, Heptamar Liquid.
Injection.	12-326, Novidrix Tablets.	0-1974, Thiamin HCL Elixir.
Chicago Pharmacal, Division Conal Pham.	12-929, Dianarit-B Capsules & Dianarit Capsules.	0-2150, Pharynoids Lozenga. 0-3636, Alpha Tocopherol Injection.
Inc., 5547 N. Ravenswood Avenue, Chi-	Cole Pharmacal Company, 3721 Laclede Ave-	0-3812, Sulfanilamide Ointment.
cago, Illinois 60640. NDA's:	nue, St. Louis, MO 63108.	0-3843, Meriold Lotion.
0-0485, Special Formula for Dr. Herbert	NDA's:	0–4265, Sulfathiazole Tablets. 0–4357, Stilbestrol Tablets.
T. Cov Tablets.	0-0536, Be-Min Liquid. 0-0537, Be-Min Tablets.	0-4454, Stilbestrol Injection.
0-0508, Special Formula for Dr. F. L. Barnes Tablets.	0-0815, Cevitanic Acid Tablets.	0-4483, Colloidal Calcium Gelatinate
0-0707, Dr. Ben H. Hoggins Special Rx	0-0908, Coles Sulfiron Liquid.	Solution. 0-4549, Sulfanilamide & Sulfathiazole
#16.	0-0929, Beeco Tablets. 0-0933, Sulfiron Tablets.	Ointment.
0-0708, Dr. Ben H. Hoggins Special Rx #17.	0-1114, Sulfanilamide & Sodium Bicar-	0-4919, Sulfathar Ointment.
0-0709, Dr. John T. McDonald Special Rx	bonate Tablets.	0-5071, Sulfathiazole & Thiourea Ointment.
#1.	0–1115, Alkamag Powder & Tablets. 0–1177, Carbromal S GR Tablets.	0-5136, Sulfathiazole & Benzocaine TRH.
0-0801, Special Formula for Dr. A. C. Archam-ault Ect.	0–1930, Coles Yeronux Tablets.	0-5921, Thiouracil Tablets.
0-0802, Special Formula for Dr. B. B.	0-2071, Colebenz Lotion.	0–6510, Prthiouracii Tablets. 0–8012, Khellin ECT.
Black,	0-2345, Calcretin Tablets & KA-EN Tab- lets.	10-863, Reconium Tablets.
0-2158, Special Formula for Dr. F. P. Krotsch Tablets.	0-2415, Glycomin Liquid.	11-513, Bronkedyl.
0-2318, Special Formula Rx #1 for Dr.	0-2551, Chloridextrose Tablets.	11-824, Nescuta Creme.
G. N. Welch Tablets.	0-2680, Thiamin CL Injection.	Cook-Waite Labs, Inc., Division Professional Services & Res., 170 Varick Street, New
0–2582, Propalcain Injection. 0–2583, #20 Solution.	0–3270, Mercuric Oxide & Ephedrine Sul- fate Ophthalmic Ointment.	York, N.Y.
0-2584, Solution #19.	0-3271, Phenacaine Hydrochloride Sul-	NDA 0-5212, Novocain-Tutocain-Cobefrin
0–2588, Sulfapyridine Tablet,	fate Ophthalmic Ointment,	Injection. Cooper Timbey Labs, Inc., Harrison, N.J.
0-2820, #1 of R. W. Kirchberg MD Tablet.	0–3300, Colbron Capsules. 0–3421, Sulfapyridine Tablets.	NDA 12-253, Cupertin Cream.
0-2829, FH Deane MD Rx #1 Ect 0-2872, Pentobarbital Sodium Tablet.	0–3451, Glin Tablets.	Cosmos Chemical Corporation, 625 Broadway,
0-3038, Phenylmercuric Nitrate w/Ben-	0–3466, Sulfathiazole Tablets.	New York, N.Y. 10012.
zocaine Lozenge.	0-3548, AL Subacetate Ointment.	NDA 0-8585, Iconiazid Tablets.
0-3052, Phenobarbital & Atropine Sul- fate Tablets.	0-3549, AL Subacetate w/Zinc Oxide Ointment.	Cowley Pharmaceutical Inc., 65 Southbridge Street, Auburn, Massachusetts, 01501.
0–3071, #132A Tablet.	0-3705, Decaps/Vitamin D/Cappules.	NDA 0-3653, Recerpine Tablets.
0-3436, Betavite Injection.	0-3710, Caloe Ointment.	Creviston & Company, Inc., Chicago, Illinois.
0–3437, Rx #7/JB Ross Tablets.	0–3715, Sulfanilamide Tablets.	NDA 10-569, Cobextin Injection.

Crookes Labs Inc., 305 E. 45th Street, New York, N.Y. NDA's: 0-0520, Enzo-Cal Liquid & Lotion. 0-1046, Feralumina Suspension. 0-4313, Neo Oestranol 1 Injection & Tablet. 0-7565, Gentexin Tablets. 0-7774, Gentisan Tablets. 0-9503, Raupertenal Tablets. Crookes-Barnes Labs Inc., Division Chemway Corporation, Fairfield Road, Wayne, N.J. NDA's: 11-656, Corphos. 12-023, Pellar Antifungal Ointment. 12–105, Pellar Powder. Cutter Labs., 4th and Parker Streets, Berkeley, California 94710. NDA's: 0-0152, Gonadin Injection. 0-677, Iodobismitol w/Saligenin. 0-1024, Sobisminol Solution. 0-1025, Sobisminol Capsules. 0-6558, D Tubocurarine CL. 0-6682, Liprinel Capsules. 0-6980, Anionium Capsules. 0-9400, Polyvinylpyrrolidone 3½% in Saline Injection. 10-541, Bynamid Lotion, Ointment, TCT, and Powder. Dabney Pharmacal Inc., Indianapolis, Indiana. NDA's: 0-4878, Male Sex Hormone Injection. 0-4880, Progesterone Injection.

Dandrug Company, 4109 Amos Avenue, Baltimore, Maryland 21215. NDA 0-6473, Sulfodandrug Solution. Darby, E. H., Box 169, Florence, Alabama. NDA 0-1867, Famous Old South Laxative Liquid. Davis & Geck, Division American Cyanamid Company, Brooklyn, N.Y. NDA 0-4152, Anacap Cotton Suture. Davis Emergency Equipment Company, Inc., 45 Hallock Street, Newark, N.J. NDA 10-659, Isodine Applicators and Swabs Dressing.

Direct Labs Inc., 377 Genesee Street, Buffalo,
N.Y. 14204 (Direct Sales Company Inc.). NDA's: 0-3273, Sulfanilamide & Sodium Bicarbonate Tablets. 0–3334, Sulfapyridine Tablets. 0–3442, Sulfathiazole Tablets. 0–3723, Digitalis Leaves Tablets. 0-4795, Stibestrol Tablet. 0–4842, Sulfathiazone 5PC Ointment. 0-482, Sunathiazone of Commercial 10-763, Dipentrate & Reserpine Tablets. 10-767, Hyoresat Tablet. Doak Company, Inc., 2000 Shames Drive, Westbury, L.I., N.Y. 11590. 0-2295, Sepolin PAS. 0-5879, Cuprosal Ointment. Doho Chemical Corporation, New York, N.Y. NDA 0-7104, Rhinalgan Solution. Dome Chemical Inc., 125 West End Avenue, New York, N.Y. NDA's: 10-459, Methoka-Dome Capsules & Solu-10-704, Stan-A-Dome Cream. 11-342, Albadome Lotion. 11-962, Sarcophen. 13-144, Ocu-Cort-Solution. Don Baxter, Inc., Division of McGraw Labs, Inc., 1015 Grandview Avenue, Glendale, California 91201. NDA's: 0-2957. 0-2957, Sulfanilamide 0.4% W/V in Phsiological Solution of S. 0-3757, Sulfanilamide Injection.

0-3758, Sulfanilamide Injection.

**NOTICES** 0-4523, Histamine Diphosphate Solution. 0-4669, Sulfanilamide Powder. 0–4726, Isotonic Lubricating Jelly. 11–040, Octylan Compound Tablets. Dow Corning Corporation, Midland, Michigan NDA 0-9568, Dymasyl Liquid. Drugmaster Inc., 2700 Wagner Place Mary-land Heights, Missouri 63042. NDA 11–286, Reserpine. Drumlin, Inc., New York, New York, NDA 0-4599, Drumlin Liquid. Dumas-Wilson & Company, St. Louis, Missouri. NDA 7-092, Alenic Enteric Coated Cap-Durr Products, 26 Vark Street, Yonkers, New York 10701. NDA 10-588, Al-Serpine Injection. E. Fougera & Company, Inc., Cantiague Rock Road, Post Office Box 73, Hicksville, New York 11800. NDA's: 0-1551, Carbismoquin W/Gum Sterculia Tablet. 0-6867, Histaphene Tablet. 0-8138, Euforil Injection. 0-8170, Epocaine Injection. 0-9381, Laudolissin Methylsulfate Injection. 11-584, Orabilex. Eaton Labs, Division of Norwich Pharmacal Company, 17 Eaton Avenue, Norwich. NDA's 0–7050, Histron Tablets. 0–7183, Euraspor Cream & Ointment. 10-545, Reserpine Alkaloid Tablets. 11-965, Altafurtab. E. I. Dupont De Nemours & Company, Wilmington, Delaware. NDA 0-0005, Delsterol Opthamic Solution. E. L. Patch Company, 38 Montvale Avenue, Stoneham, Massachusetts, NDA's: 0-0113, Kondremul W/Senna Drops Liquid. 0-1323, Suplatone Capsules. 0-1866, Patchs NAS Jelly. 0-2877, Trimagnol Tablet. 0-3303, Secremol Liquid. 0-4517, Diestrene Enteric Coated Tablets. 0-5919, Syntaclo Ointment. 0-6291, Glytheonate Powder, Solution, Suppository, Syrup and Tablets. 0-7525, Glybrom Tablets. 0-9808, Glytheonate P.S. 10-086, Myopurin Tablets. Eli Lilly and Company, Box 618, Indianapolis, Indiana 46206. NDA's: 0-0158, Nipectin Liquid. 0-0181, Monoethanolamine Morrhuate Injection. 0-0182, Picrotoxin Injection. 0-1020, Sobisminol Injection. 0-1021, Sobisminol Capsules. 0-2292, Sodium Sulfapyridine Monohydrate Injection. 0-5343, Sulfathiazole Lozenge. 0-5709, Thiouracil Tablets, 0, 1%, 0.2% Gm. 0-6294, Hesperidin ME Chalcone Capsules. 0-6307, Guanatol HCL Suspension and Tablets. 0-6713, Sodium, 5-PH-5-Thienyl Hydantoinate 2 Gr. Capsules. 0-6961, Betalin Crystalline Injection. 0-7064, Konogen Tablets.
0-7655, Thiocarbarsone Solubilized Pow-0-8009, Sol Dicurin Sod W/Theophylline Injection. 0-8029, Choline and Inositol Solution. 0-8151, Primaquine Tablets.

0-8815, Amytal Sod Injection. 0-9179, Acetyl Strophanthidin Injection. 0-9338, Sod Thiocyanate. 0–9514, I Lotycin Injection. 0–9959, Paskate Pulvules Capsules. 10–366, Pyronil & Sodium Undcoylenate 10–468, Sandril Oral Drops. 10–995, Darvon W/ASA Pulvules Capsules. 11–239, Nicotinic Acid Tablets. 12-017, Chlopropamide 100 Mg. & 250 Mg. Capsules.
12–217, Vortel Syrup.
12–629, Valdron Pulvules.
Endo Lobs, Inc., 1000 Stewart Avenue, Garden City, New York 11530. NDA 10-861, Perin Wafers. Endo Products Company, 84-101 Street, Richmond Hill, 18, Now York. NDA's: 0-0539, Aldin Tablets. 0-1598, Manibee W/Ferrous Sulfate Endo Tablets. 0-1599, Manibeo Tablets. 0-1703, Thyroid Enteric Coated Tablets and Tablets. 0-1710, Estromone W/Vitamin B1 Injection. 0-2224, Nikethamide Injection and Solution. 0-2494, Pentobarbital Sod Capsules and Injection. 0-2891, Alpha Tocopherol Injection and Tablets. 0-2904, Aminophylline Enterio Coated Tablets 0-2905, Nicobee Elixir. 0-3458, Sulfathiazolo Tablets.
0-3530, Estromone W/Thyroid Tablets.
0-3746, Trikedan Sedium Tablets.
0-3880, Sulfapyridine Tablets.
0-4189, Stilbestrol Enteric Coated Tablets. lets, Injection, and Tablets. 0–4653, Pancal Solution and TABlets. 0–4854, Sulfathiazole Cream 5% Ointment. 0-5271, Nigenol Tablets. 0-6415, Hyflavin. 0-6433, Morusul Injection. Ennis Coffee Company, Kansas City, Missouri. NDA 0-2836, Salas Granules. E. R. Squibb & Son, Division Olin Mathieson Chemical Corporation, 909 Third Avenue, New York, New York 10022. NDA's: 0-0173, Hydanyl Capsulo and Powder. 0-0291, EPinephrine in Oli Injection. 0-0350, Stabisol Suspension. 0-0422, Sulfapyridine Tablets. 0-0829, Statasan Granules.
0-0829, Vita K Concentrate Solution.
0-1022, Sobisminol Injection.
0-1023, Sobisminol Mass Squibb Capsules. 0-1920, 2-Methyl 14 Naphthoquinone Injection. 0-1998, Procholon Sod Solution Injection. 0-2096, Sulfapyridine Sod Squibb Injection. 0-2701, Sulfathiazole Ointment and Powder. 0-2767, Pyridoxine HCL Capsule and Liquid. 0-3053, Sulfathiazolo Sod Infection. 0-3129, Nicotinamido Capsules, Elixir, and Injection. 0-3416, CA Pantothenate Injection and Calcium Pantothenate Tablets. 0-3426, Synthepiex-B Capsules. 0-3728, Mannitol Hexanitrato Tablets. 0-4011, Parentosol-B Injection. 0-4217, Sulfadiazine Injection and Powder. 0-5027, Zinc Sulfathiazolo Ointment. 0-5177, Sulmefrin Opthalmic Solution. 0-5331, Sulmefrin Opthalmic Solution. 0–5375, Celteric Enteric Coated Tablets. 0–5396, Sulfamerazino Tablets. 0-5511, Dicumarol Capsules.

0-8221, Cortisone AC Tablets.

0-8273, Cortisone AC Injection. 0-8376, ACTH.

0-8624, ACTH Lilly Injection.

EW Heun Company, St. Louis, Miccourl.

NDA 0-9091, Isoniazide Tab.

Fairchild Bros. & Foster, Wachington & Light
Sts., New York, N.Y.

NDA 0-2519, Pepsencin Solution.

Fellows-Testagar Company, Division Fellows
Medical MFG Company, Inc., 1354 West
Lafayette Blvd., Detroit, Michigan 48226.

NDA 0-9681, Ascorbocaine Capsules.

Essler Company, Inc., Stamford, Connecticut. FJ Laurol Company, 7475 North Rogers Ave-nue, Chicago, Illinois 69628. NDA 12-013, Loridrene. 0-5571, Diazprin Wafer. 0-5617, Diszpini Water. 0-5617, Desoxyephedrine Inhaler. 0-5627, Thiouracil Tablets. Flint Eaton and Company, Division Baxter Labs, Inc., 6301 Lincoln Ave., Morton Grave, Illinois 65053. 0-5673, TCT PH Cellosolve Squibb. 0-5673, TCT PH Cellosoive Squibb.
0-6121, Dienestrol Tablets.
0-6126, Luteotrophin Squibb Injection.
0-6183, Chlorguanide HCL Tablets.
0-6197, Vigran W/Folic Acid Multiple Vitamin Capsules.
0-6201, Sodium Folate Solution Injection.
0-6249, Dispadal Drops.
0-6297, Delacurarine Liquid.
0-6551, Pithitiary Conadotrophine Injection. 0-0718, Glycolex Solution. 0-0735, Vitamin Bithlamin CL Tablets. 0-1313, Chlorphedrine π/Lienthol Solu-NDA 0-9881, Ascorection Capatiles.
Fester Company, Inc., Stamford, Connecticut.
NDA 0-9971, Vacid Tablet.
First Texas Chemical MFG, Company, 1810
N. Lamar, Dallas, Texas 75202. tion. 0-1625, Nocotinic Acid 25MG Tablets. 0-6551, Pituitary Gonadotrophine Injec-0-1731, Extrone 10 MG injection, 0-1732, ET-Trone-Carbonate Tablets. 0-1822, Sulfanliamine w/Sodium Bicar-NDA's: tion. 0-7688, Thylokay Injection. 0-7722, Prenderol Cancules and Tablets. 0-0024, Dr. A. Taylor Private Formula Capsule.
0-0027, Private Formula Capsule.
0-0027, Private Formula For Delaumes
Pharm. Capsule. 0-7815, Bistrium CL Injection. 0-3376, Proquinol Tableta.
0-3316, Sulfathiazola Tableta.
0-3459, Sulfathiazola Tableta.
0-3901, Alpha-Tocopherol injection.
0-3917, CA Pantothenate Injection. 0-7823, Anatensol.
0-7920, Rubramin Crystalline Hypofile.
0-7923, Parentosol B-Hypofils Injection.
0-7925, Hypofils Posterior Pituitary In-0147, Formacodin Compound Tableto. 0-0127, Formacodin Compound Tablets.
0-0325, Private Formula Capsules.
0-0250, Private Formula Ointment.
0-0488, Private Formula Capsules for Service Drug Company.
0-0563, Sulfanliamide and Soda Tablets.
0-0570, Private Formula for Dr. J. D. Hodgeson Tablets. 0-3954, Pyridoxine HCL Injection. 0–7926, Hypofilnikethamide Solution. 0–7931, Rubramin Hypofils. 0–7948, Hypofilneoamiotin. 0-4025, Pentobarbitol SOD Capsules, 0-4078, Hepralin Capsules, 0-3377, Proquinol Injection, 0-4086, Sulfanilamide Liquid. 0-7949, Hypofilprogesterone Oll. 0-8039, Physiological Salt Solution In-0-4039, Sulfathiazale Powder. 0-0536, Private Formula for Dr. D. O. jection. 0-8043, Thylokay Solution Injection. 0-8149, Talsigel Suspension & Talsutin 0-4243, Pentobarbital/Ephedrine. Haage Tablets. 0-4516, Stilbestrol Tablets. 0-4516, Stilbestrol Injection. 0-4516, Stilbestrol Suppository. 0-4602, Stilbestrol Injection. 0-0720, Thiamin CL Tablets and Elizir.
0-0791, Private Formula Capsules.
0-0841, Private Formula Capsules.
0-0895, Private Formula Capsules. 0-8222, Diagnex Powder. 0-8238, Solcthyl Injection. 0-8340, Insulin U-500. 0-4636, Progestin Injection. 0-0896, Private Formula Capsules. 0-4849, Sulfatelin Olntment. 0-4874, Sulfathlazola Olntment. 0-4916, Sulfanilamide Olntment. 0-6712, Mardrin Solution. 0-7011, Pyrathyn Capaules. 0-0964, Private Formula Capsules. 0-1180, Private Formula Capsules. 0-1207, Ima Eye Lot. 0-8374, Stilbetin In Oil Injection. 0-8437, Vergitryl IM Injection. 0-8561, Adcortyl Tablets. 0-8619, Enzodase Injection. 0-8701, Ethyl Vanillate Capsules and 0-1218, Private Formula Sodium BR Tab-0-9938, Raucylate Capsules. 0-1613, Private Formula Reark WN LID Powder. 10-655, Rautrate Tablets. 0-8812, L-Isomethadone HCL Hypodermic Tablets. Tablets.
0-8920, Bistrium CL Tablets.
0-8923, Vergitryl Tablets.
0-9080, Cotranul Tablets. 0-1614, Privato Formula Stephens MS 11-907, G-I-Tran Tablets. Frederick Steams & Company, Division Sterling Drug, Inc., 90 Park Avenue, New York, N.Y. 10016. MD Tablets. 0–1655, Private Formula Liquid. 0-1684, Private Formula for Dr. M. M. Tompkins. 0-9235, Protoveratrine Tablets. NDA's: 0-9235, Protoveratrine Tablets.
0-9518, Piperex Syrup.
0-9747, Rau-Sed Injection.
10-065, Bau-Sed Syrup.
10-311, Eubramin Parenteral Vitamin
B-12 From Bacterial Cell P.
11-800, Ademol Tablets.
11-851, Rencal Powder.
12-174, Di-Ademil Tablets. 0-1712, Private Formula for Dr. C. J. 0-0332, Muclioco W/Hamgra Granules. Roper Tablets.
0-1830, Private Formula for Dr. L. T.
Waller Clinic Tablets.
0-1859, Private Formula for City Drug
Store Capsules 8. 0-033, Gyverine HCL Capsules. 0-1013, Talamin Caloride Tablets. 0-1014, Accorbic Acid Tablets. 0-1038, Acebenide Tablets. 0-1230, Coco COD w/Vitamin B1 & B2 Liquid.
0-1540, Sulfanilamido Tablets.
0-1705, K Gluconate Tablets.
0-1717, Stearns Elizir Thiamin CL. 0-1860, Private Formula for Green Drug Store Tablets. 0-1861, Private Formula Cap. 0-1894, Private Formula for Scott Phar-12–174, Di-Ademil Tablets. 12–289, Vesprin Suppository. macy Capsules.
0–1895, Private Formula for Dr. J. M. Loning Liquid.
0–1916, Private Formula Capsules. Ernst Bischoff Company, Inc., Ivoryton, Con-0-1753, Dica Phos Wafers. necticut. NDA 0-5339, Aquakay Enteric Coated Tab-lets and Injection. 0-1754, Protamine ZN Insulin Injection. 0-2463, Nebulin A Sol. Inhaler. 0-2493, Talamin CL Solution Injection. 0-2555, Gonobia Tableto. 0-2627, Riboflavin Capcules. 0-1917, Private Formula Powder.
0-2016, Thiamin Cielisir.
0-2065, Private Formula for Dr. Paul H.
Herron MD Tablets. ES Miller Labs. 404 E. 27th Street, Los Angeles, California. 0-2030, Nicotinic Acid Tableto.
0-2039, Virox Liquid.
0-2700, Virox Elixir.
0-2701, Vitamin A Capsules.
0-2231, Sulfapyridine Tableto. NDA's: 0-1752, Sulfanilamide Compressed Tab-0–2105, Private Formula Capcules. O-2141, Private Formula for the Corner Drug Store Capsules. O-2127, Sulfapyridine Capsules. O-2298, Highlands Pharmacy Private 0-1772, Sorbitol 50PC Injection. 0-1784, Estrogenic Substance In Oil Injection. 0-4232, Sulfathiazolo Tablets. 0-3677, Sulfapyridine Tablets. 0-4379, Stilbestrol Tablets. Formula Powder. 0-4064, Menadione Tablets. 0-4117, Surfathiazole Tablets. Galen Co. Inc., Berkeley, California. 0–3040, Private Formula for Herron Paul H. MD Tablets. 0–3041, Private Formula for Herron Paul NDA's: 0-4438, Stilbestrol Tablets and Injection. 0-6194, Stilbestrol Tablets. 0-3124, Vitamin B6 HCL Injection. 0-3125, Vitamin B6 HCL. 0-3150, Elixir Galen B Fortified Elixir. H. MD Tablets. 0-7034, Dudekab Injection. 0-7177, Toluaxin Tablets. 0-8201, Neostene Injection. 0-3042, Private Formula for Herron Paul H. MD Tablets. 0-3837, Pyridoxino HCL Tablets. 0-4618, Vijex Injection. 0-2344, Sulfapyridine Tablets. 0-3218, Private Formula Capsules. 0-8817, Progesterone Injection. GD Searle & Company, Post Office, Box 540, Chicago, Illinois 60630. 0-9174, Oramestin. 10-474, Proscomide Sustained Release 0–3257, Private Formula Capculea. 0–3338, Private Formula Capcules #7127. Capsules. NDA's: 0-3652, Private Formula City Drug Store 0-2631, Furmerane TCT. 10-829, Cobalamin Concinjection. Capsules. 0-3668, Private Formula Dr. J. L. Porter Evron Company, Inc., 3402 Carmen Avenue, 0-3045, Furmerane Solution. Chicago, Illinois. 0-3393, Furmerine Ointment. Capsules. 0-3813, Private Formula Sterling Drug NDA's: 0-3804, Furmerine Drops. 0-9608, Rauwolfia-Veratrum Virides Tab-Store. 0-3942, Amodrine Enteric Coated Tablets. 0-4109, Private Formula for Bacham John J. MD Ointment. 0-4259, Gonadophysin Injection. 10-226, Pyrilamine Maleate Sustained 0-4178, Private Formula Capsules. 0-4335, Private Formula Capsules #7321. Release Capsule. 0-8518, Padenal Tablets. 11-330, Pentriltol-60 Tempules Capsules. 0-8789, Diodoquin Powder.

0-9569, Mincard Tablets. 12-132, Prozanchol Tab. 12-534, Mitronal.
0-4227, Tetrathione Injection.
Geigy Pharmaceuticals, Division Geigy Chemical Corporation, Post Office Box 430, Yonkers, N.Y., 10702. NDA 12-837, Per Santin AMP. Gelatin Products Company, 9425 Grinnell Avenue, Detroit, Michigan. NDA's: 0-4087, A-Vatine Capsules. 0-4088, AD-Vatine Capsules. 0-4089, B-Vatine Capsules. 0-4090, D-Vatine Capsules. 0-4091, Pan-Vatine Capsules. 0-4092, Tri-Vatine Capsules. George Breon & Company, Inc., Division of Sterling Drug, 90 Park Avenue, New York, N.Y. 10016. NDA's: 0-0143, Nicotinic Acid Tablets. 0-0486, Bismuth Salicylate In Oil Inlection. 0-0487, Special Formula for Bridge Clinic Powder. 0-0937, Beviplex Tablets. 0-1234, Estrogenic Substance in Oil Injection.

0-1659, Vitamin B1 Injection.

0-1690, Bismuth Subsalicylate in Oil InMDA 0-7613, DMF Mouthwash.

H. E. Maurry Biological Company, 6109 South jection. 0-1741, Sodium Benzoate Solution. 0-2163, Riboflavin Tablets. 0-2221, Progesterone Injection. 0-2222, Progesterone Injection. 0–2477, Adrenal Cortex Extract Injection. 0–2740, Pentobarbital Sod Tablets. 0–2814, Nikethiamide Injection. 0-2910, Pyridoxine HCL Injection. 0-2911, Fyndome Hold Injection.
0-2912, Vitamin BI Injection.
0-2956, Vitamin B Complex Syrup.
0-3070, Vafiol Capsules.
0-3258, Pyridoxine HCL Injection. 0-3258, Pyridoxine HCH Injection.
0-3316, Aluminum Hydroxide Tablets.
0-3364, Pyridoxine HCL Injection.
0-3617, Vircomal Liquid.
0-3791, Menadione Tablets.
0-3867, Fluagel Liquid. 0-3867, Fruaget Inquid.
0-3868, Sulfathiazole Tablets.
0-3964, Sulfapyridine Tablets.
0-3965, Ascorbic Acids Injection.
0-4009, Becaplets Capsules.
0-4042, Stilbestrol Tablets. 0-4043, Stillbestrol Injection. 0-8509, Hexamethonium CL Tablets. 0-9785, Hydrocortisone Acetate Opthalmic 1.5% Ointment. 0-9787, Hydrocortisone Tablets.

10-445, Reserpine Elixir. 10-892, Neobalin Injection. Graham Chemical Corporation, 129-21 Merrick Boulevard, Springfield Gardens, N.Y. NDA 10-617, Cordent Powder.

Gray Pharmaceutical Company, Inc., 50 Ax-minster Street, Yonkers, N.Y. 10701. NDA 12-509, Tegunor Medicated Powder.

Grove Labs Sub Bristol-Myers Company, 8877 Ladue Road, St. Louis, Missouri 63124.

10-063, Citroid Capsules. 11-052, Citroid Compound Capsules. 11-186, Citroid Jr. w/Tusilan Childrens Cold Syrup.

12–417, Product 82 Capsules. 11–232, Tusilan Syrup.

G. S. Stoddard & Company, 121–123 East 24th Street, New York, N.Y. NDA's:

0-0505, Private Formula #1381 Powder. 0-2441, Ephedrine Sul Phenobarbital & Potassium Chloride Tablets. 0-3991, Nespamal Syrup.

0-3992, Char-AL-AC-Tablets.

Guardian Chemical Corp., 4202-12 11th Street, Long Island, N.Y. NDA 10-002, Fexerol.

G. W. Carnick Company, 65 Horse Hill Road, Cedar Knolls, N.J. 07927.

NDA's:

0-4678, Stilbestrol Tablets. 0-4679, Stilbestrol Injection.

0-8600, Androdiol in Aqueous Suspension Injection & Diolandrone in Aque-ous SUS INJ. 10–200, Salserp-Tablets.

Halsey Drug Company, 1827 Pacific Street, Brooklyn, N.Y. 11233. NDA 0-9163, Anti-CAL LOT. Hance Brothers & White Company, 12th & Hamilton Streets, Philadelphia, Pennsylvanía.

0-0915, Hance Sun Tan Cream. 0-1590, GAS-ODA Liquid. 0-8438, Polycaine Solution. 0-8569, Mycozide Tablets. 11-911, Hanamine Inhaler.

Harrower Lab., Inc., St. Louis, Missouri.

NDA 0-9475, Prometic Tablets.

Hart Labs, Division A. J. Parker Company,
Station Square One, Paoli, Pennsylvania 19301.

NDA 11-454, Tritis Tablets.

Western Avenue, Los Angeles, California 90047.

NDA's:

0–7122, Dodecamin Solution. 10–792, Vitamin B12 Activity Concentrate Solution Injection.

11-547, Reserpine Alkaloid.

Hellwig Inc., 223 East Delaware Place, Chicago, Illinois 60611.

NDA 0-7182, Hellwigpas Tablets.

Henry Wampole & Company Inc., 35 Commerce Road, Stamford, Connecticut 06902.

NDA's:

10-054, Secotress Tablets.

10–572, Bioresp-C Capsules. 10–574, Orgaphen-R Liquid. International Vitamin Corporation.

DA's:
0-1255, IVC Vitamin B1 Crystalline
Thiamin CL Tablets.
0-1256, IVC Thiamin CL Elixir.
0-1276, IVC Liquavite Drops.
0-1277, IVC Pearls Capsules.
0-1282, IVC Vitamins ABDG w/C

Capsules.

0–1283, IVC Vitamin ABDG Capsules.
0–1329, IVC Vitamin Pearls Compound Containing Vitamin A–B.
0–1438, Macys Vitamin A–B–DG Capsules.
0–1439, Macys Globules Vitamins A–B–

D-G w/Vitamin C Capsules. 0-1440, Bambergers Bitamin A-B-D-G

0-1440, Bambergers Bitamin A-B-D-G
Capsules.
0-1441, Bambergers Bitamins A-B-D-G
w/Vitamin C Capsules.
0-1660, Yeast Tablets.
0-1662, Yeast & Iron Peptonate Tablets.
0-1733, IVC A-B-D-G Capsules.
0-1969, IVC Blexin Liquid.
0-1970, IVC Blexin Tablets.
0-2086 UC Vitamin B Compley Capsules.

0-2086, IVC Vitamin B Complex Capsules.

0-2598, Nicotinic Acid Tablets.

0-2599, Nicotinic Acid Tablets. 0-3076, IVC Davegol Regular Potency

Liquid.

Liquid.
0-3207, IVC Rivoflavin Tablets.
0-3613, IVC Larenim Wafer.
0-3883, IVC Nicotinamide Tablets.
0-3884, IVC Nicotinamide Tablets.
0-4128, IVC Vibramins Capsules.

0-4917, PABA Tablets.

Invenex Labs.

NDA 0-9834, Hydrocortilsone Acetate Opthalmic Suspension/Drops.

Irwin Neisler & Company, 434 N. Morgan Street, Decatur, Illinois 62525.

0-0489, Camax Ointment. 0-1531, Alantol-V Ointment.

0-1532, Tetramene TCT. 0-2505, Jecufer Capsules. 0-2902, Tetramene Solution. 0-2937, Brillosal Solution.

0-2938, K Gluconate Tablets.

0-2938, K Gluconate Tablets,
0-3586, Destrol Injection.
0-3587, Desterol Capsules,
0-4212, Methoquin Capsules,
0-4213, Tocolpha Capsules,
0-4235, Andacap Capsules,
0-4254, Digleap,
0-4278, Terformine Capsules,
0-4279, Terpiform Capsules,
0-4714, Sulfathiazolo Ointment,
0-4772, Phenodrol Liquid,
0-5022, Benzamol Emulsion.

0-5023, Benzamol Emulsion. 0-6233, Benzamold Emulsion. 0-8299, Verenteral Injection. 10-052, Uniserpen Injection.

ISO-SOL Company, Inc., Brooklyn 17, N.Y.

10-019, Hydrocortisone Acetate oph So-

lution Drops. 10-464, Prochelate 0.37 PC, 1.85 OC Solution.

Ives Cameron Company, Division American Home Products Corporation, New York, N.Y. 10017.

NDA's:

0–6363, Monitan Solution. 10–089, Periclor Capsules. 11-309, Syntussin Tablets.

Jackson-Mitchell Pharmacoutical Company, 11500 Tennessee Avenue, Los Angeles, 64, California.

NDA 0-8246, Methanabol Tablets,
J. B. Roerig & Company, Division Charles
Pfizer & Company, Inc., 235 East 42nd
Street, New York, N.Y. 10017.
NDA 12-458, Bonaboxin Parenteral Injec-

John A. Miller Company, Division Chatham Pharmaceutical, 901 Broad Street, Newark, N.J. 07152.

NDA 0-2097, Aluminoid Millar Capsules.

John T. Lloyd Labs, Inc., division of Wester-field Labs, Inc., 3941 Brotherton Road, Cincinnati, Ohio 45209.

NDA's:

DA's:
0-1421, Cindol Ointment.
0-1903, Stillingia JTL Liquid.
0-1909, Leptandra JTL Liquid.
0-1910, Krameria JTL Liquid.
0-1911, Colchicum JTL Liquid.
0-1912, Geranium JTL Liquid.
0-1913, Iris Versicolor JTL Liquid.
0-2195, Edrosen Capsules.

John Wyeth & Brothers, Inc., Philadelphia, Pennsylvania.

NDA's: 0-3049, Sulfathiazole Tab. 0-3511, Gluferate Tab.

0–3658, Sulfanilamido 5 Gr. & Sodium Bicarbonate 6 Gr. Tablet, 0–4065, Stilbestrol Injection, Suppository Tablets.

0-4159, Menadone Injection.

0-4177, Pyridoxine HCL Tablets.

0-4246, Aspirin Phenacetin Caffeine & Codeine Tablets.

0-4287, Cascara-Magnesia Tablots. 0-4327, Phenobarbitol Tablets.

0-4327, Theobromine & Phenobarbitel Tablets. 0-4345, Estrogens Solution/Injection. 0-4688, Cetro-Cirose Modified Solution. 0-4491, Sulfathiazole Ointment.

Johnson & Johnson, 500 George Street, New Brunswick, N.J. 08901.

NDA's:
0-5350, Nugauze Strip.
0-5468, Adhesive Mass Dressing.
0-6064, Hemo Pak Dressing.
11-041, Surgicel Absorbable Hemostatic Cones Dressing. Cones Dressing. 11–318, Debricin Powder. 12–503, Ioprep Presurgical Solution.

461

tions.

0-4469, Vitamin B Complex Capsules.

0-4467, Dietstilbestrol Capsules & Injec-

0-4468, Vitamin B Complex Tablets

13–992, Band Air Antiseptic Spray. . 14-116, First Aid Spray. Jr. Watkins Company, Winona, Minnesota. NDA 0-7227, Watkins Anthist Tablets. Julius Schmid, Inc., Lackawanna Avenue, West Paterson, N.J. 07424. NDA 0-8161, Ramses Vaginal Cream. Kahlenberg Labs, 41 North School Avenue, Post Office Box 3318, Saratoga, Florida 33578. NDA 0-1235, K-I. Mucotox Ointment. Kalusoff, Ltd., Post Office Box 844, Springfield, Illinois. NDA's: 0-0500, Kalusoffs General Disinfectant Liquid. 0–0501, Laundry Fungicide. 0–7965, Wilsons FGDS Solution. Keith Victor Pharmacal Company, St. Louis, Missouri. NDA's: 0-7563, Pyranisamine Maleate/ASA Com-pound Tablets. 0-7604, Visammin Tablets. 0-7669, Methiouracii Tablets. 0-7897, Sodium Gentisate Tablets. 0-8283, Cortisone AC Tablets. 0-8511, Hexamethonium CL Tablets. 0-8541, Zinadon Tablets. 0-9555, Rauhexide Tablets. 0-9612, Rauwolfia-Veratrumvirides Tab-10-233, Hydrocortisone Tablets. 10-386, Cortigesic Tablets. Kirkman Labs Inc., 934 Northeast 25th Avenue, Portland, Oregon 97232. NDA 10-388, Reserpine Alkaloid Timed Disintegration SRC.

Knoll Pharmaceutical Company, 377 Crane
Street, Orange, N.J. 07050. NDA 11-597, Rapadyne Tablets. Koch, Leo EH., 519 Flm Street, Ontario, California. NDA 0-2448, EL-KO Powder Kochs AL-KO Compound. Kremers-Urban Company, 5600 West County Line Road, Milwaukee, Wisconsin 53201. NDA's: 0-0178, Aminophyllin Injection. 0-0179, Aminophyllin Injection. 0-0211, Estrone Injection. 0-0238, SOD Morrhuate w/Benzyl ALC Injection. 0-0737, Phenacin #2 w/Codeine Tablets & Capsules. 0-1300, Potassium CL Capsules & Tablets. 0-1502, Kuorin Injection. 0-2054, Ointment Distarol. 0-2178, Sulfapyridine Tablets. 0-3546, Sulfathiazole Tablets. 0–3721, Vitamin B Complex Elixir. 0–3764, Asafoetidanux Vomica Tablets. 0–3765, Camphor Valerian & Stramonium Tablets. 0-3766, Phenolid Tablets.

0-3806, Menadione Injection.

0-4421, Stilbestrol Tablets.

tion.

ration Tablets.

0-3879, SOD Benzoate Injection. 0-4069, Effervescent Alkaline Salt W/ Vitamin C.

0-7286, Solution Vitamin B12-KU Injec-

10-088, RB #11-113 Reserpine Prepa-

11-312, Salimeph Prednisolone Tablets. 12-963, Kumotrip.

10-069, RB #11-12B Reserpine Tablets.

0-4422, Stilbestrol Injection. 0-4612; Distarzole Ointment. 0-5129, Sulfathiazole Ointment. 0-6991, Vitamin B12 K-U Injection.

0-3767, Bromide & Stramonium Elixir. 0-3768, Bromide & Stramonium Compound Elixir. 0-3805, Menadione Tablets.

NDA's: Lederle Labs, Division American Cyanamid Company, Pearl River, N.Y. 10965. NDA's:

NOTICES 13-221, Micrin Antibacterial Throat Loz- Lakeside, Sub Colgate-Palmolive Company, 1707 E. North Avenue, Milwaukee, Wisconsin 53201 NDA's: 0-0639, Anterior Pitvitary-Like Gonadotropic Hormone Injection. 0–1425, Calsamate Tablets, 0–2865, Pyridoxine HCL Injection. 0–3343, Caphemate Tablets. 0-3344 Koldin Capsules. 0-3345, Koldin Injection 0–3518, Nikethiamide Solution. 0–3519, Nikethiamide Injection. 0–3520, Sulfataiazole Tablet. 0-3566, Capantothenate Injection. 0-3566, Capantothenate Injection.
0-3905, Pyridoxine HCL Tablets.
0-3906, Pyridoxine HCL Tablets.
0-3907, Pyridoxine HCL Injection.
0-3908, Capantothenate Injection.
0-3948, Capantothenate Injection.
0-3959, Tokophin Injection.
0-3959, Tokophin Injection.
0-3960, Tokophin Injection.
0-3961, Medrocaine Injection.
0-3963, Phenokarbital SOD Injection. 0-3963, Phenobarbital SOD Injection. 0-3999, Histamine Phos Injection. 0-4138, SOD Dehydrocholate Injection. 0-4139, Dehydrocholoric Acid Tableto. 0-4160, Diethylstilbestrol Injection & Tablets. 0-4461, Tokophin AC Tablets. 0-4513, Sulfathiazole Powder. 0-4529, SOD Sulfathiazole Injection. 0-4903, Adrenal Cortex Extract Injection. 0-6362, Estradiol Trimeac Injection.
0-6363, Menacyl Tablets.
0-6532, Histamul Injection.
0-7838, Mercuhydrin Suppository.
0-7945, Oral-Estrotate Tablets. 10-680, Pipatal w/Phenobarbital Liquid & Liquid. 11-956, Catron Hydrochloride Tablets. 13-481, Delta Five. Lambert Labs, Division Warner-Lambert Pharmaceutical Company, 201 Tabor Road, Morris Plains, N.J. 07850. NDA's: 0-5218, Sulfadiazine Ointment. 0-5229, Sulfadiazine Ointment. 0-6162, Polite Cream. 0-8184, Lamberts Spray-on-dressing Liquid & Spray.

0-8778, Antizyme Mouthwash.

0-1467, Irwin Cough Syrup.

0-0568, Sulfapyridine Tab.

0-1470, Ephinephrine Elatin.

Lawrence Irwin, Wisconsin Rapids, Wiscon-Lanton Labs Inc., Sub Gold Leaf Pharmaceutical, Inc., 520 South Dean Street, Englewood, N.J. 07631.

NDA 0-8290, Mefesin Injection.

0-5239, Rhulltabo. narbitol Tablets. tion Tablets. Tablets. 0-6669, MPD Tablets. 0-6919, Inositol Tablets. 0-8320, Hibicon Capsules. 12-472, Trepidone. 0-0013, Lyzalv Ointment. Sellersville, Pa. 18960. 0-9455, Rucerp-C Tableto. 10-173, Lemizerp Tableto. 10-174, Redona Elixir. 11-579, Cotrate. 12-385, No-Derm Lotion. 0-1855, Sodium Sulfapyridine Monohyjection. 0-1855, Sodium Sulfapyridine Monohydrate Injection.
0-1873, Beliabulgara Tablets.
0-2646, Nicotinic Acid Amide Tablets.
0-2897, Vitamin K Tablets.
0-2899, Nikethiamide Injection.
0-3204, Ribofiavin Tablets.
0-3321, Vi-Ferr Capsules.
0-3410, Sodium Sulfapyridine Tablets.
0-3430, Sodium Sulfathiazole Monohydrate Powder Injection. NDA 0-9413, Piperate Solution. NDA's: drate Powder Injection. 0-3814, Sulfanilamide Surgical Powder. 0-3815, Sulfapyridine Surgical Powder. 0-8740, Somnorin Capsules. 10-956, Phobey Tablets. 11-122, Tecerene Tablets. 0-4012, Procaine HCL Injection. 0-4124, Chioracid Para-Aminocialyle

0-4493, Capantothenate Tablets.
0-4575, VI-Delta Multi-Vit Capsules.
0-4623, Pyridoxine HCL.
0-4650, Ephedrine Sul Capsules. 0-4727, Strong Epinephrine HCL Solution. 0-4767, Al Hydeoxide Gelatin. 0-4775, Sod Morrhuate Solution.
0-4853, Elixiron Sul Capsules.
0-4898, Lexatone Solution.
0-4925, Sulfadiazine Tannic Acid Jelly.
0-4926, Sulfadiazine Sur Pwd. 0-4937, Sulfadiazine Solution.
0-4934, Sulfathizole Cream & Powder.
0-4952, Pentobarbital Sodium Capsules.
0-4980, Mannitol Hexanitrate Tablets.
0-5076, Sodium Sulfapyridine Injection. 0-5284, Diazinim Dressing. 0-5358, Sulfamerazine Tablets. 0-5371, Mannitol Hexanitrate w/Pheno-0-5550, Cyclazine Benzestrol elixir Injec-0-5699, Pentobarbital Sodium Capsules. 0-5699, Deracil Tablets. 0-5699, Intrahepol Injection. 0-6418, Teropterin Injection. 0-6421, Sulfapyrazine Injection Powder, 0-7183, Para Amindsalicylic Acid Powder. 0-8419, Calcium Para Aminosalicylate. 10-149, Diamox SRC. 10-511, Milltown Capcules & Tablets. 10-912, Kynex Syrup. 11-046, Diamox Syrup. 11-452, Pathillon Pediatric Drops. 11-793, Tentone Maleate Tablets. 11-837, Versacaine HCL w/Epinephrine. 11-833, Solution HCL w/Epinephrine. 12-279, Kynex Acetyl Pediatric Drops. Lehn & Fink Products, Corporation, 2255 Summit Avenue, Montvale, N.J. 07645. 0–1263, Hinds Deodorant Cream. 0–1463, Tussy Deodorant Cream. 0–2172, Sun & Beach Cream. 0–5661, Dynal & Doyl Liquid. Lemmon Pharmaceutical Company, Box 30, 12-641, Hydro Corticone Phosphate In-Lever Brothers, Company, New York 22, N.Y. NDA 10-338, Lifebuoy Soap. Lincoln Labs, Inc., Hickory Point Road, Box 1139, Decatur, Illinois 62525. Lloyd Dabney & Westerfield, Division Wester-field Pharmaceutical Company, 3941 Brotherton Road, Cincinnati, Ohio 45209. Lustgarten Labs Inc., Lancaster and 51st., Philadelphia, Pa. 19131. NDA 10-495, Recerpine Time Caps. Macallister Lab. 9213 Wade Park Avenue, Cleveland, Ohio 44106. NDA 0-2173, Phenedrine Solution.

gical Powder.

0-3816, Sulfathlazole Surgical Powder.

0-4186, Videlta Multi-Vitamina Capsules. 0-4407, Sulfanilamide-Sulfathiazole Sur-

Mallard AE-Orig., 3021 Wabash Avenue, Detroit, Michigan 43216. NDA's: 0-0845, Sulfanilamide & Sodium Bicarbonate. 0-2602, Sulfapyridine Tablets. 0-3528, Sulfathlazole Tablets. Mallinokoot Chemical Works, 3600 North Second Street, St. Louis, Missouri 63160. NDA's: 0-0516, Soda Lime Moist & Dry. 0-7915, Isomethodone HCL Solution. Maltbie Chemical Company, Belleville, N.J. NDA's: 0-0986, Private Formula for W.D. White & Company Tablets. 0-1112, Private Formula for Dr. H. B. Harric Capsules. 0-1309, Sulfanilamide & Sodium Bicarbonate Tablets. 0-1953, ABCD Perles. 0–1954, Liro-B Peries. 0–2713, Sulfathiazole Powder Tablets. 0–4606, Stilbestrol Tablets. 0-6199, Cetyltrime Ammonium BR Solution TCT. 0-6251, Mercenex Ointment. 0-6280, Mercenex Powder. 0-4605, Sulfathiazole 5Pc Ointment. Maltine Company, 745 Fifth Avenue, New York, N.Y. NDA's: 0–0638, B-Scorbic Tablets. 0–1632, Hetoxin Powder. 0-1633, Hetoxin-O Ointment. 0-2490, Maltine-B Liquid. 0-3881, Jeciron-B Capsules. 0-4015, Phed-Aqua Drops.` 0-5154, Estrogens Maltine Injection. 0-6070, Rutin Tablets. 0-6644, Pentryl Tablets.

Mann Chemical Company, 520 West Main
Street, Louisville, Kentucky 40202.

NDA 0-5272, Mann Germicidal Hand Lo-Marion Labs Inc., 10236 Bunder Ridge Road, Kansas City, Missouri 64137. NDA 12-905, Duotrate 80 SRC. Marvin R. Thompson, Inc., Stamford, Connecticut. NDA 0-7605, Sudosal-MRT GRN. Maurry Biological Company, 6109 South Western Avenue, Los Angeles, California 90047. NDA 11-461, Rauwolfia Serpentina Tablets. McKesson & Robbins, Inc., Bridgeport, Conn. NDA 7633, Axon Caps. McNell Labs, Inc., Camp Hill Road, Fort Washington, Pennsylvania 19034. NDA's: 0-0771, Ricin Olivate Emulsion. 0-0633, Glutamic Acid Hydrochloride Capsules. 0-0792, Sol Ephedrine-Sodium Chloride Compound Spray, 0-0889, Blad Tablets, 0-1390, Liquid Minerol Syrup. 0-1391, Liquid Minerol W/Phenolphrhalein Syrup. 0-1392, Wild Cherry-White Pine Compound w/Codeine Syrup. 0-1393, Lectusol Syrup. 0-1556, Persals Tablets.
0-1776, Thiamin CL Injection.
0-1777, Acid Nicotinic Tablets.
0-1778, Sulfanilamide Sodium Bicarbonate Tablets. 0-1780, Estrogenic Hormone in Oil Injection.
0-1809, Ferromin w/Liver Concentrate Capsules. 0-1825, Soft Elastic Capsules Ascorbic Acid. 0-1826, Soft Elastic Capsules Viquad Com Improved. 0-1827, Soft Elastic Capsules Vitamin AB10DG.

0–1849, Cap Vitamin B-Complex Forti- ~

0-2026, Vitamin B6 Injection. 0-2100, Liquid Minerol w/Magnesiumt Risilicate.
0-2109, McNeil Tussal Liquid.
0-2209, Sulfapyridine Tablets.
0-2616, Butisol Ephedrine Compound Capsules. 0-2789, Pyridoxine HCL Solution. 0-3036, Acid Nicotinic Amide Tablets. 0-3226, Dymixal Jelly. 0-3378, Menadione Capsules. 0-3409, Sulfathiazole Tablets. 0-3729, Ampuls Alpha Tocopherol Injection. 0-4402, Stilbesterol Tablets. 0-4761, Amophon Compound Syrup. 0-5372, Analgesic Ointment. 0-6394, Diethylystilbestrol Enteric Coated Tablets. 0-6445, Pyriouracil Tablets. 0-6454, Tetraethylammonium CL Injection. 0-8625, Hesalin Chloride Tablets. 11-102, Pentraline R-A Prestabs SRT. Mead Johnson & Company, 2404 Pennsylvania Street, Evansville, Indiana 47721. NDA's: 0-0354, Meads Pectin-Agar in Dextrimaltose Powder. 0-0464, Meads Emulsion of Oleum Percomorphum.
0–1833, Thiamine CL Tablets.
0–3225, Menadione in Oil Capsules.
0–3241, Meads Rivoflavin Lablets. 0-5300, Sulfapyrazine Sod Tablets. 0-9310, Plasran. 10-097, Aspirin Rectal Applicator. 10-098, Aminophylline Rectal Applicator. 10-099, Phenobarbital Rectal Applicator. Medical Arts Supply Company, 706–10 Fourth Avenue, Huntington, W. Va. 25715. NDA 0-9178, Surginol Surgical Soap. Medical Chemical Corporation, 4122 West Grand Avenue, Chicago, Illinois 60651, NDA 10-960, Cobamine 100 Injection. Merck & Company, Inc., Rahway, N.J. 07065. NDA's: 0-6486, Amino Acids Solution Merck Injection. 0-8223, Aramine Bitartrate Drops & Spray. 0-8448, Mephyton Injection. 0-9280, Hydrocortone. 0-9687, Hydrocortone Injection. 0-9714, Hydrocortisone Acetate 0.5% Dental Powder. 10-128, Reserpine Tablets. 10-553, Fluorocortisone AC Ta3. 10-803, Cobalamin Concentrate Sol/Inj. 11-526, Drocode Bitartrate. 11-979. Decadron Phosphate 0.1% Lotion. 11-987, Decabomate Tablets. 12–334, Hydropres-KA Tablets 12-345, Hydrodiuril-KA Tablets. Merck Sharp & Dohme, Division Merck & Company, West Point, Pennsylvania 19486. NDA's: 0–124, Sulfanilamide Tablets. 0–125, Nicovite Tablets. 0–126, Cevitamic Acid Tablets. 0-0127, Vit B1 Crystalline Tablets 0-0416, Methenamine & Sodium Phos-phae Acid Tablets. 0–0417, Sulfanilamide Tablets. 0-0469, Sulfadyridine Tablets. 0-0946, MG Trisilicate Tablets. 0-1289, Wheat Germ Oil Capsules. 0-1404, Padrophyll Tablets. 0-1496, Riona Capsules. 0-1499, Sulfapyridine w/Sodium BiCarbonate Tablets. 0-1728, Sodium Iodide Injection. 0-1862, Prohexinol Solution. 0-2640, Alpha-Tocopherol Injection. 0–2774, Sulfathiazole Tablets.

0-3094, Pyridoxine HCL Tablets Injection. 0-3200, Menadione-1-2-5 Tablets. 0-3215, Riboflavin Tablets. 0-3229, Lucorteum Injection. 0-3666, Vinothiam Liquid.
0-3786, Alpha-Tocopherol Capsules.
0-4062, Stilbestrol Enterio Coated Tablets, Injection and Suppository. 0-4105, Tresamide Sulfonamide Triad Tablets. 0–4228, Cough Syrup. 0–4387, Thiamine Monoitrate Injection. 0–4318, Riboflavin Elixir. 0-4937, Delvinal Sodium Elixir. 0-5791, Geratine Sol 6Pc Bl0 Grade P-20 Type Injection.
0-6117, Propadrine Injection.
0-6209, Metopon HCL Capsules.
0-6216, Folic Acid 5MG Tablets. 0-6221, Methadon HCL Capsules.
0-6225, Statiein Cardnamide Tablets.
0-6273, Chlorguanide HCL Tablets.
0-6549, Thializino Capsules.
0-6567, Thiamine Mononitrate Injection. 0-6569, Olothorb Capsules.
0-6790, Benodaine HOL Injection.
0-6796, Mothapyrilene & Tablets & Enter Coated Tablets, 50 MG, 100Mg. 0-6974, Methadone HCL Syrup. 0-7469, Proferin Injection. 0-7618, Topaminic Cream. 0-8339, Liqolev Lipotropic Mixture. 0-8793, I-Isomethadone HCL Inj & Tab. 0-8830, Lukestra Injection. 0-8846, Darstine BR Tablets. 0-8658, Hydrocortone ΛΟ 2.5 Pc Dental Ointment & Injection. 0-0556, Alflerone Acetate Topicalont, 0-9648, Cyclaine Hydrochloride 5% Jelly. 0-9721, Cyclaine Hydrochloride 5% Ointment. 0-9901, Restolic Tablets. 0-9923, Glaumeba Tablets. 0-9969, Roxinoid Tablets. 10-027, Hydrobalm Cream. 10-105, Hydrodyno Tablots. 10-112, Roxel Fortcelixir. 10-294, Hexylresoreinol Liquid. 10-438, Hydrobalm Lotion. 10-438, Meprolone-1-2-5 Tablets. 10-882, Tempoplex Tablets. 10-908, Reversino Tablets. 11-933, Hydeltresol Lot. 11-083, Homorylamino HCL Capsules, 11-142, Hydeltresol Top Ointment, 12-048, Delcadron T.B.A. Sus/Inj. 13-414, Isoproterenol Sulfate. 13-538, Decadrontopoint,
Metacine Company, Division Chattanooga
Medicine Company, 1715 West 38th
Street, Chattanooga, Tennessee 37409.
NDA 0-4377, Metacine Vaginal Insufficient Powder. Metropolitan Labs Inc., Division Michigan Chemical Corporation, 500 North Bankson Street, St. Louis, Michigan. NDA 0-9991, Reserpine Injection. Miles Labs, Inc., 1127 Myrtle Street, Elkhart, Indiana 46514. NDA 0-7072, Tabein & MM185-15 Tablets. Minnesota Mining & MFG. Company 3 M Center (220-2E), St. Paul, Minn. 55101. NDA 0-7658, Scotch Appliance Discs & Surical Drapes. Modern Drugs, Inc., 4202-01 East New York Street, Indianapolis, Indiana. NDA's: 0-0022, Efedrops Solution. 0-0044, Z-Med Ointment. 0-0187, Relevo Liniment Ointment. 0-0195, Astringent Compound Liquid. 0-0196, Cascara Aloin & Fodophylium Tablets. 0-0197, Modern Tonio Tablets. 0-0199, Alkaline Laxative Liquid/Drops. 0-0200, Waferlax Wafer.

0-0202, Pepsin & Acid Compound Liquid.

0-0203, H & P Powder.

Suppository Capsules.

0-2894, Estrogenic Substance Injection,

NePara Chemical Company, Inc., Averell Avenue, Harriman, N.Y. 10926. NDA 0-9802, Salizid Tablets. 0-0204, Astringent Powder. 0-3472, Synkamin Capsules. 0-0205, Modern Stream Inhalant. 0-0206, Modern Cold Tablets. 0-3857, Synapoldin Injection. 0-3930; Sod. D-Pantothenate Capsules & 0-0207, Isopropyl Alcohol Compound NePara Labs, Division Warner-Lambert Phar-Injection. 0-0207, Isopropyl Alconol Compound
Liquid.
0-0208, Vermifuge for Large Round
Worms Syrup.
0-0222, Camfo-Phenol Liquid.
0-0224, Anti-R-Co Liquid.
0-0225, Modern Stream Inhalant.
0-0226, Composition Powder.
0-0228, Expectorant for Cough Syrup.
0-0229, Cascaralax Liquid. maceutical Company, 201 Tabor Rd., Morris Plains, N.J. 07950. 0-4233, Gluco-Fedrin w/Phemerol Solution. 0–4611, Sulfathlazole Ointment. 0–4363, Tanexin Jelly. NDA's: 0-1973, Macasol Injection. 0-5189, Sulfamone Drops. 0-5356, Sulfamerazine Tablets. 0-5376, Etalate Injection. 0-5475, Plaster Adhesive Dressing. 0-8379, Pyrizidin Tablets. Nopco Chemical Company, 60 Park Place, Newark, N.J. 07100. NDA 0-4019, Me Testosterone Tablets. Norwich Pharmacal Company, 17 Eaton Avenue, Norwich, N.Y. 13815. 0-5603, Promin Jelly. 0-0286, Altraco Liquid. 0-5635, Sod. Sulfamerazine Solution. NDA's: 0-0185, Borbro Hygienic Powder and 0-5639, Naphthocaine Hydrochloride Jelly, Injection & Solution. 0-5646, Sulfathiazole Suspension. 0-5659, Gluco-Fedrin w/Sulfadiazine 0-0287, Irene Drops. 0-0288, Modern Iodal Tablets. 0-0298, Modern Nasal Doche Tab/Solu-Solution. tion. 0-1914, Noramin-12, and Norin-12 Capsules and Norin-12 Wafers.
0-7673, Nal Tablets.
12-014, Teek W/TC-44 Syrup.
Novocal Chemical Mfg. Co., Inc., 2911 Atlantic Avenue, Brooklyn, N.Y. 11207. 0-0300, R-O Salve. Drops. 0-0301, Uno Solution. 0-0301, Uno Solution. 0-0302, Pet-Lax Tablets. 0-0303, Relevo Ointment. 0-0330, Foctex Ointment. 0–5663, Sulfanome Drops. 0–5796, Thiouracii Capsules. 0–6020, Salicylaniiide Phemerol Cream. 0-6103, Orabismol Capsules.
0-6153, Metopon HCL Capsules.
0-6172, Folic Acid & Iron Tablets.
0-6244, Diamidin Tablets.
0-6548, Steri Val D Tubocurrarine CL 0-0331, Antacid Tablets. NDA's: DA'S: 0-2736, Pembucol Capsules. 0-3363, Monocaine Formate Injection. 0-4180, Novestoil Injection. 0-4382, Sulfathiazole Tablets. 0–0332, Vaginal Wafer. 0–0333, Modern Tonic Compound Liquid. 0–0975, Modern Aspirin w/Caffeine Tab-Injection. 0–4439, Metrazol Injection. 0–5006, Sulfanliamide-Sulfathiazole 0-6627, Promizole Tablets. 0-6875, Vapceals Kutrol Capsules. 0-8878, Indon Capsules & Tablets. 0-2219, Camphorated Oil w/Eucalyptol & Gualacol Solution. 0-2971, M-D Tablets. 0-2972, M-D Tablets. 0-4194, Canfo PH DRE. Powder. 0-5840, Radiol & Novol Germicidal Solution. 0-9026, Pamsyl Sod. Powder/Injection. 0-9030, CT Chlormerodrin Tablets.
0-9172, Meralluride & Mercardan Ampoules.
0-9463, Serfin Tablets. Montcello Drug Company, 45 Broad Street, Jacksonville, Florida 32202. 0-6670, Monerone Injection. 0–9433, Primacaine HCL. Nutritionai Res. Labs., Inc., 332 S. Michigan Avenue, Chicago, Illinois. NDA 0–5638, Infron Capsules. 10–037, Serfin Elixir. 10–122, Serfin Injection 0-7093, 666 Anti-Histamine Tablets. 0-7571, Act-O-Cin Cold Tablets. 10-122. Serini injection.

10-235, Norlutin OT Tablets.
Paul Maney Labs, Cedar Rapids, Iowa.

NDA 10-076, Receppine Injection.
Pehrons Enterprises, Espanola, Washington. Nyal Company, Detroit, Michigan. NDA 0-2137, Manacea Tablets. Morton Pharms., 1625 North Highland, Memphis, Tennessee 38108. NDA 0-8833, Cortisone AC Tablets. Nysco Labs., Inc., 34-24 Vernon Boulevard, Long Island, N.Y. 11106. Mr. Thompson Inc., Division JB Williams Company, 290 Jelliff Avenue, Newark, NDA 11-897, Morehalt Cream & Tonic. Percon & Covey, Inc., 236 South Verdugo Road, Glenville, California 91205. NDA's: 10–652, Cortiscorb Tablets. 10–945, Costonate w/Danthon Double Strength Capsules. N.J. 07100. NDA 12-378, Dropsprin. NDA's: Musher Foundation, Inc., Sales Agent E. Fougera, Cantiague Rock Road, Post Office Box 73, Hicksville, N.Y. 11800. NDA 11-571, Bitupal. 0-7164, Coradon Tablets. Organon, Inc., 375 Mount Pleacant Avenue, 0-8236, Corapac Tablets. West Orange, N.J. 07052. Pfizer Labo., Division Charles Pfizer Com-pany, Inc., 235 East 42nd Street, New York, N.Y. 10017. NDA's: 0-6802, Oranesin Tablets. 0-6918, Oranixon Elixir. National Drug Company, Division Richard-son-Merrell, Inc., 4463 Stenton Avenue, Philadelphia, Pennsylvania 19144. NDA 11-881, Aller-G Sul Ointment. 0-7225, Dodex Tablets. Pharmaceutical Industries, Inc., Cranford, 0-7685, Acetoxanon Injection. 0-8237, Cortrophin Organon Injection. 0-8407, Nidaton Tablets. 0-8952, Purified Cortrophin Gelitan In-NDA's: N.J. NDA 11-037, Scrutan Plus Capsules.
Pharms, Inc., 230 Jelliff Avenue, Newark,
NJ. 07100. 0-2309, Sulfapyridine Tablets. 0–2367, Matrisil Tablets. 0–3073, Carbomal Tablets. 0–3074, Pyro-TAn Solution. 0–3787, Sulfathiazole Tablets. NJ. 07100.

NDA'6:
0-7693, Histaline Syrup.
0-9552, Zarumin Tablets.
11-553, Deodrin Liquid.
Philadelphia Ampoule Labs., Inc., 400 Green
Street, Philadelphia, Pa. jection. 0-9814, Vistabolic Tablets. 0-9815, Vistabolic Injection. 11-337, Stenisone Tablets. 0-3787, Sulfathiazole Tablets. 0-3788, Sulfathiazole Tablets. 0-4024, Gestasol-Dry Injection. 0-4349, Diethylstilbestrol Tablets. 0-5946, Thiouracil Tablets. 12–189, Trevidal A–C Tablets. 12–803, Reflora. Ortho Pharmaceutical Corporation, Raritan, 0-6073, DL Desoxvephedrine HCL Tablets. N.J. 08869. 10-269, Reserval Injection. 0-6339, Synthogen Injection. 0-6527, Hesper C Liquid & Tablets. 0-6528, Methadon HCL Injection & Tab-NDA's: 10-651, Vibrumin Injection. 0–5288, Hexital Tablets. Philips Rosane Inc., Sub Philips Electronic, 203 East 11th Avenue North, Kansas City, Mo. 64106. NDA 10-527, Spasmolyo Tablets. 0-5398, Hexestrol Tablets.
0-5954, Nidoxital Tablets.
0-6809, Diffusion Injection.
10-032, Tritheon Tablets. 0-6883, Aleudrin Tablets. 0-7107, Menophen Capsules. Physicians Drug & Supply Company, 1458 Chestnut Avenue, Hillside, N.J. 0-7156, Panaldamin Tablets. 0-7250, Natolone Tablets & Injection. 0-7505, Catakon Tablets. 0-7599, Natrinii Powder. Panray Corporation, New York, N.Y. NDA's: 0-8038, Okellol Enteric Coated Tablets. NDA's: 0-7784, Gensalate Sod. Tablets. 0-8493, Dimethylane Enteric Coated Cap. 0-8860, Androlone Injection. 0-9095, Resion PMS Suspension. 0-9096, Rau-Vert in Tablets. 0-9610, Rauwolfia-Veratrum Virides 0-8513, Idrozide. Tablets. 0-9657, Hydrocorticone Topical Oint-Parke Davis & Company, Joseph Campan Avenue, Detroit, Michigan 48232. ment Physicians Products Company, Inc., 99 Saw-mill River Road, Yonkers, N.Y. 10701. 0-9120, Parenzyme. NDA's: NDA'6: 0-9429, Rau-Tabs. 0-0367, Crysto-Vibex and Nicotinic Acid Tablets.

0-0627, Vitamin K-In Oil Capsules,
0-0627, Vitamin K-In Oil Capsules,
0-0696, Thioethamyl Sod. Injection,
0-0697, Lipo-Bismol Injection,
0-1194, Ethadon Injection,
0-2716, Sulfapyridine Sod. Injection, 10-278, Transcrpin Elixir. 10-580, Parenzyme Aqueous Injection. 10–957, Vitamin B<sub>12</sub> 10–959, Avecalm Capsules, 11–091, Cervilaxin Injection. 11–138, Corticotropin-Gelitan Purified 10-581, Hycerpin Tablets. Pitman-Mooro Company, Division Allied Labs., Inc., 1200 Madison Avenue, In-dianapolis, Ind. 46206. Injection. NDA's: 0–1450, Sulfaphyridine Tablets. 0–2454, Estrotron 2000IU Injection. 11–828, Rau-Vertin Tablets. 12–576, Tridecamine SRT. 0-2775, Vitamin K, Capsules. 0-3089, Dihexylin Dermament Solution.

701	114 71624	
<ul> <li>0-4103, Chorionic Gonadtropin Injection.</li> <li>0-4263, Pulvo-Caps Estrotron Capsules.</li> <li>0-4544, Stilbestrol Injection &amp; Tabs.</li> </ul>	Reed & Carnrick, 30 Bright Avenue, Kenii- worth, N.J. 07033. NDA's:	0-4433, Polyvit. Tablets. 0-4502, Povage Insufflator Powder. 0-4567, Surbyl Solution.
0-4545, Stilbestrol Injection. 0-4615, Collocel Tablets. 0-4616, Collocel S Tablets.	0-3389, B, Liver & Iron Injection. 0-3390, Thiamin Hydrochloride Injec- tion.	0-4629, Strasco Special Vitamin Tablets #2 Enteric Coated Tablets. 0-4771, Polyvit. Tablets #2.
0-4617, Collocel A Tablets. 0-5294, Spersoid Sulfathiazole Suspension.	0–3391, Thiamin Hydrochloride Injection. 0–3392, Calcium Gluconate Injection. 0–5837, Ferrovite Tablets & Irocine Tab-	0–5164, Sulfanilamide Lozenga. 0–5317, Sulfathiazole-Urea Cream. 0–5577, Glycophen Tablets.
0-5572, Sulfathiazole & Sod. Bicarbonate Tablets.	lets. 0–7745, Covene Tablets.	0-6265, Folic Acid Tablets. 0-9228, Skopolate Enteric Coated Tab- lets.
0–6127, Sulfacarbzol Tablets. 0–9511, Serpine Tablets. 12–581, Ropad Tablets.	0-7746, Myanil Tablets. 0-8155, Mabutone Tablets & Liquid. 0-9340, Lullamin Drops.	0-9333, Skopolate Parenteral. 0-9377, Skopolate Pam Capsules.
P. J. Noyes Company, 101 Main Street, Lan- caster, N.H. 03584. NDA 0-1490, Special Formula for Norman	0–9567, Atonine Tablets. 11–256, Sycotrol Tablets. 12–011, Sycotrol Tablets.	0–9540, Kaprylex Capsules. 12–869, Amphenidone Capsules. Roberts Biological Labs., Buffalo, N.Y.
E. Cobb. Plough, Inc., Memphis, Tennessee. NDA's:	Rexall Drug Company, 8480 Beverly Boulevard, Los Angeles, California 90048.  NDA's:	NDA 0-5277, Aller-Tabs, Allergi Tabs.  Robin Pharmacal Company, 480 Broome  Street, New York, N.Y.
0-7162, St. Joseph Antihistamine Tablets. 0-7634, St. Joseph Antihistamine Com-	0–6446, Methadon Amidone HCL Tablets. 0–6894, Undecylenic Acid Capsules. 0–7856, Pyrilamine Maleate Syrup.	NDA's: 0-8006, Wards Formula Antihistamine Tablets.
pound Tablets. 0–7636, St. Joseph Anakohl Compound.	0–8355, RD Thenylpyramine Hydrochio- ride & Benzocaine Ointment.	0-9628, Reserpino Tablets. NDA's: 0-9685, Rauwolfia Sorpentina-Mannitol
0-7786, St. Joseph Anthist Cough Syrup. 10-519, St. Joseph Buffered Aspirin Tab- lets.	0-8710, Isoniazid Tablets. 0-9430, R. D. Reserpine Tablets. 10-436, Rexall Fluoride TPT.	Hexanitrate-Rutin Tablets. 0–9883, Rauwolfia Serpentina-Veratrum
11-068, ABC Buffered Tablets.  Portland Plastics Ltd/England/Kent, England.	11-514, Insorb. 12-710, Timed-Action Antihistamine Capsules.	Virides Tablets.  Roche-Organon, Division Hoffman-LaRoche, Inc., 340 Kingsland Street, Nutley, N.J.
NDA 0-8974, Portex Plastic Skin Dressing. Premo Pharmaceutical Labs., Inc., 111 Leuning Street, South Hacksensack, N.J.	Rexar Pharmacal Corporation, 382 Schenck Avenue, Brooklyn, N.Y. 11207. NDA 0-9285, Rautina.	07110. NDA's: 0-0116, Kolpon Suppository.
07606. NDA's:	R. G. Dunwody & Sons, Inc., Atlanta, Ga. NDA 0-0963, Modern Diuretic & Analgesic Tablet.	0-0307, Med. Hombreol Desules Oint- ment. 0-327, Dimenformon Solution.
0–0681, Ferosan Tablets. 0–0682, Trisilika Tablets. 0–0911, Sulfapyridine Tablets.	Richardson-Merrell, Inc., 122 East 42nd Street, New York, N.Y. 10017.	0-919, Menformon Dosules Cintment, 0-1939, Menformon Dosules Cintment, 0-2734, Neo-Hombreol M. Dosules Cint-
0–9012, Premo Ves Grn. 0–0913. Aminoacetic Acid Tablets. 0–0914, Sulfanilamide & Sod. Bicarbonate	NDA 0-8858, Dextran Injection. Riesen Walter P., Elm Grove, Wisconsin. NDA 0-0386, Risens Antiseptic Foot Powder.	ment. 0–6326, Lynoral Eli <b>xir.</b>
Tab. 0-1042, Aminoacetic Acid Elixir. 0-1191, Aminophylline & Potassium	Riker Labs., 19901 Nordhoff Street, North- ridge, California 91326. NDA's:	0-6600, Antibason Tablets. 0-6604, Liquaemin Injection. Roussel Corporation, 155 East 44th Street,
Iodide Tablets. 0-1108, Hydrocol Tablets.	0-7703, Sol IV Veriloid Injection. 0-7914, Veriloid VMP Tablets.	New York, N.Y. 10017. NDA's: 0-9973, Topicort Cintment.
0-4448, Stilbestrol Injection, Suppository, Tablets & Enteric Coated Tablets. 0-5890, Premodrin Tablets.	0-8011, Verioid VP Tablets. 0-8502, Veriloid IM Injection Solution. 0-8699, Parephyllin Solution IM.	10–113, Topicort Spray. Rowell Labs, Inc., Baudette, Minnesota
0–6368, Diethylstilbestrol Tablets. 0–7084, Neo-Cafotan Tablets. 0–7185, Rubitrate Capsules.	0–8820, Proveratrine A Injection. 0–9158, Serpiloid Tablets. 0–9305, Rauwidrine Tablets.	56623. NDA's: 11–360, Vio-Cort Topical Ointment.
0-7523, Pregnenolone Tablets & Injec- tion. 0-9428, Rauwolfia Serpentina Powdered	0–9752, Reserpine Injection. 0–9753, Serpalkon Elixir & Tablets. 0–9823, Protoberatine Reserpine Tab.	11–764, Residerm Lotion. 12–758, Vio-Methasone Tablets. S & G Company, 2161 West Grand Boulevard,
Whole Root Tablets. 0-9548, Hycortole ½ %, 2½ %, 1% Cream,	10–381, Rescinnamine Injection. 10–578, Triserpine Tablets. 10–601, Medinaler-Nitro Inhaler.	Detroit, Michigan. NDA 0-2738, Bruce's Formula SG. 12 Lo-
1/2 %, 21/2 % Ointment, and 1 % Lotion. 10-538, Vita Respital Liquid. 10-705 Rubitrate Injection.	10-790, Medihaler-Phen Spray.  R. J. Strasenburgh Company, Division Wal-	tion. Sahyun Labs, Post Office Box 996, Santa Barbara, California 93101.
11–669, Premogen Tablets. 11–670, Cordole Tablets. 11–671, Cordole Fortified Tablets.	lace & Tiernan, Inc., 755 Jefferson Road, Rochester, N.Y. 14623. NDA's:	NDA 0-7759, Diaphino Mandolato, Sup., Sol. & Ont.
Proco Solution Chemical Company, 1209 Arch Street, Philadelphia, Pa., 19107. NDA 0-8570, Polycaine Injection.	0-0007, Vitapectose w/Karaya Grn. 0-0279, Thiamol Syrup. 0-0389, Strasco Special Vitamin Tablets.	Sandoz Chemical Works, Inc., Routo 10, Han- over, N.J. 07936. NDA's:
Procter & Gamble Company, Post Office Box 599, Cincinnati, Ohio 45201.	0-0506, A-30000 Tablets. 0-1003, Ephedrine Camphorate Com-	0-2944, Scillaron Suppository. 0-9116, Puroverine. 0-9484, Sandostene Injection, Syrup, &
NDA's: 10-313, Gleem Fluoride TPT. 10-461, Secret Super Deodorant Cream.	pound Drops & Spray. 0–1229, Sedabrome Liquid. 0–1641, Sedalix Elixir.	Tablets. 15-087, Actospar Injection. S. B. Penick & Company, 258 Brunswick
11-086, Secret Roll-On Deodorant Liq- uid. 11-910, Secret Touch-Top Liquid.	0–1756, Dispectin Tablets. 0–2116, Sulfapyridine Tablets. 0–2177, Ferromal w/B, Tablets.	Street, Jersey City, N.J. 07302. NDA 0-3155, Gynestrol Teblets.
12-328, Radar Hairdressing. Purdue Frederick Company, 99-101 Sawmill River Road, Yonkers, N.Y. 10701.	0–2882, Phenyl Mercuric Nitrate Solution. 0–2980, Estradiol Strasenburgh Tablets. 0–3032, Thiamol 2000 Solution.	Schenlabs Pharms., Inc., New York, N.Y. NDA 10-031, Rutaminal w/Reserpino Tab- lets.
NDA's: 10–326, Eumens Tablets.	<ul><li>0-3131, Maxitrate w/Nitroglycerine Tablets.</li><li>0-3284, Alopectose w/Metropine Tablets.</li></ul>	Schenley Labs., Inc., 350 Fifth Avenue, New York, N.Y. NDA's:
10–333, Somatovite Tablets. Rare Chemical, Inc., Harrison, N.J. NDA's:	0–3457, Sulfathiazole Tablets. 0–3699, Bepenta Tablets.	0–7144, Para Aminosalicylic Λcid Powder. 0–7166, Kinavosyl Tablets.
0-1892, Testosterone Propionate Injec- tion. 0-6292, Dienestrol Rare Tablets & Injec-	0–3864, Soferyl Solution. 0–3893, Tricid w/Methrophine Tablets. 0–4108, Bepenta Syrup.	0-7916, PVP-Macroso Injection. 0-8501, Isoniazido Tablets. 0-8688, Cortisono ΛΟ Tablets.
tion. 0–6515, Estradiol Rare Tablets. 0–6534, Progesterone Rare Injection.	0-4359, Apocynum & Squill Compound Tablets. 0-4414, Stilbestrol Tablets.	10–621, Dorbantyl Forto Capsules and Suspension. 10–794, Dorbantyl Suspension.
·,		

Schering Corporation, 1011 Morris Avenue, Union, N.J. 07083. 0-2535, Sulfapyridine Tablets. 0-1934, Nicotinio Acid Amide Injection. 0–3536, Sulfathiazole Tablets. 0-1985, Nicotinic Acid Amide Tablets. 0-3263, Kipsols Blancard Tablets. 0-5018, Octofollin Tablets. 0-5041, Octofollin Solution/Injection. 0-5362, Sulfathiazole & Cod Liver Oil 0-1988, Ribbilavin Tablets. 0–1937, Riboflavin Injection. 0–1933, Thiamin HCL Injection. 0–1939, Thiamin HCL Tablets. 0-0150, Progynon-DH Solution. 0-0166, Oreton Ointment. 0-0522, Oreton-F Ointment. 0-1939, Thiamin HCI Tablets. 0-1930, Vit. D Tablets. 0-1931, Caroten w/Vit. D Tablets. 0-1933, Carotene Tablets. 0-1994, B-CPX Solution. 0-0961, Progynon-DH Solution. Ointment. Ointment.
0-5531, Mebak ICT.
0-5584, Dicumarol Cap.
S. E. Massengill Company, 527 Fifth Street,
Bristol, Tennessee 37620. 0-1261, Anteron Injection. 0-1297, Progynon-DH Ointment. 0-1298, Progynon-DH Suppository. 0-1680, Oreton M. Ointment. 0-1995, Accorbic Acid Tablets. 0-1936, Accorble Acid Injection. 0-1937, Thiamin HCL Riboflavin Nico-tinic Acid Amino Injection. 0-1802, Progynon-DP Injection. NDA's: 0-0105, Calcium Gluconate Tablets. 0-0483, Nicotinic Acid Tablets. 0-1346, Glysufed Inhaler. 0-2452, Progynon-DH Spray. 0-4257, Sod. Sulfadiazine Injection. 0-5191, Cortate Tablets & Solution. -2283, Smaco Thiamine HCL Tablets. 0-5226, Eliminol Tablets. 0–1603, Kamadrox Powder. 0-2284, Smaco Thiamine HCL Ampuls 0-2333, FC Sulfapyridine Capsules. 0-2618, Semestrin Tablets & Enterio Coated Tablets. 0-5379, Ditopax Injection. 0-6392, Hyronase Injection. 0-6783, Alpha - Cyclohexyl-Beta/3.5-Injection. 0-2412, Thiamine HCL Solution Injection. D110DD-4-Hydroxyphenol/Pro. -2725, Progesterone In Oll Injection. 0-2610, Carotene In Oil Liquid. 0–3381, Noviplex Elixir. 0–3508, Sulfathiazole Tablets. 0–3533, Pentobarbital Sodium & Aspirin 0-2611, Carotene In Oil Capcules. 0-2612, Carotene and Vit. D. Conc. In 0-6893, Sevinon Capsules. 0-7027, Prenolon AC & Prenolon Injec-Oil Solution. 0-7445, Acetoxypregnenolone Injection. 0-7588, Trimeton Maleate w/Neocala-Capsules. 0-2613, Cod Liver Oil w/Carotene & Vit. 0–4592, Amercid Solution. D. Conc. Solution. mine Lotion. 0-4776, Stilbestrol Enteric Coated Tab-0-2614, Vitamin A & D Capsules Blended Fish Liver O'l w/Activated.
0-2629, Menadione Tablets.
0-3103, Pyridoxine Smaco Tablets.
0-3103, Pyridoxine Ampuls Smaco In-0-7637, Trimeton Maleate Solution lets. Drops. 0-7639, Chlor-Trimeton Maleate Oph So-0-6314, Para-Aminobenzoic Acid Solution. 0-6344, Methadon HCL Tablets. 0-6370, Vitamin B12 Injection. 0-6371, Novisyn w/B12 Injection. 0-7061, Pasem-Sod Tablets. 0-7631, Khelisem Tablets & w/Phenobar-0-7674, Methostan Injection. jections. 0-7718, Chlor-Trimeton Maleate Injec-0-3183, Oleum Percomorphum w/Carotion. tene. 0-7740, Cortogen AC Injection. 0-7876, Cortisone AC Tablets. 0-7892, Trimodan Drops. 0-3274. Halibut Liver Oil w/Carotene Liquid.
0-3630, CA Pantothenate D-Rotatory bital Tablets. 0-8168, Verasem Tablets.
0-8397, Methpoline Br. Tablets.
0-8504, Perles Semnific.
10-925, Saline Solution Vitamin B12 Ac-Tablets.
0-3691, CA Pantothenate D-Rotatory Injection.
0-3770, Sm2co Pyridoxine Injection.
0-3832, Halibut Liver Oil w/Carotene 0-7951, Methostan Injection. 0-8010, Scheritone Tablets.
0-8373, Dormison Liquid.
0-8417, Ditubin Tablets.
0-8556, Cortomyd Ophthalmic Ointment.
0-8758, Teridax Tablets. tivity Conc. Injection. 11-785, Glarubin Tab. S. F. Durst & Company, 5317 North Third Street, Philadelphia, Pa. 19120. Capsules. 0-8906, Cortomyd Drops.
0-8939, Chlor-Trimeton Maleate Cream.
0-9192, Hydrocortisone.
0-9219, Hydrocortisone. 0-3853, Oleum Percomorphum v/Caro-tene Capsules. 0-3928, Smaco Nicotinic Acid Amide NDA's: 0-0021, Special Formula #2759, #2760 Syrup. Solution. Syrup.

0-0048, Special Formula #3000 Tablets.
0-0049, Special Formula #3001 Tablets.
0-0050, Special Formula #3002 Tablets.
0-0051, Special Formula #3003 Liquid.
0-0084, Special Formula #3004 Tablets.
0-0085, Special Formula #3005 Tablets.
0-0036, Special RX #3000 Tablets. 0-4364, Vit-B Injection. 0-4478, Smaco Eliziron Elizir. 0-9289, Parabromoylamine Maleate. 0–9290, Prolegic Maleate. 10–075, Neraval Sodium Sterile Powder Smith Brothers, Inc., Poughteepsie, N.Y. NDA 11-769, Smith Brothers Medical Cough Concentrate Syrup. Injection. 11-416, Sterotril Tablets. Smith, Kline & French Lobs., 1500 Spring Garden Street, Philadelphia, Pa. 19101. 11-666, Thihexinol Mebr. Tablets. 11–930, Pro-Fem Tablets. 12–222, Pregnidox Drops. 0-003, Special Formula #3007 Tablets. 0-0038, Special Formula #3003 Tablets. 0-4136, Estrogenic Substances. 0-4791, Menadione Tablets. 10-426, Protopine Tablets. NDA's: 0-1342, Benzedrine Solution. 0-1379, Paredrinol Sulfate Injection & Schieffelin & Company, Apex, N.C. 27502. NDA's: 0-0041, Follacro Injection. Tablets. 0-0041, Foliacro Injection.
0-0107, Memban Liquid.
0-0362, Old House Cough Syrup.
0-0391, V-Vitamin Capsules.
0-0409, Athletin Powder.
0-0473, 3XB Liquid.
0-0560, Progersterone Injection. 0-2569, Paredrine Hydbr. 3PC w/Boric Acid OPH Solution. Sharp & Dohme, West Point, Pennsylvania 0-2804, Pragmol Cream. 0-3840, Echayspentaplex Solution. 0-4153, Pragmacul Ointment. NDA's: 0-1209, Depropanex Injection.
0-2544, Cremo-Silconate Suppension.
0-3148, Nicotinic Acid Amide Tablets.
0-3256, Lyovac Liquid.
0-3628, Combavia Vitamin Capsules. 0-5359, Furmethide Icdide Injection. 0-555; Fundament Tedate Info 0-555; Benzedrex Inhaler. 0-5958; Eskaya Oralator Mis. 0-6335; Eskaloza Wafer & Grn. 0-6325; Tetronyl Jelly & Powder. 0-0586, Private Formula Maltine Co., Tablets. 0-0587, Private Formula John G. Mick Green Tablets. 0-4568, Sulfathiazole Cream. 0-0590, Private Formula Natural Health Smith-Dorcey Company. 0-5028, Bimerphen Anticeptic Tincture. 0-5906, Perabeta Drops. 0-6464, Cremostaticin Caronamide Sus-Prod. Company Yellow Tablets. 0-0591, Tymex Syrup. 0-0592, Private Formula Parvin Drug 0-0446, Hyoccine HBR Hypodermic Tablet. 0-0450, Potassium CL Capsule for Dr. W. O. Horton. pension. 0-6878, Undecylenic Acid Capsules. 0-6935, Proketuss Liquid. Company Syrup.
0-0593, Private Formula NY Post Hospi-0-0490, Procaine HCL w/Epinephrine Injection. 0-7174, Propaspellervescent Tablets. 0-7279, Proketal Compound Capsules. 0-7364, Sharmone Tablets. tal Zinc Oxide Ointment. 0-0594, Private Formula NY Post Hospital Ointment. 0-035, Private Formula #1904 for Winslow Drug Company Capsules.
0-036, Bile Salts Compound & Purified 0-0595, Private Formula NY Post Hospi-0-7049, Cremotres Suspension. tal Liquid. 0-8067, Padrina Tablets. Tablets.
0-0640, Vitamin B Complex Syrup. 0-0767, Kurto Liquid. 0-9126, Cyclaine HCL. 0-9649, Alflorone Acetate Topical Lotion. 0-0768, De-Ko Ointment. 0-6732, Elixir Talamin Chloride w/Man-ganeze Elixir.
0-0783, Icotonic Sol Ephedrine Sul IPC.
0-0789, Pumice and Sodium Caloride Para Aminocalyic Acid. 0-0769, AV Ointment. 0-9828, Hydrocortone-K Tableta. 0-0890, Thiamin Chloride Tablets. 0-0894, Private Formula Tablets. Sidney Ross Company, Newark, N.J. NDA 0-7308, Ladogal Tablets. 0-0947, Glycana w/Vitamin B, Liquid. Singleton & Sons, 103 Dallas Street, Wichita 0-1200, Citrates & Carbonates Compound Falls, Texas. 0-0780, Private Formula Tab. for Dr. W. & Grn. NDA 0-0383, Royal Corn Remover Solution. Claude Davis. 0–0312, Thiamin CL Injection. 0-1488, Togal Tablets. SMA Corporation, Chagrin Falls, Ohio

0-0813, Thiamin Tablets.

NDA's:

0-1708, Glycine Hydrochloride Capsules.

0-0879, Petrolatum w/Phenolphthalein #4 Emulsion.

0-0880, EML Liquid Petrolatun w/Phenolphthalein #5 Emulsion. 0-0881, EML/Liquid Petrolatum #6

Emulsion.

0-0882, Tab. KCL 5 Grs. 0-0921, Thiamin CL Elixir. 0-1181, Private Formula Ointment.

0-1314, Private Formula RX 1919 for Dr. N. L. Beebe Liquid.

0-1400, K CL w/Citric Acid Solution. 0-1432, Chlormercuri Carvacrol Ointment.

0-1500, Private Formula for Dr. C. E. Whiting Liquid.

0-1501, Nicotinic Acid Tablets. 0-1592, Carbromal Tablets. 0-1616, Sod. Thiocyanate Tablets.

0-1635, Sulfanilamide w/Soda Tablets. 0-1681, Private Formula for Donley Stahl

Company Capsules. 0-1691, Private Formula Capsules.

0-1734, Sulfanilamide Powder. 0-1760, Ferrous Sulfate w/Thiamin Hydrochloride Tablets.

0-1764, Sodium Citrate Ammonium Chloride w/Codeine Phosphate. 0-1773, Aminoacetic Acid Elixir. 0-1782, Private RX Law Drug Co. Cap-

0-1783, Private RX Morehead DE MD Wafer.

0-1800, Aminoacetic Acid Tablets. 0-1837, Private Formula Capsules.

0-1863, Private Formula for Dr. Gardner Tablets.

0–1864, Private Formula for Dr. Gardner Tablets.

0-1865, Private Formula for Dr. Gardner

0-1901, Sodium Citrate w/Codeine Phosphate Syrup.

0-1902, Ephedrine Aminophyll Phenolphthalein #5 Emulsion. Aminophyllin &

0-1921, Private Formula for A & B Drug

Company Marysville Kans Tablets. 0-1922, Private Formula for Bellamy Drug Store Capsules.

0-1971, Sulfanilamide with Soda Tab.

O-2014, Magnesium Trisilicate w/Lac Pulvis Tablets. O-2030, Private Formula Tablets. O-2136, Theobromine Phenobarbital & Thiamine CL Tablets.

0-2143, Sulfapyridine Tablets.

0-2197, Private Formula for Dr. H. E. Abrums Capsule.

0-2310, Potassium CL Elixir.

0-2311, Ferrous Sulfate w/Vit. B1 & C Tablets.

0-2341, Aminophyllin Injection. 0-2342, Nicotinic Acid w/Vit. B1, B2, C

0-2370, Private Formula #1946 for Phillips Drug Store Capsules.

0-2391, Bismuth & Paregoric Compound/ Liquid.

0-2418, Private Formula/Dr. John Eiler

0-2470, Private Formula Powder. 0-2537, Thiamin CL Injection. 0-2538, Thiamin CL Tablets.

0-2539, Thiamin CL Tablets

0-2540, Pan Creatin Triple Strength Capsules.

0-2693, Pancreatin Triple Strength Tabsules.

0-2704, Morphine Sulfate Injection.

0-2848, Nicotinic Acid Amide Tablets.

0-2849, Thiamine CL Syrup. 0-2880, Mineral Oil w/Vitamin A Liquid. 0-2913, Thiamine CL Injection.

0-2914, Amino Acetic Acid & Thiamin Chloride Elixir.

0-3004, RX #1960-Peerless Pharm Cap-

0-3025, RX #1961 Heinz Drug Company Tablets.

0-3037, Estrogenic Hormone Substances in Oil Injection. 0-3119, RX #1963 Broadway Pharm.

**NOTICES** 

Tablets. 0-3173, Morphine Sulfate w/Atropine

Sulfate Solution.

0-3174, Kaynone Tablets.

0-3175, Ferrous Sulfate w/Vitamin D. Tablets.

0-3195, CA Phos. w/Vitamin D Tablets. 0-3251, Throat Lorenze.

0-3324, Sugar-Free Cough Mixture Liqnid.

0-3406, Astringent Gargle Solution.

0-3445, Sulfathiazole Tablets

0-3462, Ephinephine in Oil Injection. 0-3463, Methyl Salicylate Menotholcam-

phor Ointment.
0-3464, Anterior Pituitary & Ovarian

Substance Injection.

0-3465, Sol Epinephrine HCL Inhaler.

0-3538, RX 1966 Stewart Pharmacy Tablets.

0-3554, Liver & Iron w/Vit. B Tablets. 0-3555, Estrogenic Hormone Substances

Tablets. 0-3556, RX-1969 Danielson Med Arts

Pharm, Ointment. 0-3622, Private Formula RX 1971 Cap.

0-3738, Riboflavin Tab. 0-3753, RX-1973 Dr. W. G. Benjamine

Liquid. 0-3798, RX-1976 Haussamen Drug Co.

Capsules. 0-3799, RX-1977 Haussamen Drug Co. Capsules.

0-3871, Private Formula #1980 Capsules. 0-3897. Codeine Sulfate Hypodermic Tablets.

0-3914, Estrogenic Hormone in Oll Injection.

0–3922, Magma Sili-Jel Liquid. 0–3966, Vitamin B6 HCL Tablets. 0–4007, B-Vatine Elixir.

Cap.

0-4058, RX 1988 Danielson Medical Arts Pharm, Ointment.

0-4063, Private Formula Deadwood Drug Suppository

0-4156, Morphine Sulfate Injection. 0-4157, B-Vatine Injection. 0-4182, Private Formula #1994 for Gas Ease Labs Tablets.

0-4188, Private Formula #1995 Potter Drug Company Tablets. 0-4221, RX #1996—Patterson Drug Com-

pany Capsules. 0–4222, RX #1997—Drs. Patton & Carroll

Cap. 0-4223, RX #1998 HL Haussamen Co.

0-4271, RX #1999 Bailey Hospital Injection.

0-4272, RX #1948—Dr. John Eiler Wafer. 0-4326, RX #1991 Day R. J. MD Tablets. 0-4330, Glutamic Acid HCL Capsules.

0-4346, Potassium Gluconate Tablets

0-4362, RX #2001 Rankin Drug Tablets. 0-4385, Aminophyllin Tablets. 0-4389, Stilbestrol Tablets & Injection.

0-4409, RX #1703 Fregger Medicine

Company Tablets. 0-4418, Syn-Vatine Tablets.

0-4425 Private Formula RX #2003 Capsules.

0-4429, RX #2004 Corner Drug Store Capsules.

0-4443, Aminophyllin Elixir. 0-4470, Nikethamide Injection.

0-4485, Aspi-Thesin Tablets.

0-4486, Karanal Tablets.

0-4490, Sodium Chloride & Dextrose Tablets.

0-4505, Nicotinic Acid Injection. 0-4519, Sulfathiazole Ointment.

0-4520, Phenobarbital & Belladonna

0-4521, Sulfanilamide Ointment.

0-4551, Sulfathiazole Ophthalmic Ointment.

0-4571, Rban Elixir.

0-4590, S Cream.

0-4591, Sulfathiazole Grn.

0-4646, RX #2005 HL Haussamen Company Capsules.

0-4647, Aurazine Solution.

0-4648, Capantothenate Tablets.

0-4713, E-Vatino Capsules. 0-4723, B-Vatino w/Liver Injection. 0-4838, Pascafen Tablets.

0-5552, Sulfamerazine Tablets. 0-7515, San Bromai Tablets.

0-7516, Antopic Cream. 0-7711, Neutrazyme Suppository. 0-8192, Nellin Tablets.

0-8542, Isoniazido Tablets.

0-8566, Sanbrom Tablets.

0–8575, Veratra-bar Tab. 0–9343, Crystoserpine Tablets. 11–843, Meprodil Tablets.

S. R. Seaver & Company, North Kansas City, Missouri.

NDA 0-1012, Sedazano Tablots,

Standard Chemical Company, Inc., 1013-1017 High Street, Des Moines, Iowa.

NDA 0-2306, Aminophyllin Tablets Standard Pharmacal Company, 1300 Abbott Drive, Elgin, Illinois 60121.

NDA 0-9896, Reserpine Alkaloid Tablets.

Strasenburgh Labs, Division Wallaco & Tier-nan, Inc., 755 Jefferson Road, Rochester, N.Y. 14603.

NDA 12-869, Amphenidone. Strong Cobb & Company, 11700 Shaker Bottlevard, Cleveland, Ohio 44120.

0–0285, Thermed Hair Tonic Liquid. 0–1478, Mosbys Tonic Liquid. 0–7778, AAC Tablets.

0-7852, Laevo Isomethadone Injection. 0-8098, Eskel Enteric Coated Tablets and Tablets.

0-8751, Tetropentobarb 60 Capsules. 0-8752, Tetropentobarb 38 & 250 Capsules.

0-8753, Tetrosecobarb 60 Capsules. 0-9499, Pentosec-S 60.

Success Chemical Company, Inc., 800 Hins-

dale Street, Brooklyn, N.Y. NDA 0-9629, Reserpino Tablots. Sutliff & Case Company, Inc., 201 Spring

Street, Peoria, Illinois.

NDA 0-7499, Casate Sodium Tablets.

Tablerock Labs., Inc., Post Office Box 1968,
Greenville, S.C. 29602.

NDA's:

0-3013, Befaclin Elixir. 0-3014, Asoflamin Tablets.

0-9684, Neo-Rauja Tablets. 10-145, Pro-Ser Tablets.

10-517, Tacasol Tablets. Tailby-Nason Company, Inc., Boston, Massa-

chusetts. NDA's: 0-9539, Improved Portensors Forte Tab-

lets. 10-048, Rau-V-Potensors Tablets. Taylor Pharmacal Company, 1222 West Grand

Avenue, Decatur, Illinois.

NDA's:

0-9967, Reserpine Injection. 0-986, Reserving Injection.
10-852, Mydsol Testosterone Injection.
10-852, Mydsol Testosterone Injection.
10-852, Mydsol Testosterone Injection.
10-852, Mydsol Testosterone
10-9867, Reserving Injection.
10-852, Mydsol Testosterone
10-852, Mydsol Testoste

0-1428, Children's Mild Baume Bengay

Ointment.

0-8491, Calthenamine Cream.

0-9889, Amril Tablets. 10-156, Piperazate Wafers & Chewottes Lozenge

11-481, Metamine Sustained w/Reserpine

Tablets. 11-566, Clarin.

Tilden Company, New Lebanon, N.Y. NDA 0-3156, Sulfapyridine Tablets.

Travenol Labs., Inc., Division Baxter Labs., Inc., 6301 Lincoln Avenue, Morton Grove, Illinois 60053. NDA 12-798, Caregin IA, IV, ICAV Injec-Tyson & Company, Inc., 133 North Poplar Street, Paris, Tennessee 38242. NDA 0-3083, On-The-Spot Household Slv. Union Pharm. Co., Inc., Post Office Box 8105, Kansas City, Mo. 64112. NDA 08034, Inhiston Drops. United Pharms Inc., 1064 44th Avenue, Oakland, California. NDA 11604, Trimadon Improved Caps. University of Rochester Isotope Center, Rochester, N.Y. NDA 9724, Iodine I-131 Diagnostic Solution and Therapeutic Solution. Upjohn Co., 7171 Portage Road, Kalamazoo, Mich. 49002. NDA's: 0-387, Gonadogen Inj. 1-979, Vit. K Caps. 2-236, Calcium Mandelate w/Methenamine & Ammonium Acid Phos. Tabs. 2-320, Ephedrine & Cyclopal Caps. 475, Methenamine & Ammonium Acid Phosphate Tabs. 2-679, Sod. Sulfaphridine Monohydrate 3-450, Theophylline Sodium Acetate Inj. 4-583, Menadione Caps & Tabs. -997, Mercresin Ont. 4-998, Diethylstilbestrol Elixir. 5-496, Sulfamerazine Tabs. 5-500, Plasmoid Inj. 5-602, Ergot Alkaloid Inj. 5-640, Quatresin Solution. -748, Thiouracil Tabs. 6–178, Entero-Gastrone HCl Inj. 6–377, Methadon HCl Syr. 6–404, Chlorguanide HCl Tabs. 6–523, Pyroliazote Elx. & Tabs. 8-366, Acth Inj. 8-350, Actif Inj. 8-520, Isoniazid Tabs. 9-460, Cortef Acetate 1% Crm. 9-589, F Cortef 0.1%, 0.2% Lotion. 9-816, Cortef Acetate Eye & Ear Sterile Susp. Drops. 9-817, Cortef Acetate Ophthalmic 1.5% Ont. 9-865, Corticotropin Powder & Inj. 10-223, Reserpoid Sterile Sol/Inj. 10-239, Delta-Cortef Acetate Ont. 10-754, Cortef Acetate 1% Lotion. 10-755, Delta-Cortef Acetate Lotion. 10-776, Delta-Cortef Drops. 11-152, Special Formula #17875 Syr. 11-211, Lipomul IV Sterile Emulsion Inj. 11-376, Medrol Ont. 11-422, Hormozyne Tab. 11-570, Medrol Acetate. 11-747, Oxylone Topical Ont. pect, Ill. NDAs: 5-214, Vikay Inj. 5-215, Dietstilbestrol Tabs & Inj.

U.S. Standard Prods., Company, Mount Pros-

6-885, Zyclophen Ont.

U.S. Vitamin & Pharm Corp., Div. Revlon Inc., 26 Vark St., Yonkers, N.Y. 10701. NDAs:

1-948, Thiamin CL Inj. & Tabs.

2-934, Poly-B Ampules Inj. 2-935, Poly-B Brand of Vitamin B Fac-

tors Syrup. 5-148, Stilbevin Caps.

5-149, Para Amino Benzoic Acid Caps.

6-822, E-Taplex Inj.

11-004, Dodicatrate Inj.

Vale Chemical Co., Inc., 1201 Liberty St., Allentown, Pa. 18102.

NDAs: 0-418, Thiavin Elx.

1–385, KCL Tabs. 1–386, Sulfanilamide & Sodium Bicarbonate Tabs.

2-286, Strychnine & Suprarenal.

2-465, Sulfapyridine Tabs. 8-255, Kardikel ECT.

o-200, Karaikei Eur. Valentine Labs., Chicago, Ili. NDA 7-689, Ancirin APC Tab. Van Pelt & Brown, Inc., 1322 East Main Street, Richmond, Va. 23219. NDAs:

2–707, Maltimin Liquid. 4–169, Sulfapyridine Tabs. 4–171, Sufathlazole Tabs. 4-547, Stilbestrol Tabs & Inj. 4-601, Silaloid Tabs. 4-688, Sulfanilamide Ointment.

4-689, Sulfathiazole Ointment.

4-689, Sulfathiazole Ointment.
5-005, Viazole Ointment.
5-281, Sulfadrine Dps.
5-829, Stilplex Tabs.
Varick Pharm., Co., Inc., Post Office Box 73,
Hicksville, N.Y. 11800.
NDA 8-380, Digitaline Natievelle Tabs.
Veltex Co., 1711 First Avenue, North, Birmingham, Alabama 35203.

NDA 9-934, Rawpentin Tabs. Vick Chem. Co., Div. Richardson Merrell Inc., 122 E. 42nd St., N.Y., N.Y. 10017. NDAs:

DAS. 0–136, Vicks A-Q Noce Dps. 2–776, Vicklax Liq. & Powder. 5–142, Serene Anticeptic Baby Lot. 5–175, Myosan Sol.

7–159, Histaid.
Victor Hermlin & Co., 2503 So. Hanley Rd., St. Louis, Mo., 63144.
NDA 9–630, Reserpine Tabs.

Vitamix Corp., Lancaster & 51st Sts., Philadelphia, Pa., 19131. NDA 10-940, Cobalamin Conc. Saline Sol.

Inf.

Vitarine Co., Inc., 227-15 N. Conduit Ave., Springfield Gardens, N.Y., 11413. NDA's:

7-091, Histivite Tabs. 7-862, Histipac Tabs. Volk Radiochem. Co., 803 N. Lake St., Burbank, Calif., 91502.

10-186, Sodium Radiodide 131 Sol. &

Iodocaps.
11–614, Radiogold Colloid/AV–193.
Walker Labs., Div. Richardson-Merrell, 122
E. 42nd St., N.Y., N.Y., 10017. NDAs:

8–538, Isoniazid Tabs. 9–743, Serpedon Tabs. 9–932, Serpedon Elx. 10-351, Pincets Tabs. 10-487, Cortispray. 10–497, Articon Tabs. 10–804, Pinsirup Syr. 12–134, Stressoxin Caps.

12-261, Natorexic Tabs.

12-275, Vitasioup Syr.

Walker Myron, 508 Franklin Ave., Mt. Vernon,

NDA 0-314, Dicalcium Phosphate w/Vita-· min BCD Caps.

Walker Vitamin Prods., Co.

NDAs:

4–355, Walkers B Complex Tabs. 6–050, Methionine Caps.

7–848, Mensalin Tabs.

Wallace & Tiernan Products, Inc., Belleville, aAGN:

0-730, Private Formula/Dr. L. H. Mar-

shall Tab. 5-015, Monomestrol Tabs.

5-016, Monomestrol in Oll Inj. 5-104, Azochloramide Oint., Powder, Sol. Tabs.

5–202, Diethylstilbestrol Tabs. 5–234, Buffered Sulfanilamide Crystal-

line Powder. 5-235, Buffered Sulfanilamide Micro-

Crystalline Powder.

5–585, Azochlorasul Powder. 5–586, Azochlorasul Ointment. 5–726, Luciderm Dressing.

6-013, Aqua-Tabs.

6-302, Flurium Gum.

0-531, Salundex Ointment. 6-807, Lucaine HCl Inj. 6-868, Endesyn Caps.

6-894, Lorzinex Sol.

7-813, Glymylol Sol. 8-346, Salundek Ointment & Solution.

467

8-363, Salundek Lotion. 11-973, Dornwal Tabs.

Wallace Labo., Half Acre Rd., Cranbury, N.J. 03512.

NDA 5-710, Intraderm Sulfur Sol. Wampole Labe, Div. Denver Chem. Mfg., Co., 35 Commerce Rd., Stamford, Conn. 06304.

NDAS: 11-518, Nicotid.

11-930, Neo-Mercazole Tabs. 12-442, Nicobuf Tabs. Warner Chilcott Labs., Div. Warner-Lambert Pharm., Co., 201 Tabor Rd., Morris Plains, N.J. 07930. NDAs:

6-536, Stigmonene Br. Inj. 8-334, Methium Tabs. 9-633, Methium CL.

9-352, Methium W/Recerpine Tabs.

9-975, Releasin Inj.

11–543, Dolorub Tabs. 12–672, Perithiazide Tabs.

12-887, Dubarry Neomycin Deadorant & Antipercpirant Cream.

12-833, Dubarry Antiperspirant Deodorant w/Neomycin Sol.
12-889, Sportaman Antiperspirant Deodorant w/Neomycin Sol.

12-889, Sportoman Antiperspirant Decdorant w/Neomycin Crm. Warner Inst. for Therapoutic Res., New York,

N.Y.

NDA 6-636, Vitamin A. Conc. Warren-Teed Prod. Co., 532 W. Goodale St., Columbus, Ohlo 43215. NDAS:

2-976, Methoquim Caps. & Inj. 7-131, Epsilan Phos. Sterilized Sol. Inj. Westerfield Pharm. Co., 11 St. Mary's St.,

Dayton, Ohio. NDAS:

0-074. Special Formula Dowling Thomas J., M.D.

3-754, Quinidine Sul. Caps. 4-351, Sulfapyridine Caps.

White Labs., Inc., Galloping Hill Rd., Kenilworth, N.J. 07033.

#1291 for

8-524, Sulf-Urea Powder. 8-552, Gulatussin Syrup. 8-702, Eucupin u/Zolamine Syrup. 8-707, Eucupin w/Zolamine Ont.

8-707, Eucupin w/Zolamine Ont.
8-969, Quintamide Tabs.
8-970, Quintamide Dps.
9-778, Dienestrol Lotion.
10-241, Gitaligin Inj.
11-760, Normacol Tabs.
12-924, Oxypheneyclimine.
Whitehall Fnarmacol Co., Div. American
Home Prodo, Corp., 635 Third Ave., New
York, N.Y. 10017.

NDAs:

3–789, Guardo Tabs. 7–476, Minihist Tabs. 7–609, Guardo Antihist. Cold Tabs.

7-845, Primaten Analgesic Tabs.

9-231, Kolynos. 9-232, Kolynos w/Chlorophyll. 10-631, Dendryl Anti-Cough Compound

10-687, Triptone Tabs.
Whittier Labs., Div. of A. H. Robins, 2101
Dempster St., Evanston, Ill. 60201. NDA3:

6-820, Caubren Compound Tabs. 7-734, M-4 Tabs.

8-623, Pambromal Tabs.

9-877, Pambromal Tabs. William H. Rorer, 500 Virginia Dr., Ft. Washington, Pa. 19034.

1-007, Special Formula Tabs.

2-005, Thiamintol Solution.	4-949, Ceepryn Ont.	7–861, Mytolon CL. Inj.
2-630, Special Tab—Dr. R. L. Moore.	4-950, Ceepryn Oph. Ont.	7-890, Levo Isomethadone HCl Sol. &
2–970, Special Cap #13791.	5–062, Nethamine Tabs.	Tabs.
3-005, Special Formula # 13801 Tabs.	5-063, Nethacetin Tabs.	7–971, Thenfadil Tabs.
3-005, Special Formula #1138-70 Caps.	5-064, Nethacetin Syrup.	8–231, Katonium Powder.
3–307, Rotelotion Ointment.	5–100, Sulfathiazole Ont.	8-463, Thenfadil HOI Cream.
4-017, Estrogenic Substance Sup.	5-121, Sulfathiazole Cream.	8-635, Milibis Tampons Sup.
4-303, Factimen-Rorer Tabs.	5–184, Vonedrine Inhalant. 5–194, Vonedrine Hydrochloride Drps.	8–818, Thenfadil SA. SRT. 10–118, Mantomide Tabs.
4–331, Solviplex Inj. 4–432, Sulfanilamide Powder.	5-260, Hexestrol in Oil.	Wyeth Labs Inc., Div. American Home Prod-
4-347, Stilbestrol Tabs.	5–261, Hexestrol Tabs.	ucts Corp., P.O. Box 8299, Philadelphia,
4-449, Carbathiazole Ont.	5-707, Hexestrofen 1-3 Tabs.	Pa
4-550, Sulfanilamide Cones.	5-708, Hexestrofen 1-3 Elixir.	NDAs:
4-886, Sulfathiazole Powder.	5–858, Butaphyllamine ECT.	1-623, Alv Lotion.
5–670, Sulfamidazole-Ephedrine Sus.	5–859, Butaphyllamine Inj.	6–138, Propion Gel.
5–904, Thiouracil 100 mg. Tabs.	5–977, Dicumarol Tabs.	6–189, Folic Acid Tabs.
5–983, Mekasel Pwdr.	6-005, Nethaphyl ECT.	6-260, Secretin Inj.
6-082, Ansadol Rorer Ont.	6-007, Nethaphyl Caps.	6-271, Cytochrome C Inj.
7-090, Crystalline Vit. B <sub>12</sub> Inj.	6-242, Hexestrol Aqueous Sus.	6-409, Syrup Althose Syrup Methadone.
William P. Poythress & Co., Inc., 16 N. 22nd	6-316, Mercodol w/Decapryn Syr.	6-438, Metopon HCl Caps.
St., Richmond, Va. 23217. NDA 5-097, Para Amino Benzoic Acid Tabs.	7–276, Dicapryn Succinate Minergic Inj. 7–650, Ferox Intravenous Inj.	6-439, Neohetramine Syrup & Tabs.
	8-452, Oxityl-P Tabs.	6-606, Neohetramine HCl Cream.
William R. Warner, Div. Warner Hudnut Inc.,	8-684, Stilbamidine Isethionate Inj.	6–705, Methadono HCL Susp. 7–186, Pregnenolono Acetato Tabs.
113 W. 18th St., New York, N.Y. NDAs:	9-950, Meraton Hydrochloride w/Reser-	7–473, Artisone Acetate Inj.
0–146, Sulfanilamide Tabs.	pine Tabs.	7-904, Propion Opthalmic Sol.
1–120, Thiazyme Elx.	10–470, Reserpine Tabs.	8-259, Wyovin w/Phenobarbital Tabs.
1–170, Cal-Bis-Ma Pwdr. & Tabs.	10-806, Cobalamin Conc. Inj.	8-260, Wyovin Tabs.
1-577, Aromatic Spirit of Ammonia Liq.	10-889, Consolets Tabs.	8-337, Phenergan w/Neocalamine Lotion.
1-578, Expectorant Mixture Liq.	10-890, Consol Sus.	9-016, Plavolex.
1-579, Spirit of Camphor U.S.P. Liq.	11–580, Tridecamine Tabs.	9-396, Thiomerin Sod. Susp.
1–779, Ascorbic Acid Tabs.	12-610, Bevitam.	11–262, Ambutonium Bromide Tabs.
1–781, Vitamin B <sub>1</sub> Tabs.	Wilson Labs. Div. Wilson & Co., 4221 South	11–647, Artisono Tabs.
2–018, Sulfanilamide w/Sod. Bicarbonate	Western Avenue, Chicago, Ill.	Wynit Pharm., Madison, N.J.
Tabs.	NDAs:	NDA 12-381, Doderell Sus.
2–036, Lixa-Beta Elx.	3–168, Estrogenic Substance Caps. & Inj.	Xttrium Co., 415 West Pershing Road, Chi-
2–094, Analgesic Liquid.	4–337, Thiamine HCl Tabs.	cago, III. 60609.
2-558, Sulfapyridine Tabs.	4-732, Pyridoxine HCl Inj.	NDAs:
2-695, Ascorbic Acid Inj.	5-158, Epithene Jel.	6–396, Tucidor Sol. 6–552, Tucidor Obtundent Crm.
2-696, Thiamin HCl Ampul/Inj.	5-942, Hepazin Inj.	10-557, Reserpine Tabs.
2–783, Nicotinic Acid Tabs. 2–784, Riboflavin Tabs.	Winthrop Chem., 170 Varick Street, New	10-900, Hydrocortisono AO Denture Ad-
2–919, Vilexon Syr.	York, N.Y.	hesive Pwd.
3–339, Vilexon Caps.	NDAs:	Yates Drug & Chem. Co., 295-303 Lafayette
3–834, Thiamine HCl Inj.	0-002, Neoprontosil Tabs.	Street, New York, N.Y.
3-892, Sulfathiazole Tabs.	1–350, Torantil Tabs.	NDAs:
3-943, Epi-Vita ECT.	2-834, Anaesthesin Jelly.	3–955, Sulfathiazole Tabs.
4-004, Ampuls Vit. A & D in Oil Inj.	4-072, Stilbestrol Inj., Sup. & Tabs.	3–956, Sulfaphridine Tabs.
4 400 371 - 1113- 71	4 195 Cunwaranin Ini	, <u>,</u>
4–190, Nicotinamide Inj.	4-135, Suprarenin Inj.	
4–191, CA Pantothenate Inj.	4-718, Diodrast Inj.	Within 30 days after publication
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCl Inj.	4–718, Diodrast Inj. 4–760, Kappaxin Inj.	Within 30 days after publication hereof in the Federal Register, the ap-
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCl Inj. 4–290, Omni-Beta Elx.	4–718, Diodrast Inj. 4–760, Kappaxin Inj. 4–846, Salyrgan Theophylline ECT.	Within 30 days after publication hereof in the Federal Register, the ap- plicants, as well as any interested person
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs.	4–718, Diodrast Inj. 4–760, Kappaxin Inj.	Within 30 days after publication hereof in the Federal Register, the ap- plicants, as well as any interested person who would be adversely affected and who
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj.	Within 30 days after publication hereof in the Federal Register, the ap- plicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj. 4–546, Emulsified Vak Liquid.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk,
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj. 4–546, Emulsified Vak Liquid. 4–663, Syntha-Beta Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj. 4–546, Emulsified Vak Liquid. 4–663, Syntha-Beta Tabs. 4–747, Dietstilbestrol Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane,
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj. 4–546, Emulsified Vak Liquid. 4–663, Syntha-Beta Tabs. 4–747, Dietstilbestrol Tabs. 4–748, Dletstilbestrol Inj.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj. 4–546, Emulsified Vak Liquid. 4–663, Syntha-Beta Tabs. 4–747, Dietstilbestrol Tabs. 4–748, Dietstilbestrol Inj. 6–047, Heparin Pitkin Menstrum Inj.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj. 4–546, Emulsified Vak Liquid. 4–663, Syntha-Beta Tabs. 4–747, Dietstilbestrol Tabs. 4–748, Dietstilbestrol Inj. 6–047, Heparin Pitkin Menstrum Inj. 6–379, Diatrin Syr. & Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs.	Within 30 days after publication hereof in the Federal Redister, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appear-
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or
4–191, CA Pantothenate Inj. 4–289, Pyridoxine HCI Inj. 4–290, Omni-Beta Elx. 4–366, Vitamin A Tabs. 4–410, Sod. Thiosul Inj. 4–546, Emulsified Vak Liquid. 4–663, Syntha-Beta Tabs. 4–747, Dietstilbestrol Tabs. 4–748, Dietstilbestrol Inj. 6–047, Heparin Pitkin Menstrum Inj. 6–379, Diatrin Syr. & Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-181, Adanon HCl Inj., Syr., Elx., Tabs.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the oppor-
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-181, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road,	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Soi. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-181, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-181, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016.	Within 30 days after publication hereof in the Federal Redister, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCl Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT, 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs:	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing.
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Soi. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without fur-
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order with-
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thiamine HCl Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thiamine HCl Tabs. 2-185, Thiamine HCl Tabs. 2-185, Thiamine HCl Inj.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs.	Within 30 days after publication hereof in the Federal Redister, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCl Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-186, Thiamine HCl Inj.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT, 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostilosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-966, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs.	Within 30 days after publication hereof in the Federal Redister, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCl Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Tabs. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Elx. 2-187, Sulfanilamide & Sod. Bicarbonate	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-043, Lutawin Caplets.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to avail-
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCl Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-186, Thiamine HCl Inj.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Soi. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-181, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-943, Thiamine HCl Tabs. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 9-121, Aralis Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Tabs. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquinoline Benzoate Ont. 2-468, Beta Concemin Elixir.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-181, Adanon HCl Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-054, Mytelase Chloride Tabs. 11-054, Mytelase Chloride Tabs. 11-054, Mytelase Cl. Sol. 11-247, Isuprel Sol Inj. and Sublinguar	Within 30 days after publication hereof in the Federal Redister, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing.  If such persons elect not further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-943, Thiamine HCl Tabs. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublinguar	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to avail-themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCl Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thiamine HCl Tabs. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 1-943, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublinguar Tabs. 1-728, Superinone.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCl Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-960, Pentobarbital—Sod. Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT, 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublinguar Tabs. 11-728, Superinone. 12-637, Isuprel Ethanesulfonate.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops. 2-960, Pentobarbital—Sod. Tabs. 3-194, Sulfathiazole Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-181, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase Chloride Tabs. 11-047, Isuprel Sol Inj. and Sublingual Tabs. 11-728, Superinone. 12-637, Isuprel Ethanesulfonate. Winthrop Stearns Inc., 170 Varick \$t., New	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  Register a written appearance request-
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops. 2-960, Pentobarbital—Sod. Tabs. 3-299, Pentobarbital—Sod. Elx.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublinguar Tabs. 11-728, Superinone. 12-637, Isuprel Ethanesulfonate. Winthrop Stearns Inc., 170 Varick St., New York, N.Y.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  Register a written appearance requesting a hearing, giving the reasons why
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCl Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Tabs. 2-185, Thiamine HCl Tabs. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Elx. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops. 2-960, Pentobarbital—Sod. Tabs. 3-194, Sulfathiazole Tabs. 3-299, Pentobarbital—Sod. Elx.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-167, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublingual Tabs. 11-728, Superinone. 12-637, Isuprel Ethanésulfonate. Winthrop Stearns Inc., 170 Varick \$t., New York, N.Y. NRAs:	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to avail-themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing, they must file within 30 days after publication of this notice in the Federal Register a written appearance requesting a hearing, giving the reasons why the new-drug application should not be
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops. 2-960, Pentobarbital—Sod. Tabs. 3-299, Pentobarbital—Sod. Elx. 3-896, Diothoid Sup. 4-142, Stilbestrol Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT, 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostilbosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-181, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-043, Lutawin Caplets. 10-054, Mytelase Ch. Sol. 11-247, Isuprel Sol Inj. and Sublinguar Tabs. 11-728, Superinone. 12-637, Isuprel Ethanesulfonate. Winthrop Stearns Inc., 170 Varick St., New York, N.Y. NRAs: 4-029, Amino Acids Inj.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  Areasser a written appearance requesting a hearing, giving the reasons why the new-drug application should not be withdrawn, together with a full-factual
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops. 2-960, Pentobarbital—Sod. Tabs. 3-194, Sulfathiazole Tabs. 3-299, Pentobarbital—Sod. Elx. 3-896, Diothold Sup. 4-142, Stilbestrol Tabs.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-167, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-043, Lutawin Caplets. 10-757, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublingual Tabs. 11-728, Superinone. 12-637, Isuprel Ethanésulfonate. Winthrop Stearns Inc., 170 Varick \$t., New York, N.Y. NRAs:	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  Register a written appearance requesting a hearing, giving the reasons why the new-drug application should not be withdrawn, together with a full-factual analysis, and setting forth specific facts
4-191, CA Pantothenate Inj. 4-289, Pyridoxine HCI Inj. 4-290, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Inj. 2-185, Thiamine HCl Inj. 2-186, Thiamine HCl Inj. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-183, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-463, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops. 2-960, Pentobarbital—Sod. Tabs. 3-194, Sulfathiazole Tabs. 3-299, Pentobarbital—Sod. Elx. 3-896, Diothold Sup. 4-142, Stilbestrol Tabs. 4-476, Diethylstilbestrol Inj. 4-947, Ceepryn Jelly.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-043, Lutawin Caplets. 10-054, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublinguar Tabs. 11-728, Superinone. 12-637, Isuprel Ethanesulfonate. Winthrop Stearns Inc., 170 Varick \$t., New York, N.Y. NRAs: 4-029, Amino Acids Inj. 6-136, Hemokin Tabs.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  Register a written appearance requesting a hearing, giving the reasons why the new-drug application should not be withdrawn, together with a full-factual analysis, and setting forth specific facts showing that a genuine and substantial
4-191, CA Pantothemate Inj. 4-289, Pyridoxine HCl Inj. 4-289, Omni-Beta Elx. 4-366, Vitamin A Tabs. 4-410, Sod. Thiosul Inj. 4-546, Emulsified Vak Liquid. 4-663, Syntha-Beta Tabs. 4-747, Dietstilbestrol Tabs. 4-748, Dietstilbestrol Inj. 6-047, Heparin Pitkin Menstrum Inj. 6-379, Diatrin Syr. & Tabs. 8-001, W-290 Tabs. William S. Merrell Co., Div. Richardson-Merrell Inc., 110 East Amity Road, Cincinnati, Ohio 45215. NDAs: 0-035, Concemind Caps. 0-930, Sulfapyridine Tabs. 1-459, Thydron Syrup. 1-847, Byleric Caps. 1-942, Thydson Tabs. 1-943, Thiamine HCl Tabs. 2-186, Thiamine HCl Inj. 2-186, Thiamine HCl Elx. 2-187, Sulfanilamide & Sod. Bicarbonate Tabs. 2-188, Diothane Oph. Ont. w/Oxyquino-line Benzoate Ont. 2-468, Beta Concemin Elixir. 2-632, Digitalis Tabs. 2-907, Cetedrin Drops. 2-960, Pentobarbital—Sod. Tabs. 3-194, Sulfathiazole Tabs. 3-299, Pentobarbital—Sod. Elx. 3-896, Diothold Sup. 4-142, Stilbestrol Tabs. 4-476, Diethylstilbestrol Inj. 4-824, Beta-Concemin Inj.	4-718, Diodrast Inj. 4-760, Kappaxin Inj. 4-846, Salyrgan Theophylline ECT. 4-904, Dietstilbestrol Dipropionate Inj. & ECT. 4-908, Sulfathiazole Sod. Tabs. 5-024, Flavaxin Sol. Inj. 5-283, Neostibosan. 5-847, Thiouracil Tabs. 5-888, Gelatine Sol. 6-039, Butanefrine HCl Inj. 6-102, Desyphed HCl Tabs. 6-165, Companol Tabs. 6-165, Companol Tabs. 6-161, Adanon HCl Inj., Syr., Elx., Tabs. 6-217, Folic Acid Elx., Inj., Tabs. Winthrop Labs. Div. Sterling Drug Inc., 90 Park Ave., N.Y., N.Y. 10016. NDAs: 3-366, Tofaxin Caps. 3-641, Sulfathiazole Sodium Inj., Pwd. 6-337, Zettyn Eye Lotion & Mouthwash. 8-395, Dinacrin Tabs. 8-396, Dinacrin Tabs. 9-121, Aralis Tabs. 10-034, Dovial Tabs. 10-034, Dovial Tabs. 11-054, Mytelase Chloride Tabs. 11-054, Mytelase CL. Sol. 11-247, Isuprel Sol Inj. and Sublinguar Tabs. 11-728, Superinone. 12-637, Isuprel Ethanésulfonate. Winthrop Stearns Inc., 170 Varick St., New York, N.Y. NRAs: 4-029, Amino Acids Inj. 6-166, Hemokin Tabs. 6-608, Testocaptate.	Within 30 days after publication hereof in the Federal Register, the applicants, as well as any interested person who would be adversely affected and who wants an opportunity for a hearing, are required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-62, 5600 Fishers Lane, Rockville, MD 20852, a written appearance electing whether:  1. To avail themselves of the opportunity for a hearing; or  2. Not to avail themselves of the opportunity for a hearing.  If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application. Failure of such persons to file a written appearance of election within said 30 days will be construed as an election by such persons not to availthemselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  If such persons elect to avail themselves of the opportunity for a hearing.  Register a written appearance requesting a hearing, giving the reasons why the new-drug application should not be withdrawn, together with a full-factual analysis, and setting forth specific facts

will be defined, a hearing examiner will be named by the Commissioner, and he shall issue a written notice of the time and place at which the hearing will commence.

The hearing contemplated by this notice will be open to the public, except that any portion of the hearing that concerns a method or process the Commissioner finds entitled to protection as a trade secret will not be open to the public, unless the respondent specifies otherwise in his appearance.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under authority delegated to the Commissioner (21 CFR 2.120).

Dated: January 4, 1971.

SAM D. FINE, Associate Commissioner for Compliance.

[FR Doc.71-333 Filed 1-12-71;8:45 am]

### DEPARTMENT OF TRANSPORTATION

Coast Guard [CGFR 70-151]

SCHLUMBERGER TECHNOLOGY CORP.

#### Notice of Qualification as a Citizen

This is to give notice that pursuant to 46 CFR 67.23-7 issued under the provisions of section 27A of the Merchant Marine Act, 1920, as amended by the Act of September 2, 1958 (46 U.S.C. 883-1), Schlumberger Technology Corp., 277 Park Avenue, New York, NY, incorporated under the laws of the State of Texas, did on December 8, 1970, file with the Commandant, U.S. Coast Guard, in duplicate, an oath for qualification of a corporation as a citizen of the United States following the form of oath prescribed in Form 1260.

The oath shows that:

- (a) A majority of the officers and directors of the corporation are citizens of the United States (list of names, home addresses, and citizenship attached to the oath);
- (b) Not less than 90 percent of the employees of the corporation are residents of the United States;
- (c) The corporation is engaged primarily in a manufacturing or mineral industry in the United States, or in a territory, district, or possession thereof;
- (d) The aggregate book value of the vessels owned by the corporation does not exceed 10 percent of the aggregate book value of the assets of the corporation; and
- (e) The corporation purchases or produces in the United States, its territories or possessions not less than 75 percent of the raw materials used or sold in its operations.

The Commandant, U.S. Coast Guard, having found this oath to be in compliance with the law and regulations, on December 31, 1970, issued to Schlumberger Technology Corp., a certificate of compliance on Form 1262, as provided in 46 CFR 67.23-7. The certificate and any authorization granted thereunder will expire 3 years from the date thereof unless there first occurs a change in the corporate status requiring a report under 46 CFR 67.23-7(c).

This continues in effect the notice of qualification of Schlumberger Technology Corp. as a citizen of the United States dated September 12, 1969.

Dated: December 31, 1970.

C. R. BENDER, Admiral, U.S. Coast Guard, Commandant.

[FR Doc.71-387 Filed 1-12-71;8:46 aml

### ATOMIC ENERGY COMMISSION

[Dockets Nos. 50-338, 59-339]

#### VIRGINIA ELECTRIC & POWER CO.

#### Notice of Application for Construction Permit and Operating License

Virginia Electric & Power Co., 700 East Franklin Street, Richmond, Va., pursuant to the Atomic Energy Act of 1954, as amended, has filed an application, dated March 21, 1969, for permits to construct and licenses to operate two pressurized water nuclear power reactors, designated as the North Anna Power Station, Units Nos. 1 and 2, at a 1,075-acre site adjacent to the North Anna River in Louisa County, Va., about 24 miles southwest of Fredericksburg,

Each of the proposed reactors is designed for initial operation at approximately 2,652 thermal megawatts with a gross electrical output of approximately 892 megawatts.

Any person who wishes to have his views on the antitrust aspects of the application presented to the Attorney General for consideration shall submit such views to the Commission within 60 days after December 31, 1970,

A copy of the application and the amendments thereto are available for public inspection at the Commission's Public Document Room, 1717 H Street NW., Washington, D.C., and at the offices of the County Board of Supervisors, Louisa County Courthouse, Louisa, Va.

For the Atomic Energy Commission. Dated at Bethesda, Md., this 24th day of December 1970.

Peter A. Morris, Director. Division of Reactor Licensing. [FR Doc.70-17504 Filed 12-29-70;8:45 am]

### CIVIL AERONAUTICS BOARD

[Docket Nos. 21866, 22784; Order 71-1-30]

CONTINENTAL AIR LINES, INC.

#### Order of Investigation and Suspension

Adopted by the Civil Aeronautics Board at its office in Washington, D.C., on the 7th day of January 1971.

By tariff revisions marked to become effective January 11, 1971, Continental proposes to increase first-class, coach, and economy-class fares by 3 percent in all of its markets over 800 miles in distance. First-class fares would bear a ratio of 130 percent to coach, and various discount fares would be adjusted to maintain existing or reduced percentage relationships recently permitted by the Board.

In justification of its proposal, Continental alleges that the markets involved (principally its east-west and Pacific Northwest-Southwest markets) present unique circumstances warranting the minimal increase sought. Its east-west services are characterized as highly competitive without the advantage of backup traffic which enables its competitors to mount and support heavy frequencies.

The Pacific Northwest-Southwest services are characterized as involving relatively new markets which the Board recognized, at the time of the award, would require a substantial developmental endeavor before becoming profitable. It is also noted that these markets have subsequently been subjected to competitive services. Finally, Continental alleges that the existence of economy service in the markets in question is an important consideration since, even with the fare increases proposed, travelers will continue to have available a basic fare well below that produced by the present fare structure.

Continental's proposal to increase. normal fares comes within the scope of the ongoing Domestic Passenger-Fare Investigation and its lawfulness will be determined in that proceeding. The Board has announced its intention to reach a decision in the fare level and related phases of that proceeding by the first of April 1971. The immediate question then is whether to permit the proposed increases to become effective or to suspend them pending conclusion of that investigation.

The proposal here to increase fares for the basic classes of service in markets over 800 miles involves the fare level over a substantial portion of Continental's system, and as such involves an evaluation of basic costs of service now under review in the general investigation. It also poses the structural question of whether or not existence of a third-level service justifies a level of coach fares differing from that in markets not afforded such service, a matter likewise to be decided in the investigation now in progress. For these reasons, and consistent with several recent actions relating to proposals of similarly broad scope,2 we will suspend the proposed coach and economy fares and the discount fares which are derived therefrom. However, we will not suspend the proposed increases in first-class fares since the first-class fares appear to be underpriced in relation to both costs and value of service and we have permitted other recent increases.

Revisions to Airline Tariff Publishers, Inc., Agent, Tariff CAB No. 136.

2 Ordero 70-9-123, 70-11-133.

Upon consideration of the proposed military fares, the Board finds that they may be unjust, unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful and should be investigated. The Board further concludes that they should be suspended pending investigation.

Accordingly, pursuant to the Federal Aviation Act of 1958, and particularly sections 204, 403, 404, and 1002 thereof, It is ordered, That:

1. An investigation is instituted to determine whether the YM and M class fares and provisions described in Appendix A attached hereto,3 and rules, regulations, or practices affecting such fares and provisions, are or will be unjust or unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful, and if found to be unlawful, to determine and prescribe the lawful fares and provisions, and rules, regulations, and practices affecting such fares and provisions;

2. Pending hearing and decision by the Board, the fares and provisions described in Appendix A attached hereto are suspended and their use deferred to and including April 10, 1971, unless otherwise ordered by the Board, and that no changes be made therein during the period of suspension except by order or special permission of the Board;

- 3. The investigation of the military fares ordered herein is hereby consolidated into Docket 22784; and
- 4. A copy of this order will be filed with the aforesaid tariffs and served upon Continental Air Lines, Inc.

This order will be published in the FEDERAL REGISTER.

By the Civil Aeronautics Board.4

[SEAL]

HARRY J. ZINK, Secretary.

[FR Doc.71-429 Filed 1-12-71;8:49 am]

[Docket No. 21866, etc.; Order 71-1-29]

#### EASTERN AIR LINES, INC. AND NATIONAL AIRLINES, INC.

#### Order of Investigation and Suspension

Adopted by the Civil Aeronautics Board at its office in Washington, D.C., on the 6th day of January 1971.

By tariff revisions 1 marked to become effective January 11, 1971, Eastern Air Lines, Inc. (Eastern) and National Airlines, Inc. (National) propose to increase certain markets under 500 miles in distance which involve the Boston, New York, and Washington/Baltimore terminals. The increases range from \$0.93 to \$3.70 under both proposals. In addition, Eastern proposes to increase children's fares and fares for minors accompanied by a family member from 50 percent to 66% percent of the normal coach fare.

Agent.-Tariffs CAB No. 136.

In justification of its proposal Eastern alleges that its proposed fares are consistent with recent orders permitting similar increases for American, Mohawk, and Northeast; that it conducts a large portion of its operations in highly congested short-haul markets; and that the added costs incurred in these operations fully warrant fare increases similar to those previously permitted in Orders 70-11-134 and 70-11-136. National makes only the general assertion that its proposal is in conformance with Order 70-11-136.

Complaints have been filed by Mr. Reuben B. Robertson, III, and Representative John Moss and 39 other Members of Congress requesting investigation and suspension. Mr. Robertson's complaint alleges that the carriers have utterly failed to demonstrate any showing of a special need or any other economic or social justification for raising fares now in these markets; that it is not necessary from the standpoint of remaining competitive "to meet" higher fares; and that Board action based on American's submissions cannot serve as justification, per se, for raising everyone's prices. The complaint contends that quite apart from the question of who is responsible for congestion and who must pay for it, no carrier should be permitted to profit from the existence of congestion unless it can demonstrate that it has not been able to turn a profit in high density markets despite efficient operations. It is further alleged that under the law carriers filing for fare increases have the burden of proof that the filings are economically justified and they have not done so in this case; that unless the Board enforces its own rules on economic justification of fare and rate filings it, effectively freezes the public out of these regulatory proceedings; and that the Board has a duty to estimate and take into account demand elasticity factors before granting any fare increase.

The Moss complaint touches on most of the points raised by Mr. Robertson, emphasizing that the carriers have failed to show that they are incurring losses in the markets in which they are seeking fare increases, nor have they furnished cost estimates necessary to support the allegation that the increases are required to bring revenues more into line with the costs of service.

In answer to the complaints, Eastern alleges that each of the fare increases it proposes involves markets in which the Board has already found atypically higher costs due to congestion; that complainants are incorrect in contending that the costs previously relied upon by the Board were unique to the proponent carriers; and that they are unique to specific markets and common to all carriers in that market. Eastern estimates system costs attributable to congestion delays at \$17.8 million in 1969, and states that obviously a substantial portion of those added costs are incurred in the markets in question. It is contended that, while the question of demand elasticity is pertinent, this factor can only be an estimate, and past estimates indicate a lack of elasticity in short-haul business markets. With respect to the need for market load factor data, it is alleged that this is immaterial here, in light of American's earlier demonstration that carrier efficiency cannot overcome the short-haul cost/revenue gap. Finally, Eastern contends that unless all carriers in a market are permitted similar increases, those that have been will be unable for competitive reasons to maintain their higher fares which have been found warranted.

National contends in answer that references in the complaints to the Board's "rate-determining process" and the carriers' "burden of proof" misconstrue the requirements of the Act; that there are no such requirements in connection with finding a tariff filing as prima facie lawful; and that such requirements only come into play in connection with the hearing process. National alleges that neither complaint points out in what ways its proposal is unlawful; that the markets in question have twice been characterized as having atypical high congestion/density cost-related features (Orders 70-11-134 and 70-11-136); and denies the allegation that its proposal is not just and reasonable on its face, Finally, National states that it expects to realize additional revenues of some \$1,220,000 for calendar 1971.

The proposals here to increase certain coach fares come within the scope of the Domestic Passenger-Fare Investigation now actively in process and the lawfulness of these fares will be determined in that proceeding. It is anticipated that a decision on the fare level and directly related issues will be reached by about April 1, 1971. The issue now before us is whether to permit to become effective or suspend these proposed fares pending a final determination of their lawfulness in that investigation.

Eastern's filing involves only 16 markets and National's only 23 markets out of their entire domestic systems and both purport to be justified on facts and circumstances peculiar to operations at and between these particular points. As such, these filings do not involve an evaluation of basic costs of service, including load factors, now underway in the passenger fare investigation to the came degree as the earlier tariff proposals to increase all or most coach fares which were suspended pending investigation.

Eastern's proposal is limited entirely to markets in which the Board has recently permitted fare increases to compensate for demonstrated additional costs associated with airport and airway congestion, and 11 of the markets encompassed in National's filing fall in this same category. We believe there is merit to Eastern's contention that costs attributable to congestion are unique as among markets but common as among carriers. It is reasonable to conclude that its costs, as well as National's, in these particular markets are comparable to

<sup>&</sup>lt;sup>3</sup> Filed as part of the original document. \*Concurring and dissenting statements of ice Chairman Gilliland and Member Minetti filed as part of the original document. <sup>1</sup> Revisions to Airline Tariff Publishers, Inc.,

<sup>&</sup>lt;sup>2</sup> Order 70-9-123.

those previously demonstrated by other carriers, and that their abilities to achieve profitable operations in these markets would be similarly affected. Accordingly, the Board will permit the increases proposed by Eastern and National in these markets, despite the fact that the carriers have not provided specific data related to each. We will also permit National to increase its fares in the Washington/New York-Providence markets, again despite the lack of marketby-market information. These two markets lie directly along the northeast corridor, which is acknowledged as one of the most congested areas in the country, and we have previously permitted similar increases between these terminals and the adjacent point of Hartford.3 Finally, the Board will permit Eastern's proposal to increase its fares for children and minors accompanied by an adult family member, consistent with our action in Order 70-11-133.

The Board has concluded to suspend the fare increases proposed by National in the remaining 10 markets in the absence of a showing of losses sustained as a result of airport and airway congestion. We distinguish between a "terminal" versus a "market" approach and believe that trunkline carriers should be permitted increases only when it is reasonably demonstrated that particular markets have characteristics which could normally be expected to result in profitable operations. To do otherwise could lead to a general erosion of the concept of a fare over-ride to compensate for atypical operating conditions, and lead to fare increases of a general nature inconsistent with our action in Order 70-9-123.

Upon consideration of all relevant matters, the Board finds that the proposed military fare increases, which stem from higher basic fares we are herein suspending, may be unjust, unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful and should be investigated. We further conclude that these fares should be suspended together with all other fare increases in the same markets pending investigation.

Accordingly, pursuant to the Federal Aviation Act of 1958, and particularly sections 204(a) and 1002 thereof,

It is ordered. That:

1. An investigation is instituted to determine whether the YM (Military Reservation) class and M (Military standby) class fares and provisions described in Appendix A attached hereto, and rules, regulations, or practices affecting such fares and provisions, are or will be unjust or unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful, and if found to be unlawful, to determine and prescribe the lawful fares and provisions, and rules, regulations, and practices affecting such fares and provisions;

2. Pending hearing and decision by the Board, the fares and provisions described

in Appendix A hereto are suspended and their use deferred to and including April 10, 1971, unless otherwise ordered by the Board, and that no changes be made therein during the period of suspension except by order or special permission of the Board;

- The investigation of the military fares ordered herein is hereby consolidated into Docket 22784;
- 4. A copy of this order will be filed with the aforesaid tariff and be served on Eastern Air Lines, Inc., National Airlines, Inc., and the complainants in Dockets 22905 and 22915; and
- 5. Except to the extent granted herein, the complaints in Dockets 22905 and 22915 insofar as they apply to the filings considered herein are dismissed.

This order will be published in the FEDERAL REGISTER.

By the Civil Aeronautics Board.5

[SEAL]

Hanny J. Zmik, Secretary.

[FR Doc.71-428 Filed 1-12-71;8:49 am]

[Docket No. 20993; Order 71-1-19]

# INTERNATIONAL AIR TRANSPORT ASSOCIATION

Order Regarding Specific Commodity
Rates

Issued under delegated authority January 6, 1971.

By Order 70-12-125, dated December 21, 1970, action was deferred with a view toward eventual approval, on an agreement embodied in the resolutions of Traffic Conference 1 of the International Air Transport Association (IATA) and adopted by the 27th Meeting of the Traffic Conference 1 Specific Commodity Rates Board. The agreement proposes revisions to the specific commodity rate structure currently applicable within the Western Hemisphere, including reduced rates under new commodity descriptions. the addition of several rates to added points and the cancellation of other rates under existing commodity descriptions, and increases in the majority of remaining rates currently effective.

In deferring action on the agreement, 10 days were granted in which interested persons might file petitions in support of or in opposition to the proposed action. No petitions have been received within the filing period, and the tentative conclusions in Order 70-12-125 will herein be made final.

Accordingly, it is ordered, That:

Agreement CAB 22097 be and it hereby is approved, provided that approval shall not constitute approval of the specific commodity descriptions contained therein for purposes of tariff publication; provided further that tariff filings shall not be made to implement the agreement prior to this date, and such tariff filings shall be marked to become

effective on not less than 30 days' notice from the date of filing.

This order will be published in the Federal Register.

[SEAL]

Harry J. Zink, Secretary.

[FR Doc.71-425 Filed 1-12-71;8:49 am]

[Docket No. 20393; Order 71-1-25]

# INTERNATIONAL AIR TRANSPORT ASSOCIATION

# Order Regarding Specific Commodity Rates

Issued under delegated authority January 6, 1971.

By Order 70-12-124, dated December 21, 1970, action was deferred with a view toward eventual approval, on an agreement embodied in the resolutions of the Joint Conferences of the International Air Transport Association (IATA) and adopted by the Tenth Meeting of the Joint Specific Commodity Rates Board. As it applies in air transportation, the agreement is essentially limited to matters relating to transpacific commodity rates. Certain specific commodity rates previously approved by the Board would be extended for a further period of effectiveness; the agreement also names several rates to added points, cancels other rates under existing commodity descriptions, reduces a limited number of currently applicable rates, and proposes reduced rates under new commodity descriptions.

In deferring action on the agreement, 10 days were granted in which interested persons might file petitions in support of or in opposition to the proposed action. No petitions have been received within the filing period, and the tentative conclusions in Order 70–12–124 will herein be made final.

Accordingly, it is ordered, That:

Agreement CAB 22096 be and it hereby is approved, provided that approval shall not constitute approval of the specific commodity descriptions contained therein for purposes of tariff publication; provided further that tariff filings shall not be made to implement the agreement prior to this date, and such tariff filings shall be marked to become effective on not less than 30 days' notice from the date of filling.

This order will be published in the Federal Register.

[SEAL]

HARRY J. ZEIK, Secretary.

[FR Doc.71-426 Filed 1-12-71;8:49 am]

[Docket No. 20393; Order 71-1-31]

# INTERNATIONAL AIR TRANSPORT ASSOCIATION

Order Regarding Specific Commodity
Rates

Issued under delegated authority, January 7, 1970.

An agreement has been filed with the Board pursuant to section 412(a) of the

<sup>&</sup>lt;sup>3</sup>The markets in which we are permitting the proposed fare increases are listed in the attachment hereto.

Filed as part of the original document.

<sup>&</sup>lt;sup>5</sup>Concurring and dissenting statements of Vice Chairman Gillilland and Member Minetti filed as part of the original document.

Federal Aviation Act of 1958 (the Act) and Part 261 of the Board's Economic Regulations, between various air carriers, foreign air carriers, and other carriers, embodied in the resolutions of the Joint Conferences of the International Air Transport Association (IATA), and adopted pursuant to the provisions of Resolution 590 dealing with specific commodity rates.

The agreement, adopted pursuant to unprotested notices to the carriers and promulgated in an IATA letter dated December 28, 1970, names additional specific commodity rates, as set forth below, which reflect significant reductions from the general cargo rates.

R-7:

Commodity Item No. 4201—Surface Vehicles N.E.S. Excluding Steamship and/or Motorship Parts, 140 cents per kg., minimum weight 100 kgs., Auckland to Los Angeles.

R-8:

Commodity Item No. 4123—Aircraft Parts and Accessories, 150 cents per kg., minimum weight 100 kgs.; 104 cents per kg., minimum weight 200 kgs.; 89 cents per kg., minimum weight 1,000 kgs. Auckland to Los Angeles.

Pursuant to authority duly delegated by the Board in the Board's Regulations, 14 CFR 385.14, it is not found, on a tentative basis, that the subject agreement is adverse to the public interest or in violation of the Act, provided that tentative approval thereof is conditioned as hereinafter ordered.

Accordingly, it is ordered, That:

Action on Agreement CAB 22096, R-7 and R-8, be and hereby is deferred with a view toward eventual approval, provided that approval shall not constitute approval of the specific commodity descriptions contained therein for purposes of tariff publication; provided further that, insofar as air transportation as defined by the Act is concerned, tariff filings shall not be made to implement the agreement prior to eventual approval, and such tariff filings shall be marked to become effective on not less than 30 days' notice from the date of filing.

Persons entitled to petition the Board for review of this order, pursuant to the Board's Regulations, 14 CFR 385.50, may, within 10 days after the date of service of this order, file such petitions in support of or in opposition to our proposed action herein.

This order will be published in the Federal Register.

[SEAL]

Harry J. Zink, Secretary.

[FR Doc.71-427 Filed 1-12-71;8:49 am]

[Docket No. 21866; Order 71-1-35]

#### MOHAWK AIRLINES, INC.

#### Order of Investigation and Suspension

Adopted by the Civil Aeronautics Board at its office in Washington, D.C., on the 7th day of January 1971.

By tariff revisions 1 marked to become effective January 11, 1971, Mohawk Airlines, Inc. (Mohawk), proposes to increase its regular fares in 69 short-haul markets in amounts ranging from \$1.85 to \$3.70. Mohawk proposed fare increases in these same markets effective December 1, 1970, and those fares were suspended by Order 70-11-136 because rounding techniques inconsistent with previous Board Orders were employed in their construction. The fares proposed herein are at the same level in all instances as those suspended by our previous order. These proposed fares appear to circumvent the intent of Order 70-11-136, and will therefore be suspended. These fares are under investigation in the above Docket.

Accordingly, pursuant to the Federal Aviation Act of 1958, and particularly sections 204(a) and 1002 thereof,

It is ordered, That:

1. Pending hearing and decision by the Board, the fares and provisions described in Appendix A hereto,<sup>2</sup> are suspended and their use deferred to and including April 10, 1971, unless otherwise ordered by the Board, and that no changes be made therein during the period of suspension except by order or special permission of the Board; and

2. A copy of this order will be filed with the aforesaid tariff and be served upon Mohawk Airlines, Inc.

This order will be published in the FEDERAL REGISTER.

By the Civil Aeronautics Board.3

[SEAL]

Harry J. Zink, Secretary.

[FR Doc.71-430 Filed 1-12-71;8:49 am]

[Dockets Nos. 21866, 22784; Order 71-1-33]

#### UNITED AIR LINES, INC.

#### Order of Investigation and Suspension

Adopted by the Civil Aeronautics Board at its office in Washington, D.C., on the 7th day of January 1971.

By tariff revisions <sup>12</sup> marked to become effective January 11, 1971, United Air Lines, Inc. (United) proposes to increase coach fares to pre-October 1969 levels in longer haul markets where fares were reduced at that time, and to reduce the

<sup>1</sup> Revisions to Airline Tariff Publishers, Inc., Agent, Tariff CAB No. 136.

military discount from 50 to 40 percent of coach.3

In support of its proposed increases, United alleges that the serious financial condition of it and the domestic trunkline industry generally has not improved since last August: that earnings continue to deteriorate: that United's current outlook for the year 1970 is for a traffic level reflecting no increase over the previous year and a \$35 million net loss; and that while United and the industry continue to exert all possible efforts to improve their dismal outlook by capacity reductions and other forms of cost control, several factors indicate that this will be a very difficult undertaking with limited potential. United further alleges that its cost per available ton mile continues to increase, the increases for the months of July, August, and September over the preceding year being 9 percent, 10 percent, and 6 percent, respectively. Finally, it is alleged that the proposed military standby fares will still be its lowest promotional fare for individual passengers

Representative John E. Moss and 39 other Members of Congress have filed a complaint against the carrier's proposal to increase certain long- and mediumhaul fares. The complaint asserts that no estimate of cost of service is provided nor are there facts to support an allegation that increases are required to bring revenues more into line with cost of service in these markets, even with excess capacity. The complaint further alleges that the proposal may be self-defeating because of the possible loss of traffic due to the fare increases.

The proposal to increase normal coach fares comes within the scope of the ongoing Domestic Passenger-Fare Investigation and their lawfulness will be determined in that proceeding. We expect to issue a decision on the fare level and directly related issues by approximately the first of April 1971. The immediate question then is whether to permit the increases to become effective or to suspend them pending investigation. The proposal with respect to military-standby fares is not within the general investigation.

The proposal to restore coach fares to the pre-October 1969 level involves the basic normal fares applicable over a fairly substantial portion of the carrier's system, and will materially alter the fare structure, thus raising questions to be resolved in the general investigation. By Order 70-9-123, the Board suspended various tariff filings proposing general fare increases pending resolution of the underlying issues in Docket 21866. United does not attempt to justify the instant proposal in terms of special circumstances in the affected markets, but instead its rationale is based essentially on

<sup>&</sup>lt;sup>1</sup>Upon effectiveness of these rates the present rate of 173 cents per kg., minimum weight 100 kgs. is canceled.

<sup>&</sup>lt;sup>2</sup> Filed as part of the original document. <sup>3</sup> Dissenting statement of Vice Chairman Gilliliand filed as part of the original docu-

<sup>&</sup>lt;sup>14</sup> Revisions to Airline Tariff Publishers, Inc., Agent, Tariff CAB Nos. 136 and 142.

<sup>&</sup>lt;sup>2</sup>United also proposes to increase coach fares in 24 short-haul markets. A complaint has been filed against this proposal, and the matter will be disposed of by subsequent order.

its general revenue need, a matter which will be considered by the Board in Docket 21866. In view of the interim nature of all fare changes made at this time, we do not believe it in the public interest to permit fare increases except where special circumstances are shown. Accordingly since United makes no such showing and consistent with our action in Order 70-9-123, we have decided to suspend the proposed increases in coach fares, and other increased fares based thereon.

The Board has recently suspended proposals of other carriers to increase military-reservation fares from 66% to 75 percent of coach, and military-standby fares from 50 to 66% percent of coach. Consistent with those actions, we will suspend United's proposal to increase military standby fares by approximately 20 percent. As we have previously indicated, we believe the broad public interest and national defense considerations invested in such fares should be carefully explored before significant increases are permitted.

Upon consideration of all relevant matters, the Board finds that the proposed military-standby fares may be unjust, unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful and should be investigated. For the reasons stated above, we find that all fares considered herein should be suspended pending investigation.

Accordingly, pursuant to the Federal Aviation Act of 1958, and particularly sections 204(a) and 1002 thereof,

It is ordered, That:

1. An investigation is instituted to determine whether the YM and M class fares and provisions described in Appendix A attached hereto,3 and rules, regulations, or practices affecting such fares and provisions, are or will be unjust, unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful, and if found to be unlawful, to determine and prescribe the lawful fares and provisions, and rules, regulations, and practices affecting such fares and provisions;

2. Pending hearing and decision by the Board, the fares and provisions described in Appendix A hereto's are suspended and their use deferred to and including April 10, 1971, unless otherwise ordered by the Board, and that no changes be made therein during the period of suspension except by order or special permission of the Board:

3. The investigation of the military

fares ordered herein is hereby consolidated into Docket 22784;

4. A copy of this order will be filed with the aforesaid tariffs and served upon certain members of Congress, and United Air Lines, Inc.; and

Except to the extend granted herein, the complaint in Docket 22915 is hereby dismissed insofar as it applies to filings considered herein. The complaint was also filed against other proposals which will be disposed of by subsequent orders. FEDERAL REGISTER.

By the Civil Aeronautics Board. HARRY J. ZENK. ISEAL. Secretary.

[FR Doc.71-424 Filed 1-12-71;8:48 am]

[Docket Nos. 21866, 22784; Order 71-1-34]

#### UNITED AIR LINES, INC.

#### Order of Investigation and Suspension

Adopted by the Civil Aeronautics Board at its office in Washington, D.C., on the 7th day of January 1971.

By tariff revisions marked to become effective January 11, 1971, United Air Lines, Inc. (United) proposes to increase coach fares in 24 markets of less than 750 miles by \$3. In addition, it proposes to match recently permitted fares of American Airlines, Inc., in 6 additional markets.

In support of its proposed increases, United alleges that the serious financial condition of it and the domestic trunkline industry generally has not improved since last August; that earnings continue to deteriorate: that United's current outlook for the year 1971 is for a traffic level reflecting no increase over the previous year and a \$35 million net loss; that while United and the industry continue to exert all possible efforts to improve their dismal outlook by capacity reductions and other forms of cost control, several factors indicate that this will be a very difficult undertaking with limited potential; and that its cost per available ton mile continues to increase, the increases for the months of July, August, and September over the preceding year being 9 percent, 10 percent, and 6 percent, respectively. United further alleges that the 24 short-haul markets are high density in nature and that the concept is similar to a filing made by American and estimates that the proposed increases would result in additional annual revenues of about \$11 million.

Complaints have been filed by Mr. Reuben B. Robertson, III, and Representative John Moss and 39 other Members of Congress requesting investigation and suspension. Mr. Robertson's complaint alleges that the carrier has utterly failed to demonstrate any showing of special need or any other economic or social justification for raising fares now in these markets; that it did not submit justification in conformance with section 221.165 of the Board's economic regulations; that it is not necessary from the standpoint of remaining competitive "to meet" higher fares; and that Board action based on American's submissions cannot serve as justification, per se, for raising everyone's prices. The complaint contends that, quite apart from the ques-

This order will be published in the tion of who is responsible for congestion and who must pay for it, no carrier should be permitted to profit from the existence of congestion unless it can demonstrate that it has not been able to turn a profit in high density markets despite efficient operations.

It is further alleged that the Board should not place itself in the position of allowing carriers to play fast and loose with the requirements for justification once one carrier has been allowed to increase rates; that under the law carriers filing for fare increases have the burden of proof that the filings are economically justified and they have not done so in this case; and that unless the Board enforces its own rules on economic justification of fare and rate filings it joins in complicity with the carriers in effectively freezing the public out of these regulatory proceedings. Finally, it is contended that the Board has a duty to estimate and take into account demand elasticity factors before granting any fare increase.

In answer to the complaints, United alleges that its filing corresponds to tariff revisions of American recently approved by Board Order 70-11-134; that it can be concluded from that order that a demonstrated revenue need resulting from substandard carrier earnings when coupled with a sound basis for applying a fare increase to a particular market is sufficient justification for permitting an interim fare increase, and that, unlike American, it did not submit supporting data with this revision since revenue need has been frequently demonstrated. and the Board had already found that the high cost of operating into congested airport areas was generally acknowledged. United also alleges that the specific market and traffic data sought by the complainants is not pertinent to its filing; and that it is not necessary to demonstrate a loss operation in each and every market to which a fare increase is to be applied where it has been demonstrated that a substantial system revenue need exists and particularly where system revenues are not meeting system expenses.

The proposals to increase normal coach fares come within the scope of the ongoing Domestic Passenger Fare Investigation and their lawfulness will be determined in that proceeding. We expect to issue a decision on the fare level and directly related issues by approximately the first of April 1971. The immediate question then is whether to permit the increases to become effective or to suspend them pending investigation.

United's filing involves only 30 markets out of its entire domestic system and purports to be justified on facts and circumstances peculiar to operations at and between these particular points. As such, this filing does not involve an evaluation of basic costs of service now underway in the passenger fare investigation to the same degree as the earlier tariff proposals to increase all or most coach fares which were suspended pending investigation.3

<sup>&</sup>lt;sup>3</sup> Filed as part of the original document.

Concurring and dissenting statement of Vice Chairman Gillilland and ceparate statement of concurrence and dissent by Member Minetti filed as part of the original document.

<sup>&</sup>lt;sup>1</sup>Revisions to Airline Tariff Publishers, Inc., Agent, Tariff CAB No. 136.

<sup>2</sup> Order 70-9-123.

In eight of the 30 markets,3 the Board has previously permitted fare increases to compensate for demonstrated additional costs associated with airport and airway congestion. We believe it reasonable to conclude that costs attributable to congestion are common to all carriers operating in a market and would similarly affect all carriers' ability to achieve profitable operations in markets affected by congestion. Accordingly, we will permit United's proposed increases in these eight markets to become effective.

The Board has concluded to suspend the fare increases proposed by United in the remaining 22 markets in the absence of a showing of losses sustained as a result of airport and airway congestion. As we have previously indicated, we distinguish between a "terminal" versus a "market" approach and believe that trunkline carriers should be permitted increases only when it is reasonably demonstrated that particular markets have characteristics which, but for severe congestion, could be expected to result in profitable operations. To do otherwise could lead to a general erosion of the concept of a fare over-ride solely to compensate for atypical operating conditions, and lead to fare increases of a general nature inconsistent with our action in Order 70-9-123.

Upon consideration of the tariff filing, the complaints and answer thereto, and all other relevant matters, the Board finds that the proposed military fare increases, which stem from higher basic fares we are herein suspending, may be unjust, unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful, and should be investigated. We further conclude that these fares should be suspended, together with the other fare increases indicated above, pending investigation.

Accordingly, pursuant to the Federal Aviation Act of 1958, and particularly sections 204(a) and 1002 thereof.

It is ordered, That:

- 1. An investigation is instituted to determine whether the YM class fares and provisions described in Appendix A attached hereto, and rules, regulations, or practices affecting such fares and provisions, are or will be unjust or unreasonable, unjustly discriminatory, unduly preferential, unduly prejudicial, or otherwise unlawful, and if found to be unlawful, to determine and prescribe the lawful fares and provisions, and rules, regulations, and practices affecting such fares and provisions;
- 2. Pending hearing and decision by the Board, the fares and provisions described in Appendix A hereto are suspended and their use deferred to and including April 10, 1971, unless otherwise ordered by the Board, and that no

changes be made therein during the period of suspension except by order or special permission of the Board;

3. The investigation of the military fares ordered herein is hereby consolidated into Docket 22784; and

4. A copy of this order will be filed with the aforesaid tariff and served upon United Air Lines, Inc.

This order will be published in the FEDERAL REGISTER.

By the Civil Aeronautics Board.

HARRY J. ZINK, Secretary.

[FR Doc.71-431 Filed 1-12-71;8:49 am]

### **ENVIRONMENTAL PROTECTION AGENCY**

Air Pollution Control Office

INTERSTATE AIR POLLUTION IN MOUNT STORM, WEST VIRGINIA-GORMAN, MARYLAND, AND LUKE, MARYLAND-KEYSER, WEST VIR-**GINIA AREAS** 

#### Conference of Air Pollution Control Agencies

Whereas the Governor of Maryland has made a written request pursuant to section 108(d)(1)(A), 42 U.S.C. 1857d (d)(1)(A) of the Clean Air Act, as amended (now Section 115(b) (1) under amendments at sections 4(a) and 4(b) of Public Law 91-604) that a conference be called in the Mount Storm, W. Va .-Gorman, Md., area regarding air pollution originating in the State of West Virginia which is alleged to endanger the health or welfare of persons in the State of Maryland, and

Whereas the Governor of West Virginia has made a written request that any conference called under the Clean Air Act, as amended, to consider air pollution in the Mount Storm, W. Va.-Gorman, Md., area, also consider air pollution in the Luke, Md.-Keyser, W. Va., area, originating in the State of Maryland, and

Whereas in addition to the alleged existing air pollution in the Mount Storm, W. Va.-Gorman, Md., area, an air pollution problem of substantial significance may result from potential discharge or discharges into the discharge or discharges into atmosphere in such area.

Now, therefore, pursuant to section 115(b)(1) of the Clean Air Act, as amended and section 103(e) of such Act (42 U.S.C. 1857b(e) as amended by section 4(b) (2) of Public Law 91-604), I hereby give formal notification of the air pollution described above to, and call a conference of, the air pollution control agencies of the following:

State of Maryland (Maryland State De-

partment of Health).
State of West Virginia (West Virginia Air Pollution Control Commission).

All the following named countles and all All the following named counties and an municipalities (as defined in section 302(f) of the Clean Air Act, as amonded (42 U.S.C. 1857h(f))), located therein:

In the State of Maryland: Allegheny County; Garrett County.

In the State of West Virginia: Grant County; Mineral County.

The specific portions of the above named counties with which the conference will be concerned will be defined in a technical report to be published prior to the conference. Such report will be available to all interested persons at least 30 days prior to the conference.

Mr. William H. Megonnell is hereby designated as presiding officer of the conference, and Mr. Donald F. Walters is hereby designated as the official conference participant for the Environ-mental Protection Agency. The presiding officer will fix the date, time, and place for convening the conference after consultation with representatives of the air pollution control agencies of the States of Maryland and West Virginia.

Dated: January 8, 1971.

JOHN T. MIDDLETON, Acting Commissioner.

[FR Doc.71-315 Filed 1-12-71;8:45 am]

### FEDERAL COMMUNICATIONS COMMISSION

[Docket No. 18920; PCC 71-8]

SPECIALIZED COMMON CARRIER SERVICES IN THE DOMESTIC PUB-LIC POINT-TO-POINT MICROWAVE RADIO SERVICE

#### Order Instituting Oral Argument

Upon consideration of the notices of intent to participate in oral argument submitted in response to the Memorandum Opinion and Order released on December 18, 1970, in this proceeding (FCC 70-1339),

It is hereby ordered, That the Commission will hear oral argument by the following parties, in the order and for the amount of time specified below, in the Commission meeting room at Washington, D.C., commencing at 9:30 a.m. on January 21 and 22, 1971:

#### JANUARY 21, 1971

Mint	ites
Microwave Communications, Inc. and	
the MCI Carriers	30
Data Transmission Co	30
Southern Pacific Communications Co	20
Interdata Communications, Inc.	16
New York-Penn Microwave Corp	10
United Video, Inc., et al.	18
West Texas Microwave Co., et al	16
Nebraska Consolidated Communications	
Corp	15
Western-Telecommunications, Inc.	15
January 22, 1971	
American Telephone & Telegraph Co	48
The Western Union Telegraph Co	40

<sup>&</sup>lt;sup>2</sup> Boston-Washington; Chicago-Detroit; Chicago-Pittsburgh; New York-Baston; New York-Buffalo; New York-Pittsburgh; New York-Rochester, N.Y.; New York-Washing-

<sup>\*</sup>Filed as part of the original document.

<sup>&</sup>lt;sup>5</sup> Concurring and dissenting statements of Vice Chairman Gillilland and Member Minetti filed as part of the original document.

-	January 22, 1971—Continued
ites	Minu
15	General Telephone & Electronics Corp.
10	United Telephone System
-	National Association of Regulatory
20	Utility Commissioners
	United States Independent Telephone
15	Association
15	Department of Justice
10	Small Business Administration
10	Electronic Industries Association
	Business Equipment Manufacturers
10	Association
	AssociationAmerican Society for Information
10	Science
	Computer Timesharing Services Section
10	of ADAPSO:
10	National Retail Merchants Association
	Consulting Communications Engineers,
10	Inc
	Greyhound Corp
5	Mitran, Inc.
	Joint Council on Educational Telecom-
5	munications
	National Association of Radiotelephone
	Systems
	Resalab, Inc
	American Bankers Association
	Computer Transmission Corp
5	Utilities Telecommunications Council.

Adopted January 6, 1971.

Released: January 7, 1971.

FEDERAL COMMUNICATIONS COMMISSION, DEN. F. WAPLE,

ISEAL BEN F. WAPLE, Secretary.

[FR Doc.71-447 Filed 1-12-71:8:50 am]

### FEDERAL MARITIME COMMISSION

# AMERICAN MAIL LINE, LTD. AND EVERETT ORIENT LINE

#### Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

. Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202; or may inspect the agreement at the Field Offices located at New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, within 20 days after publication of this notice in the FEDERAL REGISTER. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged,

the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed by:

Mr. W. R. Purnell, District Manager, American Mail Line, Ltd., 601 California Street, Suite 610, San Francisco, CA 94103.

Agreement No. 9840-1 amends the basic transshipment agreement between the two carriers listed above engaged in transporting general cargo from Everett Orient Line's (Everett) ports of call in Indonesia to American Mail Line's (AML) ports of call in the Pacific Northwest by reapportioning the through rate and transshipment expenses on the basis of one-third to Everett and two-thirds to AML.

Dated: January 7, 1971.

By order of the Federal Maritime Commission.

FRANCIS C. HURNEY, Secretary.

[FR Doc.71-397 Filed 1-12-71;8:47 am]

### CARIBBEAN CRUISE ASSOCIATION

Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202, or may inspect the agreement at the offices of the District Managers, New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Sec-retary, Federal Maritime Commission, 1405 I Street NW., Washington, DC 20573, within 20 days after publication of this notice in the Federal Register. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged, the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed for approval by:

Mr. William J. Armstrong, Secretary, Caribbean Cruice Accoclation, 17 Battery Place, Suite 631, New York, NY 10004.

Agreement No. 9823-1 modifies the Conference's self-policing provisions to comply with General Order 7 (Revised) published in the Federal Register on October 28, 1970.

Dated: January 7, 1971.

By order of the Federal Maritime Commission.

FRANCIS C. HURNEY, Secretary,

[FR Dcc.71-393 Filed 1-12-71;8:47 am]

# FOSS LAUNCH & TUG CO. AND FOSS ALASKA LINE, INC.

#### Application for Exemption

Notice is hereby given that the following application for exemption has been filed with the Commission for approval pursuant to section 35 of the Shipping Act, 1916, as amended (80 Stat. 1358, 46 U.S.C. 833a).

Interested parties may inspect and obtain a copy of this application at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Washington, D.C., Room 1015; or may inspect a copy of the application at the Field Offices, New York, N.Y.; New Orleans, La.; and San Francisco, Calif. Comments with reference to the application including a request for hearing if desired, may be submitted to the Secretary, Federal Maritime Commission, Washington, D.C. 20473 within 10 days after publication of this notice in the Federal Register. A copy of any such statement shall also be forwarded to the party filing the application (as indicated hereinafter), and the comments should indicate that this has been done.

Notice of application filed by:

Edward G. Lowry, III, Bogle, Gates Dobrin, Wakefield & Long, 14th Floor Norton Bullding, Scattle, WA 98104.

Application designated Exemption No. 6 is hereby made pursuant to section 35 of the Shipping Act, 1916, for exemption from the Intercoastal Shipping Act, 1933 and the Shipping Act, 1916, and regulations aplicable thereunder for the carriage of general cargo between Seattle, Wash, and the Arctic Coast of Alaska between Beechey Point and Tigvariak Island, via the Gulf of Alaska, the Bering Sea, and the Arctic Ocean.

The grounds for the application for exemption are the same as those asserted in the application of Puget Sound Tugand Barge Co. and Alaska Barge and Transport, Inc. in Exemption No. 4, which was approved by the Commission (46 CFR § 531.26(c) 35 FR. 9925 June 17, 1970), and Foss Launch & Tug Co. and Foss Alaska Line, Inc., in Exemption No. 5, which was approved by the Commission (46 CFR § 531.26(c) 35 FR. 10622 June 30, 1970).

The proposed service is designed for the movement of general cargo including bulk liquids to and from the oil field discovered in 1968 near Prudhoe Bay,

<sup>&</sup>lt;sup>1</sup> Commissioners Bartley and H. Rex Lee absent; Commissioner Houser not participating.

Alaska. The major oil companies engaged in operations at the site and their suppliers urgently require water transportation for their food, clothing, shelter, communications gear, drilling equipment, pipeline material, supplies, and equipment. No port or port facilities exist on this coast and due to the difficulty of construction it is doubtful that ports will be developed in the foreseeable future.

The timing of operations is determined by the ice conditions in Prudhoe Bay. Vessels must arrive off Point Barrow in time for the earliest movement of pack ice offshore. Vessels must move to the destination, discharge and return South of Point Barrow before the ice returns, which is normally within 4 to 6 weeks. Owing to its specialized character, the movement does not lend itself to rate regulation.

This exemption from the requirements of the Shipping Act, 1916, and the Intercoastal Shipping Act, 1933, will become effective upon approval of the Commission pursuant to section 35 of the Shipping Act, 1916.

Dated: January 8, 1971.

By order of the Federal Maritime Commission.

Francis C. Hurney, Secretary.

[FR Doc.71-432 Filed 1-12-71;8:49 am]

# OUTWARD CONTINENTAL NORTH PACIFIC FREIGHT CONFERENCE

#### Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202; or may inspect the agreement at the Field Offices located at New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, within 20 days after publication of this notice in the FEDERAL REGISTER. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged, the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done. Notice of agreement filed by:

John P. Meade, Esq., 919 18th Street NW., Washington, DC 20008.

Agreement No. 93-5 would:

- 1. Reduce the scope of the basic agreement by eliminating its application to the Hawaiian Islands;
- 2. Reduce the required majority vote for affirmative action on rate matters to three-fourths of those entitled to vote.

Dated: January 8, 1971.

By order of the Federal Maritime Commission.

FRANCIS C. HURNEY, Secretary.

[FR Doc.71-434 Filed 1-12-71;8:49 am]

# PORT OF OAKLAND AND SEATRAIN TERMINALS OF CALIFORNIA, INC.

#### Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 314).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202; or may inspect the agreement at the Field Offices located at New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, within 10 days after publication of this notice in the FEDERAL REGISTER. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged. the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed by:

Mr. Edward D. Ransom, Lillick, McHose, Wheat, Adams & Charles, Attorneys at Law, 311 California Street, San Francisco, CA 94104.

Agreement No. T-2480 between the Port of Oakland (Port) and Seatrain Terminals of California, Inc. (Seatrain) provides for the lease of certain marine terminal area facilities and the non-exclusive preferential assignment of berthing area by the Port to Seatrain for a term of not less than 25 years and not more than 30 years depending upon the maturity dates of certificates of indebtedness issued by the Port to acquire

the premises and improvements thereon from Seatrain and to provide for additional improvements. The leased and assigned areas are to be used by Seatrain primarily for the berthing of Scatrain Lines' vessels, the receipt, handling, loading, unloading, storage and delivery of cargo, cargo containers, container chassis and tractors, the operation and maintenance of container facilities, warehouses, maintenance and repair facilities and offices and uses incidental thereto. Annual base rental for the premises is a sum sufficient to pay principal and interest on outstanding certificates of indebtedness. Said base rental is estimated to bo at least \$1,500,000. Seatrain will also reimburse the Port for certain expenses. The Port retains secondary berthing rights provided such use shall not interfere with the operations of Seatrain. Revenues from secondary use of premises accrue pursuant to Port's tariff and are divided equally between the parties.

Dated: January 7, 1971.

By order of the Federal Maritime Commission.

Francis C. Hurney, Secretary.

[FR Doc.71-400 Filed 1-12-71;8:47 am]

### PUGET SOUND TUG & BARGE CO.

#### Application for Exemption

Notice is hereby given that the following application for exemption has been filed with the Commission for approval pursuant to section 35 of the Shipping Act, 1916, as amended (80 Stat. 1358, 46 U.S.C. 833a).

Interested parties may inspect and obtain a copy of this application at the Washington office of the Federal Maritime Commission, 1405 I Street NW, Washington, DC, Room 1015; or may inspect a copy of the application at the Field Offices, New York, N.Y.; New Orleans, La.; and San Francisco, Calif. Comments with reference to the application including a request for hearing if desired, may be submitted to the Scoretary, Federal Maritime Commission, Washington, D.C. 20573 within 20 days after publication of this notice in the FEDERAL REGISTER. A copy of any such statement shall also be forwarded to the party filing the application (as indicated hereinafter), and the comments should indicate that this has been done. Notice of application filed by:

John Cunningham, Kominers, Fort, Schlefer & Boyer, 1401 K Street NW., Washington, DC 20005.

Application designated Exemption No. 7 is hereby made pursuant to section 35 of the Shipping Act, 1916, for exemption from the Intercoastal Shipping Act, 1933, and the Shipping Act, 1916, and regulations applicable thereunder for the carriage of general cargo between Seattle, Wash., and the Arctic Coast of Alaska between Beechey Point and Tigvarial: Island, via the Gulf of Alaska, the Bering Sea and the Arctic Ocean.

The proposed service is designed for the movement of general cargo, including bulk liquids, to and from the oil field the statement shall set forth with pardiscovered in 1968 near Prudhoe Bay, Alaska. The major oil companies engaged in operations at the site and their suppliers urgently require water transportation for their food, clothing, shelter, communications gear, drilling equipment, pipeline material, supplies, and equipment. No port or port facilities exist on this coast and due to the difficulty of construction it is doubtful that ports will be developed in the foreseeable future.

The timing of operations is controlled by ice. Cargoes must be held at the carrier's dock in Seattle until shortly after midsummer, at which time all vessels engaged in the movement depart for the Arctic as a flotilla so as to arrive off Point Barrow in time for the earliest movement of pack ice offshore. Vessels must move to the destination, discharge and return south of Point Barrow before the ice returns, which is normally within 4 to 6 weeks. Owing to its specialized character, the movement does not lend itself to rate regulation and applicant doubts that the movement is common carriage subject to regulations.

This exception from the tariff filing requirements and regulations of the Shipping Act, 1916, and the Intercoastal Shipping Act, 1933, will become effective upon approval of the Commission pursuant to section 35, Shipping Act, 1916.

Dated: January 8, 1971.

By order of the Federal Maritime Commission.

> FRANCIS C. HURNEY. Secretary.

[FR Doc.71-433 Filed 1-12-71;8:49 am]

#### SEATRAIN TERMINALS OF CALIFOR-NIA, INC. AND PORT OF OAKLAND

#### Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202; or may inspect the agreement at the Field Offices located at New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, Washington. DC 20573, within 10 days after publication of this notice in the FEDERAL REGISTER. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged,

ticularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed by:

Mr. Edward D. Rancom, Lillick, McHeco, Wheat, Adams & Charles, Attorneys at Law, 311 California Street, San Francisco, CA

Agreement No. T-2479 between Seatrain Terminals of California, Inc. (Seatrain) and the Port of Oakland (Port) is a sales agreement whereby Seatrain agrees to sell to Port certain land, buildings, improvements and equipment. The purchase price paid by Port will be financed by a bond issue which in turn will be secured by a Lease and Preferential Assignment entered into by the parties and identified as Federal Maritime Commission Agreement No. T-2480. The sale and leaseback of the property are parts of one single transaction and each part is contingent upon the occurrence of the other.

Dated: January 7, 1971.

By order of the Federal Maritime Commission.

FRANCIS C. HURNEY, Secretary.

[FR Doc.71-399 Filed 1-12-71;8:47 am]

#### SHOWA SHIPPING CO., LTD. AND SANKYO KAIUN KABUSHIKI KAISHA

#### Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202; or may inspect the agreement at the Field Offices located at New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, within 20 days after publication of this notice in the FEDERAL REGISTER. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged. the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the

agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed by:

Mr. M. Kichi, Manager, Container Operations Section, Liner Department, Showa Shipping Co., Ltd., Muremachi Building, 1, 4chome, Nihonbashi-Muromachi, Chuo-ku, Tokyo, Japan.

Agreement No. 9920, between the two carriers listed above pertains to the transportation of containerized cargo from Hong Kong to U.S. Pacific Coast ports under through bills of lading issued by Showa Shipping with transshipment from Sankyo K.K.K. vessels to Showa vessels in Japanese ports.

Dated: January 7, 1971.

By order of the Federal Maritime Commission.

> FRANCIS C. HURNEY. Secretary.

[FR Doc.71-401 Filed 1-12-71;8:47 am]

#### SHOWA SHIPPING CO. LTD., AND SANKYO KAIUN KABUSHIKI KAISHA

#### Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202; or may inspect the agreement at the Field Offices located at New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, within 20 days after publication of this notice in the FEDERAL Recister. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged, the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed by:

Mr. M. Kichi, Manager, Container Operations Section, Liner Department, Showa Shipping Co., Ltd., Muromachi Building, 1, 4chome, Nihonbachi-Muromachi, Chuo-ku, Tekyo, Japan.

Agreement No. 9921 between the two carriers listed above, pertains to the transportation of containerized cargo from U.S. Pacific Coast ports to Hong Kong under through bills of lading issued by Showa Shipping with transshipment from Showa vessels to Sankyo K.K.K. vessels in Japanese ports.

Dated: January 8, 1971.

By order of the Federal Maritime Commission.

Francis C. Hurney, Secretary.

[FR Doc.71-435 Filed 1-12-71;8:49 am]

# THAILAND/U.S. ATLANTIC & GULF CONFERENCE

#### Notice of Agreement Filed

Notice is hereby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street NW., Room 1202; or may inspect the agreement at the Field Offices located at New York, N.Y., New Orleans, La., and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, within 20 days after publication of this notice in the FEDERAL REGISTER. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged, the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed by:

Mr. S. S. Marr, Secretary, Thailand/U.S. Atlantic & Gulf Conference, c/o The Borneo Co. (Thailand) Ltd., 1/1041, Silom Road, Bangkok, Thailand.

Thailand/U.S. Atlantic & Gulf Conference and Straits Steamship Co., Ltd., K.P.M. (Far East) Private Ltd., and Heap, Eng Moh Steamship Co. Private Ltd.

Agreement No. 9919 between the Thailand/U.S. Atlantic and Gulf Conference lines and the three carriers listed above (First Carriers), pertains to the through movement of rubber loaded in ports along the East Coast of Thailand by First Carriers under through bills of lading issued by the Conference lines and

transported to Conference destination ports by Conference lines after transshipment in Singapore.

Dated: January 7, 1971.

By order of the Federal Maritime Commission

Francis C. Hurney, Secretary.

[FR Doc.71-402 Filed 1-12-71;8:47 am]

# TRANS-ATLANTIC PASSENGER STEAMSHIP CONFERENCE

#### Notice of Agreement Filed

Notice is herby given that the following agreement has been filed with the Commission for approval pursuant to section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814).

Interested parties may inspect and obtain a copy of the agreement at the Washington office of the Federal Maritime Commission, 1405 I Street, NW., Room 1202, or may inspect the agreement at the offices of the District Managers, New York, N.Y. New Orleans, La, and San Francisco, Calif. Comments on such agreements, including requests for hearing, may be submitted to the Secretary, Federal Maritime Commission, 1405 I Street NW., Washington, DC 20573, within 20 days after publication of this notice in the Federal Register. Any person desiring a hearing on the proposed agreement shall provide a clear and concise statement of the matters upon which they desire to adduce evidence. An allegation of discrimination or unfairness shall be accompanied by a statement describing the discrimination or unfairness with particularity. If a violation of the Act or detriment to the commerce of the United States is alleged, the statement shall set forth with particularity the acts and circumstances said to constitute such violation or detriment to commerce.

A copy of any such statement should also be forwarded to the party filing the agreement (as indicated hereinafter) and the statement should indicate that this has been done.

Notice of agreement filed for approval

Mr. William J. Armstrong, Secretary, Trans-Atlantic Passenger Steamship Conference, 17 Battery Place, New York, NY 10004.

Agreement No. 120-91 modifies the Conference's self-policing provisions to comply with General Order 7 (Revised) published in the FEDERAL REGISTER on October 28, 1970.

Dated: January 7, 1971.

By order of the Federal Maritime Commission.

Francis C. Hurney, Secretary.

[FR Doc.71-403 Filed 1-12-71;8:47 am]

### FEDERAL POWER COMMISSION

[Docket No. RI71-552 etc.]

#### CONTINENTAL OIL CO. ET AL.

Order Providing for Hearing on and Suspension of Proposed Changes in Rates; and Allowing Rate Changes To Become Effective Subject to Refund <sup>1</sup>

JANUARY 5, 1971.

The respondents named herein have filed proposed changes in rates and charges of currently effective rate schedules for sales of natural gas under Commission jurisdiction, as set forth in Appendix A hereof.

The proposed changed rates and charges may be unjust, unreasonable, unduly discriminatory, or preferential, or

otherwise unlawful.

The Commission finds: It is in the public interest and consistent with the Natural Gas Act that the Commission enter upon hearings regarding the lawfulness of the proposed changes, and that the supplements herein be suspended and their use be deferred as ordered below.

The Commission orders:

(A) Under the Natural Gas Act, particularly sections 4 and 15, the regulations pertaining thereto (18 CFR Chapter I), and the Commission's rules of practice and procedure, public hearings shall be held concerning the lawfulness

of the proposed changes.

(B) Pending hearings and decisions thereon, the rate supplements herein are suspended and their use deferred until date shown in the "Date Suspended Until" column, and thereafter until made effective as prescribed by the Natural Gas Act: Provided, however, That the supplements to the rate schedules filed by respondents, as set forth herein, shall become effective subject to refund on the date and in the manner herein prescribed if within 20 days from the date of the issuance of this order respondents shall each execute and file under its abovedesignated docket number with the Secretary of the Commission its agreement and undertaking to comply with the refunding and reporting procedure required by the Natural Gas Act and § 154.102 of the regulations thereunder, accompanied by a certificate showing service of copies thereof upon all purchasers under the rate schedule involved. Unless respondents are advised to the contrary within 15 days after the filing of

<sup>1</sup>Does not consolidate for hearing or dispose of the several matters herein.

<sup>&</sup>lt;sup>2</sup> If an acceptable general undertaking, as provided in Order No. 377, has proviously been filed by a producer, then it will not be necessary for that producer to file an agreement and undertaking as provided herein. In such circumstances the producer's proposed increased rate will become effective as of the expiration of the suspension period without any further action by the producer.

their respective agreements and undertakings, such agreements and undertakings shall be deemed to have been accepted.

day.

(C) Until otherwise ordered by the Commission, neither the suspended supplements, nor the rate schedules sought

to be altered, shall be changed until of practice and procedure (18 CFR 1.8 disposition of these proceedings or expiration of the suspension period.

(D) Notices of intervention or petitions to intervene may be filed with the Federal Power Commission, Washington, D.C. 20426, in accordance with the rules

and 1.37(f)) on or before March 1, 1971.

By the Commission.

[SEAL]

KERNETH F. PLUME, Acting Secretary.

#### APPENDIX A

Dooltest	· Respondent	sched- ple	Sup-		Amount Date		Effective	Date	Cents per Mel		Rate in effect sub-
Docket No.			ment No.	Purchaser and producing area	el ennual increases	filing tendered		curponded until—	Rate in effect	Proposed increased rate	fact to refund in dockets Nos.
RI71-552	Continental Oil Co	138	<b>2</b> 28	Tennessee Gas Pipeline Co., a divicient of Tennece, Inc. (Grand Isle Bleck 43 Field) (Offshere Louisiana) (Disputed Zone).	\$1,408	12-14-70	12-14-70	• 12-15-70	19.5	120.0	
RI71-553	Mobil Oil Corp	466	1	Southern Union Gathering Co. (Fulcher Kutz and Basin Dakota Fields, San Juan County, N. Mex.) (San Juan Basin).	4 <u>00</u> 410	12- 0-70	12- 9-70	12-19-70	13.0 15.0	* 13, 2175 * 13, 0	-

The proposed increase of Continental Oil

Co. involves gas well gas produced from a

newly discovered reservoir in the Offshore

Louisiana "Disputed Zone." The gas quali-

fies as third vintage gas pursuant to Opinion

No. 567. The proposed 20-cent rate is equal to

the area base rate established in Opinion No.

546 for third vintage gas well gas produced

from within the State's taxing jurisdiction

but exceeds the 18.5-cent rate for gas well

gas produced from the Federal domain. The

proposed increased rate is suspended for 1

Mobil Oil Corp. requests waiver of the 30-

day notice requirement and a 1-day sus-

pension period from the date of filing. This

request is pursuant to the order issued De-

cember 11, 1970. Accordingly, such request is

granted. The proposed increase by Mobil also

includes partial reimbursement for the full

2.55 percent New Mexico Emergency School

Tax. The buyer, Southern Union Gathering

Co., has previously protested tax reimburse-

ment. In view of the contractual problem

presented, the hearing herein shall be con-

cerned with the contractual basis for such

rate filings, as well as the statutory lawful-

[FR Doc.71-353 Filed 1-12-71;8:45 am]

ness of the proposed increased rates.

[Docket No. RI71-554 etc.]

#### GETTY OIL CO. ET AL.

Order Providing for Hearings on and Suspension of Proposed Changes in Rates 1

January 5, 1971.

The respondents named herein have filed proposed increased rates and charges of currently effective rate schedules for sales of natural gas under Commission jurisdiction, as set forth in Appendix A hereof.

The proposed changed rates and charges may be unjust, unreasonable, unduly discriminatory, or preferential,

or otherwise unlawful.

The Commissions finds: It is in the public interest and consistent with the Natural Gas Act that the Commission enter upon hearings regarding the lawfulness of the proposed changes, and that the supplements herein be suspended and their use be deferred as ordered below.

The Commission orders:

(A) Under the Natural Gas Act, particularly sections 4 and 15, the regulations pertaining thereto (18 CFR Chapter I). and the Commission's rules of practice and procedure, public hearings shall be held concerning the lawfulness of the proposed changes.

(B) Pending hearings and decisions thereon, the rate supplements herein are suspended and their use deferred until date shown in the "Date Suspended Until" column, and thereafter until made effective as prescribed by the Natural Gas Act.

(C) Until otherwise ordered by the Commission, neither the suspended supplements, nor the rate schedules sought to be altered, shall be changed until disposition of these proceedings or expiration of the suspension period.

(D) Notices of intervention or petitions to intervene may be filed with the Federal Power Commission, Washington, D.C. 20426, in accordance with the rules of practice and procedure (18 CFR 1.3 and 1.37(f)) on or before March 1,

By the Commission.

[SEAL]

KENNETH F. PLUMB. Acting Secretary.

<sup>\*</sup>The pressure base is 15.025 p.s.l.a.

1 Pursuant to Opinion No. 557.

2 Includes documents required by Opinion No. 557. Applicable to gas well gas sold from the LA-Sand Reservoir.

Applicable to Pictured Cliffs formation gas.
Applicable to Dakota formation gas.
Includes partial reimburgement for the full 2.75 percent New Mexico Emergency School Tax.

<sup>1</sup> Does not consolidate for hearing or dispose of the several matters herein.

#### APPENDIX A

Docket No.	Respondent	Rate sched- ulo No.	Sup- plo- ment No.	Purchaser and producing area	Amount of annual increase	Date filing tendered	Effective date unless suspended	Date suspended until—	Cents Rate in effect	per Mef*  Proposed increased rato	Rate in effect cub- ject to refund in dockets Nos.
RI71-554 (	Jetty Oil Co	125	4	Trunkline Gas Co. (Quicksand Creek, Newton County, Tex., RR. Dis- trict No. 3).	\$240	12-14-70	1-14-71	6-14-71	<b>2 17.</b> 8653	2 19, 07	R 170-129.
RI71-555 I	dobil Oil Corp	. 286	23			. 12-16-70	1-16-71	* Accepted	15.0376	4-44444444	•
R171-556 J	ohn W Pace (Operator) et al.	1	24 3 2	do	63,308 15,033	12-16-70 12- 7-70	1-16-71 1- 7-71	6-16-71 6- 7-71		25. 0 10. 0J	RI67-463.
RI70-82 I	Amerada Hess Corp	. 55 56	12 17			12-10-70 12-10-70		D Accepted  DAccepted	17, 9023 17, 9023		R170-82,
RI71-557 1	Pan American Petroleum Corp. (Operator) et al.	123	7 20	Northern Natural Gas Co. (Eumont et al. Fields, Lea County, N. Mex.) (Permian Basin).		12-14-70		6-14-71		8 8 15, 7513 6 8 15, 2574	

All of the producers' proposed increased rates and charges exceed the applicable area price levels for increased rates as set forth in the Commission's statement of general policy No. 61-1, as amended (18 CFR Chapter I Part 2 § 2.56).

[FR Doc.71-354 Filed 1-12-71;8:45 am]

[Docket No. RI71-530 etc.]

#### SUN OIL CO. ET AL.

#### Order Providing for Hearings on and Suspension of Proposed Changes in Rates 1

DECEMBER 31, 1970.

The respondents named herein have filed proposed increased rates and charges of currently effective rate sched-

ules for sales of natural gas under Commission jurisdiction, as set forth in Appendix A hereof.

The proposed changed rates and charges may be unjust, unreasonable, unduly discriminatory, or preferential, or otherwise unlawful.

The Commission finds: It is in the public interest and consistent with the Natural Gas Act that the Commission enter upon hearings regarding the lawfulness of the proposed changes, and that the supplements herein be suspended and their use be deferred as ordered below.

The Commission orders:

(A) Under the Natural Gas Act, particularly sections 4 and 15, the regulations pertaining thereto (18 CFR Chapter 1), and the Commission's rules of practice and procedure, public hearings shall be held concerning the lawfulness of the proposed changes.

(B) Pending hearings and decisions thereon, the rate supplements herein are suspended and their use deferred until date shown in the "Date Suspended Un-

til" column, and thereafter until made effective as prescribed by the Natural Gas Act.

(C) Until otherwise ordered by the Commission, neither the suspended supplements, nor the rate schedules sought to be altered, shall be changed until disposition of these proceedings or expiration of the suspension period.

(D) Notices of intervention or petitions to intervene may be filed with the Federal Power Commission, Washington, DC 20426, in accordance with the rules of practice and procedure (18 CFR 1.8 and 1.37(f)) on or before February 26, 1971.

By the Commission.

GORDON M. GRANT. [SEAL] Secretary.

				APPENDIX A	·			•			
Docket	Respondent	Rate sched-	Sup- ple-	Purchaser and producing area	Amount	Date filing	Effective date	Date suspended	Cents	per Met	Rate in effect sub-
No.	·	ule No.	ment No.	z aronace and producing area	annual increase	tendered	unless suspended	until—	Rato in effect	Proposed increased rato	ject to refund in declets Nes
RI71-530 1	Sun Oil Co	. 6	1 19	Transcontinental Gas Pipe Line Corp. (Various Fields, Starr County, Tex. RR. District No. 4).	-	12- 4-70	1- 4-71	Accepted.	13. 01575		-
R171-531	H. L. Hawkins & H. L. Hawkins, Jr.	18	20 1	do Texas Eastern Transmission Corp (East Provident City Field Layace County, Tex. RR. District 2).	. 9.079	12- 4-70 12- 7-70	1- 4-71 1- 7-71	6- 4-71 6- 7-71	13, 04975 15, 0	10, 0 15, 5	
	J. R. Perkins d.b.s. Per- kins Production Co.	5	2	Lone Star Gas Co. (Woolsey Field Stephens County, Okla. Other Area).	480	12- 4-70	1 4-71	6- 4-71	15.0	16.0	
	John L. Cox	• ''		El Paso Natural Gas Co. (Spraberry Trend Area; Reagan County, Tex. (RR. District No. 7-C) (Permiar Basin).	) .	12- 7-70	1- 7-71	6- 7-71	14.5	<sup>8</sup> 10.3278	
	dododo	(i)			197 750 21,990	12- 7-70 12- 7-70 12- 7-70	1- 7-71 1- 7-71 1- 7-71 1- 7-71	6- 7-71 6- 7-71 6- 7-71 6- 7-71	14.5 14.5 14.5 14.5	\$ 10, 3278 • 19, 0713 • 15, 5 • 19, 3278	`
	do	8	( <sup>6</sup> )	El Paso Natural Gas Co. (South Andrews Field Area; Andrews County Tex.) (RR. District No. 8) (Permian Basin).	43	12- 7-70 12- 7-70	1- 7-71 1- 7-70	6- 7-71 6- 7-71	14.5 14.5	19, 0713 10, 2769	
	do	(g)		El Paso Natural Gas Co. (Bonedum Spraberry Field, Upton County, Tex.) (RR. District No.7-C). (Per- mian Basin).	101	12- 7-70 12- 7-70	1- 7-71 1- 7-71	6- 7-71 6- 7-71	14.5 14.5	16,2760 19,3278	

<sup>\*</sup>Unless otherwise stated, the pressure base is 14.65 p.s.i.a.

1 Agreement dated Nov. 30, 1970, among other things provides for renegotiated increases to 10 cents, 21 cents, and 25 cents for period from Jan. 1, 1971, to Jan. 1, 1975, with 1-cent increases each 4 years thereafter; also extends term of contract until Apr. 1, 1991, and from year to year thereafter.

2 Contractually entitled to base rate of 15.5 cents plus 0.0878125-cent tax reimburgement.

<sup>\*</sup>The pressure base is 14.65 p.s.i.a.'

1 Amendatory agreement dated Nov. 18, 1970, provides, among other things, for a renegotiated rate of 25 cents for the 5-year period, commencing Dec. 1, 1970 with 1-cent increase each 5 years thereafter.

2 Subject to a 0.25-cent dehydration adjustment charged to seller.

<sup>3</sup> As corrected.
4 Reflects deduction by buyer of 0.4467 cents per Mcf for compression.

<sup>1</sup> Does not consolidate for hearing or dispose of the several matters herein.

<sup>6</sup> Low pressure gas. 7 Not applicable to new gas-well gas dedicated to the contract by Supplement

<sup>1</sup> Not applicable to how gastren has defined by the No. 12.

2 Converted from 15.025 p.s.i.a. pressure base.

2 Accepted as a contract amendment effective as of the date set forth in the "Effective Date Unless Suspended" column. The proposed increased rate contained therein, however, is suspended as provided herein.

10 Accepted, subject to refund in Docket No. RI79-S2, as of Dec. 3, 1970.

burrement.

\* Includes 0.3278-cent per Mef tax reimbursement.

<sup>4</sup> No rate schedules on file by Applicant. Sales made under Small Producer certificate issued in Docket No. C866-65.
5 Includes 0.0713-cent per Met tax reimbursement.
6 Includes 0.2760-cent per Met tax reimbursement.
7 Accepted as a contract amendment effective as of the date set forth in the "Effective Date Unless Suspended" column. The proposed increased rate contained therein, however, is suspended as provided herein.

The agreement filed by Sun Oil Co. in addition to providing for the proposed increased rate also provides for future escalations to any higher area ceiling or settlement rate prescribed by the Commission. The provisions relating to the area rate do not conform with § 154.93 (b-1) of the Commission's regulations. Consistent with Commission action taken on similar filings not in conformity with § 154.93 (b-1), the agreement is accepted for filing upon expiration of statutory notice with the condition that the provisions relating to the area rate will only apply upon the Commission's approval of a just and reasonable rate, or settlement rate, in an applicable area rate proceeding, for gas of comparable quality and vintage. H. L. Hawkins & H. L. Hawkins, Jr., and J. R. Perkins doing business as Perkins Production Co. request effective dates for which adequate notice has not been given. Good cause has not been shown for granting any of these requests and they are denied.

All of the producers' proposed increased rates and charges exceed the applicable area price levels for increased rates as set forth in the Commission's statement of general policy No. 61–1, as amended (18 CFR Chapter I Part 2 § 2.56).

[FR Doc.71-355 Filed 1-12-71;8:45 am]

[Dockets Nos. CP70-199 etc.]

# CUMBERLAND NATURAL GAS CO., INC., ET AL.

# Notice of Applications and Consolidation

JANUARY 11, 1971.

Take notice that on January 7, 1971, National Chemical Corp. (applicant), 406 Kenyon Building, Louisville, KY 40202, filed in Dockets Nos. CI71-506 and CI71-507 applications pursuant to section 7(c) of the Natural Gas Act for certificates of public convenience and necessity authorizing the sales of natural gas in interstate commerce to Cumberland Natural Gas Co. (Cumberland) and pursuant to section 7(b) of the Natural Gas Act for permission and approval to abandon said sales, all as more fully set forth in the applications which are on file with the Commission and open to public inspection.

By order issued November 25, 1970, in Docket No. CP70-199 applicant was ordered to show cause why it should not be found to be a "natural-gas company" within the meaning of the Natural Gas Act and to be required to obtain a certificate to continue and permission and approval to abandon the operation of facilities and transportation of natural gas as assignee of Cumberland and the sales of natural gas hereinafter described. The proceeding in Docket No. CP70-199 was initiated-by the filing by Cumberland of an application pursuant to section 7(b) of the Natural Gas Act for permission and approval to abandon the transportation and sale of natural gas produced from applicant's properties and the facilities used therefor.

In Docket No. CI71-506 applicant requests a certificate authorizing it to continue the sale of natural gas to Cumberland from the White Plains Field, Hopkins County, Ky., heretofore authorized in Docket No. CI64-457 to be made by Creek Oil Co. (Creek). Applicant

states that on April 9, 1966, Creek assigned the subject producing properties to Tartan Oil Company (Tartan); that in January 1967 Tartan discontinued service to Cumberland; and that by assignment of January 31, 1970, Tartan assigned the subject properties to applicant. Applicant states further that at the time the sale was discontinued by Tartan the cumulative production from the lease including the subject properties exceeded . the original gas in place, that since January 1967 neither Tartan nor applicant has produced any gas from the subject properties, and that presently there is no native gas in place available for delivery in interstate commerce. Applicant requests permission and approval to abandon the subject sale.

In Docket No. CI71-501 Applicant requests a certificate authorizing it to continue the sale of natural gas to Cum-berland from the Collier Unit, Harp's Hill area Muhlenberg County, Ky., hereto-fore authorized in Docket No. G-18743 to be made by J. C. Miller Co., Inc. (Miller). Applicant states that in 1963 Miller assigned to Tartan part of the acreage from which sales were authorized; that part of the assigned acreage was unitized by Tartan into the Collier Unit; that by assignment of January 31, 1970, Tartan assigned the subject properties to Applicant; and that from January 31, 1970, until April 27, 1970, Tartan continued to own, operate, manage, and control the properties under contract of sale to applicant. Applicant states further that the necessary connecting line was never installed by Cumberland to the Collier Unit well; that on and after April 27, 1970, no gas has been produced from the subject properties; and that estimated reserves on April 27, 1970, were 15,414 Mcf of gas. Applicant requests permission and approval to abandon that part of the sale authorized in Docket No. G-18743 from acreage in the Collier Unit.

As noted in the aforementioned order to show cause the matters now formally presented in the applications in Dockets Nos. CI71-506 and CI71-507 involve questions of law and fact common to and first raised in the proceedings now pending in Docket No. CP70-199. The instant applications filed pursuant to the order to show cause issued in Docket No. CP 70-199 are, therefore, to be heard on a consolidated basis with the latter application.

In order not to delay unduly the hearings which have commenced, it is reasonable and consistent with the public interest that the time fixed for the filing of petitions to intervene and protests should be less than the 15 days prescribed by the Commission's rules of practice and procedure (18 CFR 1.19). Accordingly, any person wishing to become a party to the consolidated proceeding should on or before January 22, 1971, file with the Federal Power Commission, Washington, D.C. 20426, a petition to intervene or a protest in accordance with the requirements of the Commission's rules of practice and procedure (18 CFR 1.8 or 1.10). Those already parties to the proceeding in Docket No. CP70-199 need not refile to intervene. All protests filed with the

Commission will be considered by it in determining the appropriate action to be taken but will not serve to make the protestants parties to the proceeding. Any person wishing to become a party to a proceeding or to participate as a party in any hearing therein must file a petition to intervene in accordance with the Commission's rules.

Gordon M. Grant, Secretary.

[FR Doc.71-533 Filed 1-12-71;10:00 am]

# SMALL BUSINESS ADMINISTRATION

AMOCO VENTURE CAPITAL CO.

Notice of Issuance of License To Operate as Minority Enterprise Small Business Investment Company

On December 10, 1970, a notice was published in the Federal Register (35 F.R. 18766) stating that an application had been filed with the Small Business Administration pursuant to § 107.102 of the Regulations Governing Small Business Investment Companies (33 F.R. 326, 13 CFR Part 107) for a license to operate as a minority enterprise small business investment company by AMOCO Venture Capital Co., 910 South Michigan Avenue, Chicago, IL 60605.

Interested parties were invited to submit their written comments to SBA. No

comments were received.

Notice is hereby given that pursuant to the provisions of the Small Business Investment Act of 1958, as amended (15 U.S.C. 661 et seq.), after having considered the application and all other pertinent information and facts with regard thereto, SBA has issued License No. 07/07-5083 to AMOCO Venture Capital Co., to operate as a minority enterprise small business investment company.

James Thomas Phelan, Acting Associate Administrator for Investment.

DECEMBER 22, 1970.

[FR Doc.71-392 Filed 1-12-71;8:46 am]

[Delegations of Authority Nos. 30-C through 30-F and 30-H, Amdt. 3; Delegations of Authority Nos. 30-B and 30-G, Amdt. 4; Delegation of Authority No. 30-A, Amdt. 6]

# REGIONAL DIRECTORS, REGIONS I THROUGH X

Delegation of Authority To Conduct Program Activities in Field Offices

Delegations of Authority Nos. 30-A, to Region IX (34 FR. 18836), as amended (34 F.R. 20076, 35 FR. 1073, 35 FR. 12683, 35 FR. 15033, and 35 FR. 17156); 30-B, to Region V (34 FR. 19842), as amended (35 F.R. 1073, 35 F.R. 15033, and 35 FR. 17156); 30-C, to Regions VI, VII, and X (35 FR. 2840), as amended (35 F.R. 15033 and 35 F.R. 17156); 30-D, to Region VIII (35 F.R. 5144), as amended (35 F.R. 15033 and

35 F.R. 17156); 30-E, to Region III (35 F.R. 6033), as amended (35 F.R. 15033 and 35 F.R. 17156); 30-F, to Region I (35 F.R. 6886), as amended (35 F.R. 15033 and 35 F.R. 17156); 30-G, to Region IV (35 F.R. 9955), as amended (35 F.R. 12630, 35 F.R. 15033, and 35 F.R. 17156); and 30-H, to Region II (35 F.R. 11603), as amended (35 F.R. 15033 and 35 F.R. 17156) are hereby further amended by revising Item I.A., to read as follows:

I. Regional Director, Regions Through X-A. Financing Program. 1. To approve or decline business loans not exceeding \$350,000 (SBA share) and economic opportunity loans not exceed-

ing \$25,000 (SBA share).

2. To approve displaced business loans, coal mine health and safety loans, and economic injury disaster loans in connection with declarations made by the Secretary of Agriculture for natural disasters not exceeding \$1 million (SBA share) and to decline them in any amount.

3. To enter into business, economic opportunity, and disaster loan participation agreements with banks.

4. To execute loan authorizations for Central Office approved loans and for loans approved under delegated authority, said execution to read as follows:

> (Name), Administrator, By \_\_\_\_\_(Name) Regional Director

5. To cancel, reinstate, modify, and amend authorizations for business, economic opportunity, and disaster loans.

6. To extend the disbursement period on all loan authorizations or undis-

bursed portions of loans.

7. To approve service charges by participating banks not to exceed 2 percent per annum on the outstanding principal balance of construction loans and loans involving accounts receivable and inventory financing.

8. No authority is hereby delegated to declare the nonapplicability of eligibility limitations to a community emergency as set forth in § 120.2(e) of SBA Loan Policy Regulations.

Effective date: January 11, 1971.

EINAR JOHNSON. Acting Administrator.

[FR Doc.71-390 Filed 1-12-71;8:46 am]

### INTERSTATE COMMERCE **COMMISSION**

#### FOURTH SECTION APPLICATIONS FOR RELIEF

JANUARY 8, 1971.

Protests to the granting of an application must be prepared in accordance with § 1100.40 of the general rules of practice (49 CFR 1100.40) and filed within 15 days from the date of publication of this notice in the FEDERAL REGISTER.

LONG-AND-SHORT HAUL

FSA No. 42102-Chlorine from Brand. Tex. Filed by Southwestern Freight Bureau, agent (No. B-201), for interested rail carriers. Rates on chlorine, in tank carloads, as described in the application, from Brand, Tex., to La Place and Plaquemine, La.

Grounds for relief-Market competi-

Tariff-Supplement 50 to Southwestern Freight Bureau, agent, tariff ICC 4877.

FSA No. 42103-Peanuts between points in Oklahoma and Texas. Filed by Southwestern Freight Bureau, agent (No. B-205), for interested rail carriers. Rates on peanuts, unshelled, raw, in bulk or in sacks, in boxes or in barrels, in carloads, as described in the application, between points in Oklahoma, on the one hand, and points in Texas, on the other.

Grounds for relief-Private truck competition.

Tariff-Supplement 91 to Southwestern Freight Bureau, agent, tariff ICC 4702.

By the Commission.

ROBERT L. OSWALD, Secretary.

[FR Doc.71-440 Filed 1-12-71;8:50 am]

[Notice 1]

#### MOTOR CARRIER ALTERNATE ROUTE **DEVIATION NOTICES**

JANUARY 8, 1971.

The following letter-notices of proposals to operate over deviation routes for operating convenience only have been filed with the Interstate Commerce Commission under the Commission's Revised Deviation Rules—Motor Carriers of Passengers, 1969 (49 CFR 1042.2(c) (9) and notice thereof to all interested persons is hereby given as provided in such rules (49 CFR 1042.2(c) (9)).

Protests against the use of any proposed deviation route herein described may be filed with the Interstate Commerce Commission in the manner and form provided in such rules (49 CFR 1042.2(c) (9)) at any time, but will not operate to stay commencement of the proposed operations unless filed within 30 days from the date of publication.

Successively filed letter-notices of the same carrier under the Commission's Revised Deviation Rules-Motor Carriers of Property, 1969, will be numbered consecutively for convenience in identification and protests, if any, should refer to such letter-notices by number.

#### Motor Carriers of Passengers

No. MC-70353 (Deviation No. 1), THE PITTSBURGH AND WEIRTON BUS COMPANY, 401 Pennsylvania Avenue, Weirton, WV, filed December 30, 1970. Carrier proposes to operate as a common carrier, by motor vehicle, of passengers and their baggage, and express and newspapers in the same vehicle with passengers, over deviation routes as follows: (1) From Pittsburgh, Pa., over relocated U.S. Highway 22 to junction

Pennsylvania Highway 18 exit at Florence, Pa., thence over old U.S. Highway 22 by way of Fort Steuben Bridge, to Steubenville, Ohio; and (2) from Pittsburgh, Pa., over relocated U.S. Highway 22 to junction Pennsylvania Highway 18 exit at Florence, Pa., thence over old U.S. Highway 22 to junction West Virginia Highway 2, thence over West Virginia Highway 2 and the Market Street Bridge to Steubenville, Ohio, and return over the same routes, for operating convenience only. The notice indicates that the carrier is presently authorized to transport passengers and the same property, over pertinent service routes as follows: (1) From Pittsburgh, Pa., over U.S. Highway 22 to junction unnumbered highway (formerly portion U.S. Highway 22), thence over unnumbered highway via Fayett-ville and Tyre, Pa., to junction U.S. Highway 22 at junction Pennsylvania Highway 18 exit at Florence, Pa., thence over U.S. Highway 22 and the Fort Steuben Bridge to Steubenville, Ohio; and (2) from Pittsburgh, Pa., over the route described in (1) above to junction U.S. Highway 22 and West Virginia Highway 2, thence over West Virignia Highway 2 and the Market Street Bridge to Steubenville. Ohio, and return over the same routes.

By the Commission:

[SEAL]

ROBERT L. OSWALD. Secretary.

[FE Doc.71-448 Filed 1-12-71;8:50 am]

[Notice 1]

#### MOTOR CARRIER ALTERNATE ROUTE **DEVIATION NOTICES**

JANUARY 8, 1971.

The following letter-notices of proposals to operate over deviation routes for operating convenience only have been filed with the Interstate Commerce Commission under the Commission's Revised Deviation Rules-Motor Carriers of Property, 1969 (49 CFR 1042.4(d) (11)) and notice thereof to all interested persons is hereby given as provided in such rules (49 CFR 1042.4(d) (11)).

Protests against the use of any proposed deviation route herein described may be filed with the Interstate Commerce Commission in the manner and form provided in such rules (49 CFR 1042.4(d) (12)) at any time, but will not operate to stay commencement of the proposed operations unless filed within 30 days from the date of publication.

Successively filed letter-notices of the same carrier under the Commission's Revised Deviation Rules-Motor Carriers of Property, 1969, will be numbered consecutively for convenience in identification, and protests, if any, should refer to such letter-notices by number.

#### Motor Carriers of Property

No. MC-33641 (Deviation No. 24), IML FREIGHT, INC., Post Office Box 2277, Salt Lake City, UT 84110, filed December 30, 1970. Carrier proposes to operate as a common carrier, by motor vehicle, of

general commodities, with certain exceptions, over a deviation route, as follows: From junction Interstate Highway 71 and U.S. Highway 30 near Mifflin, Ohio, over Interstate Highway 71 to junction Interstate Highway 80S, near Leroy, Ohio, thence over Interstate Highway 80S to junction Interstate Highway 80, near North Jackson, Ohio, thence over Interstate Highway 80 to Columbia, N.J., and return over the same route, for operating convenience only. The notice indicates that the carrier is presently authorized to transport the same commodities, over a pertinent service route as follows: From junction Interstate Highway 71 and U.S. Highway 30 near Mifflin, Ohio, over U.S. Highway 30 to East Liverpool, Ohio, thence over Ohio Highway 39 to the Ohio-Pennsylvania State line, thence over Pennsylvania Highway 68 to Rochester, Pa., thence over Pennsylvania Highway 65 to Pittsburgh, Pa., thence over U.S. Highway 22 to junction unnumbered highway (formerly portion of U.S. Highway 22), thence over unnumbered highway via Export and Delmont, Pa., to junction U.S. Highway 22, thence over U.S. Highway 22 to Lewistown, Pa., thence over U.S. Highway 522 to Selingsgrove, Pa., thence over U.S. Highway 11 to Northumberland, Pa., thence over U.S. Highway 11 to Scranton Pa., thence over U.S. Highway 611 to Portaland, Pa., thence over U.S. Highway 46 to Columbia, N.J., and return over the same route.

No. MC-50544 (Deviation No. 9), THE TEXAS AND PACIFIC MOTOR TRANS-PORT COMPANY, 210 North 13th Street, St. Louis, MO 63103, filed December 30, 1970. Carrier proposes to operate as a common carrier, by motor vehicle, of general commodities, with certain exceptions, over a deviation route as follows: Between Shreveport, La., and Texar-kana, Tex., over U.S. Highway 71, for operating convenience only. The notice indicates that the carrier is presently authorized to transport the same commodities, over pertinent service routes as follows: (1) From Marshall Tex., over U.S. Highway 59 to Texarkana, Tex.; and (2) from Gladewater, Tex., over U.S. Highway 80 to Shreveport, La., and return over the same routes.

By the Commission.

[SEAL] ROBERT L. OSWALD. Secretary.

[FR Doc.71-449 Filed 1-12-71;8:50 am]

#### [Notice 1]

#### MOTOR CARRIER APPLICATIONS AND **CERTAIN OTHER PROCEEDINGS**

JANUARY 8, 1971.

The following publications are governed by the new Special Rule 247 of the Commission's rules of practice, published in the Federal Register, issue of December 3, 1963, which became effective January 1, 1964.

The publications hereinafter set forth reflect the scope of the applications as filed by applicant, and may include descriptions, restrictions, or limitations which are not in a form acceptable to the Commission. Authority which ultimately may be granted as a result of the applications here noticed will not necessarily reflect the phraseology set forth in the application as filed, but also will eliminate any restrictions which are not acceptable to the Commission.

APPLICATIONS ASSIGNED FOR ORAL HEARING

MOTOR CARRIERS OF PROPERTY

No. MC 128938 (Sub-No. 3) (Republication), filed October 20, 1969, published in the Federal Register Issues of November 20, 1969, and December 4, 1969, and republished this issue. Applicant: JO/ KEL, INC., Post Office Box 22265, Los Angeles, CA 90022. Applicant's repre-sentative: J. Max Harding, 605 South 14th Street, Post Office Box 2028, Lincoln, NE 68501. An order of the Commission, Division 1, Acting as an Appellate Division, dated December 18, 1970, and served January 4, 1971, finds; that operation by applicant, in interstate or foreign commerce, as a contract carrier by motor vehicle, over irregular routes, (1) of upholstery or carpet tacking rims or strips, nails, adhesive cement, mechanic hand tools, and advertising materials, racks, and stands therefor, from Industry, Calif., to points in the United States in and east of North Dakota, South Dakota, Nebraska, Kansas, Oklahoma, and Texas, and (2) materials, equipment, and supplies used in the manufacture and distribution of the commodities in (1) above, on return, restricted against the transportation of commodities in bulk, in both (1) and (2) above, under a continuing contract or contracts with Taylor Industries, Inc., of City of Industry, Calif., will be consistent with the public interest and the national transportation policy. Because it is possible that other persons who have relied upon the notice of the application as published, may have an interest in would be prejudiced by the lack of proper notice of the authority described in the findings in this order a notice of authority actually granted will be published in the FEDERAL REGISTER and issuance of a permit in this proceeding will be withheld for a period of 30 days from the date of such publication, during which period any proper party in interest may file a petition to reopen or for other appropriate relief setting forth in detail the precise manner in which it has been so prejudiced.

#### APPLICATIONS UNDER SECTIONS 5 AND 210a(b)

The following applications are governed by the Interstate Commerce Commission's special rules governing notice of filing of applications by motor carriers of property or passengers under sections 5(a) and 210a(b) of the Interstate Commerce Act and certain other proceedings with respect thereto (49 CFR 1.240).

MOTOR CARRIERS OF PROPERTY

No. MC-F-11016. (Correction) (LAID-LAW TRANSPORT LIMITED-Purchase-PETTAPIECE CARTAGE LIM-TTED), published in November 18, 1970, issue of the Federal Register on page 17767. This correction to modify prior publication to exclude Edible salt, dry, in bull:, in pressure tank vehicles, from St. Clair, Mich., to the United States-Canada boundary line at Port Huron, Mich.

No. MC-F-11039. (Correction) (H. S. ANDERSON TRUCKING COMPANY— Purchase (Portion)-M. A. DAVIS TRANSPORT, INC.), published in December 9, 1970, issue of the Federal Register on pages 18707 and 18708. This correction to show line 10 on page 18703 should read the completion of holes or wells drilled in lieu of the completion of holds or wells drilled.

No. MC-F-11046. (Correction) (La-NETA M. ABLER-Control-CANADA TRANSPORT, INC.), published in December 16, 1970, issue of Federal Regis-TER on page 19048. This correction to show LONETA M. ABLER holds no authority from this Commission in lieu of CANADA TRANSPORT, INC., holds no authority from this Commission, as shown in prior register.

No. MC 46300 (Sub-No. 2 TA) filed purchase by PENN YAN EXPRESS, INC., 100 West Lake Road, Penn Yan, NY 14527, of the operating rights of FRANK'S-VAN NAMEE'S EXPRESS CORP., (STANLEY R. RUDIN, TRUSTEE IN BANKRUPTCY), 825 University Building, Syracuse, NY 13202, and for acquisition by ROBERT L. HINSON, 9 Rosewood Drive, Penn Yan, NY 14527, of control of such rights through the purchase. Applicants' attorneys: Norman M. Pinsky and Herbert M. Canter both of 345 South Warren Street, Syracuse, NY 13202. Operating rights sought to be transferred: General commodities, excepting among others classes A and B explosives, household goods and commodities in bulk, as a common carrier, over regular routes, between Binghamton, N.Y., and Utica, N.Y., serving all intermediate points, from Utica, N.Y., to Norwich, N.Y., serving to the intermediate point of Sherburne, N.Y., restricted to delivery only, between South New Berlin, N.Y., and Utica, N.Y., serving no intermediate points, but serving the off-route point of Hubbardsville, N.Y., between South New Berlin, N.Y., and Binghamton, N.Y., serving all intermediate points on New York Highway 12 between Norwich and Binghamton, inciuding Norwich, between South New Berlin, N.Y., and Oneonta, N.Y., serving the intermediate points of Morris and Sidney, N.Y.; between points in New York, serving all intermediate points; and certain off-route points; packing house products, over irregular routes, from Syracuse, N.Y., to Richfield Springs, N.Y., and certain specified points; and under a certificate of registration, in Docket No. MC-109303 Sub-3, covering the transportation of general commodities, as a common carrier, in interstate commerce, within the State of New York. Vendee is authorized to operate as a common carrier in New York, Pennsylvania, New Jersey, Maryland, Dalaware, Connecticut, and the District of Columbia. Application has not been filed for temporary authority under section 210a a matter directly related.

No. MC-F-11061. Authority sought for purchase by BELGER CARTAGE SERV-ICE, INC., 2100 Walnut Street, Kansas City, MO 64108, of the operating rights and certain property of ROY L. JONES, INC., 915 McCarty Avenue, Houston, TX 77029, and for acquisition by JOHN BEL-GER, LARRY BELGER, EDNA M. BEL-GER, and BETTY G. BELGER, all also of Kansas City, Mo., of control of such rights and certain property through the purchase. Applicants' attorneys and representative: F. W. Taylor, 1221 Baltimore Avenue, Kansas City, MO 64105, W. E. Griffin, 1221 Baltimore Avenue, Kansas City, MO 64105, Austin L. Hatchell, Suite 1102, Perry-Brooks Building, Austin TX 78701 and Ralph Wood, 2100 Walnut Street, Kansas City, MO 64108. Operating rights sought to be transferred: Machinery, equipment, materials, and supplies used in, or in connection with, the discovery, development, production, refining, manufacture, processing, storage, transmission, and distribution of natural gas and petroleum and their products and byproducts, and machinery, equipment, materials, and supplies used in, or in connection with, the construction, operation, repair, servicing, maintenance, and dismantling of pipelines, in-cluding the stringing and picking up thereof, as a common carrier over irregular routes between points in New Mexico, on the one hand, and, on the other, points in Oklahoma, Kansas, Missouri, Arkansas, and Tennessee, between points in Mississippi, Alabama, Georgia, and Florida, between points in Alabama, Georgia, and Florida, on the one hand, and, on t' e other, points in New Mexico, Texas, Arkansas, and Louisiana:

Machinery, equipment, materials, and supplies used in, or in connection with, the discovery, development, production, refining, manufacture, processing, storage, transmission, and distribution of nautral gas and petroleum, and their products and byproducts; and machinery, equipment, materials, and supplies used in or in connection with, the construction, operation, repair servicing, maintenance, and dismantling of pipelines, including the stringing and picking up thereof, except in connection with main or trunk pipelines, between points in Oklahoma, on the one hand, and, on the other, points in North Dakota on and west of North Dakota Highway 30, and those in South Dakota west of the Missouri River and on and north of U.S. Highway 14; between points in Louisiana, Arkansas, Oklahoma, Mississippi, and Texas; machinery and equipment used in, or in connection with, the discovery, development, production, refining, manufacture, processing, storage, transmission, and distribution of sulphur and its products, and materials and supplies (not including sulphur) used in, or in connection with, the discovery, development, production refining, manufacture, processing, storage, transmission, and distribution of sulphur and its products, restricted to the transportation of shipments of materials and supplies

(b). Note: No. MC-105902 Sub-No. 16 is moving to or from exploration, drilling, production, job construction, plant (including refining, manufacturing, and processing plant) sites or storage sites, between points in New Mexico, on the one hand, and, on the other, points in Oklahoma and Kansas, between points in Louisiana, New Mexico, and Texas:

Machinery, equipment, materials, and supplies used in, or in connection with, the drilling of water wells, between points in New Mexico, on the one hand, and, on the other, points in Oklahoma, Kansas, Missouri, Arkansas, and Tennessee, between points in Oklahoma, on the one hand, and, on the other, points in North Dakota on and west of North Dakota Highway 30 extending through St. John, York, Medina, and Ashley, N. Dak., and those in South Dakota west of the Missouri River and on and north of U.S. Highway 14, extending through Hayes, Midland, Rapid City, and Sturgis, S. Dak.; fertilizer, from Shreveport, La., to points in Louisiana and Arkansas, from points in Arkansas, to Minden, Monroe, and Shreveport, La., from Minden, and Monroe, La., to points in Arkansas, from Texarkana, Ark., to points in Louisiana within 250 miles of Texarkana, except Minden, Monroe, and Shreveport; heavy machinery, contractors' equipment, and parts and accessories thereof, between points in Alabama, Louisiana, and Mississippi, between points in Alabama, and Louisiana, and points in that part of Mississippi on and south of U.S. Highway 82, on the one hand, and, on the other, points in Arkansas and Tennessee; road, levee, and dam building equipment and machinery, between points in Georgia, on the one hand, and, on the other, points in Alabama and Mississippi;

Machinery, equipment, materials, and supplies, used in or in connection with the construction, operation, repair, servicing, maintenance, and dismantling of pipelines, other than pipelines used for the transmission of natural gas, petroleum, their products and byproducts, water, or sewerage, restricted to the transportation of shipments moving to or from pipeline rights of way, between points in New Mexico, on the one hand, and, on the other, points in Oklahoma, Kansas, Missouri, Arkansas, and Tennessee, between points in Oklahoma, on the one hand, and, on the other, points in North Dakota on and west of a line beginning at the United States-Canada boundary line and extending along North Dakota Highway 30 to junction unnumbered highway, at Lehr, N. Dak., thence along unnumbered highway to Ashley, N. Dak., and thence along North Dakota Highway 3 to the North Dakota-South Dakota State line, and points in South Dakota west of the Missouri River and on and north of U.S. Highway 14 extending through Hayes, Midland, Rapid City, and Sturgis, S. Dak., between points in Louisiana, Arkansas, Oklahoma, Mississippi, and Texas, between points in Mississippi, Alabama, Georgia, and Florida, between points in Alabama, Georgia, and Florida, on the one hand, and, on the other, points in New Mexico, Texas, Arkansas,

and Louisiana; machinery, equipment, materials, and supplies used in, or in connection with, the drilling of water wells, between points in Arkansas, Louisiana, New Mexico, and Texas, between points in Mississippi, Alabama, Georgia, and Florida, between points in Alabama, Georgia, and Florida, on the one hand, and, on the other, points in New Mexico, Texas, Arkansas, and Louisiana, between points in Texas, on the one hand, and, on the other, points in South Dakota west of the Missouri River and on and north of U.S. Highway 14 extending through Hayes, Midland, Rapid City, and Sturgis, S. Dak.;

Self-propelled articles, each weighing 15,000 pounds or more, and related machinery, tools, parts, and supplies moving in connection therewith, between points in Texas, on the one hand, and, on the other points in Oklahoma, New Mexico, and Kansas, with restriction; carth drilling machinery and equipment, and machinery, equipment, materials, supplies, and pipe incidental to, used in, or in connection with (a) the transportation, installation, removal, operation, repair, servicing, maintenance, and dismantling of drilling machinery and equipment, (b) the completion of holes or wells drilled, (c) the production, storage, and transmission of commodities resulting from drilling operations at well or hole sites and (d) the injection or removal of commodities into or from holes or wells, between points in New Mexico, on the one hand, and, on the other, points in Oklahoma, Kansas, Missouri, Arkansas, and Tennessee, between points in Oklahoma, on the one hand, and, on the other, points in North Dakota on and west of a line beginning at the United States-Canada boundary line and extending along North Dakota Highway 30 to junction unnumbered highway at Lehr, N. Dak., thence along unnumbered highway to Ashley, N. Dak., and thence along North Dakota Highway 3 to the North Dakota-South Dakota State line. and points in South Dakota west of the Missouri River, and on and north of U.S. Highway 14, extending through Hayes, Midland, Rapid City, and Sturgis, S. Dak., between points in Louisiana, Arkansas, Oklahoma, Mississippi, and Texas, between points in Mississippi, Alabama, Georgia, and Florida, between points in Alabama, Georgia, and Florida, on the one hand, and, on the other, points in New Mexico, Texas, Arkansas, and Louisiana:

Commodities (other than machinery, equipment, materials, and supplies used in, or in connection with, the discovery, development, production, refining, manufacture, processing, storage, transmission, and distribution of natural gas and petroleum and their products and byproducts, and machinery, materials, equipment and supplies used in, or in connection with, the construction, operation, repair, servicing maintenance, and dismantling of pipelines, including the stringing and picking up thereof), the transportation of which because of size

or weight require the use of special equipment and related parts when their transportation is incidental to the transportation by said carrier of commodities which by reason of size or weight require special equipment, between points in Texas, on the one hand, and, on the other, points in Kansas, New Mexico, and Oklahoma; iron and steel articles, from Corpus Christi, Galveston, and Houston, Tex., to points in New Mexico, Oklahoma, and Texas; in pending Docket No. MC-4964 Sub-36, commodities which require the use of special equipment by reason of size or weight (except household goods and commodities in bulk), between points in Alabama, Arkansas, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, Tennessee, and Texas, restricted to traffic moving to, from, or between military installation or Defense Department establishments and moving on Government bills of lading or on commercial bills of lading containing an endorsement approved in Interpretation of Government Rate Tariff for Eastern Central Motor Carrier, 322 ICC 161; in pending Docket No. MC-4964 Sub-36, iron and steel and/or iron and steel articles, from Baytown and East Baytown, Tex., to points in Arkansas, Kansas, Louisiana, Mississippi, New Mexico, and Oklahoma; and in pending Docket No. MC-4964 Sub-39:

(a) Antipollution systems, equipment and parts; liquid cooling and vapor condensing systems, equipment and parts; environmental control and protective systems, equipment and parts; (b) equipment, materials, and supplies used in the construction or installation of antipollution and environmental control and protective systems, and liquid cooling and vapor condensing systems (1) between points in Alabama, Arkansas, Florida, Georgia, Kansas, Louisiana, Mississippi, New Mexico, Missouri, Oklahoma, Tennessee, and Texas, and (2) between points in the States named in (1) above, on the one hand, and, on the other, points in the United States (except Hawaii). Vendee is authorized to operate as a common carrier in all States in the United States (except Alaska and Hawaii). Application has been filed for temporary authority under section 210a(b).

By the Commissioner.

[SEAL]

ROBERT L. OSWALD, Secretary.

[FR Doc.71-439 Filed 1-12-71;8:50 am]

[Notice 225]

# MOTOR CARRIER TEMPORARY AUTHORITY APPLICATIONS

JANUARY 7, 1971.

The following are notices of filing of applications for temporary authority under section 210a(a) of the Interstate Commerce Act provided for under the new rules of Ex Parte No. MC-67 (49 CFR. Part 1131), published in the Federal Register, issue of April 27, 1965, effective July 1, 1965. These rules provide that

protests to the granting of an application must be filed with the field official named in the Federal Register publication, within 15 calendar days after the date of notice of the filing of the application is published in the Federal Register. One copy of such protests must be served on the applicant, or its authorized representative, if any, and the protests must certify that such service has been made. The protests must be specific as to the service which such protestant can and will offer, and must consist of a signed original and six (6) copies.

A copy of the application is on file, and can be examined at the Office of the Secretary, Interstate Commerce Commission, Washington, D.C., and also in field office to which protests are to be

transmitted.

#### MOTOR CARRIERS OF PROPERTY

No. MC 703 (Sub-No. 20 TA), filed December 31, 1970. Applicant: HINCH-CLIFF MOTOR SERVICE, INC., 3400 South Pulaski Road, Chicago, IL 60623. Applicant's representative: R. D. Hinchcliff (same address as above). Authority sought to operate as a common carrier, by motor vehicle, over regular routes, transporting: Urethane and urethane products, from Bourbon, Ind., to Bremen, Ind., over Indiana Highway 331, for 180 days. Applicant intends to tack. Applicant holds irregular route authority from Bremen, Ind. to points in Michigan as contained in their Sub 18 authority. Supporting shipper: Philip Cupertino, Product Transportation Manager, Stauffer Chemical Co., Post Office Box 98, Bremen, IN 46506. Send protests to: Robert G. Anderson, District Supervisor, Interstate Commerce Commission, Bureau of Operations, Everett McKinley Dirksen Building, 219 South Dearborn Street, Room 1086, Chicago, IL 60604.

No. MC 46300 (Sub-No. 2 TA) filed December 30, 1970. Applicant: KEN-NETH NARROD MOVING CO., 1120 Glen Rock Avenue, Waukegan, IL 60085. Applicant's representative: Carl L. Applicant's representative: Carl L. Steiner, 39 South La Salle Street, Chicago, IL 60603. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Household goods and hold baggage, between North Chicago, Ill., on the one hand, and, on the other, points in Boone, Bureau, Cook, De Kalb, Du Page, Kane, Kendall, Lake, La Salle, Lee, McHenry, Ogle, Putnam, Will, and Winnebago Counties, Ill. Restricted to the transportation of traffic having a prior or subsequent movement, in containers, beyond the points authorized, and further restricted to the performance of pickup and delivery service in connection with packing, crating, and containerization, or unpacking, uncrating, and decontainerization of such traffic, for 150 days. Supporting shipper: Department of the Army, Headquarters Fort Sheridan, Fort Sheridan, IL 60037. Send protests to: William J. Gray, Jr., District Supervisor, Bureau of Operations, Interstate Commerce Commission, Everett McKinley Dirksen Building, 219

South Dearborn Street, Room 1036, Chicago, IL, 60604.

No. MC 96093 (Sub-No. 50 TA), filed December 31, 1970. Applicant: MILTON TRANSPORTATION, INC., Post Office Box 207, Rural Delivery A1, Milton, PA 17847. Applicant's representative: George A. Olsen, 69 Tonnele Avenue, Jersey City, NJ 07306. Authority sought to operate as a contract carrier, by motor vehicle, over irregular routes, transporting: Printing paper, from Stamford, Conn., to Dayton, Ohlo; under continuing contract with St. Regis Paper Co., for 150 days. Supporting shipper: St. Regis Paper Co., 150 East 42d Street, New York, NY 10017. Send protests to: Robert W. Ritenour, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 508 Federal Building, Post Office Box 869, Harrisburg, PA 17103.

No. MC 103191 (Sub-No. 32 TA), filed December 30, 1970. Applicant: THE GEO. A. RHEMAN CO. INC., 2019 Elgin Street, Post Office Box 2095 Station A, Charleston, SC 29403. Applicant's representative: Harold P. Boss, 1100 17th Street NW., Washington, DC 20036. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Petroleum and petroleum products, in bulk, in tank vehicles, from points within the Charleston, S.C., commercial zone, to points in Virginia, for 120 days. Supporting shipper: Gulf Oil Co., Gulf Oll Building, 1375 Peachtree Street NE., Atlanta, GA 30309. Send protests to: E. E. Strotheid, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 300 Columbia Building, 1200 Main Street, Columbia, SC 29201.

No. MC 106398 (Sub-No. 519 TA) filed December 31, 1970. Applicant: NATIONAL TRAILER CONVOY, INC., 1925 National Plaza, Box 51096, Dawson Station, Tulsa, OK 74151. Applicant's representative: Irvin Tull (same address as above). Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Panelized house products, from the plant site of Panelfab International Corp., Miami, Fla., to points in Alabama, Georgia, South Carolina, North Carolina, Virginia, Tennessee, and Mississippi, for 180 days. Supporting shipper: Panelfab International Corp., T. S. Ferguson, Vice President, Housing, 1600 Northwest Le-Jeune Road, Miami, FL 33126. Send protests to: C. L. Phillips, District Supervisor, Interstate Commerce Commission, Bureau of Operations, Room 240, Old Post Office Building, 215 Northwest Third, Oklahoma City, OK 73102.

No. MC 108119 (Sub-No. 26 TA) filed December 31, 1970. Applicant: E. L. MURPHY TRUCKING COMPANY, 3303 Sibley Memorial Highway, Post Office Box 3010, St. Paul, MN 55111. Applicant's representative: Andrew R. Clark, 1000 First National Bank Building, Minneapolis, MN 55402. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Iron and steel and iron and steel

articles, from Duluth, Minn., to points in Colorado, Connecticut, Delaware, Idaho, Illinois, Kansas, Maryland, Massachusetts, Missouri, Montana, New Jersey, New York, North Carolina, North Dakota, Oklahoma, Oregon, South Carolina, Texas, Utah, Vermont, West Virginia, and Wyoming, for 180 days. Supporting shipper: United States Steel Corp., Chicago, Ill. Send protests to: District Supervisor A. N. Spath, Interstate Commerce Commission, Bureau of Operations, 448 Federal Building & U.S. Courthouse, 110 South Fourth Street, Minneapolis, MN 55401.

No. MC 109677 (Sub-No. 38 TA), filed December 30, 1970. Applicant: FORT EDWARD EXPRESS CO. INC., Route 9, Saratoga Road, Fort Edward, NY 12828. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Petroleum products, in bulk, in tank vehicles, from Plattsburgh, N.Y., to Seanton, Milton, Newport, Essex Junction, Randolph, Rochester, Pittsfield, and West Cornwall, Vt., for 150 days. Supporting shipper: Shell Oil Co., Shell Building, Post Office Box 2099, Houston, TX 77001. Send protests to: Charles F. Jacobs, District Supervisor, Bureau of Operations, Interstate Commerce Commission, 518 Federal Building, Albany, NY 12207.

No. MC 110525 (Sub-No. 992 TA), filed December 30, 1970. Applicant: CHEMICAL LEAMAN TANK LINES, INC., 520 East Lancaster Avenue, Downingtown, PA 19335. Applicant's representative: Thomas J. O'Brien (same address as above). Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Muriatic acid, in bulk, in tank vehicles, from Fort Worth, Tex., to Heraldton, Okla., for 150 days. Supporting shipper: Stauffer Chemical Co., Suite 300 South, 6910 Fanin Street, Houston, TX 77025. Send protests to: Peter R. Guman, District Supervisor, Bureau of Operations, Interstate Commerce Commission, 1518 Walnut Street, Philadlephia, PA 19102.

No. MC 110525 (Sub-No. 993 TA) filed December 31, 1970. Applicant: CHEMICAL LEAMAN TANK LINES, INC., 520 East Lancaster Avenue, Dowingtown, PA 19335. Applicant's representative: Thomas J. O'Brien (same address as above). Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Liquid chemicals, in bulk, in tank vehicles, from points in Fulton County, Ga., to Indianapolis, Ind., Bridgeton, Mount Vernon, and St. Louis, Mo., and Cincinnati, Ohio; for 180 days. Supporting shipper: Dewey and Almy Chemical Division, W. R. Grace & Co., 5225 Philip Lee Drive, Atlanta, GA 30336. Send protests to: Peter R. Guman, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 1518 Walnut Street, Room 1600, Philadelphia, PA 19106.

No. MC 116073 (Sub-No. 147 TA) filed December 30, 1970. Applicant: BARRETT MOBILE HOME TRANSPORT, INC., 1825 Main Avenue, Post Office Box 919,

Moorhead, MN 56560. Applicant's representative: Robert G. Tessar (same address as above). Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Buildings, complete, knocked down, or in sections with parts and materials needed for the erection and completion of such buildings, from the plantsite and warehouse facilities of the Cuckler Steel Span Co., Monticello, Iowa; to points in Minnesota, Nebraska, Illinois, Indiana, Ohio, Michigan, Wisconsin, Kansas, Missouri, Colorado, and South Dakota, for 180 days. Supporting shipper: Cuckler Steel Span Co., Monticello, IA 52310. Send protests to: J. H. Ambs, District Supervisor, Interstate Commerce Commission, Bureau of Operations, Post Office Box 2340, Fargo, ND 58201.

No. MC 117765 (Sub-No. 116 TA), filed December 30, 1970. Applicant: HAHN TRUCK LINE, INC., 5315 Northwest Fifth, Box 75267, Oklahoma City, OK 73107. Applicant's representative: R. E. Hagan (same address as above). Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Malt beverages, in containers, from Galveston and Houston, Tex., to points in Iowa, Kansas, Missouri, Nebraska, and Oklahoma, for 150 days. Supporting shippers: Oklahoma Distributing Co., L. L. Robinson, President, 729 Southwest Third Street, Oklahoma City, OK 73125; Midwest Distributing Co., D. A. Altiere, Owner, 7300 Kaw Drive, Kansas City, KS; Sullivan Beverages, Inc., Thos. Sullivan, Treasurer, 3030 Roanoke Road, Kansas City, MO 64108. Send protests to: C. L. Phillips, District Supervisor, Interstate Commerce Commission, Bureau of Operations, Room 240, Old Post Office Building, 215 Northwest Third, Oklahoma City, OK 73102.

No. MC 119789 (Sub-No. 51 TA), filed December 30, 1970. Applicant: CARA-VAN REFRIGERATED CARGO, INC., Post Office Box 6188, Dallas, TX 75222. Applicant's representative: James T. Moore (same address as above). Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Meats, meat products, meat byproducts and articles distributed by meat packinghouses, from Emporia, Kans., to points in Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Connecticut, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Rhode Island, Virginia, and the District of Columbia. Note: Carrier does not intend to tack authority for 180 days. Supporting shipper: Iowa Beef Packers, Inc., Dakota City, Nebr. 68731. Send protests to: E. K. Willis, Jr., Interstate Commerce Commission, Bureau of Operations, 513 Thomas Building, 1314 Wood Street, Dallas, TX 75202.

No. MC 123383 (Sub-No. 51 TA), filed December 30, 1970. Applicant: BOYLE BROTHERS, INC., 941 South Second Street, Camden, NJ 08103. Applicant's representative: Thomas E. Kiley (same address as above). Authority sought to

operate as a common carrier, by motor vehicle, over irregular routes, transporting: Poly styrene beads, in bags, from Farmingdale, N.J. to Chesapeake, Va., for 180 days. Supporting shipper: Evans Products Co., Post Office Box 880, Corona, CA 91720. Send protests to: Raymond T. Jones, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 410 Post Office Building, Trenton, NJ 08608.

No. MC 124211 (Sub-No. 168 TA), filed December 30, 1970. Applicant: HILT TRUCK LINE, INC., Post Office Box 988, Downtown Station, Omaha, NE 68101. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Printed and dated publications, and supplies and materials, used in the production thereof, between the plantsite of Mid-American Webpress, Inc., in Lancaster County, Nebr., on the one hand, and, on the other, in Brownsville, Laredo, Fasadena, Houston, Dallas, and Fort Worth, Tex., Los Angeles and Redondo Beach, Calif., Now Orleans, La., New York, N.Y., and Pitts-burg, Pa., including points in their commercial zones, for 180 days. Supporting shipper: Mid-American Webpress, Inc., Post Office Box 81608, Lincoln, NE 68501. Send protests to: Carroll Russell, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 705 Federal Office Building, Omaha, NE 68102.

No. MC 126118 (Sub-No. 12 TA), filed December 31, 1970. Applicant: GEORGE M. HILL, doing business as HILL TRUCKING COMPANY, Route No. 8, Johnson City, TN 37601. Applicant's representative: R. Cameron Rollins, 321 East Center Street, Kingsport, TN 37660. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Peppers and pi-mientos, in cans or barrels, from the plantsite of Moody Dunbar, Inc., Lime-stone, Tenn., to points in Virginia, Maryland, Delaware, New York, Pennsylvanic, New Jersey, Maine, New Hampshire, Verlmont, Massachusetts, Connecticut, Rhode Island, and St. Louis, Mo.; Chicago, Ill.; and Evansville, Ind., for 180 days. Supporting shipper: Moody Dunbar, Inc., Post Office Box 68, Limestone, TN 37681. Send protests to: Joe J. Tate, District Supervisor, Interstate Commerce Commission, Bureau of Operations, 803-1808 West End Building, Nashville, TN 37203.

No. MC 127346 (Sub-No. 5 TA), filed December 31, 1970. Applicant: HAILI'S FAST MOTOR FREIGHT, INC., 330 Oak Tree Avenue, Post Office Box 183, South Plainfield, NJ 07080. Applicant's representative: George A. Olsen, 69 Tonnelo Avenue, Jersey City, NJ 07306. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Plastic granules, in bulk, in water carrier containers, from New Castle, Del., to Sea Land Terminal at Elizabeth, N.J., for 150 days. Supporting shipper: Amoco Chemicals Corp., 130 East Randolph Drive, Chicago, IL 60601. Send protests to: District Supervisor

Robert S. H. Vance, Bureau of Operations, Interstate Commerce Commission, 970 Broad Street, Newark, NJ 07102.

No. MC 133966 (Sub-No. 7 TA), filed December 30, 1970. Applicant: NORTH EAST EXPRESS, INC., Post Office Box 61, Mountaintop, PA 18707. Applicant's representative: Kenneth R. Davis, 999 Union Street, Taylor, PA 18517. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: Cellular or expanded plastic sheet, from West Hazleton, Pa., to points in Ohio, Michigan, Illinois, Indiana, and Massachusetts, for 150 days. Supporting Shipper: Tenneco Chemicals, Inc., General Foam Division,

Valmont Industrial Park, Hazleton, Pa. 18201. Send protests to: Paul J. Kenworthy, District Supervisor, Bureau of Operations, Interstate Commerce Commission, 309 U.S. Post Office Building, Scranton, PA 18503.

No. MC 135200 (Sub-No. 1 TA), filed December 31, 1970. Applicant: W. H. & HILTON SAPP, doing business as SAPP BROS. TRUCKING CO., Tifton Highway, R.F.D. 1, Box 135-A, Barney, GA 31625. Applicant's representative: Sol H. Proctor, 2501 Gulf Life Tower, Jackson-ville, FL 32207. Authority sought to operate as a common carrier, by motor vehicle, over irregular routes, transporting: (1) Peanut meal and peanut hulls, from

Moultrie, Ga., to points in Florida and (2) Soybean meal, soybean hulls and mill run, from Valdosta, Ga., to Dothan and Enterprise, Ala., and points in Florida, for 180 days. Supporting shipper: Gold Kist, Division of Cotton Producers Association, 3348 Peachtree Road NE., Atlanta, GA 30301. Send protests to: District Supervisor G. H. Fauss, Jr., Bureau of Operations, Interstate Commerce Commission, Box 35008, 400 West Bay Street, Jacksonville, FL 32202.

By the Commission.

[SEAL] ROBERT L. OSWALD,

[FR Doc.71-433 Filed 1-12-71;8:50 am]

#### CUMULATIVE LIST OF PARTS AFFECTED—JANUARY

The following numerical guide is a list of parts of each title of the Code of Federal Regulations affected by documents published to date during January.

3 CFR	Page	8 CFR Page 16 CFR—Continue	d Page
Proclamations:		3 316 PROPOSED RULES:	-
3548 (see Proc. 4026)	5	100 316	000
3558 (see Proc. 4026)	5	103 316 415 429	
3562 (see Proc. 4026)	5	#12 V1   400	
3597 (see Proc. 4026)	5	40x	
3709 (see Proc. 4026)	5	444 SII	,
3790 (see Proc. 4026) 3822 (see Proc. 4026)	5 5	118 CFR	
3856 (see Proc. 4026)	5	O CED	
3870 (see Proc. 4026)	5	76 14, 144, 265, 318, 353 201	
3884 (see Proc. 4026)	5	260	
4026	5	10 CFR PROPOSED RULES:	
EXECUTIVE ORDERS:		30 145	
. 10427 (revoked by EO 11575)_	37	40 145   2	
10737 (revoked by EO 11575)_	37	70146	
11495 (revoked by EO 11575).	37	170146   201	
11575	37	13 CFR	
11576	347 349	12143, 213, 315, 421 19 CFR	
11011	949	PROPOSED RULES: PROPOSED RULES:	,
5 CFR		191	400
213 11, 39, 261, 315,	. 353`	IV	
2410	315	14 CFR 13	
7 CFR		1 43 25	
		37 15 54	
0	413	39 15, 214, 421, 422	
20 270	40 261	7144, 147, 214-216, 319   20 CFR	
301 ^ 139		73 44 615	46
401	262	9143	
722 11	40	97147, 353   21 CFR	
725	11	12145   20	422
730 139,	140 140	135 45   120	423
812 814	141	Proposed Rules: 121	
815	$\overline{11}$	37 23   135a	
90540		71 165, 224, 225, 323–325   148h	
906	143	73 435'   420	424
907144	, 213	75 165 PROPOSED RULES:	
91041, 966	315	91 325   121	224
971	421	15 CFR	
142141		Proposed Rutes	
Proposed Rules:	-	7 113 200	424
907	22	004	
908	22	10 CFR 220	216
987	112	421 45   1914	263
1061	370	422 354   1915	264

#### FEDERAL REGISTER

26	CFR	Page	36	CFR	Page	43 CFR—Continued	Pago
1		266	1		. 154	PUBLIC LAND ORDERS-Continued	
		150				4979	60
		151		5		4980	61
						4981	61
	POSED RULES:					4982	61
	1 17, 70, 106, 292,	370			. 156	4983	61
•	31	20		POSED RULES:		4984	61
	42	107		2	. 167	4985	62
			00	<b>6</b> 25		4986	62
29	CFR		ঔឋ	CFR		4987	367
4		285	6		. 368	4988	321
		287	8		368	4 4 4 4 4	
		201 50				45 CFR	
610°		221	36		. 320	177	62
		221		<b>4</b> 775			
		427	39	CFR ,		46 CFR	
683		428	171_		157	390	368
721		428	3001	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	. 396	050	500
723_		52		POSED RULES:		47 CFR	
724_		427		124	433		
		222	ı	141	- 400	0	158
		427	41	CFR		97	158
		367			. 288	PROPOSED RULES:	
	OSED RULES:					73	329
	525	69					040
	040	05				49 CFR	
~~	CER					1 367	430
30	CFR					5	430
Prof	POSED RULES:			>		763	
				}		9	431
'	71	252		6		95	431
^^	CED		5A-	72	15	99	431
32	CFR		50-2	01	288	173	64
155		319	50-2	03	. 288	391	222
			114-	26	. 59	571	289
		367	114-	38	. 59	1033	64
	<b>_</b>		114-	45	59, 221	1056	158
32A	\ CFR		114-	47	_ 221	1201	64
		*				PROPOSED RULES:	
	(Ch. X):		42	CFR		- 71	225
	OI Reg. 1 52,	320	481_		222	173	202
NSA	(Ch. XVIII):		PRO	noann Derreas		571 166	326
	AGE 2	429		481 226, 293, 4	35 436	Ch. X	226
Prop	OSED RULES:		l	101 220, 200, 1		1100	438
		004	43	CFR			
,	Ch. X	224	1			50 CFR	
22	CFR		LOBI	LIC LAND ORDERS:		28 368	. 369
			l	4582 (modified by PLO 4988) _		3316, 322, 369	431
208_		54	1	4669 (see PLO 4988)		240	158
Prop	osed Rules:			4962 (see PLO 4988)		Proposed Rules:	
		323		4976			940
	117	323	l	4978	. 60	80	370